

CNO FINANCIAL GROUP, INC.

FORM 10-K (Annual Report)

Filed 03/28/08 for the Period Ending 12/31/07

Address	11825 N PENNSYLVANIA ST CARMEL, IN 46032
Telephone	3178176100
CIK	0001224608
Symbol	CNO
SIC Code	6321 - Accident and Health Insurance
Industry	Insurance (Life)
Sector	Financial
Fiscal Year	12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

Form 10-K

Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2007 or

Transition report pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934
For the transition period from _____ to _____

Commission file number: 001-31792

Conseco, Inc.

Delaware	No. 75-3108137
----- State of Incorporation	----- IRS Employer Identification No.
11825 N. Pennsylvania Street Carmel, Indiana 46032	(317) 817-6100
----- Address of principal executive offices	----- Telephone

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	of Each Exchange on which Registered
-----	-----
Common Stock, par value \$0.01 per share	New York Stock Exchange
Series A Warrants	New York Stock Exchange

**Securities registered pursuant to Section 12(g) of the Act:
3.50% Convertible Debentures due September 30, 2035**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes No

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days: Yes No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes No

At June 30, 2007, the last business day of the Registrant's most recently completed second fiscal quarter, the aggregate market value of the Registrant's common equity held by nonaffiliates was approximately \$3,919,718,000.

Indicate by check mark whether the Registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes [] No [X]

Shares of common stock outstanding as of March 20, 2008: 184,655,525

DOCUMENTS INCORPORATED BY REFERENCE: Portions of the Registrant's definitive proxy statement for the 2008 annual meeting of shareholders are incorporated by reference into Part III of this report.

TABLE OF CONTENTS

	Page

PART I	
Item 1. Business of Conseco.....	3
Item 1A. Risk Factors.....	22
Item 1B. Unresolved Staff Comments.....	33
Item 2. Properties.....	33
Item 3. Legal Proceedings.....	34
Item 4. Submission of Matters to a Vote of Security Holders.....	34
Executive Officers of the Registrant.....	35
PART II	
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.....	37
Item 6. Selected Consolidated Financial Data.....	40
Item 7. Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations.....	44
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.....	98
Item 8. Consolidated Financial Statements and Supplementary Data.....	99
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.....	181
Item 9A. Controls and Procedures.....	181
Item 9B. Other Information.....	183
PART III	
Item 10. Directors, Executive Officers and Corporate Governance.....	183
Item 11. Executive Compensation.....	183
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.....	183
Item 13. Certain Relationships and Related Transactions, and Director Independence...	183
Item 14. Principal Accountant Fees and Services.....	183
PART IV	
Item 15. Exhibits and Financial Statement Schedules.....	184

PART I

ITEM 1. BUSINESS OF CONSECO.

Conseco, Inc., a Delaware corporation ("CNO"), is the holding company for a group of insurance companies operating throughout the United States that develop, market and administer supplemental health insurance, annuity, individual life insurance and other insurance products. CNO became the successor to Conseco, Inc., an Indiana corporation ("Old Conseco" or our "Predecessor"), in connection with our bankruptcy reorganization which became effective on September 10, 2003 (the "Effective Date"). The terms "Conseco," the "Company," "we," "us," and "our" as used in this report refer to CNO and its subsidiaries or, when the context requires otherwise, Old Conseco and its subsidiaries.

We focus on serving the senior and middle-income markets, which we believe are attractive, underserved, high growth markets. We sell our products through three distribution channels: career agents, professional independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing. As of December 31, 2007, we had shareholders' equity of \$4.2 billion and assets of \$33.5 billion. For the year ended December 31, 2007, we had revenues of \$4.6 billion and a net loss of \$179.9 million. See our consolidated financial statements and accompanying footnotes for additional financial information about the Company and its segments.

We manage our business through the following: three primary operating segments, Bankers Life, Conseco Insurance Group and Colonial Penn, which are defined on the basis of product distribution; a fourth segment comprised of other business in run-off; and corporate operations. Our segments are described below:

o Bankers Life, which consists of the business of Bankers Life and Casualty Company ("Bankers Life and Casualty"), markets and distributes Medicare supplement insurance, life insurance, long-term care insurance, Medicare Part D prescription drug program, Medicare Advantage products and certain annuity products to the senior market through approximately 5,100 career agents and sales managers. Bankers Life and Casualty markets its products under its own brand name and Medicare Part D and Medicare Advantage products primarily through marketing agreements with Coventry Health Care ("Coventry").

o Conseco Insurance Group, which markets and distributes specified disease insurance, Medicare supplement insurance, and certain life and annuity products to the senior and middle-income markets through approximately 350 independent marketing organizations ("IMOs") that represent over 5,200 producing independent agents. This segment markets its products under the "Conseco" and "Washington National" (a wholly-owned insurance subsidiary of Conseco) brand names. Conseco Insurance Group includes primarily the business of Conseco Health Insurance Company ("Conseco Health"), Conseco Life Insurance Company ("Conseco Life"), Conseco Insurance Company and Washington National Insurance Company ("Washington National"), other than any run-off long-term care and major medical insurance issued by those companies. Such run-off business is included in the Other Business in Run-off segment.

o Colonial Penn, which consists of the business of Colonial Penn Life Insurance Company ("Colonial Penn"), markets graded benefit and simplified issue life insurance directly to customers through television advertising, direct mail, the internet and telemarketing. Colonial Penn markets its products under its own brand name.

o Other Business in Run-off, which includes blocks of business that we no longer market or underwrite and are managed separately from our other businesses. This segment consists of: (i) long-term care insurance sold in prior years through independent agents; and (ii) major medical insurance. The Other Business in Run-off segment is primarily comprised of long-term care business issued by Conseco Senior Health Insurance Company ("Conseco Senior") and Washington National, subsidiaries that were acquired in 1996 and 1997, respectively. Long-term care collected premiums represented more than 99 percent of this segment's total collected premiums in 2007. Of the long-term care collected premiums in this segment for the year ended December 31, 2007, approximately 88 percent related to Conseco Senior, approximately 8 percent related to Washington National and 4 percent related to other Conseco insurance subsidiaries. In 2007, long-term care premiums represented approximately 84 percent of the premiums collected by Conseco Senior and approximately 6 percent of the premiums collected by Washington National.

o Corporate operations, which consists of holding company activities and certain noninsurance company businesses that are not part of our other segments.

OUR STRATEGIC DIRECTION AND 2008 PRIORITIES

It is our vision to be a premier provider of insurance products to America's middle-income families and seniors. Our insurance companies help protect them from financial adversity: Medicare supplement, long-term care, cancer, heart/stroke and accident policies protect people against unplanned expenses; annuities and life products help people plan for their financial future. We believe our products meet the needs of our target markets.

We believe our middle market target is underserved by a majority of financial service providers and that the aging population will create strong growth in these target markets. Important trends impacting middle market consumers include:

- o Increased life expectancy.
- o Discontinuance or reduction in employer-sponsored benefit programs.
- o Rising healthcare costs.
- o Projected gaps between the annual costs and revenues of government-sponsored plans such as Social Security and Medicare.

We believe our multiple distribution channels provide broad reach across the market since consumers can access our products through an agent (Bankers Life or Conseco Insurance Group), without an agent (Colonial Penn), and at the worksite (Conseco Insurance Group).

Our major goals for 2008 include:

- o Maintaining strong growth at Bankers Life and Colonial Penn.
- o Continuing to improve the focus and profitability mix of sales at Conseco Insurance Group.
- o Improving earnings stability and reducing volatility.
- o Improving the performance of the long-term care business in our Other Business in Run-off segment by continuing to aggressively seek actuarially justified rate increases and by improving claims management.
- o Completing the remediation project relating to our material weakness in internal controls.
- o Reducing our enterprise exposure to long-term care business.
- o Improving or disposing of underperforming blocks of business.
- o Re-deploying capital to generate improved returns.
- o Positioning the Company to achieve an 11 percent operating return on equity in 2009.

OTHER INFORMATION

CNO is the successor to Old Conseco. We emerged from bankruptcy on the Effective Date. Old Conseco was organized in 1979 as an Indiana corporation and commenced operations in 1982. Our executive offices are located at 11825 N. Pennsylvania Street, Carmel, Indiana 46032, and our telephone number is (317) 817-6100. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act are available free of charge on our website at www.conseco.com as soon as reasonably practicable after they are electronically filed with, or furnished to, the Securities and Exchange Commission (the "SEC"). These filings are also available on the SEC's website at www.sec.gov. In addition, the public may read and copy any document we file at the SEC's Public Reference Room located at 100 F Street, NE, Room 1580, Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Copies of these filings are also available, without charge, from Conseco Investor

Our website also includes the charters of our Audit and Enterprise Risk Committee, Executive Committee, Governance and Strategy Committee, Human Resources and Compensation Committee and Investment Committee, as well as our Corporate Governance Operating Principles and our Code of Business Conduct and Ethics that applies to all officers, directors and employees. Copies of these documents are available free of charge on our website at www.conseco.com or from Conseco Investor Relations at the address shown above. Within the time period specified by the SEC and the New York Stock Exchange, we will post on our website any amendment to our Code of Business Conduct and Ethics and any waiver applicable to our principal executive officer, principal financial officer or principal accounting officer.

In June 2007, we filed with the New York Stock Exchange the Annual CEO Certification regarding the Company's compliance with their Corporate Governance listing standards as required by Section 303A.12(a) of the New York Stock Exchange Listed Company Manual. In addition, we have filed as exhibits to this 2007 Form 10-K the applicable certifications of the Company's Chief Executive Officer and Chief Financial Officer required under Section 302 of the Sarbanes-Oxley Act of 2002 regarding the Company's public disclosures.

Data in Item 1 are provided as of or for the year ended December 31, 2007 (as the context implies), unless otherwise indicated.

MARKETING AND DISTRIBUTION

Insurance

Our insurance subsidiaries develop, market and administer supplemental health insurance, annuity, individual life insurance and other insurance products. We sell these products through three primary distribution channels: career agents, professional independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing. We had premium collections of \$4.3 billion, \$4.3 billion and \$3.9 billion in 2007, 2006 and 2005, respectively.

Our insurance subsidiaries collectively hold licenses to market our insurance products in all fifty states, the District of Columbia, and certain protectorates of the United States. Sales to residents of the following states accounted for at least five percent of our 2007 collected premiums: Florida (8.5 percent), California (7.3 percent), Texas (6.6 percent) and Pennsylvania (6.1 percent).

We believe that most purchases of life insurance, accident and health insurance and annuity products occur only after individuals are contacted and solicited by an insurance agent. Accordingly, the success of our distribution system is largely dependent on our ability to attract and retain experienced and highly motivated agents. A description of our primary distribution channels is as follows:

Career Agents. This agency force of approximately 5,100 agents and sales managers working from 159 branch offices, establishes one-on-one contact with potential policyholders and promotes strong personal relationships with existing policyholders. The career agents sell primarily supplemental health and long-term care insurance policies, life insurance and annuities. In 2007, this distribution channel accounted for \$2,631.6 million, or 61 percent, of our total collected premiums. These agents sell only Bankers Life and Casualty policies and typically visit the prospective policyholder's home to conduct personalized "kitchen-table" sales presentations. After the sale of an insurance policy, the agent serves as a contact person for policyholder questions, claims assistance and additional insurance needs.

Professional Independent Producers. Professional independent producers are a diverse network of independent agents, insurance brokers and marketing organizations. The general agency and insurance brokerage distribution system is comprised of independent licensed agents doing business in all fifty states, the District of Columbia, and certain protectorates of the United States. In 2007, this distribution channel in our Conseco Insurance Group segment collected \$1,014.4 million, or 24 percent, of our total premiums, and in our Other Business in Run-off segment collected \$308.1 million, or 7 percent, of Conseco's total collected premiums.

Marketing organizations typically recruit agents for the Conseco Insurance Group segment by advertising our products and commission structure through direct mail advertising or through seminars for agents and brokers. These organizations bear most of the costs incurred in marketing our products. We compensate the marketing organizations by paying them a percentage of the commissions earned on new sales generated by agents recruited by such organizations. Certain of these marketing organizations are specialty organizations that have a marketing expertise or a distribution system related to a

particular product or market, such as worksite and individual supplemental health products. During 1999 and 2000, the Conseco Insurance Group segment purchased three organizations that specialize in marketing and distributing supplemental health products and combined them under the name Performance Matters Associates, Inc. ("PMA"). In 2007, the PMA distribution channel accounted for \$235.9 million, or 5 percent, of our total collected premiums.

Direct Marketing. This distribution channel is engaged primarily in the sale of graded benefit life insurance policies through Colonial Penn. In 2007, this channel accounted for \$124.1 million, or 3 percent, of our total collected premiums.

Products

The following table summarizes premium collections by major category and segment for the years ended December 31, 2007, 2006 and 2005 (dollars in millions):

Total premium collections

	2007	2006	2005
	----	----	----
Supplemental health:			
Bankers Life.....	\$1,546.1	\$1,308.3	\$1,213.7
Conseco Insurance Group.....	594.4	611.6	661.5
Colonial Penn.....	10.4	12.0	13.8
Other Business in Run-off.....	308.1	327.8	351.9
	-----	-----	-----
Total supplemental health.....	2,459.0	2,259.7	2,240.9
	-----	-----	-----
Annuities:			
Bankers Life.....	885.5	997.5	951.1
Conseco Insurance Group.....	368.6	433.3	161.7
	-----	-----	-----
Total annuities.....	1,254.1	1,430.8	1,112.8
	-----	-----	-----
Life:			
Bankers Life.....	200.0	184.2	152.1
Conseco Insurance Group.....	287.3	314.6	335.0
Colonial Penn.....	113.7	97.2	85.1
	-----	-----	-----
Total life.....	601.0	596.0	572.2
	-----	-----	-----
Total premium collections.....	\$4,314.1	\$4,286.5	\$3,925.9
	=====	=====	=====

Our insurance companies collected premiums from the following products:

Supplemental Health

Supplemental Health Premium Collections (dollars in millions)

	2007	2006	2005
	----	----	----
Medicare supplement:			
Bankers Life.....	\$ 636.1	\$ 629.1	\$ 638.8
Conseco Insurance Group.....	225.9	244.2	288.8
Colonial Penn.....	9.4	10.9	12.4
	-----	-----	-----
Total.....	871.4	884.2	940.0
	-----	-----	-----
Long-term care:			
Bankers Life	622.4	592.4	564.2
Other Business in Run-off	305.8	323.0	349.1
	-----	-----	-----
Total.....	928.2	915.4	913.3
	-----	-----	-----
Prescription Drug Plan and Medicare Advantage products included in Bankers Life.....	277.8	76.7	-
	-----	-----	-----
Specified disease products included in Conseco Insurance Group.....	359.2	357.7	359.5
	-----	-----	-----
Major medical business included in Other Business in Run-off.....	2.3	4.8	2.8
	-----	-----	-----
Other:			
Bankers Life	9.8	10.1	10.7
Conseco Insurance Group.....	9.3	9.7	13.2
Colonial Penn.....	1.0	1.1	1.4
	-----	-----	-----
Total.....	20.1	20.9	25.3
	-----	-----	-----
Total supplemental health premium collections.....	\$2,459.0	\$2,259.7	\$2,240.9
	=====	=====	=====

The following describes our major supplemental health products:

Medicare Supplement. Medicare supplement collected premiums were \$871.4 million during 2007 or 20 percent of our total collected premiums. Medicare is a federal health insurance program for disabled persons and seniors (age 65 and older). Part A of the program provides protection against the costs of hospitalization and related hospital and skilled nursing facility care, subject to an initial deductible, related coinsurance amounts and specified maximum benefit levels. The deductible and coinsurance amounts are subject to change each year by the federal government. Part B of Medicare covers doctor's bills and a number of other medical costs not covered by Part A, subject to deductible and coinsurance amounts for charges approved by Medicare. The deductible amount is subject to change each year by the federal government.

Medicare supplement policies provide coverage for many of the hospital and medical expenses which the Medicare program does not cover, such as deductibles, coinsurance costs (in which the insured and Medicare share the costs of medical expenses) and specified losses which exceed the federal program's maximum benefits. Our Medicare supplement plans automatically adjust coverage to reflect changes in Medicare benefits. In marketing these products, we currently concentrate on individuals who have recently become eligible for Medicare by reaching the age of 65. Approximately 50 percent of new sales of Medicare supplement policies in 2007 were to individuals who had recently reached the age of 65.

Both Bankers Life and Consec Insurance Group sell Medicare supplement insurance.

Long-Term Care. Long-term care collected premiums were \$928.2 million during 2007, or 22 percent of our total collected premiums. Long-term care products provide coverage, within prescribed limits, for nursing homes, home healthcare, or a combination of both. We sell the long-term care plans primarily to retirees and, to a lesser degree, to older self-employed individuals in the middle-income market.

Current nursing home care policies cover incurred charges up to a daily fixed-dollar limit with an elimination period (which, similar to a deductible, requires the insured to pay for a certain number of days of nursing home care before the insurance coverage begins), subject to a maximum benefit. Home healthcare policies cover incurred charges after a deductible or elimination period and are subject to a weekly or monthly maximum dollar amount, and an overall benefit maximum. Comprehensive policies cover both nursing home care and home healthcare. We monitor the loss experience on our long-term care products and, when necessary, apply for rate increases in the jurisdictions in which we sell such products. Regulatory filings are made before we increase our premiums on these products.

A portion of our long-term care business resides in the Other Business in Run-off segment. This business was sold through the independent producer distribution channel and was largely underwritten by certain of our subsidiaries prior to their acquisitions by Old Consec in 1996 and 1997. The performance of these blocks of business did not meet the expectations we had when the blocks were acquired. As a result, we ceased selling new long-term care policies through this distribution channel in 2003.

We continue to sell long-term care insurance through the Bankers Life career agent distribution channel. This business is underwritten using stricter underwriting and pricing standards than had previously been used on our acquired blocks of long-term care business included in the Other Business in Run-off segment.

Prescription Drug Plan and Medicare Advantage. The Medicare Prescription Drug, Improvement and Modernization Act of 2003 (the "MMA") provided for the introduction of a prescription drug program under Medicare Part D. Persons eligible for Medicare can receive their Part D coverage through a stand-alone Prescription Drug Plan ("PDP"). In order to offer a PDP product to our current and potential future policyholders without investment in management and infrastructure, we entered into a national distribution agreement with Coventry to use our career and independent agents to distribute Coventry's PDP product, Advantra Rx. We receive a fee based on the premiums collected on plans sold through our distribution channels. In addition, Consec has a quota-share reinsurance agreement with Coventry for Consec enrollees that provides Consec with 50 percent of net premiums and related profits subject to a risk corridor. The Part D program was effective January 1, 2006. PDP collected premiums were \$82.3 million during 2007 or 2 percent of our total collected premiums.

Consec expanded its strategic alliance with Coventry by entering into a national distribution agreement under which our career agents began distributing Coventry's Private-Fee-For-Service ("PFFS") plan, with coverage beginning January 1, 2007. The PFFS product, Advantra Freedom, is a Medicare Advantage plan designed to provide seniors with more choices and better coverage at lower cost than original Medicare and Medicare Advantage plans offered through HMOs. Under the agreement, we receive a fee based on the number of PFFS plans sold through our distribution channels. In addition, Consec has a quota-share reinsurance agreement with Coventry for Consec enrollees that provide Consec in 2007 with approximately 50 percent of the net premiums and related profits.

Effective July 1, 2007, Consec entered into a quota-share reinsurance agreement with Coventry related to the PFFS business written by Coventry under certain group policies. Consec receives 50 percent of the net premiums and related profits associated with this business as long as the ceded revenue margin is less than or equal to five percent. Consec receives 25 percent of the net premiums and related profits on the ceded margin in excess of five percent. PFFS collected premiums were \$195.5 million in 2007 or 5 percent of our total collected premiums.

During the fourth quarter of 2007, we initiated a pilot program to test the marketing and distribution of Coventry's PFFS plan through Colonial Penn's direct response distribution channel.

Specified Disease Products. Specified disease collected premiums were \$359.2 million during 2007, or 8 percent of our total collected premiums. These policies generally provide fixed or limited benefits. Cancer insurance and heart/stroke products are guaranteed renewable individual accident and health insurance policies. Payments under cancer insurance policies are generally made directly to, or at the direction of, the policyholder following diagnosis of, or treatment for, a covered type of cancer. Heart/stroke policies provide for payments directly to the policyholder for treatment of a covered

heart disease, heart attack or stroke. Accident products combine insurance for accidental death with limited benefit disability income insurance. Hospital indemnity products provide a fixed dollar amount per day of confinement in a hospital. The benefits provided under the specified disease policies do not necessarily reflect the actual cost incurred by the insured as a result of the illness, or accident, and benefits are not reduced by any other medical insurance payments made to or on behalf of the insured.

Approximately 78 percent of the total number of our specified disease policies in force was sold with return of premium or cash value riders. The return of premium rider generally provides that, after a policy has been in force for a specified number of years or upon the policyholder reaching a specified age, we will pay to the policyholder, or in some cases, a beneficiary under the policy, the aggregate amount of all premiums paid under the policy, without interest, less the aggregate amount of all claims incurred under the policy. For some policies, the return of premium rider does not have any claim offset. The cash value rider is similar to the return of premium rider, but also provides for payment of a graded portion of the return of premium benefit if the policy terminates before the return of premium benefit is earned.

Major Medical. Our major medical business is included in our Other Business in Run-off segment. Sales of our major medical health insurance products were targeted to self-employed individuals, small business owners, large employers and early retirees. This business was not profitable, and during 2001 and 2002, we decided to discontinue our major medical business by not renewing these policies except for certain business that is guaranteed renewable. During 2007, we collected major medical premiums of \$2.3 million.

Other Supplemental Health Products. Other supplemental health product collected premiums were \$20.1 million during 2007. This category includes various other health products such as senior hospital indemnity and disability income products which are sold in small amounts or other products which are no longer actively marketed.

Annuities

Annuity premium collections (dollars in millions)

	2007	2006	2005
	----	----	----
Equity-indexed annuity:			
Bankers Life	\$ 437.4	\$ 276.5	\$ 130.3
Conseco Insurance Group.....	344.6	378.5	104.4
	-----	-----	-----
Total equity-indexed annuity premium collections	782.0	655.0	234.7
	-----	-----	-----
Other fixed annuity:			
Bankers Life	448.1	721.0	820.8
Conseco Insurance Group.....	24.0	54.8	57.3
	-----	-----	-----
Total fixed annuity premium collections	472.1	775.8	878.1
	-----	-----	-----
Total annuity premium collections.....	\$1,254.1	\$1,430.8	\$1,112.8
	=====	=====	=====

During 2007, we collected annuity premiums of \$1,254.1 million or 29 percent of our total premiums collected. Annuity products include equity-indexed annuity, traditional fixed rate annuity and single premium immediate annuity products sold through both Bankers Life and Conseco Insurance Group. Annuities offer a tax-deferred means of accumulating savings for retirement needs, and provide a tax-efficient source of income in the payout period. Our major source of income from fixed rate annuities is the spread between the investment income earned on the underlying general account assets and the interest credited to contractholders' accounts. For equity-indexed annuities, our major source of income is the spread between the investment income earned on the underlying general account assets and the cost of the index options purchased to provide index-based credits to the contractholders' accounts.

Sales of many of our annuity products have been affected by the financial strength ratings assigned to our insurance subsidiaries by independent rating agencies. Many of our professional independent agents discontinued marketing our annuity products after A.M. Best Company ("A.M. Best") lowered the financial strength ratings assigned to our insurance subsidiaries in 2002. During the second half of 2007, we changed the pricing of specific products and we no longer emphasized the sale of certain products resulting in a decrease in collected premiums, partially offset by the sales of several new products distributed through new national partners. Career agents selling annuity products in the Bankers Life segment

are less sensitive in the near-term to A.M. Best ratings, since these agents only sell our products.

We believe the sales of our equity-indexed products in both segments were favorably impacted in 2007 due in part to general stock market conditions which made these products attractive relative to fixed annuities.

The increase in short-term interest rates in 2007 resulted in lower first-year fixed annuity sales as certain other competing products, such as certificates of deposits, have become attractive relative to fixed annuities.

The following describes the major annuity products:

Equity-Indexed Annuities. These products accounted for \$782.0 million, or 18 percent, of our total premium collections during 2007. The account value (or "accumulation value") of these annuities is credited in an amount that is based on changes in a particular index during a specified period of time. Within each contract issued, each equity-indexed annuity specifies:

- o The index to be used;
- o The time period during which the change in the index is measured, and at the end of which, the change in the index is applied to the account value. The time period of the contract ranges from 1 to 4 years.
- o The method used to measure the change in the index.
- o The measured change in the index may be multiplied by a "participation rate" (percentage of change in the index) before the credit is applied. Some policies guarantee the initial participation rate for the life of the contract, and some vary the rate for each period.
- o The measured change in the index may also be limited to a "cap" before the credit is applied. Some policies guarantee the initial cap for the life of the contract, and some vary the cap for each period.
- o The measured change in the index may also be limited to the excess in the measured change over a "margin" before the credit is applied. Some policies guarantee the initial margin for the life of the contract, and some vary the margin for each period.

These products have guaranteed minimum cash surrender values, regardless of actual index performance and the resulting indexed-based interest credits applied.

We generally buy call options and similar investments on the applicable indices in an effort to hedge potential increases to policyholder benefits resulting from increases in the indices to which the product's return is linked.

Fixed Rate Annuities. These products include fixed rate single-premium deferred annuities ("SPDAs"), flexible premium deferred annuities ("FPDAs") and single-premium immediate annuities ("SPIAs"). These products accounted for \$472.1 million, or 11 percent, of our total premium collections during 2007. Our fixed rate SPDAs and FPDAs typically have an interest rate (the "crediting rate") that is guaranteed by the Company for the first policy year, after which we have the discretionary ability to change the crediting rate to any rate not below a guaranteed minimum rate. The guaranteed rates on annuities written recently range from 2.5 percent to 3.0 percent, and the rates, on all policies inforce range from 2.5 percent to 6.0 percent. The initial crediting rate is largely a function of:

- o the interest rate we can earn on invested assets acquired with the new annuity fund deposits;
- o the costs related to marketing and maintaining the annuity products; and
- o the rates offered on similar products by our competitors.

For subsequent adjustments to crediting rates, we take into account current and prospective yields on investments, annuity surrender assumptions, competitive industry pricing and the crediting rate history for particular groups of annuity policies with similar characteristics.

In 2007, substantially all of our new annuity sales were "bonus interest" products. The initial crediting rate on these products specifies a bonus crediting rate generally ranging from 2.0 percent to 3.0 percent of the annuity deposit for the first policy year only. After the first year, the bonus interest portion of the initial crediting rate is automatically discontinued, and the renewal crediting rate is established. As of December 31, 2007, the average crediting rate, excluding bonuses, on our outstanding traditional annuities was 3.7 percent.

Withdrawals from deferred annuities (including equity-indexed annuities) are generally subject to a surrender charge of 3 percent to 19 percent in the first year, declining to zero over a 4 to 16 year period, depending on issue age and product. Surrender charges are set at levels intended to protect us from loss on early terminations and to reduce the likelihood that policyholders will terminate their policies during periods of increasing interest rates. This practice is intended to lengthen the duration of policy liabilities and to enable us to maintain profitability on such policies.

Penalty-free withdrawals from deferred annuities of up to 10 percent of either premiums or account value are available in most plans after the first year of the annuity's term.

Some deferred annuity products apply a market value adjustment during the surrender charge period. This adjustment is determined by a formula specified in the annuity contract, and may increase or decrease the cash surrender value depending on changes in the amount and direction of market interest rates or credited interest rates at the time of withdrawal. The resulting cash surrender values will be at least equal to the guaranteed minimum values.

SPIAs accounted for \$38.0 million, or .9 percent, of our total premiums collected in 2007. SPIAs are designed to provide a series of periodic payments for a fixed period of time or for life, according to the policyholder's choice at the time of issuance. Once the payments begin, the amount, frequency and length of time over which they are payable are fixed. SPIAs often are purchased by persons at or near retirement age who desire a steady stream of payments over a future period of years. The single premium is often the payout from a terminated annuity contract. The implicit interest rate on SPIAs is based on market conditions when the policy is issued. The implicit interest rate on our outstanding SPIAs averaged 6.9 percent at December 31, 2007.

Life Insurance

Life insurance premium collections (dollars in millions)

	2007	2006	2005
	----	----	----
Interest-sensitive life products:			
Bankers Life.....	\$ 63.4	\$ 62.2	\$ 50.9
Conseco Insurance Group.....	214.0	235.0	251.1
Colonial Penn.....	.5	.6	.6
	-----	-----	-----
Total interest-sensitive life premium collections.....	277.9	297.8	302.6
	-----	-----	-----
Traditional life:			
Bankers Life.....	136.6	122.0	101.2
Conseco Insurance Group.....	73.3	79.6	83.9
Colonial Penn.....	113.2	96.6	84.5
	-----	-----	-----
Total traditional life premium collections.....	323.1	298.2	269.6
	-----	-----	-----
Total life insurance premium collections.....	\$601.0	\$596.0	\$572.2
	=====	=====	=====

Life products include traditional and interest-sensitive life insurance products. These products are currently sold through Bankers Life, Conseco Insurance Group and Colonial Penn. During 2007, we collected life insurance premiums of \$601.0 million, or 14 percent, of our total collected premiums. Sales of life products are affected by the financial strength ratings assigned to our insurance subsidiaries by independent rating agencies. See "Competition" below.

Interest-Sensitive Life Products. These products include universal life and other interest-sensitive life products that provide whole life insurance with adjustable rates of return related to current interest rates. They accounted for \$277.9 million, or 6.4 percent, of our total collected premiums in 2007. These products are marketed by professional independent producers and, to a lesser extent, career agents (including professional independent producers and career agents specializing

in worksite sales). The principal differences between universal life products and other interest-sensitive life products are policy provisions affecting the amount and timing of premium payments. Universal life policyholders may vary the frequency and size of their premium payments, and policy benefits may also fluctuate according to such payments. Premium payments under other interest-sensitive policies may not be varied by the policyholders. Universal life products include equity-indexed universal life products. The account value of these policies is credited with interest at a guaranteed rate, plus additional interest credits based on changes in a particular stock index during a specified time period.

Traditional Life. These products accounted for \$323.1 million, or 7.5 percent, of our total collected premiums in 2007. Traditional life policies, including whole life, graded benefit life, term life and single premium whole life products, are marketed through professional independent producers, career agents and direct response marketing. Under whole life policies, the policyholder generally pays a level premium over an agreed period or the policyholder's lifetime. The annual premium in a whole life policy is generally higher than the premium for comparable term insurance coverage in the early years of the policy's life, but is generally lower than the premium for comparable term insurance coverage in the later years of the policy's life. These policies, which we continue to market on a limited basis, combine insurance protection with a savings component that gradually increases in amount over the life of the policy. The policyholder may borrow against the savings component generally at a rate of interest lower than that available from other lending sources. The policyholder may also choose to surrender the policy and receive the accumulated cash value rather than continuing the insurance protection. Term life products offer pure insurance protection for life with a guaranteed level premium for a specified period of time -- typically 10, 15, 20 or 30 years. In some instances, these products offer an option to return the premium at the end of the guaranteed period. We ceased most term life product sales through the professional independent producer distribution channel during 2003, but reentered the market in 2006.

Traditional life products also include graded benefit life insurance products. Graded benefit life products accounted for \$108.8 million, or 2.5 percent, of our total collected premiums in 2007. Graded benefit life insurance products are offered on an individual basis primarily to persons age 50 to 80, principally in face amounts of \$350 to \$30,000, without medical examination or evidence of insurability. Premiums are paid as frequently as monthly. Benefits paid are less than the face amount of the policy during the first two years, except in cases of accidental death. Our Colonial Penn segment markets graded benefit life policies under its own brand name using direct response marketing techniques. New policyholder leads are generated primarily from television, print advertisements and direct response mailings.

Traditional life products also include single premium whole life insurance. This product requires one initial lump sum payment in return for providing life insurance protection for the insured's entire lifetime. Single premium whole life products accounted for \$40.2 million, or .9 percent, of our total collected premiums in 2007.

INVESTMENTS

40|86 Advisors, Inc. ("40|86 Advisors"), a registered investment adviser and wholly-owned subsidiary of Consecro, Inc., manages the investment portfolios of our insurance subsidiaries. 40|86 Advisors had approximately \$24.7 billion of assets (at fair value) under management at December 31, 2007, of which \$23.8 billion were assets of our subsidiaries and \$.9 billion were assets managed for third parties. Our general account investment strategies are to:

- o maintain a largely investment-grade, diversified fixed-income portfolio;
- o maximize the spread between the investment income we earn and the yields we pay on investment products within acceptable levels of risk;
- o provide adequate liquidity;
- o construct our investment portfolio considering expected liability durations, cash flows and other requirements; and
- o maximize total return through active investment management.

During 2007, 2006 and 2005, we recognized net realized investment losses of \$155.4 million, \$47.2 million and \$2.9 million, respectively. During 2007, net realized investment losses included: (i) \$48.7 million of net losses from the sales of investments (primarily fixed maturities) with proceeds of \$7.2 billion; (ii) \$33.0 million of writedowns of investments for other than temporary declines in fair value; and (iii) \$73.7 million of writedowns of investments (which were subsequently transferred pursuant to a coinsurance agreement as further discussed in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Reinsurance") as a result of our intent not to hold such investments

for a period of time sufficient to allow for any anticipated recovery in value. A substantial portion of the net investment losses realized on sales of investments in 2007 were recognized on the sale of securities collateralized by sub prime residential mortgage loans. We decided to sell these securities given our concerns regarding the effect future adverse developments could have on the value of these securities. For further information on our sub prime holdings, refer to the caption entitled "Structured Securities Collateralized by Sub Prime Residential Mortgage Loans" in the "Investments" section of Management's Discussion and Analysis of Financial Condition and Results of Operations.

Investment activities are an integral part of our business because investment income is a significant component of our revenues. The profitability of many of our insurance products is significantly affected by spreads between interest yields on investments and rates credited on insurance liabilities. Although substantially all credited rates on SPDAs and FPDAs may be changed annually (subject to minimum guaranteed rates), changes in crediting rates may not be sufficient to maintain targeted investment spreads in all economic and market environments. In addition, competition, minimum guaranteed rates and other factors, including the impact of surrenders and withdrawals, may limit our ability to adjust or to maintain crediting rates at levels necessary to avoid narrowing of spreads under certain market conditions. As of December 31, 2007, the average yield, computed on the cost basis of our actively managed fixed maturity portfolio, was 6.0 percent, and the average interest rate credited or accruing to our total insurance liabilities was 4.7 percent.

We manage the equity-based risk component of our equity-indexed annuity products by:

- o purchasing equity-based options with similar payoff characteristics; and
- o adjusting the participation rate to reflect the change in the cost of such options (such cost varies based on market conditions).

We seek to manage the interest rate risk inherent in our invested assets with the interest rate characteristics of our insurance liabilities. We attempt to minimize this exposure by managing the durations and cash flows of our fixed maturity investments and insurance liabilities. For example, duration measures the expected change in the fair value of assets and liabilities for a given change in interest rates. If interest rates increase by 1 percent, the fair value of a fixed maturity security with a duration of 5 years is typically expected to decrease in value by approximately 5 percent. When the estimated durations of assets and liabilities are similar, a change in the value of assets should be largely offset by a change in the value of liabilities.

We calculate asset and liability durations using our estimates of future asset and liability cash flows. At December 31, 2007, the duration of our fixed maturity investments (as modified to reflect prepayments and potential calls) was approximately 7.6 years and the duration of our insurance liabilities was approximately 7.9 years. The difference between these durations indicates that our investment portfolio had a shorter duration and, consequently, was less sensitive to interest rate fluctuations than that of our liabilities at that date. We generally seek to minimize the gap between asset and liability durations.

For information regarding the composition and diversification of the investment portfolio of our subsidiaries, see "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations -- Investments."

COMPETITION

The markets in which we operate are highly competitive. Our current ratings have had a material adverse impact on our ability to compete in certain markets. Compared to Consec, many companies in the financial services industry are larger, have greater capital, technological and marketing resources, have better access to capital and other sources of liquidity at a lower cost, offer broader and more diversified product lines and have larger staffs. An expanding number of banks, securities brokerage firms and other financial intermediaries also market insurance products or offer competing products, such as mutual fund products, traditional bank investments and other investment and retirement funding alternatives. We also compete with many of these companies and others in providing services for fees. In most areas, competition is based on a number of factors, including pricing, service provided to distributors and policyholders and ratings. Consec's subsidiaries must also compete to attract and retain the allegiance of agents, insurance brokers and marketing companies.

In the individual health insurance business, companies compete primarily on the bases of marketing, service and price. Pursuant to federal regulations, the Medicare supplement products offered by all companies have standardized policy features. This increases the comparability of such policies and intensifies competition based on other factors. See "Insurance Underwriting" and "Governmental Regulation." In addition to competing with the products of other insurance companies,

commercial banks, thrifts, mutual funds and broker dealers, our insurance products compete with health maintenance organizations, preferred provider organizations and other health care-related institutions which provide medical benefits based on contractual agreements.

An important competitive factor for life insurance companies is the ratings they receive from nationally recognized rating organizations. Agents, insurance brokers and marketing companies who market our products and prospective purchasers of our products use the ratings of our insurance subsidiaries as one factor in determining which insurer's products to market or purchase. Ratings have the most impact on our annuity, interest-sensitive life insurance and long-term care products. Insurance financial strength ratings are opinions regarding an insurance company's financial capacity to meet the obligations of its insurance policies in accordance with their terms. They are not directed toward the protection of investors, and such ratings are not recommendations to buy, sell or hold securities.

On August 7, 2007, A.M. Best downgraded the financial strength ratings of our primary insurance subsidiaries to "B+ (Good)" from "B++ (Very Good)", except Conseco Senior (the issuer of most of our long-term care business in our Other Business in Run-off segment), whose "B- (Fair)" rating was downgraded to "C++ (Marginal)". A.M. Best also revised the outlook for the ratings of our primary insurance subsidiaries, as well as Conseco Senior, to negative from stable. The "B+" rating is assigned to companies that have a good ability, in A.M. Best's opinion, to meet their ongoing obligations to policyholders. The "C++" rating is assigned to companies which have a marginal ability, in A.M. Best's opinion, to meet their current obligations to policyholders, but are financially vulnerable to adverse changes in underwriting and economic conditions. A.M. Best ratings for the industry currently range from "A++ (Superior)" to "F (In Liquidation)" and some companies are not rated. An "A++" rating indicates a superior ability to meet ongoing obligations to policyholders. The "B+" rating and the "C++" rating from A.M. Best are the sixth and ninth highest, respectively, of sixteen possible ratings.

On August 7, 2007, Standard & Poor's Corporation ("S&P") affirmed the financial strength ratings of "BB+" of our primary insurance subsidiaries, except Conseco Senior, whose "CCC" rating was downgraded to "CCC-". S&P also revised the outlook for the ratings of our primary insurance subsidiaries to negative from stable, except for Conseco Senior, whose outlook of negative was affirmed. S&P financial strength ratings range from "AAA" to "R" and some companies are not rated. Rating categories from "BB" to "CCC" are classified as "vulnerable", and pluses and minuses show the relative standing within a category. In S&P's view, an insurer rated "BB" has marginal financial security characteristics and although positive attributes exist, adverse business conditions could lead to an insufficient ability to meet financial commitments. In S&P's view, an insurer rated "CCC" has very weak financial security characteristics and is dependent on favorable business conditions to meet financial commitments. The "BB+" rating and the "CCC-" rating from S&P are the eleventh and nineteenth highest, respectively, of twenty-one possible ratings.

The current financial strength ratings of our primary insurance subsidiaries (except Conseco Senior) from Moody's Investor Services, Inc. ("Moody's") are "Baa3" and Conseco Senior's rating is "Caal". On September 7, 2007, Moody's affirmed the financial strength ratings of our core insurance subsidiaries and Conseco Senior and revised its outlook on all our insurance subsidiaries to negative from stable. Moody's financial strength ratings range from "Aaa" to "C". Rating categories from "Aaa" to "Baa" are classified as "Secure" by Moody's and rating categories from "Ba" to "C" are considered "vulnerable" and these ratings may be supplemented with numbers "1", "2", or "3" to show relative standing within a category. In Moody's view, an insurer rated "Baa3" offers adequate financial security, however, certain protective elements may be lacking or may be characteristically unreliable over any great length of time. In Moody's view, an insurer rated "Caa" offers very poor financial security and may default on its policyholder obligations or there may be elements of danger with respect to punctual payment of policyholder obligations and claims. The "Baa3" rating and the "Caal" rating from Moody's are the tenth and seventeenth highest, respectively, of twenty-one possible ratings.

A.M. Best, S&P and Moody's review our ratings from time to time. We cannot provide any assurance that the ratings of our insurance subsidiaries will remain at their current levels or predict the impact of any future rating changes on our business.

INSURANCE UNDERWRITING

Under regulations promulgated by the National Association of Insurance Commissioners ("NAIC") (an association of state regulators and their staffs) and adopted as a result of the Omnibus Budget Reconciliation Act of 1990, we are prohibited from underwriting our Medicare supplement policies for certain first-time purchasers. If a person applies for insurance within six months after becoming eligible by reason of age, or disability in certain limited circumstances, the application may not be rejected due to medical conditions. Some states prohibit underwriting of all Medicare supplement policies. For other

prospective Medicare supplement policyholders, such as senior citizens who are transferring to our products, the underwriting procedures are relatively limited, except for policies providing prescription drug coverage.

Before issuing long-term care products, we generally apply detailed underwriting procedures to assess and quantify the insurance risks. We require medical examinations of applicants (including blood and urine tests, where permitted) for certain health insurance products and for life insurance products which exceed prescribed policy amounts. These requirements vary according to the applicant's age and may vary by type of policy or product. We also rely on medical records and the potential policyholder's written application. In recent years, there have been significant regulatory changes with respect to underwriting certain types of health insurance. An increasing number of states prohibit underwriting and/or charging higher premiums for substandard risks. We monitor changes in state regulation that affect our products, and consider these regulatory developments in determining the products we market and where we market them.

Our specified disease policies are individually underwritten using a simplified issue application. Based on an applicant's responses on the application, the underwriter either: (i) approves the policy as applied for; (ii) approves the policy with reduced benefits; or (iii) rejects the application.

Most of our life insurance policies are underwritten individually, although standardized underwriting procedures have been adopted for certain low face-amount life insurance coverages. After initial processing, insurance underwriters obtain the information needed to make an underwriting decision (such as medical examinations, doctors' statements and special medical tests). After collecting and reviewing the information, the underwriter either: (i) approves the policy as applied for; (ii) approves the policy with an extra premium charge because of unfavorable factors; or (iii) rejects the application.

We underwrite group insurance policies based on the characteristics of the group and its past claim experience. Graded benefit life insurance policies are issued without medical examination or evidence of insurability. There is minimal underwriting on annuities.

LIABILITIES FOR INSURANCE PRODUCTS

At December 31, 2007, the total balance of our liabilities for insurance products was \$26.7 billion. These liabilities are generally payable over an extended period of time. The profitability of our insurance products depends on pricing and other factors. Differences between our expectations when we sold these products and our actual experience could result in future losses.

Liabilities for insurance products are calculated using management's best judgments, based on our past experience and standard actuarial tables, of mortality, morbidity, lapse rates, investment experience and expense levels. For all of our insurance products, we establish an active life reserve, a liability for due and unpaid claims, claims in the course of settlement and incurred but not reported claims. In addition, for our supplemental health insurance business, we establish a reserve for the present value of amounts not yet due on incurred claims. Many factors can affect these reserves and liabilities, such as economic and social conditions, inflation, hospital and pharmaceutical costs, changes in doctrines of legal liability and extra-contractual damage awards. Therefore, our reserves and liabilities are necessarily based on extensive estimates, assumptions and historical experience. Establishing reserves is an uncertain process, and it is possible that actual claims will materially exceed our reserves and have a material adverse effect on our results of operations and financial condition. Our financial results depend significantly upon the extent to which our actual claims experience is consistent with the assumptions we used in determining our reserves and pricing our products. If our assumptions with respect to future claims are incorrect, and our reserves are insufficient to cover our actual losses and expenses, we would be required to increase our liabilities, which would negatively affect our operating results.

REINSURANCE

Consistent with the general practice of the life insurance industry, our subsidiaries enter into both facultative and treaty agreements of indemnity reinsurance with other insurance companies in order to reinsure portions of the coverage provided by our insurance products. Indemnity reinsurance agreements are intended to limit a life insurer's maximum loss on a large or unusually hazardous risk or to diversify its risk. Indemnity reinsurance does not discharge the original insurer's primary liability to the insured. Our reinsured business is ceded to numerous reinsurers. Based on our periodic review of their financial statements, insurance industry reports and reports filed with state insurance departments, we believe the assuming companies are able to honor all contractual commitments.

As of December 31, 2007, the policy risk retention limit of our insurance subsidiaries was generally \$.8 million or less. Reinsurance ceded by Conseco represented 21 percent of gross combined life insurance inforce and reinsurance assumed represented 1.6 percent of net combined life insurance inforce. Our principal reinsurers at December 31, 2007 were as follows (dollars in millions):

Name of Reinsurer -----	Ceded life insurance inforce -----	A.M. Best rating -----
Swiss Re Life and Health America Inc.....	\$ 3,874.6	A+
Security Life of Denver Insurance Company.....	3,349.4	A+
Reassure America Life Insurance Company ("REALIC") (a).....	1,617.1	A+
RGA Reinsurance Company.....	998.5	A+
Munich American Reassurance Company.....	938.5	A+
Lincoln National Life Insurance Company.....	733.2	A+
Scor Global Life Re Insurance Co of Texas.....	611.0	A-
General Re Life Corporation.....	447.0	A++
Hannover Life Reassurance Company.....	455.3	A
All others (b).....	1,692.6	

	\$14,717.2	
	=====	

-
- (a) In addition to the life insurance business summarized above, REALIC has assumed certain annuity business from our insurance subsidiaries through a coinsurance agreement. Such business had total insurance policy liabilities of \$2.6 billion at December 31, 2007.
 - (b) No other single reinsurer assumed greater than 3 percent of the total ceded business inforce.

EMPLOYEES

At December 31, 2007, we had approximately 3,950 full time employees, including 950 employees supporting our Bankers Life segment, 350 employees supporting our Colonial Penn segment and 2,650 employees supporting our Conseco Insurance Group segment, Other Business in Run-off segment and corporate segment. None of our employees are covered by a collective bargaining agreement. We believe that we have good relations with our employees.

GOVERNMENTAL REGULATION

Our insurance businesses are subject to extensive regulation and supervision by the insurance regulatory agencies of the jurisdictions in which they operate. This regulation and supervision is primarily for the benefit and protection of customers, and not for the benefit of investors or creditors. State laws generally establish supervisory agencies that have broad regulatory authority, including the power to:

- o grant and revoke business licenses;
- o regulate and supervise sales practices and market conduct;
- o establish guaranty associations;
- o license agents;
- o approve policy forms;
- o approve premium rates for some lines of business such as long-term care and Medicare supplement;
- o establish reserve requirements;
- o prescribe the form and content of required financial statements and reports;
- o determine the reasonableness and adequacy of statutory capital and surplus;
- o perform financial, market conduct and other examinations;
- o define acceptable accounting principles; and
- o regulate the types and amounts of permitted investments.

In addition, the NAIC issues model laws and regulations, many of which have been adopted by state insurance regulators, relating to:

- o reserve requirements;
- o risk-based capital ("RBC") standards;
- o codification of insurance accounting principles;
- o investment restrictions;
- o restrictions on an insurance company's ability to pay dividends; and
- o product illustrations.

In addition to the regulations described above, most states have also enacted laws or regulations regarding the activities of insurance holding company systems, including acquisitions, the terms of surplus debentures, the terms of transactions between insurance companies and their affiliates and other related matters. Various notice and reporting requirements generally apply to transactions between insurance companies and their affiliates within an insurance holding company system, depending on the size and nature of the transactions. These requirements may include prior regulatory approval or prior notice for certain material transactions. Currently, the Company and its insurance subsidiaries are registered as a holding company system pursuant to such laws and regulations in the domiciliary states of the insurance subsidiaries. In addition, the Company's insurance subsidiaries routinely report to other jurisdictions.

Insurance regulators may prohibit the payment of dividends or other payments by our insurance subsidiaries to parent companies if they determine that such payment could be adverse to our policyholders or contract holders. Otherwise, the

ability of our insurance subsidiaries to pay dividends is subject to state insurance department regulations and is based on the financial statements of our insurance subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities, which differ from generally accepted accounting principles ("GAAP"). These regulations generally permit dividends to be paid from statutory earned surplus of the insurance company for any 12-month period in amounts equal to the greater of, or in a few states, the lesser of:

- o statutory net gain from operations or statutory net income for the prior year; or
- o 10 percent of statutory capital and surplus at the end of the preceding year.

Any dividends in excess of these levels require the approval of the director or commissioner of the applicable state insurance department.

In accordance with orders from the Florida Office of Insurance Regulation, Consecro Senior may not distribute funds to any affiliate or shareholder unless such distributions have been approved by the Florida Office of Insurance Regulation and Washington National may not make similar distributions without prior notice to the Florida Office of Insurance Regulation. In addition, the RBC and other capital requirements described below can also limit, in certain circumstances, the ability of our insurance subsidiaries to pay dividends.

In connection with monitoring the financial condition of insurers, certain state insurance departments have requested additional information from two of the Company's insurance subsidiaries, Consecro Senior and Consecro Life, because each such insurance subsidiary has incurred statutory losses in a 12 month period in excess of 50 percent of its capital and surplus. The statutory losses of Consecro Life are primarily attributable to a litigation settlement. For further information related to this case, refer to the caption entitled "Cost of Insurance Litigation" included in the note to our consolidated financial statements entitled "Commitments and Contingencies". The statutory losses of Consecro Senior are primarily attributable to the adverse development of prior period claim reserves, an increase in claims incurred in 2006 and 2007 and strengthening of statutory active life reserves using the prospective unlocking method (as permitted by insurance regulators), all of which related to long-term care policies. Based on our discussions with state insurance departments, we do not expect the regulators to take any actions against Consecro Senior or Consecro Life that would have a material adverse effect on the financial position or results of operations of these companies.

Consecro Senior has been aggressively seeking actuarially justified rate increases and pursuing other actions on our long-term care policies. During the third quarter of 2006, we began a new program to file requests for rate increases on various long-term care products in the Other Business in Run-off segment as we believe the existing rates were too low to fund expected future benefits. These filings are expected to be the first of three rounds of rate increase filings for many of the same policies, and in some cases we requested three years of successive rate increases. Based on recent experience, certain of the policies in this segment will continue to be unprofitable even if we obtain the three rounds of rate increases, and it is likely that we will request additional rate increases when the current program is complete. We have chosen to request a series of smaller rate increases, rather than a single large increase, to limit the impact on a policyholder's premiums in any single year. The effects of the first round of rate filings have been partially realized in our premium revenue with the remaining impact expected to be realized by the end of 2008. In the second quarter of 2007, we began filing requests for the second round of rate increases on many of the same policies. As of December 31, 2007, almost all of the expected second round filings had been submitted for regulatory approval, and approximately 42 percent of the expected amounts had been approved by regulators. The full effect of all three rounds of rate increases may not be fully realized until 2011. It is possible that it will take more time than we expect to prepare rate increase filings and obtain approval from the state insurance regulators. In addition, it is likely that we will not be able to obtain approval for some of the actuarially justified rate increases currently pending or for the additional rate increases we plan to file especially in light of the magnitude of some past premium rate increases and current consumer and regulator sentiment. Most of our long-term care business is guaranteed renewable, and, if necessary rate increases are not approved, we may be required to write off all or a portion of the insurance acquisition costs and establish a premium deficiency reserve. If we are unable to raise our premium rates because we fail to obtain approval for actuarially justified rate increases in one or more states, our financial condition and results of operations could be adversely affected.

During 2006, the Florida legislature enacted a statute, known as House Bill 947, intended to provide new protections to long-term care insurance policyholders. Among other requirements, this statute requires: (i) claim experience of affiliated long-term care insurers to be pooled in determining justification for rate increases for Florida policyholders; and (ii) insurers with closed blocks of long-term care insurance to not raise rates above the comparable new business premium rates offered by affiliated insurers. The manner in which the requirements of this statute are applied to our long-term care policies

in Florida (including policies subject to the order from the Florida Office of Insurance Regulation as described in "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations - Other Business in Run-off") may affect our ability to achieve our anticipated rate increases on this business.

Most states have also enacted legislation or adopted administrative regulations that affect the acquisition (or sale) of control of insurance companies. The nature and extent of such legislation and regulations vary from state to state. Generally, these regulations require an acquirer of control to file detailed information and the plan of acquisition, and to obtain administrative approval prior to the acquisition of control. "Control" is generally defined as the direct or indirect power to direct or cause the direction of the management and policies of a person and is rebuttably presumed to exist if a person or group of affiliated persons directly or indirectly owns or controls 10 percent or more of the voting securities of another person.

Using statutory statements filed with state regulators annually, the NAIC calculates certain financial ratios to assist state regulators in monitoring the financial condition of insurance companies. A "usual range" of results for each ratio is used as a benchmark. In the past, variances in certain ratios of our insurance subsidiaries have resulted in inquiries from insurance departments, to which we have responded. These inquiries have not led to any restrictions affecting our operations.

The NAIC's RBC requirements provide a tool for insurance regulators to determine the levels of statutory capital and surplus an insurer must maintain in relation to its insurance and investment risks and the need for possible regulatory attention. The RBC requirements provide four levels of regulatory attention, varying with the ratio of the insurance company's total adjusted capital (defined as the total of its statutory capital and surplus, asset valuation reserve ("AVR") and certain other adjustments) to its RBC (as measured on December 31 of each year), as follows:

- o if a company's total adjusted capital is less than 100 percent but greater than or equal to 75 percent of its RBC (the "Company Action Level"), the company must submit a comprehensive plan to the regulatory authority proposing corrective actions aimed at improving its capital position;

- o if a company's total adjusted capital is less than 75 percent but greater than or equal to 50 percent of its RBC, the regulatory authority will perform a special examination of the company and issue an order specifying the corrective actions that must be taken;

- o if a company's total adjusted capital is less than 50 percent but greater than or equal to 35 percent of its RBC (the "Authorized Control Level"), the regulatory authority may take any action it deems necessary, including placing the company under regulatory control; and

- o if a company's total adjusted capital is less than 35 percent of its RBC (the "Mandatory Control Level"), the regulatory authority must place the company under its control.

In addition, the RBC requirements provide for a trend test if a company's total adjusted capital is between 100 percent and 125 percent of its RBC at the end of the year. The trend test calculates the greater of the decrease in the margin of total adjusted capital over RBC:

- o between the current year and the prior year; and

- o for the average of the last 3 years.

It assumes that such decrease could occur again in the coming year. Any company whose trended total adjusted capital is less than 95 percent of its RBC would trigger a requirement to submit a comprehensive plan as described above for the Company Action Level.

The 2007 statutory annual statements filed with the state insurance regulators of each of our insurance subsidiaries reflected total adjusted capital in excess of the levels subjecting the subsidiaries to any regulatory action. However, the RBC ratio of Conseco Senior, which has experienced losses on its long-term care business in our Other Business in Run-off segment, was near the level at which it would have been required to submit a comprehensive plan to insurance regulators proposing correcting actions aimed at improving its capital position. In order to avoid triggering the trend test with respect to Conseco Senior, we elected to make capital contributions totaling \$202.0 million during 2007 to Conseco Senior, including \$56.0 million which was accrued at December 31, 2007, and paid in February 2008. In the aggregate, we have made more than \$900 million of capital contributions to Conseco Senior since its acquisition by Old Conseco in 1996. We were under

no obligation to make such capital contributions to Consecro Senior, and we may determine not to make additional contributions in the future. No assurances can be given that we will make future contributions or otherwise make capital available to our insurance subsidiaries, including Consecro Senior.

In addition to the RBC requirements, certain states have established minimum capital requirements for insurance companies licensed to do business in their state. These additional requirements generally have not had a significant impact on the Company's insurance subsidiaries, but the capital requirements in Florida have caused Consecro Health to maintain a higher level of capital and surplus than it would otherwise maintain and have thus limited its ability to pay dividends. Refer to the note entitled "Statutory Information" in our notes to consolidated financial statements for more information on our RBC ratios.

In addition, although we are under no obligation to do so, we may elect to contribute additional capital to strengthen the surplus of certain insurance subsidiaries. Any election regarding the contribution of additional capital to our insurance subsidiaries could affect the ability of our insurance subsidiaries to pay dividends to the holding company. The ability of our insurance subsidiaries to pay dividends is also impacted by various criteria established by rating agencies to maintain or receive higher ratings and by the capital levels that we target for our insurance subsidiaries. During 2007, we made capital contributions of \$48.0 million (including \$25.0 million which was accrued at December 31, 2007, and paid in February 2008) to Consecro Life in an effort to meet such criteria and our targeted capital level.

The NAIC has adopted model long-term care policy language providing nonforfeiture benefits and has proposed a rate stabilization standard for long-term care policies. Various bills are introduced from time to time in the U.S. Congress which propose the implementation of certain minimum consumer protection standards in all long-term care policies, including guaranteed renewability, protection against inflation and limitations on waiting periods for pre-existing conditions. Federal legislation permits premiums paid for qualified long-term care insurance to be tax-deductible medical expenses and for benefits received on such policies to be excluded from taxable income.

Our insurance subsidiaries are required, under guaranty fund laws of most states, to pay assessments up to prescribed limits to fund policyholder losses or liabilities of insolvent insurance companies. Assessments can be partially recovered through a reduction in future premium taxes in some states.

Most states mandate minimum benefit standards and benefit ratios for accident and health insurance policies. We are generally required to maintain, with respect to our individual long-term care policies, minimum anticipated benefit ratios over the entire period of coverage of not less than 60 percent. With respect to our Medicare supplement policies, we are generally required to attain and maintain an actual benefit ratio, after three years, of not less than 65 percent. We provide to the insurance departments of all states in which we conduct business annual calculations that demonstrate compliance with required minimum benefit ratios for both long-term care and Medicare supplement insurance. These calculations are prepared utilizing statutory lapse and interest rate assumptions. In the event that we fail to maintain minimum mandated benefit ratios, our insurance subsidiaries could be required to provide retrospective refunds and/or prospective rate reductions. We believe that our insurance subsidiaries currently comply with all applicable mandated minimum benefit ratios.

The federal government does not directly regulate the insurance business. However, federal legislation and administrative policies in several areas, including pension regulation, age and sex discrimination, financial services regulation, securities regulation, privacy laws and federal taxation, do affect the insurance business. Legislation has been introduced from time to time in Congress that could result in the federal government assuming some direct role in the regulation of insurance.

Numerous proposals to reform the current health care system (including Medicare) have been introduced in Congress and in various state legislatures. Proposals have included, among other things, modifications to the existing employer-based insurance system, a quasi-regulated system of "managed competition" among health plans, and a single-payer, public program. Changes in health care policy could significantly affect our business. For example, Federal comprehensive major medical or long-term care programs, if proposed and implemented, could partially or fully replace some of Consecro's current products. Recent federal and state legislation and legislative proposals relating to healthcare reform contain features that could severely limit or eliminate our ability to vary our pricing terms or apply medical underwriting standards, which could have the effect of increasing our benefit ratios and adversely affecting our financial results. Also, Medicare reform and legislation concerning prescription drugs could affect our ability to price or sell our products.

The United States Department of Health and Human Services has issued regulations under the Health Insurance

Portability and Accountability Act relating to standardized electronic transaction formats, code sets and the privacy of member health information. These regulations, and any corresponding state legislation, affect our administration of health insurance.

A number of states have passed or are considering legislation that limits the differentials in rates that insurers could charge for health care coverages between new business and renewal business for similar demographic groups. State legislation has also been adopted or is being considered that would make health insurance available to all small groups by requiring coverage of all employees and their dependents, by limiting the applicability of pre-existing conditions exclusions, by requiring insurers to offer a basic plan exempt from certain benefits as well as a standard plan, or by establishing a mechanism to spread the risk of high risk employees to all small group insurers. Congress and various state legislators have from time to time proposed changes to the health care system that could affect the relationship between health insurers and their customers, including external review. We cannot predict with certainty the effect of any legislative proposals on our insurance businesses and operation.

The asset management activities of 401(k) Advisors are subject to various federal and state securities laws and regulations. The SEC and certain state securities commissions are the principal regulators of our asset management operations. In addition, Conesco has a subsidiary that is registered as a broker/dealer, which is regulated by the Financial Industry Regulatory Authority and by state securities commissioners.

FEDERAL INCOME TAXATION

Our annuity and life insurance products generally provide policyholders with an income tax advantage, as compared to other savings investments such as certificates of deposit and bonds, because taxes on the increase in value of the products are deferred until received by policyholders. With other savings investments, the increase in value is generally taxed as earned. Annuity benefits and life insurance benefits, which accrue prior to the death of the policyholder, are generally not taxable until paid. Life insurance death benefits are generally exempt from income tax. Also, benefits received on immediate annuities (other than structured settlements) are recognized as taxable income ratably, as opposed to the methods used for some other investments which tend to accelerate taxable income into earlier years. The tax advantage for annuities and life insurance is provided in the Internal Revenue Code (the "Code"), and is generally followed in all states and other United States taxing jurisdictions.

In recent years, Congress enacted legislation to lower marginal tax rates, reduce the federal estate tax gradually over a ten-year period, with total elimination of the federal estate tax in 2010, and increase contributions that may be made to individual retirement accounts and 401(k) accounts. While these tax law changes will sunset at the beginning of 2011 absent future congressional action, they could in the interim diminish the appeal of our annuity and life insurance products. Additionally, Congress has considered, from time to time, other possible changes to the U.S. tax laws, including elimination of the tax deferral on the accretion of value of certain annuities and life insurance products. It is possible that further tax legislation will be enacted which would contain provisions with possible adverse effects on our annuity and life insurance products.

Our insurance company subsidiaries are taxed under the life insurance company provisions of the Code. Provisions in the Code require a portion of the expenses incurred in selling insurance products to be deducted over a period of years, as opposed to immediate deduction in the year incurred. This provision increases the tax for statutory accounting purposes, which reduces statutory earnings and surplus and, accordingly, decreases the amount of cash dividends that may be paid by the life insurance subsidiaries.

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities, capital loss carryforwards and net operating loss carryforwards ("NOLs"). In evaluating our deferred income tax assets, we consider whether it is more likely than not that the deferred income tax assets will be realized. The ultimate realization of our deferred income tax assets depends upon generating future taxable income during the periods in which our temporary differences become deductible and before our NOLs expire. In addition, the use of our NOLs is dependent, in part, on whether the Internal Revenue Service ("IRS") ultimately agrees with the tax position we plan to take in our current and future tax returns. Accordingly, with respect to our deferred tax assets, we assess the need for a valuation allowance on an ongoing basis.

Based upon information existing at the time of our emergence from bankruptcy, we established a valuation allowance equal to our entire balance of net deferred income tax assets because, at that time, the realization of such deferred tax assets in future periods was uncertain. As of December 31, 2007 and 2006, we determined that a full valuation allowance was no

longer necessary. However, as further discussed in the note to the consolidated financial statements entitled "Income Taxes", we continue to believe that it is necessary to have a valuation allowance on a portion of our deferred tax asset. This determination was made by evaluating each component of the deferred tax assets and assessing the effects of limitations or issues on the value of such component to be fully recognized in the future.

ITEM 1A. RISK FACTORS.

Conseco and its businesses are subject to a number of risks including general business and financial risk factors. Any or all of such factors could have a material adverse effect on the business, financial condition or results of operations of Conseco. In addition, please refer to the "Cautionary Statement Regarding Forward-Looking Statements" included in "Item 7 - Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations".

The limited historical claims experience on our long-term care products could negatively impact our operations if our estimates prove wrong and we have not adequately set premium rates.

In setting premium rates, we consider historical claims information and other factors, but we cannot predict future claims with certainty. This is particularly applicable to our long-term care insurance products, for which we have relatively limited historical claims experience. Long-term care products tend to have fewer claims than other health products such as Medicare supplement, but when claims are incurred, they tend to be much higher in dollar amount. Also, long-term care products have a much longer tail, meaning that claims are incurred much later in the life of the policy than most other supplemental health products. As a result of these traits, it is difficult to appropriately price this product. For our long-term care insurance, actual persistency in later policy durations that is higher than our persistency assumptions could have a negative impact on profitability. If these policies remain in force longer than we assumed, then we could be required to make greater benefit payments than anticipated when the products were priced. Mortality is a critical factor influencing the length of time a claimant receives long-term care benefits. Mortality continues to improve for the general population, and life expectancy has increased. Improvements in actual mortality trends relative to assumptions may adversely affect our profitability.

Our Bankers Life segment has offered long-term care insurance since 1985. The claims experience on our Bankers Life long-term care blocks has generally been lower than our pricing expectations. However, the persistency of these policies has been higher than our pricing expectations and this may result in higher benefit ratios in the future.

The long-term care insurance businesses included in the Other Business in Run-off segment were acquired through acquisitions completed in 1996 and 1997. The experience on these acquired blocks has generally been worse than the acquired companies' original pricing expectations. We have received regulatory approvals for numerous premium rate increases in recent years pertaining to these blocks. Even with these rate increases, these blocks experienced benefit ratios of 191 percent in 2007, 134 percent in 2006 and 95 percent in 2005. If future claims experience proves to be worse than anticipated as our long-term care blocks continue to age, our financial results could be adversely affected. In addition, such rate increases may cause existing policyholders to allow their policies to lapse, resulting in reduced profitability.

The results of operations of our insurance business will decline if our premium rates are not adequate or if we are unable to obtain regulatory approval to increase rates.

We set the premium rates on our health insurance policies based on facts and circumstances known at the time we issue the policies and on assumptions about numerous variables, including the actuarial probability of a policyholder incurring a claim, the probable size of the claim, maintenance costs to administer the policies and the interest rate earned on our investment of premiums. In setting premium rates, we consider historical claims information, industry statistics, the rates of our competitors and other factors, but we cannot predict with certainty the future actual claims on our products. If our actual claims experience proves to be less favorable than we assumed and we are unable to raise our premium rates to the extent necessary to offset the unfavorable claims experience, our financial results may be adversely affected.

We review the adequacy of our premium rates regularly and file proposed rate increases on our products when we believe existing premium rates are too low. It is possible that we will not be able to obtain approval for premium rate increases from currently pending requests or from future requests. If we are unable to raise our premium rates because we fail to obtain approval in one or more states, our financial results will be adversely affected. Moreover, in some instances, our ability to exit unprofitable lines of business is limited by the guaranteed renewal feature of the policy. Due to this feature, we cannot exit such business without regulatory approval, and accordingly, we may be required to continue to service those products at a loss for an extended period of time. Most of our long-term care business is guaranteed renewable, and, if

necessary rate increases were not approved, we would be required to recognize a loss and establish a premium deficiency reserve. During 2007, the financial statements of two of our subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities reflected the establishment of asset adequacy and premium deficiency reserves related to long-term care policies. The asset adequacy and premium deficiency reserves related to health products for Washington National and Bankers Consec Life Insurance Company were \$57.8 million and \$30.6 million, respectively, at December 31, 2007. Due to differences between statutory and GAAP insurance liabilities, we were not required to recognize a similar premium deficiency reserve in our consolidated financial statements prepared in accordance with GAAP.

If, however, we are successful in obtaining regulatory approval to raise premium rates, the increased premium rates may reduce the volume of our new sales and cause existing policyholders to allow their policies to lapse. This could result in a significantly higher ratio of claim costs to premiums if healthier policyholders who get coverage elsewhere allow their policies to lapse, while policies of less healthy policyholders continue inforce. This would reduce our premium income and profitability in future periods.

Most of our supplemental health policies allow us to increase premium rates when warranted by our actual claims experience. These rate increases must be approved by the applicable state insurance departments, and we are required to submit actuarial claims data to support the need for such rate increases. The re-rate application and approval process on supplemental health products is a normal recurring part of our business operations and reasonable rate increases are typically approved by the state departments as long as they are supported by actual claims experience and are not unusually large in either dollar amount or percentage increase. For policy types on which rate increases are a normal recurring event, our estimates of insurance liabilities assume we will be able to raise rates if experience on the blocks warrants such increases in the future.

The benefit ratio for our long-term care products included in the Other Business in Run-off segment has increased in recent periods and was 191 percent during 2007. We will have to continue to raise rates or take other actions with respect to some of these policies or our financial results will be adversely affected.

As a result of higher persistency in our long-term care block in the Bankers Life segment than assumed in the original pricing, our premium rates were too low. Accordingly, we began a program in 2006 to seek approval from regulatory authorities for rate increases on approximately 65 percent of this block. In addition, another round of increases was filed during the second and third quarters of 2007 on newer long-term care, home health care, and short-term care policies not included in the first round of rate increases. The policies in this round represent approximately 25 percent of the inforce block. As of December 31, 2007, all such filings had been submitted for regulatory approval, and approximately 38 percent of the amounts had been approved by regulators and implemented. However, it is possible that we will not be able to obtain approval for all or a portion of the premium rate increases from currently pending requests or future requests. If we are unable to obtain these rate increases, the profitability of these policies and the performance of this block of business could be adversely affected. In addition, such rate increases may reduce the volume of our new sales and cause existing policyholders to allow their policies to lapse, resulting in reduced profitability.

We have implemented and will continue to implement from time to time and when actuarially justified, premium rate increases in our long-term care business. In some cases, we offer policyholders the opportunity to reduce their coverage amounts or accept non-forfeiture benefits as alternatives to increasing their premium rates. The financial impact of our rate increase actions could be adversely affected by policyholder anti-selection, meaning that policyholders who are less likely to incur claims may lapse their policies or reduce their benefits, while policyholders who are more likely to incur claims may maintain full coverage and accept their rate increase.

We have identified a material weakness in our internal control over financial reporting, and our business and stock price may be adversely affected if we have not adequately addressed the weakness or if we have other material weaknesses or significant deficiencies in our internal control over financial reporting.

We did not maintain effective controls over the accounting and disclosure of insurance policy benefits and the liabilities for insurance products. We identified a material weakness in internal controls over the actuarial reporting processes related to the design of controls to ensure the completeness and accuracy of certain inforce policies in our Bankers Life segment, Consec Insurance Group segment, and Other Business in Run-off segment. These control deficiencies resulted in adjustments to insurance policy benefits and the liabilities for insurance products in the consolidated financial statements for the years ended December 31, 2006 and December 31, 2007. As a result of the errors we identified related to these deficiencies during remediation procedures performed in 2007, Consec has restated its financial statements for the

years ended December 31, 2006 and 2005, along with affected Selected Consolidated Financial Data for 2004 and 2003, and quarterly financial information for 2006 and the first three quarters of 2007. If we cannot produce reliable financial reports, investors could lose confidence in our reported financial information, the market price of our stock could decline significantly, we may be unable to obtain additional financing to operate and expand our business, and our business and financial condition could be harmed. In addition, we face the risk that, notwithstanding our efforts to date to identify and remedy all material errors in those financial statements, we may discover other errors in the future; and that the cost of identifying and remedying the errors and remediating our material weakness in internal controls will be high and have a material adverse affect on our financial condition and results of operation. See Item 9A of this annual report for additional information.

Our reserves for future insurance policy benefits and claims may prove to be inadequate, requiring us to increase liabilities which results in reduced net income and shareholders' equity.

Liabilities for insurance products are calculated using management's best judgments, based on our past experience and standard actuarial tables, of mortality, morbidity, lapse rates, investment experience and expense levels. For our health insurance business, we establish an active life reserve, a liability for due and unpaid claims, claims in the course of settlement, and incurred but not reported claims, and a reserve for the present value of amounts on incurred claims not yet due. We establish reserves based on assumptions and estimates of factors either established at the fresh-start date for business inforce then or considered when we set premium rates for business written after that date.

Many factors can affect these reserves and liabilities, such as economic and social conditions, inflation, hospital and pharmaceutical costs, changes in life expectancy, regulatory actions, changes in doctrines of legal liability and extra-contractual damage awards. Therefore, the reserves and liabilities we establish are necessarily based on estimates, assumptions and prior years' statistics. It is possible that actual claims will materially exceed our reserves and have a material adverse effect on our results of operations and financial condition. We have incurred significant losses beyond our estimates as a result of actual claim costs and persistency of our long-term care business included in the Other Business in Run-off segment. In prior periods, we have increased our estimates of incurred claims on this block due to prior period deficiencies, including an increase of \$118 million in the second quarter of 2007, \$22 million in the first quarter of 2007 and \$54.1 million in the fourth quarter of 2006. Our financial performance depends significantly upon the extent to which our actual claims experience and future expenses are consistent with the assumptions we used in setting our reserves. If our assumptions with respect to future claims are incorrect, and our reserves prove to be insufficient to cover our actual losses and expenses, we would be required to increase our liabilities, and our financial results could be adversely affected.

We may be required to accelerate the amortization of the cost of policies produced or the value of policies inforce at the Effective Date.

Cost of policies produced represent the costs that vary with, and are primarily related to, producing new insurance business. The value of policies inforce at the Effective Date represents the value assigned to the right to receive future cash flows from contracts existing at September 10, 2003. The balances of these accounts are amortized over the expected lives of the underlying insurance contracts. Management, on an ongoing basis, tests these accounts recorded on our balance sheet to determine if these amounts are recoverable under current assumptions. In addition, we regularly review the estimates and assumptions underlying these accounts for those products for which we amortize the cost of policies produced or the value of insurance inforce at the Effective Date in proportion to gross profits or gross margins. If facts and circumstances change, these tests and reviews could lead to reduction in the balance of those accounts that could have an adverse effect on the results of our operations and our financial condition.

Our net income and revenues will suffer if policyholder surrender levels differ significantly from our assumptions.

Surrenders of our annuities and life insurance products can result in losses and decreased revenues if surrender levels differ significantly from assumed levels. At December 31, 2007, approximately 18 percent of our total insurance liabilities, or approximately \$4.8 billion, could be surrendered by the policyholder without penalty. The surrender charges that are imposed on our fixed rate annuities typically decline during a penalty period, which ranges from five to twelve years after the date the policy is issued. Surrenders and redemptions could require us to dispose of assets earlier than we had planned, possibly at a loss. Moreover, surrenders and redemptions require faster amortization of either the acquisition costs or the commissions associated with the original sale of a product, thus reducing our net income. We believe policyholders are generally more likely to surrender their policies if they believe the issuer is having financial difficulties, or if they are able to reinvest the policy's value at a higher rate of return in an alternative insurance or investment product.

Our investment portfolio is subject to several risks that may diminish the value of our invested assets and negatively impact our profitability.

The value of our investment portfolio is subject to numerous factors, which are difficult to predict, and are often beyond our control. These factors include, but are not limited to, the following:

- o Changes in interest rates can reduce the value of our investments as further discussed in the risk factor entitled "Changing interest rates may adversely affect our results of operations".

- o Changes in patterns of relative liquidity in the capital markets for various asset classes.

- o Changes in the ability of issuers to make timely repayments on actively managed fixed maturity investments can reduce the value of our investments. This risk is significantly greater with respect to below-investment grade securities, which comprised 8.0 percent of our actively managed fixed maturity investments as of December 31, 2007.

- o Changes in the estimated timing of receipt of cash flows. For example, our structured security investments, which comprised 23 percent of our actively managed fixed maturity investments at December 31, 2007, are subject to risks relating to variable prepayment on the assets underlying such securities, such as mortgage loans. When structured securities prepay faster than expected, investment income may be adversely affected due to the acceleration of the amortization of purchase premiums or the inability to reinvest at comparable yields in lower interest rate environments.

- o Changes in the relative risk premium required in the market for a given level of risk.

We have recorded writedowns of fixed maturity investments, equity securities and other invested assets as a result of conditions which caused us to conclude a decline in the fair value of the investment was other than temporary as follows: \$106.7 million in 2007 (including \$73.7 million of writedowns of investments (which were subsequently transferred pursuant to a coinsurance agreement as further discussed in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies") as a result of our intent not to hold investments for a period of time sufficient to allow for any anticipated recovery in value); \$22.4 million in 2006; and \$14.7 million in 2005. Our investment portfolio is subject to the risks of further declines in realizable value. However, we attempt to mitigate this risk through the diversification and active management of our portfolio.

In the event of substantial product surrenders or policy claims, we may choose to maintain highly liquid, and potentially lower-yielding, assets, or to sell assets at a loss, thereby eroding the performance of our portfolio.

Because a substantial portion of our net income is derived from returns on our investment portfolio, significant losses in the portfolio may have a direct and materially adverse impact on our results of operations. In addition, losses on our investment portfolio could reduce the investment returns that we are able to credit to our customers of certain products, thereby impacting our sales and eroding our financial performance.

Changing interest rates may adversely affect our results of operations.

Our profitability is affected by fluctuating interest rates. While we monitor the interest rate environment and, in some cases, employ hedging strategies to mitigate such impact, our financial results could be adversely affected by changes in interest rates. Our spread-based insurance and annuity business is subject to several inherent risks arising from movements in interest rates, especially if we fail to anticipate or respond to such movements. First, interest rate changes can cause compression of our net spread between interest earned on investments and interest credited to customer deposits. Our ability to adjust for such a compression is limited by the guaranteed minimum rates that we must credit to policyholders on certain products, as well as the terms on most of our other products that limit reductions in the crediting rates to pre-established intervals. As of December 31, 2007, approximately 38 percent of our insurance liabilities were subject to interest rates that may be reset annually; 47 percent had a fixed explicit interest rate for the duration of the contract; 11 percent had credited rates that approximate the income we earn; and the remainder had no explicit interest rates. Second, if interest rate changes produce an unanticipated increase in surrenders of our spread-based products, we may be forced to sell invested assets at a loss in order to fund such surrenders. Third, the profits from many non-spread-based insurance products, such as long-term care policies, can be adversely affected when interest rates decline because we may be unable to reinvest the cash from

premiums received at the interest rates anticipated when we sold the policies. Finally, changes in interest rates can have significant effects on the market value and performance of our investments in general and specifically on the performance of our structured securities portfolio, including collateralized mortgage obligations ("CMOs"), as a result of changes in the prepayment rate of the loans underlying such securities. We employ asset/liability strategies that are designed to mitigate the effects of interest rate changes on our profitability but do not currently extensively employ derivative instruments for this purpose. We may not be successful in implementing these strategies and achieving adequate investment spreads.

We use computer models to simulate our cash flows expected from existing business under various interest rate scenarios. These simulations help us measure the potential gain or loss in fair value of our interest-sensitive financial instruments. With such estimates, we seek to manage the relationship between the duration of our assets and the expected duration of our liabilities. When the estimated durations of assets and liabilities are similar, exposure to interest rate risk is minimized because a change in the value of assets should be largely offset by a change in the value of liabilities. At December 31, 2007, the duration of our fixed maturity investments (as modified to reflect prepayments and potential calls) was approximately 7.6 years, and the duration of our insurance liabilities was approximately 7.9 years. We estimate that our fixed maturity securities and short-term investments, net of corresponding changes in insurance acquisition costs, would decline in fair value by approximately \$490 million if interest rates were to increase by 10 percent from rates as of December 31, 2007. This compares to a decline in fair value of \$515 million based on amounts and rates at December 31, 2006. The calculations involved in our computer simulations incorporate numerous assumptions, require significant estimates and assume an immediate change in interest rates without any management reaction to such change. Consequently, potential changes in the values of our financial instruments indicated by the simulations will likely be different from the actual changes experienced under given interest rate scenarios, and the differences may be material. Because we actively manage our investments and liabilities, our net exposure to interest rates can vary over time.

General market conditions affect investments and investment income.

The performance of our investment portfolio depends in part upon the level of and changes in interest rates, risk spreads, real estate values, market volatility, the performance of the economy in general, the performance of the specific obligors included in our portfolio and other factors that are beyond our control. Changes in these factors can affect our net investment income in any period, and such changes can be substantial.

Financial market conditions can also affect our realized and unrealized investment gains (losses). During periods of rising interest rates, the fair values of our investments will typically decline. Conversely, during periods of falling interest rates, the fair values of our investments will typically rise.

Concentration of our investment portfolios in any particular sector of the economy may have an adverse effect on our financial position or results of operations.

The concentration of our investment portfolios in any particular industry, group of related industries, asset classes (such as residential mortgage-backed securities and other asset-backed securities), or geographic area could have an adverse effect on its value and performance and, consequently, on our results of operations and financial position. While Conseco seeks to mitigate this risk by having a broadly diversified portfolio, events or developments that have a negative impact on any particular industry, group of related industries or geographic area may have an adverse effect on the investment portfolios to the extent that the portfolios are concentrated.

Litigation and regulatory investigations are inherent in our business, may harm our financial strength and reputation and negatively impact our financial results.

Insurance companies historically have been subject to substantial litigation. In addition to the traditional policy claims associated with their businesses, insurance companies face policyholder suits and class action suits. We also face significant risks related to regulatory investigations and actions. The litigation and regulatory investigations we are, have been, or may become subject to include matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, administration, additional premium charges for premiums paid on a periodic basis, calculation of cost of insurance charges, changes to certain non-guaranteed policy features, denial or delay of benefits, charging excessive or impermissible fees on products and recommending unsuitable products to customers. Certain of the Company's insurance policies allow or require us to make changes based on experience to certain non-guaranteed elements such as cost of insurance charges, expense loads, credited interest rates and policyholder bonuses. The Company intends to make changes to certain non-guaranteed elements in the future. In some instances in the past, such action has resulted in litigation and similar litigation may arise in the future. The Company's

exposure, if any, arising from any such action cannot presently be determined. Our pending legal and regulatory actions include matters that are specific to us, as well as matters faced by other insurance companies. State insurance departments focus on sales and claims payment practices and product issues in their market conduct examinations. Negotiated settlements of class action and other lawsuits have had a material adverse effect on the business, financial condition and results of operations of our insurance companies. We are, in the ordinary course of our business, a plaintiff or defendant in actions arising out of our insurance business, including class actions and reinsurance disputes, and, from time to time, we are also involved in various governmental and administrative proceedings and investigations and inquiries such as information requests, subpoenas and books and record examinations, from state, federal and other authorities. The ultimate outcome of these lawsuits and investigations, however, cannot be predicted with certainty. In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations or cash flows. We could also suffer significant reputational harm as a result of such litigation, regulatory action or investigation which could have a material adverse effect on our business, financial condition, results of operations or cash flows.

For a description of current legal proceedings, see note 9 of the consolidated financial statements.

Our business is subject to extensive regulation, which limits our operating flexibility and could result in our insurance subsidiaries being placed under regulatory control or otherwise negatively impact our financial results.

Our insurance business is subject to extensive regulation and supervision in the jurisdictions in which we operate. Our insurance subsidiaries are subject to state insurance laws that establish supervisory agencies. Such agencies have broad administrative powers including the power to:

- o grant and revoke business licenses;
- o regulate and supervise sales practices and market conduct;
- o establish guaranty associations;
- o license agents;
- o approve policy forms;
- o approve premium rates for some lines of business such as long-term care and Medicare supplement;
- o establish reserve requirements;
- o prescribe the form and content of required financial statements and reports;
- o determine the reasonableness and adequacy of statutory capital and surplus;
- o perform financial, market conduct and other examinations;
- o define acceptable accounting principles; and
- o regulate the types and amounts of permitted investments.

The regulations issued by state insurance agencies can be complex and subject to differing interpretations. If a state insurance regulatory agency determines that one of our insurance company subsidiaries is not in compliance with applicable regulations, the subsidiary is subject to various potential administrative remedies including, without limitation, monetary penalties, restrictions on the subsidiary's ability to do business in that state and a return of a portion of policyholder premiums. In addition, regulatory action or investigations could cause us to suffer significant reputational harm, which could have an adverse effect on our business, financial condition and results of operations.

In connection with monitoring the financial condition of insurers, certain state insurance departments have requested additional information from two of the Company's insurance subsidiaries, Conseco Senior and Conseco Life, because each such insurance subsidiary has incurred statutory losses in a 12 month period in excess of 50 percent of its capital and surplus. The statutory losses of Conseco Life are primarily attributable to a litigation settlement. For further information related to this case, refer to the caption entitled "Cost of Insurance Litigation" included in the note to our consolidated financial statements entitled "Commitments and Contingencies". The statutory losses of Conseco Senior are primarily attributable to the adverse development of prior period claim reserves, an increase in claims incurred in 2006 and 2007 and strengthening of statutory active life reserves using the prospective unlocking method (as permitted by insurance regulators), all of which related to long-term care policies. Based on our discussions with state insurance departments, we do not expect the regulators to take any actions against Conseco Senior or Conseco Life that would have a material adverse effect on the financial position or results of operations of these companies.

Our insurance subsidiaries are also subject to RBC requirements. These requirements were designed to evaluate the adequacy of statutory capital and surplus in relation to investment and insurance risks associated with asset quality, mortality

and morbidity, asset and liability matching and other business factors. The requirements are used by states as an early warning tool to discover companies that may be weakly-capitalized for the purpose of initiating regulatory action. Generally, if an insurer's RBC falls below specified levels, the insurer is subject to different degrees of regulatory action depending upon the magnitude of the deficiency. The 2007 statutory annual statements filed with the state insurance regulators of each of our insurance subsidiaries reflected total adjusted capital in excess of the levels subjecting the subsidiaries to any regulatory action. However, the RBC ratio of Conseco Senior, which has experienced losses on its long-term care business in our Other Business in Run-off segment, was near the level at which it would have been required to submit a comprehensive plan to insurance regulators proposing corrective actions aimed at improving its capital position. In order to avoid triggering the trend test with respect to Conseco Senior, we elected to contribute \$202.0 million to the capital and surplus of Conseco Senior in 2007, including \$56.0 million which was accrued at December 31, 2007, and paid in February 2008. We were under no obligation to make such capital contributions to Conseco Senior, and we may determine not to make additional contributions in the future. No assurances can be given that we will make future contributions or otherwise make capital available to our insurance subsidiaries, including Conseco Senior.

The value of our deferred tax asset may be impaired to the extent our future profits are less than we have projected; and such impairment may have a material adverse affect on our results of operations and our financial condition.

As of December 31, 2007, we had deferred tax assets of \$1,909.4 million. During the fourth quarter of 2007, we increased the deferred tax valuation allowance by \$68.0 million primarily related to losses incurred in 2007. Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities, capital loss carryforwards and NOLs. We evaluate the realizability of our deferred income tax assets and assess the need for a valuation allowance on an ongoing basis. In evaluating our deferred income tax assets, we consider whether it is more likely than not that the deferred income tax assets will be realized. The ultimate realization of our deferred income tax assets depends upon generating sufficient future taxable income during the periods in which our temporary differences become deductible and before our capital loss carryforwards and NOLs expire. This assessment requires significant judgment. However, recovery is dependent on achieving such projections and failure to do so would result in an increase in the valuation allowance in a future period. Any future increase in the valuation allowance would result in additional income tax expense and reduce shareholders' equity, and such an increase could have a material adverse affect upon our earnings in the future.

Our results of operations may be negatively impacted if our initiatives to restructure our insurance operations are unsuccessful or if our planned conversions result in valuation differences.

Our Conseco Insurance Group segment has experienced decreases in premium revenues and new annualized premiums in recent years as well as expense levels that exceed product pricing expense assumptions. We have implemented several initiatives to improve operating results, including: (i) focusing sales efforts on higher margin products; (ii) reducing operating expenses by eliminating or reducing marketing costs of certain products; (iii) streamlining administrative procedures and reducing personnel; and (iv) increasing retention rates on our more profitable blocks of inforce business. Many of our initiatives address issues resulting from the substantial number of acquisitions of our predecessor. Between 1982 and 1997, our predecessor completed 19 transactions involving the acquisitions of 44 separate insurance companies. Our efforts involve improvements to our policy administration procedures and significant systems conversions, such as the elimination of duplicate processing systems for similar business. These initiatives may result in unforeseen expenses, complications or delays, and may be inadequate to address all issues. Some of these initiatives have only recently begun to be executed, and may not ultimately be successfully completed. While our future operating performance depends greatly on the success of these efforts, even if we successfully implement these measures, they alone may not sufficiently improve our results of operations.

Conversions to new systems can result in valuation differences between the prior system and the new system. We have recognized such differences in the past. During the fourth quarter of 2005, our conversion to a seriatim-based valuation system to determine reserves for the long-term care block of business in run-off resulted in decreases to insurance liabilities of approximately \$38 million. Our planned conversions could result in future valuation adjustments, and there can be no assurance that these adjustments will not have a material adverse effect on future earnings.

Our financial position may be negatively impacted if we are unable to achieve our goals for 2008.

We have identified a number of goals for 2008, including maintaining strong growth at Bankers Life and Colonial Penn, improving earnings stability and reducing volatility, improving the performance of our long-term care business in the Other Business in Run-off segment and reducing our enterprise exposure to long-term care business. The most consistent

components of our operations in recent years have been Bankers Life and Colonial Penn, and the continued growth and profitability of those businesses is critical to our overall results. By contrast, the long-term care business in our Other Business in Run-off segment has been very volatile and has produced substantial losses in the last two years. We are continuing to pursue a number of measures designed to improve the performance of that segment, including aggressively seeking actuarially justified rate increases and improving claims management. These measures may be inadequate to address the issues of that segment. In addition, our efforts to improve claims management by changing claim adjudication procedures have resulted in increased complaints from our policyholders, and, in some cases, have resulted in inquiries from state regulators. The relative size and volatility of our combined long-term care business presents a risk that our results of operations will be materially impacted by the changes in the performance of that business, and we are exploring ways to reduce our enterprise exposure to the long-term care business. The failure to achieve these and our other goals for 2008 could have a material adverse effect on our results of operations, financial condition and the price of our common stock.

A failure to improve the financial strength ratings of our insurance subsidiaries or a decline from the current ratings could cause us to experience decreased sales, increased agent attrition and increased policyholder lapses and redemptions.

An important competitive factor for our insurance subsidiaries is the ratings they receive from nationally recognized rating organizations. Agents, insurance brokers and marketing companies who market our products, and prospective policyholders view ratings as an important factor in evaluating an insurer's products. This is especially true for annuity, interest-sensitive life insurance and long-term care products. The current financial strength ratings of our primary insurance subsidiaries (other than Consecro Senior) from A.M. Best, S&P and Moody's are "B+ (Good)," "BB+" and "Baa3," respectively. The ratings of Consecro Senior from A.M. Best, S&P and Moody's are "C++ (Marginal)," "CCC-" and "Caa1," respectively. The "B+" rating and the "C++" rating from A.M. Best are the sixth and ninth highest, respectively, of sixteen possible ratings. The "BB+" rating and the "CCC-" rating from S&P are the eleventh and nineteenth highest, respectively, of twenty-one possible ratings. The "Baa3" rating and the "Caa1" rating from Moody's are the tenth and seventeenth highest of twenty-one possible ratings. Most of our competitors have higher financial strength ratings and, to be competitive over the long term, we believe it is critical to achieve improved ratings.

If we fail to achieve and maintain an "A" category rating from A.M. Best or if our ratings are downgraded, we may experience declining sales of certain of our insurance products, defections of our independent and career sales force, and increased policies being redeemed or allowed to lapse. These events would adversely affect our financial results, which could then lead to ratings downgrades.

Competition from companies that have greater market share, higher ratings, greater financial resources and stronger brand recognition, may impair our ability to retain existing customers and sales representatives, attract new customers and sales representatives and maintain or improve our financial results.

The supplemental health insurance, annuity and individual life insurance markets are highly competitive. Competitors include other life and accident and health insurers, commercial banks, thrifts, mutual funds and broker-dealers.

Our principal competitors vary by product line. Our main competitors for agent sold long-term care insurance products include Genworth Financial, John Hancock Financial Services and MetLife. Our main competitors for agent sold Medicare supplement insurance products include United HealthCare, Blue Cross and Blue Shield Plans, Mutual of Omaha and United American.

In some of our product lines, such as life insurance and fixed annuities, we have a relatively small market share. Even in some of the lines in which we are one of the top five writers, our market share is relatively small. For example, while our Bankers Life segment ranked fourth in annualized premiums of individual long-term care insurance in 2007 with a market share of approximately six percent, the top three writers of individual long-term care insurance had annualized premiums with a combined market share of approximately 60 percent during the period. In addition, while our Bankers Life segment was ranked fourth in direct premiums earned for individual Medicare supplement insurance in 2007 with a market share of 3.8 percent, the top writer of individual Medicare supplement insurance had direct premiums with a market share of 14.1 percent during the period.

Virtually all of our major competitors have higher financial strength ratings than we do. Many of our competitors are larger companies that have greater capital, technological and marketing resources and have access to capital at a lower cost. Recent industry consolidation, including business combinations among insurance and other financial services companies, has resulted in larger competitors with even greater financial resources. Furthermore, changes in federal law have narrowed the

historical separation between banks and insurance companies, enabling traditional banking institutions to enter the insurance and annuity markets and further increase competition. This increased competition may harm our ability to maintain or improve our profitability.

In addition, because the actual cost of products is unknown when they are sold, we are subject to competitors who may sell a product at a price that does not cover its actual cost. Accordingly, if we do not also lower our prices for similar products, we may lose market share to these competitors. If we lower our prices to maintain market share, our profitability will decline.

We must attract and retain sales representatives to sell our insurance and annuity products. Strong competition exists among insurance and financial services companies for sales representatives. We compete for sales representatives primarily on the basis of our financial position, financial strength ratings, support services, compensation, products and product features. Our competitiveness for such agents also depends upon the relationships we develop with these agents. Our Predecessor's bankruptcy continues to be an adverse factor in developing relationships with certain agents. If we are unable to attract and retain sufficient numbers of sales representatives to sell our products, our ability to compete and our revenues and profitability would suffer.

Volatility in the securities markets, and other economic factors, may adversely affect our business, particularly our sales of certain life insurance products and annuities.

Fluctuations in the securities markets and other economic factors may adversely affect sales and/or policy surrenders of our annuities and life insurance policies. For example, volatility in the equity markets may deter potential purchasers from investing in equity-indexed annuities and may cause current policyholders to surrender their policies for the cash value or to reduce their investments. In addition, significant or unusual volatility in the general level of interest rates could negatively impact sales and/or lapse rates on certain types of insurance products.

Our ability to meet our obligations may be constrained by our subsidiaries' ability to distribute cash to us.

Conseco, Inc. and CDOC, Inc. ("CDOC"), our wholly owned subsidiary and a guarantor under our \$875.0 million secured credit agreement (the "Second Amended Credit Facility"), are holding companies with no business operations of their own; they depend on their operating subsidiaries for cash to make principal and interest payments on debt and to pay administrative expenses and income taxes. Conseco and CDOC receive cash from insurance subsidiaries, consisting of dividends and distributions, principal and interest payments on surplus debentures and tax-sharing payments, as well as cash from our non-insurance subsidiaries consisting of dividends, distributions, loans and advances. A deterioration in the financial condition, earnings or cash flow of the significant subsidiaries of Conseco or CDOC for any reason could hinder the ability of such subsidiaries to pay cash dividends or other disbursements to Conseco and/or CDOC which, in turn, would limit the ability of Conseco and/or CDOC to meet debt service requirements and satisfy other financial obligations. In addition, we may elect to contribute additional capital to certain insurance subsidiaries to strengthen their surplus and this could affect the ability of our top tier insurance subsidiary to pay dividends. Accordingly, this would limit our ability to meet debt service requirements and satisfy other holding company financial obligations.

The obligations under our Second Amended Credit Facility are guaranteed by our current and future domestic subsidiaries, other than our insurance subsidiaries and certain immaterial subsidiaries. CDOC's guarantee under the Second Amended Credit Facility is secured by a lien on substantially all of the assets of the guarantors, including the stock of our top tier insurance company, Conseco Life Insurance Company of Texas. If we fail to make the required payments, do not meet the financial covenants or otherwise default on the terms of the Second Amended Credit Facility, the stock of Conseco Life Insurance Company of Texas, which at December 31, 2007 owned the stock of all of our other insurance subsidiaries, could be transferred to the lender under such facility. Any such transfer would have a material adverse effect on our business, financial condition and results of operations, and would have a significant adverse effect on the market value of our common stock.

Insurance regulators may prohibit the payment of dividends or other payments by our insurance subsidiaries to parent companies if they determine that such payment could be adverse to our policyholders or contract holders. Otherwise, the ability of our insurance subsidiaries to pay dividends is subject to state insurance department regulations. Insurance regulations generally permit dividends to be paid from statutory earned surplus of the insurance company without regulatory approval for any 12-month period in amounts equal to the greater of (or in a few states, the lesser of): (i) statutory net gain from operations or statutory net income for the prior year; or (ii) 10 percent of statutory capital and surplus as of the end of the preceding year. Any dividends in excess of these levels require the approval of the director or commissioner of the

applicable state insurance department. All of the dividends we plan to have our insurance subsidiaries pay in 2008 will require regulatory approval.

In accordance with orders from the Florida Office of Insurance Regulation, Conseco Senior may not distribute funds to any affiliate or shareholder unless such distributions have been approved by the Florida Office of Insurance Regulation and Washington National may not make similar distributions without prior notice to the Florida Office of Insurance Regulation. In addition, the RBC and other capital requirements described below can also limit, in certain circumstances, the ability of our insurance subsidiaries to pay dividends.

Certain states have established minimum capital requirements for insurance companies licensed to do business in their state. These additional requirements generally have not had a significant impact on the Company's insurance subsidiaries, but the capital requirements in Florida have caused Conseco Health to maintain a higher level of capital and surplus than it would otherwise maintain and have thus limited its ability to pay dividends.

In addition, although we are under no obligation to do so, we may elect to contribute additional capital to strengthen the surplus of certain insurance subsidiaries. Any election regarding the contribution of additional capital to our insurance subsidiaries could affect the ability of our top tier insurance subsidiary to pay dividends. The ability of our insurance subsidiaries to pay dividends is also impacted by various criteria established by rating agencies to maintain or receive higher ratings and by the capital levels that we target for our insurance subsidiaries. During 2007, we made capital contributions of \$48.0 million (including \$25.0 million which was accrued at December 31, 2007, and paid in February 2008) to Conseco Life in an effort to meet such criteria and our targeted capital level for this subsidiary.

The following table sets forth the aggregate amount of dividends and other distributions that our insurance subsidiaries paid to us in each of the last two fiscal years (dollars in millions):

	Years ended December 31,	
	2007	2006
	-----	-----
Dividends.....	\$ 50.0	\$ 72.5
Surplus debenture interest.....	69.9	68.2
Fees for services provided pursuant to service agreements.....	92.9	89.4
Tax sharing payments.....	91.5	(5.5)
	-----	-----
Total paid.....	\$304.3	\$224.6
	=====	=====

Federal and state legislation could adversely affect the financial performance of our insurance operations.

During recent years, the health insurance industry has experienced substantial changes, including those caused by healthcare legislation. Recent federal and state legislation and pending legislative proposals concerning healthcare reform contain features that could severely limit, or eliminate, our ability to vary pricing terms or apply medical underwriting standards to individuals, thereby potentially increasing our benefit ratios and adversely impacting our financial results. In particular, Medicare reform could affect our ability to price or sell our products or profitably maintain our blocks in force. For example, the Medicare Advantage program provides incentives for health plans to offer managed care plans to seniors. The growth of managed care plans under this program could decrease sales of the traditional Medicare supplement products we sell.

Proposals currently pending in Congress and some state legislatures may also affect our financial results. These proposals include the implementation of minimum consumer protection standards in all long-term care policies, including: guaranteed premium rates; protection against inflation; limitations on waiting periods for pre-existing conditions; setting standards for sales practices for long-term care insurance; and guaranteed consumer access to information about insurers, including information regarding lapse and replacement rates for policies and the percentage of claims denied. Enactment of any proposal that would limit the amount we can charge for our products, such as guaranteed premium rates, or that would increase the benefits we must pay, such as limitations on waiting periods, or that would otherwise increase the costs of our business, could adversely affect our financial results.

Our Second Amended Credit Facility contains various restrictive covenants and required financial ratios that limit our operating flexibility; our current credit ratings may adversely affect our ability to access capital and the cost of such capital, which could have a material adverse effect on our financial condition and results of operations.

As of December 31, 2007, we had \$865.5 million principal amount of debt outstanding under our Second Amended Credit Facility. The Second Amended Credit Facility imposes a number of covenants and financial ratios as defined in the Second Amended Credit Facility that we must meet or maintain, including:

- o a debt to total capitalization ratio;
- o an interest coverage ratio;
- o an aggregate RBC ratio; and
- o a combined statutory capital and surplus level.

At December 31, 2007, we were in compliance with all of the Second Amended Credit Facility's covenants and financial ratios. Although our forecasts indicate we will meet and/or maintain all of the Second Amended Credit Facility's covenants and financial ratios, our ability to do so may be affected by events beyond our control.

Our Second Amended Credit Facility also imposes restrictions that limit our flexibility to plan for and react to changes in the economy and industry, thereby increasing our vulnerability to adverse economic and industry conditions. These restrictions include limitations on our ability to:

- o incur additional indebtedness;
- o transfer or sell assets;
- o enter into mergers or other business combinations;
- o pay cash dividends or repurchase stock; and
- o make investments and capital expenditures.

S&P has assigned a "B+" rating on our senior secured debt with a negative outlook. In S&P's view, an obligation rated "B+" is more vulnerable to nonpayment than obligations rated "BB", but has the capacity to meet its financial commitment on the obligation. Adverse business, financial or economic conditions would likely impair the obligator's capacity or willingness to meet its financial commitment on the obligation. S&P has a total of twenty-two separate categories rating senior debt, ranging from "AAA (Extremely Strong)" to "D (Payment Default)." A "B+" rating is the fourteenth highest rating. Moody's has assigned a "Ba3" rating on our senior secured debt with a negative outlook. In Moody's view, an obligation rated "Ba3" is judged to have speculative elements and is subject to substantial credit risk. Moody's has a total of twenty-one separate categories in which to rate senior debt, ranging from "Aaa (Exceptional)" to "C (Lowest Rated)." A "Ba3" rating is the thirteenth highest rating. A negative outlook by S&P and Moody's is an opinion regarding the likely direction of a rating over the medium term. If we were to require additional capital, either to refinance our existing indebtedness or for any other reason, our current senior debt ratings, as well as economic conditions in the credit markets generally, could restrict our access to and the cost of such capital.

Tax law changes could adversely affect our insurance product sales and profitability.

We sell deferred annuities and some forms of life insurance that are attractive, in part, because policyholders generally are not subject to United States Federal income tax on increases in policy values until some form of distribution is made. Congress has enacted legislation to lower marginal tax rates, to reduce the federal estate tax gradually over a ten-year period (with total elimination of the federal estate tax in 2010) and to increase contributions that may be made to individual retirement accounts and 401(k) accounts. While these tax law changes will expire at the beginning of 2011 absent future congressional action, they could in the interim diminish the appeal of our annuity and life insurance products because the benefit of tax deferral is lessened when tax rates are lower and because fewer people may purchase these products when they can contribute more to individual retirement accounts and 401(k) accounts. Additionally, Congress has considered, from time to time, other possible changes to U.S. tax laws, including elimination of the tax deferral on the accretion of value within certain annuities and life insurance products. Such a change would make these products less attractive to prospective purchasers and therefore would likely cause our sales of these products to decline.

We face risk with respect to our reinsurance agreements.

We transfer exposure to certain risks to others through reinsurance arrangements. Under these arrangements, other insurers assume a portion of our losses and expenses associated with reported and unreported claims in exchange for a portion of policy premiums. The availability, amount and cost of reinsurance depend on general market conditions and may vary significantly. As of December 31, 2007, our reinsurance receivables totaled \$3.6 billion. Our ceded life insurance inforce totaled \$14.7 billion. Our nine largest reinsurers accounted for 89 percent of our ceded life insurance inforce. We face credit risk with respect to reinsurance. When we obtain reinsurance, we are still liable for those transferred risks if the reinsurer cannot meet its obligations. Therefore, the inability of our reinsurers to meet their financial obligations may require us to increase liabilities, thereby reducing our net income and shareholders' equity.

Our insurance subsidiaries may be required to pay assessments to fund other companies' policyholder losses or liabilities and this may negatively impact our financial results.

The solvency or guaranty laws of most states in which an insurance company does business may require that company to pay assessments up to certain prescribed limits to fund policyholder losses or liabilities of other insurance companies that become insolvent. Insolvencies of insurance companies increase the possibility that these assessments may be required. These assessments may be deferred or forgiven under most guaranty laws if they would threaten an insurer's financial strength and, in certain instances, may be offset against future premium taxes. We cannot estimate the likelihood and amount of future assessments. Although past assessments have not been material, if there were a number of large insolvencies, future assessments could be material and could have a material adverse effect on our operating results and financial position.

ITEM 1B. UNRESOLVED STAFF COMMENTS.

On July 3, 2007, we received written comments from the staff of the Division of Corporation Finance of the SEC (the "SEC staff") relating to our Form 10-K for the fiscal year ended December 31, 2006 and our Form 10-Q for the quarterly period ended March 31, 2007. The one remaining unresolved comment relates to the release of reserves totaling \$19.3 million related to the return of premium benefit on specified disease policies during the first quarter of 2007. As described in our Form 10-Q for the quarterly period ended March 31, 2007, we determined that the coding in our administrative system related to policies with the return of premium rider was inaccurate resulting in an overstatement of prior reserves. The SEC staff has requested an explanation as to why the reserve release was recorded in the first three months of 2007 rather than in the period in which the inaccurate coding occurred. We have provided the SEC staff with our evaluation of the out-of-period adjustment and the basis upon which we concluded we were not required to restate our previously filed financial statements based on the guidance of Staff Accounting Bulletin 99 "Materiality."

Subsequent to providing the evaluation of out-of-period adjustments to the SEC staff, we identified additional errors in our previously filed financial statements. On February 25, 2008, we announced that due to the significance of those errors, we would restate our financial statements for the years ended December 31, 2006 and 2005, along with affected selected Consolidated Financial Data for 2004 and 2003, and quarterly financial information for 2006 and the first three quarters of 2007. In conjunction with the restatement process, we also corrected previously identified errors, including the \$19.3 million reserve correction related to return of premium benefits on specified disease policies that is the subject of the SEC staff's unresolved comment. For further information on these and other restatement adjustments, refer to the notes to the consolidated financial statements entitled "Restatement of Previously Issued Financial Statements" and "Restated Quarterly Financial Data (Unaudited)".

With the completion of the restated financial statements included in this filing, the SEC staff will consider resolving the remaining open comment.

ITEM 2. PROPERTIES.

Our headquarters and the administrative operations of our Conseco Insurance Group segment as well as our Other Business in Run-off segment are located on a Company-owned 117-acre corporate campus in Carmel, Indiana, immediately north of Indianapolis. The six buildings on the campus contain approximately 626,000 square feet of space and house Conseco's executive offices and certain administrative operations of its subsidiaries. In May 2007, we entered into a listing agreement for the sale/lease of one of these buildings (approximately 100,000 square feet). Management believes that our remaining office space is adequate for our needs.

Our Bankers Life segment is primarily administered from a facility in downtown Chicago, Illinois. Bankers Life has

approximately 222,000 square feet leased under an agreement which expires in 2018. In addition, Bankers Life leases approximately 114,000 square feet that it expects to vacate in 2008. This space is expected to be subleased through November 2013, the early termination date of the lease. We also lease 227 sales offices in various states totaling approximately 650,000 square feet. These leases are short-term in length, with remaining lease terms expiring between 2008 and 2013.

Our Colonial Penn segment is administered from a Company-owned office building in Philadelphia, Pennsylvania with approximately 127,000 square feet. We occupy approximately 60 percent of this space, with the remainder leased to tenants.

ITEM 3. LEGAL PROCEEDINGS.

Information required for Item 3 is incorporated by reference to the discussion under the heading "Legal Proceedings" in note 9 "Commitments and Contingencies" to our consolidated financial statements included in Item 8 of this Form 10-K.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

None.

Executive Officers of the Registrant

Officer Name and Age (a) -----	Since -----	Positions with Conseco, Principal Occupation and Business Experience (b) -----
C. James Prieur, 56.....	2006	Since September 2006, chief executive officer. From April 1999 until September 2006, president and chief operating officer of Sun Life Financial, Inc. and chief operating officer of its principal subsidiary, Sun Life Assurance Company.
Edward J. Bonach, 54.....	2007	Since May 2007, executive vice president and chief financial officer. From 2002 until 2007, Mr. Bonach served as chief financial officer of National Life Group.
Mark E. Alberts, 42.....	2004	Since January 2007, executive vice president and chief actuary. Mr. Alberts has served in various actuarial capacities with Conseco since 2004 and also from 1991 to 2001. From 2001 until April 2004, senior vice president, chief actuary, Standard Life Insurance Company of Indiana.
Russell M. Bostick, 51.....	2005	Since 2005, executive vice president and chief information officer. From 1998 until 2005, chief technology officer of Chase Insurance and its predecessors.
Dan R. Bardin, 57.....	2007	Since December 2007, president of Conseco Insurance Group. From 2006 until 2007, Mr. Bardin was an insurance industry consultant. From 1999 until 2006, Mr. Bardin held several executive positions with Prudential Corporation, Asia, including managing director and chief executive of insurance.
Eric R. Johnson, 47.....	1997	Since September 2003, president and chief executive officer of 40 86 Advisors, Conseco's wholly-owned registered investment advisor. Mr. Johnson has held various investment management positions since joining Conseco in 1997.
John R. Kline, 50.....	1990	Since July 2002, senior vice president and chief accounting officer. Mr. Kline has served in various accounting and finance capacities with Conseco since 1990.
Susan L. Menzel, 42.....	2005	Since May 2005, executive vice president, human resources. From 2004 to May 2005, senior vice president, human resources of APAC Customer Services. From 1997 to 2004, vice president, human resources of Sears Roebuck.
Christopher J. Nickele, 51.....	2005	Since October 2005, executive vice president, product management. From 2002 until September 2005, vice president - product development of Lincoln National Corporation.
Scott R. Perry, 45.....	2001	Since 2006, president of Bankers Life. Employed in various capacities for Bankers Life since 2001.

Steven M. Stecher, 47..... 2004 Since January 2007, executive vice president, operations. From August 2004 until January 2007, executive vice president of Conseco Insurance Group. From 2003 until May 2004 chief information officer of Orix Financial Services. From 1997 until 2002, Mr. Stecher held several executive positions with ING Americas, including chief information officer, vice president of strategic marketing and head of shared services.

Mr. Kline served as an officer of our Predecessor company, which filed a bankruptcy petition on December 17, 2002.

-
- (a) The executive officers serve as such at the discretion of the Board of Directors and are elected annually.
 - (b) Business experience is given for at least the last five years.

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

MARKET INFORMATION

The following table sets forth the ranges of high and low sales prices per share for our common stock on the New York Stock Exchange for the quarterly periods beginning January 1, 2006. There have been no dividends paid or declared on our common stock during this period.

Period -----	Market price -----	
	High ----	Low ---
2006:		
First Quarter.....	\$25.95	\$23.16
Second Quarter.....	25.86	22.00
Third Quarter.....	23.46	19.91
Fourth Quarter.....	21.17	19.53
2007:		
First Quarter.....	\$20.46	\$16.56
Second Quarter.....	21.25	17.25
Third Quarter.....	21.02	13.25
Fourth Quarter.....	16.26	12.05

As of February 22, 2008, there were approximately 77,000 holders of the outstanding shares of common stock, including individual participants in securities position listings.

PERFORMANCE GRAPH

The Performance Graph below compares Consecos cumulative total shareholder return on its common stock for the period from September 12, 2003 (the first day of trading of the common stock on the New York Stock Exchange after Consecos emergence from bankruptcy) through December 31, 2007 with the cumulative total return of the Standard & Poor's 500 Composite Stock Price Index (the "S&P 500 Index") and the Dow Jones Life Insurance Index. The comparison for each of the periods assumes that \$100 was invested on September 12, 2003 in each of Consecos common stock, the stocks included in the S&P 500 Index and the stocks included in the Dow Jones Life Insurance Index and that all dividends were reinvested. The stock performance shown in this graph represents past performance and should not be considered an indication of future performance of Consecos common stock.

COMPARISON OF CUMULATIVE TOTAL RETURN AMONG CONSECO, S&P 500 INDEX AND DOW JONES LIFE INSURANCE INDEX

[GRAPH OMITTED]

Cumulative Total Returns -----	9/12/03 -----	12/31/03 -----	12/31/04 -----	12/31/05 -----	12/31/06 -----	12/31/07 -----
DJ Life Insurance Index	\$ 100	\$ 113	\$ 137	\$ 168	\$ 189	\$ 201
S&P 500 Index	\$ 100	\$ 110	\$ 122	\$ 128	\$ 148	\$ 156
Consecos, Inc.	\$ 100	\$ 107	\$ 98	\$ 114	\$ 98	\$ 62

DIVIDENDS

The Company does not anticipate declaring or paying cash dividends on its common stock in the foreseeable future, and is currently limited in doing so pursuant to our credit agreement. Please refer to "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations - Liquidity of the Holding Companies" for a further discussion of these restrictions.

ISSUER PURCHASES OF EQUITY SECURITIES

Period -----	Total number of shares (or units)(a) -----	Average price paid per share (or unit) -----	Total number of shares (or units) purchased as part of publicly announced plans or programs -----	Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs(b) ----- (dollars in millions)
October 1 through October 31.....	4,784	\$15.70	-	\$285.7
November 1 through November 30.....	1,330,000	13.48	1,330,000	267.8
December 1 through December 31.....	403,089 -----	12.66	394,300 -----	262.8
Total.....	1,737,873 =====	13.29	1,724,300 =====	262.8

- (a) The Company purchased 4,784 and 8,789 shares of its common stock in October and December 2007, respectively, in connection with employee benefit compensation plans. Such purchases are not included against the maximum number of shares that may be purchased as part of our publicly announced share repurchase program.
- (b) On December 21, 2006, the Company announced a common share repurchase program of up to \$150 million. On May 8, 2007, the Company announced that the maximum amount that was authorized under the common share repurchase program had been increased to \$350 million.

EQUITY COMPENSATION PLAN INFORMATION

The following table summarizes information, as of December 31, 2007, relating to our common stock that may be issued under the Consec, Inc. 2003 Amended and Restated Long-Term Incentive Plan.

	Number of securities to be issued upon exercise of outstanding options, warrants or rights -----	Weighted-average exercise price of outstanding options, warrants or rights -----	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column) -----
Equity compensation plans approved by security holders.....	4,827,925	\$19.82	2,794,017
Equity compensation plans not approved by security holders.....	-	-	-
	-----	-----	-----
Total.....	4,827,925 =====	\$19.82 =====	2,794,017 =====

ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA.

Conseco has restated its consolidated financial statements for each of 2007, 2006, 2005, 2004 and for the four months ended December 31, 2003. The restated consolidated financial statements reflect: (i) the correction of errors, the majority of which were identified in 2007 during procedures performed in an effort to remediate the material weakness in internal controls disclosed in our 2006 Form 10-K and subsequent quarterly filings with the SEC; (ii) restatement of accounting for premium rate increases; and (iii) the correction of previously identified immaterial errors. Refer to the note to the restated consolidated financial statements entitled "Restatement of Previously Issued Financial Statements" for further information related to the restatement. The Selected Consolidated Financial Data should be used in conjunction with Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations and the consolidated financial statements and accompanying notes included elsewhere herein.

	Successor				Predecessor	
	Years ended December 31,				Four months ended December 31,	Eight months ended August 31,
	2007	2006	2005	2004	2003	2003
	(Restated)	(Restated)	(Restated)	(Restated)	(Restated)	
(Amounts in millions, except per share data)						
STATEMENT OF OPERATIONS DATA						
Insurance policy income.....	\$3,167.3	\$2,989.0	\$2,930.1	\$2,949.3	\$1,005.8	\$2,204.3
Net investment income.....	1,536.6	1,506.4	1,374.6	1,322.7	474.6	969.0
Net realized investment gains (losses)	(155.4)	(47.2)	(2.9)	40.6	11.8	(5.4)
Total revenues.....	4,572.3	4,467.4	4,326.5	4,334.1	1,505.5	3,203.4
Interest expense (contractual interest: \$268.5 for the eight months ended August 31, 2003).....	117.3	73.5	58.3	79.5	36.8	202.5
Total benefits and expenses.....	4,745.3	4,300.2	3,842.2	3,888.0	1,356.0	1,031.2
Income (loss) before income taxes, minority interest, discontinued operations and cumulative effect of accounting change.....	(173.0)	167.2	484.3	446.1	149.5	2,172.2
Net income (loss).....	(179.9)	106.0	312.7	289.7	96.3	2,201.7
Preferred stock dividends	14.1	38.0	38.0	65.5	27.8	-
Net income (loss) applicable to common stock....	(194.0)	68.0	274.7	224.2	68.5	2,201.7
PER SHARE DATA						
Net income, basic.....	\$ (1.12)	\$.45	\$ 1.82	\$ 1.70	\$.68	
Net income, diluted.....	(1.12)	.45	1.69	1.59	.67	
Book value per common share outstanding.....	22.94	26.50	25.27	21.34	19.28	
Weighted average shares outstanding for basic earnings.....	173.4	151.7	151.2	132.3	100.1	
Weighted average shares outstanding for diluted earnings.....	173.4	152.5	185.0	155.9	143.5	
Shares outstanding at period-end.....	184.7	152.2	151.5	151.1	100.1	
BALANCE SHEET DATA - AT PERIOD END						
Total investments.....	\$23,801.9	\$25,736.4	\$25,041.2	\$24,306.3	\$22,792.6	\$22,018.3
Goodwill	-	-	-	-	952.2	99.4
Total assets.....	33,514.8	32,724.0	31,557.9	30,794.6	30,002.3	28,318.1
Corporate notes payable.....	1,193.7	1,000.8	851.5	768.0	1,300.0	-
Liabilities subject to compromise.....	-	-	-	-	-	6,951.4
Total liabilities.....	29,278.9	28,023.9	27,060.6	26,902.7	27,184.7	30,519.5
Shareholders' equity (deficit).....	4,235.9	4,700.1	4,497.3	3,891.9	2,817.6	(2,201.4)
STATUTORY DATA(a) - AT PERIOD END						
Statutory capital and surplus.....	\$1,336.2	\$1,554.5	\$1,603.8	\$1,510.0	\$1,514.1	
Asset valuation reserve ("AVR").....	161.3	179.1	142.7	117.0	40.9	
Total statutory capital and surplus and AVR.....	1,497.5	1,733.6	1,746.5	1,627.0	1,555.0	

(a) We have derived the statutory data from statements filed by our insurance subsidiaries with regulatory authorities which are prepared in accordance with statutory accounting principles, which vary in certain respects from GAAP. The statutory data presented above reflects our current financial statement filings with various regulatory authorities. It is our intention to evaluate each of the items that have been restated in our consolidated financial statements prepared in accordance with GAAP to determine whether restatement to our previously filed statutory financial statements is needed. We cannot reasonably estimate the effects of any such restatements should they occur.

The effects of the restatement adjustments on selected consolidated financial data are presented below.

	Year ended December 31, 2006				
	As previously reported	Adjustments			As restated
		Remediation procedures	Accounting for premium rate increases	Previously identified errors	
(Dollars in millions, except per share data)					
STATEMENT OF OPERATIONS DATA					
Insurance policy income.....	\$2,989.0	\$ -	\$ -	\$ -	\$2,989.0
Net investment income.....	1,506.4	-	-	-	1,506.4
Net realized investment gains (losses) ...	(47.2)	-	-	-	(47.2)
Total revenues	4,467.4	-	-	-	4,467.4
Interest expense	73.5	-	-	-	73.5
Total benefits and expenses.....	4,315.1	(4.0)	(14.1)	3.2	4,300.2
Income (loss) before income taxes, minority interest, discontinued operations and cumulative effect of accounting change	152.3	4.0	14.1	(3.2)	167.2
Net income (loss)	96.5	2.6	9.0	(2.1)	106.0
Preferred stock dividends	38.0	-	-	-	38.0
Net income (loss) applicable to common stock	58.5	2.6	9.0	(2.1)	68.0
PER SHARE DATA					
Net income, basic.....	\$.39				\$.45
Net income, diluted.....	.38				.45
Book value per common share outstanding	26.58				26.49
Weighted average shares outstanding for basic earnings.....	151.7				151.7
Weighted average shares outstanding for diluted earnings.....	152.5				152.5
Shares outstanding at period-end	152.2				152.2
BALANCE SHEET DATA - AT PERIOD END					
Total investments.....	\$25,736.4	\$ -	\$ -	\$ -	\$25,736.4
Total assets.....	32,717.3	29.7	(21.6)	(1.4)	32,724.0
Corporate notes payable.....	1,000.8	-	-	-	1,000.8
Total liabilities.....	28,004.2	50.3	(30.6)	-	28,023.9
Shareholders' equity (deficit)	4,713.1	(20.6)	9.0	(1.4)	4,700.1

	Adjustments			As restated
	As previously reported	Remediation procedures	Previously identified errors	
(Dollars in millions, except per share data)				
STATEMENT OF OPERATIONS DATA				
Insurance policy income.....	\$2,930.1	\$ -	\$ -	\$2,930.1
Net investment income.....	1,374.6	-	-	1,374.6
Net realized investment gains (losses) ...	(2.9)	-	-	(2.9)
Total revenues	4,326.5	-	-	4,326.5
Interest expense.....	58.3	-	-	58.3
Total benefits and expenses.....	3,823.1	22.2	(3.1)	3,842.2
Income (loss) before income taxes, minority interest, discontinued operations and cumulative effect of accounting change	503.4	(22.2)	3.1	484.3
Net income (loss)	324.9	(14.2)	2.0	312.7
Preferred stock dividends	38.0	-	-	38.0
Net income (loss) applicable to common stock	286.9	(14.2)	2.0	274.7
PER SHARE DATA				
Net income, basic.....	\$1.90			\$1.82
Net income, diluted.....	1.76			1.69
Book value per common share outstanding	25.42			25.27
Weighted average shares outstanding for basic earnings.....	151.2			151.2
Weighted average shares outstanding for diluted earnings.....	185.0			185.0
Shares outstanding at period-end	151.5			151.5
BALANCE SHEET DATA - AT PERIOD END				
Total investments.....	\$25,041.2	\$ -	\$ -	\$25,041.2
Total assets.....	31,525.3	32.6	-	31,557.9
Corporate notes payable.....	851.5	-	-	851.5
Total liabilities.....	27,005.5	55.8	(.7)	27,060.6
Shareholders' equity (deficit)	4,519.8	(23.2)	.7	4,497.3

Year ended December 31, 2004

	Adjustments			As restated
	As previously reported	Remediation procedures	Previously identified errors	
(Dollars in millions, except per share data)				
STATEMENT OF OPERATIONS DATA				
Insurance policy income.....	\$2,949.3	\$ -	\$ -	\$2,949.3
Net investment income.....	1,318.6	-	4.1	1,322.7
Net realized investment gains (losses) ...	40.6	-	-	40.6
Total revenues	4,330.0	-	4.1	4,334.1
Interest expense.....	79.5	-	-	79.5
Total benefits and expenses.....	3,875.9	6.5	5.6	3,888.0
Income (loss) before income taxes, minority interest, discontinued operations and cumulative effect of accounting change	454.1	(6.5)	(1.5)	446.1
Net income (loss)	294.8	(4.2)	(.9)	289.7
Preferred stock dividends	65.5	-	-	65.5
Net income (loss) applicable to common stock	229.3	(4.2)	(.9)	224.2
PER SHARE DATA				
Net income, basic.....	\$1.73			\$1.70
Net income, diluted.....	1.63			1.59
Book value per common share outstanding	21.41			21.34
Weighted average shares outstanding for basic earnings.....	132.3			132.3
Weighted average shares outstanding for diluted earnings.....	155.9			155.9
Shares outstanding at period-end	151.1			151.1
BALANCE SHEET DATA - AT PERIOD END				
Total investments.....	\$24,306.3	\$ -	\$ -	\$24,306.3
Total assets.....	30,732.6	26.0	36.0	30,794.6
Corporate notes payable.....	768.0	-	-	768.0
Total liabilities.....	26,830.4	35.0	37.3	26,902.7
Shareholders' equity (deficit)	3,902.2	(9.0)	(1.3)	3,891.9

December 31, 2003

	Adjustments			As restated
	As previously reported	Remediation procedures	Previously identified errors	
(Dollars in millions)				
BALANCE SHEET DATA - AT PERIOD END				
Total investments.....	\$22,796.7	\$ -	\$ (4.1)	\$22,792.6
Goodwill	952.2	4.8	.4	957.4
Total assets.....	29,990.4	30.0	(18.1)	30,002.3
Corporate notes payable.....	1,300.0	-	-	1,300.0
Total liabilities.....	27,172.8	30.0	(18.1)	27,184.7
Shareholders' equity (deficit)	2,817.6	-	-	2,817.6

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF CONSOLIDATED FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

In this section, we review the consolidated financial condition of Conseco at December 31, 2007, and the consolidated results of operations for the years ended December 31, 2007, 2006 and 2005 and, where appropriate, factors that may affect future financial performance. Please read this discussion in conjunction with the consolidated financial statements and notes included in this Form 10-K.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Our statements, trend analyses and other information contained in this report and elsewhere (such as in filings by Conseco with the SEC, press releases, presentations by Conseco or its management or oral statements) relative to markets for Conseco's products and trends in Conseco's operations or financial results, as well as other statements, contain forward-looking statements within the meaning of the federal securities laws and the Private Securities Litigation Reform Act of 1995. Forward-looking statements typically are identified by the use of terms such as "anticipate," "believe," "plan," "estimate," "expect," "project," "intend," "may," "will," "would," "contemplate," "possible," "attempt," "seek," "should," "could," "goal," "target," "on track," "comfortable with," "optimistic" and similar words, although some forward-looking statements are expressed differently. You should consider statements that contain these words carefully because they describe our expectations, plans, strategies and goals and our beliefs concerning future business conditions, our results of operations, financial position, and our business outlook or they state other "forward-looking" information based on currently available information. The "Risk Factors" in Item 1A provide examples of risks, uncertainties and events that could cause our actual results to differ materially from the expectations expressed in our forward-looking statements. Assumptions and other important factors that could cause our actual results to differ materially from those anticipated in our forward-looking statements include, among other things:

- o our ability to obtain adequate and timely rate increases on our supplemental health products, including our long-term care business;
- o mortality, morbidity, usage of health care services, persistency, the adequacy of our previous reserve estimates and other factors which may affect the profitability of our insurance products;
- o changes in our assumptions related to the cost of policies produced or the value of policies inforce at the Effective Date;
- o the recoverability of our deferred tax asset;
- o changes in accounting principles and the interpretation thereof;
- o our ability to achieve anticipated expense reductions and levels of operational efficiencies including improvements in claims adjudication and continued automation and rationalization of operating systems;
- o performance of our investments;
- o our ability to identify products and markets in which we can compete effectively against competitors with greater market share, higher ratings, greater financial resources and stronger brand recognition;
- o the ultimate outcome of lawsuits filed against us and other legal and regulatory proceedings to which we are subject;
- o our ability to remediate the material weakness in internal controls over the actuarial reporting process that we identified at year-end 2006 and to maintain effective controls over financial reporting;
- o our ability to continue to recruit and retain productive agents and distribution partners and customer response to new products, distribution channels and marketing initiatives;
- o our ability to achieve eventual upgrades of the financial strength ratings of Conseco and our insurance company subsidiaries as well as the potential impact of rating downgrades on our business;

o the risk factors or uncertainties listed from time to time in our filings with the SEC;

o regulatory changes or actions, including those relating to regulation of the financial affairs of our insurance companies, such as the payment of dividends to us, regulation of financial services affecting (among other things) bank sales and underwriting of insurance products, regulation of the sale, underwriting and pricing of products, and health care regulation affecting health insurance products;

o general economic conditions and other factors, including prevailing interest rate levels, stock and credit market performance and health care inflation, which may affect (among other things) our ability to sell products and access capital on acceptable terms, the returns on and the market value of our investments, and the lapse rate and profitability of policies; and

o changes in the Federal income tax laws and regulations which may affect or eliminate the relative tax advantages of some of our products.

Other factors and assumptions not identified above are also relevant to the forward-looking statements, and if they prove incorrect, could also cause actual results to differ materially from those projected.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by the foregoing cautionary statement. Our forward-looking statements speak only as of the date made. We assume no obligation to update or to publicly announce the results of any revisions to any of the forward-looking statements to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the forward-looking statements.

OVERVIEW

We are a holding company for a group of insurance companies operating throughout the United States that develop, market and administer supplemental health insurance, annuity, individual life insurance and other insurance products. We focus on serving the senior and middle-income markets, which we believe are attractive, underserved, high growth markets. We sell our products through three distribution channels: career agents, professional independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing.

We manage our business through the following: three primary operating segments, Bankers Life, Consecos Insurance Group and Colonial Penn, which are defined on the basis of product distribution; a fourth segment comprised of other business in run-off; and corporate operations. Our segments are described below:

o Bankers Life, which consists of the business of Bankers Life and Casualty, markets and distributes Medicare supplement insurance, life insurance, long-term care insurance, Medicare Part D prescription drug program, Medicare Advantage products and certain annuity products to the senior market through approximately 5,100 career agents and sales managers. Bankers Life and Casualty markets its products under its own brand name and Medicare Part D and Medicare Advantage products primarily through marketing agreements with Coventry.

o Consecos Insurance Group, which markets and distributes specified disease insurance, Medicare supplement insurance, and certain life and annuity products to the senior and middle-income markets through approximately 350 IMOs that represent over 5,200 producing independent agents. This segment markets its products under the "Consecos" and "Washington National" brand names. Consecos Insurance Group includes the business of Consecos Health, Consecos Life, Consecos Insurance Company and Washington National, other than any run-off long-term care and major medical insurance issued by those companies. Such run-off business is included in the Other Business in Run-off segment.

o Colonial Penn, which consists of the business of Colonial Penn, markets graded benefit and simplified issue life insurance directly to customers through television advertising, direct mail, the internet and telemarketing. Colonial Penn markets its products under its own brand name.

o Other Business in Run-off, which includes blocks of business that we no longer market or underwrite and are managed separately from our other businesses. This segment consists of: (i) long-term care insurance sold in prior years through independent agents; and (ii) major medical insurance. The Other Business in Run-off segment is primarily comprised of long-term care business issued by Consecos Senior and Washington National, subsidiaries

that were acquired in 1996 and 1997, respectively. Long-term care collected premiums represented more than 99 percent of this segment's total collected premiums in 2007. Of the long-term care collected premiums in this segment for the year ended December 31, 2007, approximately 88 percent related to Conseco Senior and approximately 8 percent related to Washington National and 4 percent related to other Conseco insurance subsidiaries. In 2007, long-term care premiums represented approximately 84 percent of the premiums collected by Conseco Senior and approximately 6 percent of the premiums collected by Washington National.

o Corporate operations, which consists of holding company activities and certain noninsurance company businesses that are not part of our other segments.

For the year ended December 31, 2007, net loss after dividends on our preferred stock totaled \$194.0 million, or \$1.12 per diluted share.

Our major goals for 2008 include:

o Maintaining strong growth at Bankers Life and Colonial Penn.

o Continuing to improve the focus and profitability mix of sales at Conseco Insurance Group.

o Improving earnings stability and reducing volatility.

o Improving the performance of the long-term care business in our Other Business in Run-off segment by continuing to aggressively seek actuarially justified rate increases and by improving claims management.

o Completing the remediation project relating to our material weakness in internal controls.

o Reducing our enterprise exposure to long-term care business.

o Improving or disposing of underperforming blocks of business.

o Re-deploying capital to generate improved returns.

o Positioning the Company to achieve an 11 percent operating return on equity in 2009.

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management has made estimates in the past that we believed to be appropriate but were subsequently revised to reflect actual experience. If our future experience differs materially from these estimates and assumptions, our results of operations and financial condition could be affected.

We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. We continually evaluate the information used to make these estimates as our business and the economic environment change. The use of estimates is pervasive throughout our financial statements. The accounting policies and estimates we consider most critical are summarized below. Additional information on our accounting policies is included in the note to our consolidated financial statements entitled "Summary of Significant Accounting Policies".

Investments

At December 31, 2007, the carrying value of our investment portfolio was \$23.8 billion.

We defer any fees received or costs incurred when we originate investments. We amortize fees, costs, discounts and premiums as yield adjustments over the contractual lives of the investments. We consider anticipated prepayments on structured securities when we estimate yields on such securities. When actual prepayments differ from our estimates, the adjustment to yield is recognized as investment income (loss).

We regularly evaluate our investments for possible impairment based on current economic conditions, credit loss experience and other investee-specific circumstances and developments. When we conclude that a decline in a security's net realizable value is other than temporary, the decline is recognized as a realized loss and the cost basis of the security is reduced to its estimated fair value. During the year ended December 31, 2007, writedowns of investments included: (i) \$33.0 million of writedowns of investments for other than temporary declines in fair value; and (ii) \$73.7 million of writedowns of investments (which were subsequently transferred pursuant to a coinsurance agreement as further discussed in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies") as a result of our intent not to hold such investments for a period of time sufficient to allow for any anticipated recovery in value.

Our evaluation of investments for impairment requires significant judgments, including: (i) the identification of potentially impaired securities; (ii) the determination of their estimated fair value; and (iii) the assessment of whether any decline in estimated fair value is other than temporary.

Our assessment of whether unrealized losses are "other than temporary" requires significant judgment. Factors considered include: (i) the extent to which market value is less than the cost basis; (ii) the length of time that the market value has been less than cost; (iii) whether the unrealized loss is event-driven, credit-driven or a result of changes in market risk premium or interest rates; (iv) the near-term prospects for improvement in the issuer and/or its industry; (v) our view of the investment's rating and whether the investment is investment-grade and/or has been downgraded since its purchase; (vi) whether the issuer is current on all payments in accordance with the contractual terms of the investment and is expected to meet all of its obligations under the terms of the investment; (vii) our ability and intent to hold the investment for a period of time sufficient to allow for any anticipated recovery; and (viii) the underlying current and prospective asset and enterprise values of the issuer and the extent to which our investment may be affected by changes in such values. At December 31, 2007, our net accumulated other comprehensive income (loss) included gross unrealized losses on fixed maturity securities of \$630.9 million, which we consider to be temporary declines in estimated fair value.

When the cost basis of a security is written down to fair value due to an other than temporary decline, we review the circumstances of that particular investment in relation to other investments in our portfolio. If such circumstances exist with respect to other investments, those investments may also be written down to fair value. Future events may occur, or additional or updated information may become available, which may necessitate future realized losses of securities in our portfolio. If new information becomes available or the financial condition of the investee changes, our judgments may change resulting in the recognition of a realized investment loss at that time. Significant realized losses on our investments could have a material adverse effect on our earnings in future periods.

Estimated fair values for our investments are determined by using nationally recognized pricing services, broker-dealer market makers and internally developed methods. Our internally developed methods require us to make judgments about the security's credit quality, liquidity and market spread.

Below-investment grade securities have different characteristics than investment grade corporate debt securities. Based on historical performance, risk of default by the borrower is significantly greater for below-investment grade securities and in many cases, severity of loss is relatively greater as such securities are generally unsecured and often subordinated to other indebtedness of the issuer. Also, issuers of below-investment grade securities usually have higher levels of debt and may be more financially leveraged hence, all other things being equal, more sensitive to adverse economic conditions, such as recession or increasing interest rates. The Company attempts to reduce the overall risk related to its investment in below-investment grade securities, as in all investments, through careful credit analysis, strict investment policy guidelines, and diversification by issuer and/or guarantor and by industry.

During 2007, we sold \$7.0 billion of fixed maturity investments which resulted in net realized investment losses of \$39.1 million. Our fixed maturity investments are generally purchased in the context of a long-term strategy to fund

insurance liabilities, so we do not generally seek to purchase and sell such securities to generate short-term realized gains. In certain circumstances, including those in which securities are selling at prices which exceed our view of their current fair value, and it is possible to reinvest the proceeds to better meet our long-term asset-liability objectives, we may sell certain securities. During 2007, we sold \$3.3 billion of fixed maturity investments which resulted in gross investment losses (before income taxes) of \$134.0 million. We sell securities at a loss for a number of reasons including, but not limited to: (i) changes in the investment environment; (ii) expectation that the market value could deteriorate further; (iii) desire to reduce our exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected liability cash flows.

We generally seek to balance the duration and cash flows of our invested assets with the estimated duration and cash flows of benefit payments arising from contract liabilities. These efforts may cause us to sell investments before their maturity date and could result in the realization of net realized investment gains (losses). When the estimated durations of assets and liabilities are similar, exposure to interest rate risk is minimized because a change in the value of assets should be largely offset by a change in the value of liabilities. In certain circumstances, a mismatch of the durations or related cash flows of invested assets and insurance liabilities could have a significant impact on our results of operations and financial position. See "-- Quantitative and Qualitative Disclosures About Market Risks" for additional discussion of the duration of our invested assets and insurance liabilities.

For more information on our investment portfolio and our critical accounting policies related to investments, see the note to our consolidated financial statements entitled "Investments".

Value of Policies Inforce at the Effective Date and Cost of Policies Produced

In conjunction with the implementation of fresh start accounting, we eliminated the historical balances of Old Conseco's cost of policies purchased and cost of policies produced as of the Effective Date and replaced them with the value of policies inforce at the Effective Date.

The value assigned to the right to receive future cash flows from contracts existing at the Effective Date is referred to as the value of policies inforce at the Effective Date. We also defer renewal commissions paid in excess of ultimate commission levels related to the existing policies in this account. The balance of this account is amortized, evaluated for recovery, and adjusted for the impact of unrealized gains (losses) in the same manner as the cost of policies produced described below. We expect to amortize approximately 13 percent of the December 31, 2007 balance of value of policies inforce in 2008, 12 percent in 2009, 11 percent in 2010, 7 percent in 2011 and 6 percent in 2012.

The cost of policies produced are those costs that vary with, and are primarily related to, producing new insurance business in the period after September 10, 2003. For universal life or investment products, we amortize these costs using the interest rate credited to the underlying policy in relation to the estimated gross profits. For other products, we amortize these costs using the projected investment earnings rate in relation to future anticipated premium revenue. The value of policies inforce and the cost of policies produced are collectively referred to as "insurance acquisition costs."

Insurance acquisition costs are amortized to expense over the lives of the underlying policies in relation to future anticipated premiums or gross profits. The insurance acquisition costs for policies other than universal life and investment-type products are amortized with interest (using the projected investment earnings rate) over the estimated premium-paying period of the policies, in a manner which recognizes amortization expense in proportion to each year's premium income. Limited-payment policies are amortized over the contract period. The insurance acquisition costs for universal life and investment-type products are amortized with interest (using the interest rate credited to the underlying policy) in proportion to estimated gross profits. The interest, mortality, morbidity and persistency assumptions used to amortize insurance acquisition costs are consistent with those assumptions used to estimate liabilities for insurance products. For universal life and investment-type products, these assumptions are reviewed on a regular basis. When actual profits or our current best estimates of future profits are different from previous estimates, we adjust cumulative amortization of insurance acquisition costs to maintain amortization expense as a constant percentage of gross profits over the entire life of the policies.

During 2007, we were required to accelerate the amortization of insurance acquisition costs related to our universal life products because the prior balance was not recoverable by the value of future estimated gross profits on this block. This additional amortization was necessary so that our insurance acquisition costs would not exceed the value of future estimated gross profits and is expected to continue to be recognized in subsequent periods. Because our insurance acquisition costs are now equal to the value of future estimated gross profits, this block is expected to generate break-even earnings in the future. We continue to hold insurance acquisition costs of approximately \$140 million related to these products, which we determined are recoverable by the value of estimated gross profits. In addition, results for this block are expected to exhibit

increased volatility in the future, because the entire difference between our assumptions and actual experience is expected to be reflected in earnings in the period such differences occur.

During the fourth quarter of 2007, we recognized additional amortization expense of \$14.8 million to reflect changes in our estimates of future mortality rates on our universal life business, net of planned increases to associated policyholder charges.

During the fourth quarter of 2006, we recognized additional amortization expense of \$7.8 million to reflect a change in an actuarial assumption related to a block of interest-sensitive life insurance policies based on a change in management's intent on the administration of such policies. The policies affected by the adjustments described above were issued through a subsidiary prior to its acquisition by Conseco in 1996.

During the first quarter of 2006, we made certain adjustments to our assumptions of expected future profits for the annuity and universal life blocks of business in this segment related to investment returns, lapse rates, the cost of options underlying our equity-indexed products and other refinements. We recognized additional amortization expense of \$12.4 million in 2006 due to these changes. This increase to amortization expense was offset by a reduction to insurance policy benefit expense of \$11.5 million, to reflect the effect of the changes in these assumptions on the calculation of certain insurance liabilities, such as the liability to purchase future options underlying our equity-indexed products.

When lapses of our insurance products exceed levels assumed in determining the amortization of insurance intangibles, we adjust amortization to reflect the change in future premiums or estimated gross profits resulting from the unexpected lapses. We recognized additional amortization expense of \$7.9 million during the first six months of 2006 as a result of higher than expected lapses of our Medicare supplement products. We believe the unexpected lapses were primarily related to premium rate increases and competition from companies offering Medicare Advantage products. During the first nine months of 2006, we changed our estimates of the future gross profits of certain universal life products, which under certain circumstances are eligible for interest bonuses in addition to the declared base rate. These interest bonuses are not required in the current crediting rate environment and our estimates of future gross profits have been changed to reflect the discontinuance of the bonus. We reduced amortization expense by \$4.0 million during the first six months of 2006 as a result of this change. During 2005, we conducted a review of our methodology for identifying and capitalizing deferred acquisition costs related to the traditional life block of business in our Bankers Life segment. Based on our review, we reduced the total cost capitalized in prior years by \$1.1 million, which was reflected as an increase in amortization expense for the year ended December 31, 2005. There have been no other significant changes to assumptions used to amortize insurance acquisition costs during 2007, 2006 or 2005. Revisions to assumptions in future periods could have a significant adverse or favorable effect on our results of operations and financial position.

When we realize a gain or loss on investments backing our universal life or investment-type products, we adjust the amortization of insurance acquisition costs to reflect the change in estimated gross profits from the products due to the gain or loss realized and the effect on future investment yields. We decreased amortization expense for such changes by \$35.7 million, \$10.1 million and \$2.8 million during the years ended December 31, 2007, 2006 and 2005, respectively. We also adjust insurance acquisition costs for the change in amortization that would have been recorded if actively managed fixed maturity securities had been sold at their stated aggregate fair value and the proceeds reinvested at current yields. We include the impact of this adjustment in accumulated other comprehensive income (loss) within shareholders' equity. The total pre-tax impact of such adjustments on accumulated other comprehensive income (loss) was an increase of \$62.0 million at December 31, 2007.

At December 31, 2007, the balance of insurance acquisition costs was \$3.1 billion. The recoverability of this amount is dependent on the future profitability of the related business. Each year, we evaluate the recoverability of the unamortized balance of insurance acquisition costs. These evaluations are performed to determine whether estimates of the present value of future cash flows, in combination with the related liability for insurance products, will support the unamortized balance. These future cash flows are based on our best estimate of future premium income, less benefits and expenses. The present value of these cash flows, plus the related balance of liabilities for insurance products, is then compared with the unamortized balance of insurance acquisition costs. In the event of a deficiency, such amount would be charged to amortization expense. The determination of future cash flows involves significant judgment. Revisions to the assumptions which determine such cash flows could have a significant adverse effect on our results of operations and financial position.

The table presented below summarizes our estimates of cumulative adjustments to insurance acquisition costs resulting from hypothetical revisions to certain assumptions. Although such hypothetical revisions are not currently required or anticipated, we believe they could occur based on past variances in experience and our expectations of the ranges of future experience that could reasonably occur. We have assumed that revisions to assumptions resulting in the adjustments summarized below would occur equally among policy types, ages and durations within each product classification. Any actual adjustment would be dependent on the specific policies affected and, therefore, may differ from the estimates summarized below. In addition, the impact of actual adjustments would reflect the net effect of all changes in assumptions during the period.

Change in assumptions	Estimated adjustment to income before income taxes based on revisions to certain assumptions ----- (dollars in millions)
Universal life-type products (a):	
5% increase to assumed mortality.....	\$(103.4)
5% decrease to assumed mortality.....	36.0
15% increase to assumed expenses.....	(19.4)
15% decrease to assumed expenses.....	6.3
10 basis point decrease to assumed spread.....	(22.5)
10 basis point increase to assumed spread.....	9.4
10% increase to assumed lapses.....	6.5
10% decrease to assumed lapses.....	(7.2)
Investment-type products:	
20% increase to assumed surrenders.....	(4.0)
20% decrease to assumed surrenders.....	4.8
15% increase to assumed expenses.....	(1.6)
15% decrease to assumed expenses.....	1.5
10 basis point decrease to assumed spread.....	(5.1)
10 basis point increase to assumed spread.....	4.9
Other than universal life and investment-type products (b):	
5% increase to assumed morbidity.....	(130.2)
50 basis point decrease to investment earnings rate.....	(39.3)

(a) A significant portion of our universal life-type products inforce are in loss recognition status. A favorable change in experience on such blocks may slow down future amortization; however, the current period adjustment to insurance acquisition costs would be small. This causes the downside sensitivities above to be lower in magnitude than the upside results.

(b) We have excluded the effect of reasonably likely changes in mortality, lapse, surrender and expense assumptions for policies other than universal life and investment-type products. Our estimates indicate such changes would not result in any portion of the \$2.4 billion balance of unamortized insurance acquisition costs related to these policies being unrecoverable.

Accounting for marketing and reinsurance agreements with Coventry

Prescription Drug Benefit

The MMA provided for the introduction of a PDP product. In order to offer this product to our current and potential future policyholders without investing in management and infrastructure, we entered into a national distribution agreement with Coventry to use our career and independent agents to distribute Coventry's prescription drug plan, Advantra Rx. We receive a fee based on the premiums collected on plans sold through our distribution channels. In addition, Conesco has a quota-share reinsurance agreement with Coventry for Conesco enrollees that provides Conesco with 50 percent of net premiums and related policy benefits subject to a risk corridor. The Part D program was effective January 1, 2006.

The following describes how we account for and report our PDP business:

Our accounting for the national distribution agreement

o We recognize distribution and licensing fee income from Coventry based upon negotiated percentages of collected premiums on the underlying Medicare Part D contracts. This fee income is recognized over the calendar year term as premiums are collected.

o We also pay commissions to our agents who sell the plans on behalf of Coventry. These payments are deferred and amortized over the remaining term of the initial enrollment period (the one-year life of the initial policy).

Our accounting for the quota-share agreement

o We recognize premium revenue evenly over the period of the underlying Medicare Part D contracts.

o We recognize policyholder benefits and ceding commission expense as incurred.

o We recognize risk-share premium adjustments consistent with Coventry's risk-share agreement with the Centers for Medicare and Medicaid Services.

The following summarizes the pre-tax income of the PDP business (dollars in millions):

	2007	2006
Insurance policy income.....	\$70.8	\$74.4
Fee revenue and other.....	2.4	5.3
	-----	-----
Total revenues.....	73.2	79.7
	-----	-----
Insurance policy benefits.....	57.2	59.6
Commission expense.....	6.4	8.7
Other operating expenses.....	1.0	6.5
	-----	-----
Total expense.....	64.6	74.8
	-----	-----
Pre-tax income.....	\$ 8.6	\$ 4.9
	=====	=====

Private-Fee-For-Service

Conseco expanded its strategic alliance with Coventry by entering into a national distribution agreement under which our career agents began distributing Coventry's PFFS plan, beginning January 1, 2007. The Advantra Freedom product is a Medicare Advantage plan designed to provide seniors with more choices and better coverage at lower cost than original Medicare and Medicare Advantage plans offered through HMOs. Under the agreement, we receive a fee based on the number of PFFS plans sold through our distribution channels. In addition, Conseco has a quota-share reinsurance agreement with Coventry for Conseco enrollees that provides Conseco in 2007 with approximately 50 percent of the net premiums and related profits. During the fourth quarter of 2007, we initiated a pilot program to test the marketing and distribution of Coventry's PFFS plan through Colonial Penn's direct response distribution channel.

We receive distribution fees from Coventry and we pay sales commissions to our agents for these enrollments. In addition, we participate at an approximately 50 percent level in the income (loss) related to this business pursuant to a quota-share agreement with Coventry.

The following summarizes our accounting and reporting practices for the PFFS business.

Our accounting for the distribution agreement

o We receive distribution income from Coventry and other parties based on a fixed fee per PFFS contract. This income is deferred and recognized over the remaining calendar year term of the initial enrollment period.

o We also pay commissions to our agents who sell the plans on behalf of Coventry and other parties. These payments are deferred and amortized over the remaining term of the initial enrollment period (the one-year life of the initial policy).

Our accounting for the quota-share agreement

o We recognize revenue evenly over the period of the underlying PFFS contracts.

o We recognize policyholder benefits and ceding commission expense as incurred.

The following summarizes the pre-tax income of the PFFS business (dollars in millions):

	2007

Insurance policy income.....	\$100.8
Fee revenue and other.....	8.6

Total revenues.....	109.4

Insurance policy benefits.....	82.7
Commission expense.....	4.2
Other operating expenses.....	8.8

Total expense.....	95.7

Pre-tax income.....	\$ 13.7
	=====

Large Group Private-Fee-For-Service Block

Effective July 1, 2007, Conseco entered into a quota-share reinsurance agreement with Coventry related to the PFFS business written by Coventry under certain group policies. Conseco receives 50 percent of the net premiums and related profits associated with this business as long as the ceded revenue margin is less than or equal to five percent. Conseco receives 25 percent of the net premiums and related profits on the ceded margin in excess of five percent. The following summarizes the pre-tax income of this business (dollars in millions):

	2007

Premium income.....	\$99.8

Policy benefits.....	91.2
Commission expense.....	4.1

Total expenses.....	95.3

Pre-tax income.....	\$ 4.5
	=====

Income Taxes

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities, capital loss carryforwards and NOLs. We evaluate the realizability of our deferred income tax assets and assess the need for a valuation allowance on an ongoing basis. In evaluating our deferred income tax assets, we consider whether it is more likely than not that the deferred income tax assets will be realized. The ultimate realization of our deferred income tax assets depends upon generating sufficient future taxable income during the periods in which our temporary differences become deductible and before our capital loss carryforwards and NOLs expire. This assessment requires significant judgment. However, recovery is dependent on achieving such projections and failure to do so would result in an increase in the valuation allowance in a future period. Any future increase in the valuation allowance would result in additional income tax expense and reduce shareholders' equity, and such an increase could have a significant impact upon our earnings in the future. In addition, the use of the Company's NOLs is dependent, in part, on

whether the IRS does not take an adverse position in the future regarding the tax position we have taken in our tax returns with respect to the allocation of cancellation of indebtedness income.

Based upon information existing at the time of our emergence from bankruptcy, we established a valuation allowance against our entire balance of net deferred income tax assets because we believed that the realization of such net deferred income tax assets in future periods was uncertain. During 2005 and 2006, we concluded that it was no longer necessary to hold certain portions of the previously established valuation allowance. Accordingly, we reduced our valuation allowance by \$585.8 million and \$260.0 million in 2005 and 2006, respectively. However, we are required to continue to hold a valuation allowance of \$672.9 million at December 31, 2007 because we have determined that it is more likely than not that a portion of our deferred tax assets will not be realized. This determination was made by evaluating each component of the deferred tax asset and assessing the effects of limitations or interpretations on the value of such component to be fully recognized in the future.

The Code limits the extent to which losses realized by a non-life entity (or entities) may offset income from a life insurance company (or companies) to the lesser of: (i) 35 percent of the income of the life insurance company; or (ii) 35 percent of the total loss of the non-life entities (including NOLs of the non-life entities). There is no limitation on the extent to which losses realized by a life insurance entity (or entities) may offset income from a non-life entity (or entities).

In addition, the timing and manner in which the Company will be able to utilize some of its NOLs is limited by Section 382 of the Code. Section 382 imposes limitations on a corporation's ability to use its NOLs when the company undergoes an ownership change. Because the Company underwent an ownership change pursuant to its reorganization, this limitation applies to the Company. Any losses that are subject to the Section 382 limitation will only be utilized by the Company up to approximately \$142 million per year with any unused amounts carried forward to the following year. Our Section 382 limitation for 2008 will be approximately \$587 million (including \$445 million of unused amounts carried forward from prior years).

Changes in our valuation allowance are summarized as follows (dollars in millions):

Balance at December 31, 2004.....	\$1,629.6
Release of valuation allowance (a).....	(585.8)

Balance at December 31, 2005.....	1,043.8
Expiration of NOL and capital loss carryforwards.....	(6.0)
Release of valuation allowance (a).....	(260.0)

Balance at December 31, 2006.....	777.8
Increase in 2007.....	68.0
Expiration of capital loss carryforwards.....	(157.6)
Write off of certain state NOLs (recovery is remote).....	(15.3)

Balance at December 31, 2007.....	\$ 672.9
	=====

(a) There is a corresponding increase to additional paid-in capital.

As of December 31, 2007, we had \$5.0 billion of federal NOLs and \$.7 billion of capital loss carryforwards, which expire as follows (dollars in millions):

Year of expiration	Net operating loss carryforwards(a)		Capital loss carryforwards	Total loss carryforwards	Total loss carryforwards	
	Life	Non-life			Subject to ss.382	Not subject to ss.382
2008	\$ -	\$ -	\$583.7	\$ 583.7	\$ 583.7	\$ -
2009.....	-	.9	86.2	87.1	.9	86.2
2010.....	-	1.0	-	1.0	1.0	-
2011.....	-	.1	-	.1	.1	-
2012.....	-	10.6	72.2	82.8	10.6	72.2
2016.....	16.9	-	-	16.9	16.9	-
2017.....	33.2	-	-	33.2	33.2	-
2018.....	2,170.6 (a)	20.3	-	2,190.9	64.4	2,126.5
2020.....	-	2.5	-	2.5	2.5	-
2021.....	61.8	-	-	61.8	-	61.8
2022.....	266.2	.6	-	266.8	-	266.8
2023.....	-	2,092.9 (a)	-	2,092.9	71.7	2,021.2
2024.....	-	3.2	-	3.2	-	3.2
2025.....	-	118.8	-	118.8	-	118.8
2026.....	-	1.6	-	1.6	-	1.6
2027.....	-	158.3	-	158.3	-	158.3
Total.....	\$2,548.7	\$2,410.8	\$742.1	\$5,701.6	\$ 785.0	\$4,916.6

(a) The allocation of the NOLs summarized above assumes the IRS does not take an adverse position in the future regarding the tax position we plan to take in our tax returns with respect to the allocation of cancellation of indebtedness income. If the IRS disagrees with the tax position we plan to take with respect to the allocation of cancellation of indebtedness income, and their position prevails, approximately \$631 million of the NOLs expiring in 2018 would be characterized as non-life NOLs.

The Company adopted FASB Interpretation No. 48 "Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109" ("FIN 48") on January 1, 2007, which resulted in a \$6 million increase to additional paid-in capital. As of January 1, 2007 and December 31, 2007, the amount of unrecognized tax benefits was not significant. While it is expected that the amount of unrecognized tax benefits will change in the next twelve months, the Company does not expect the change to have a significant impact on its results of operations.

As more fully discussed below, the Company's interpretation of the tax law, as it relates to the application of the cancellation of indebtedness income to its NOLs, is an uncertain tax position. Since all other life NOLs must be utilized prior to this portion of the NOL, it has not yet been utilized nor is it expected to be utilized within the next twelve months. As a result, an uncertain tax position has not yet been taken on the Company's tax return.

Although FIN 48 allowed a change in accounting, the Company has chosen to continue its past accounting policy of classifying interest and penalties as income tax expense in the consolidated statement of operations. No such amounts were recognized in 2007. The liability for accrued interest and penalties was not significant at December 31, 2007 or December 31, 2006.

Tax years 2004 through 2006 are open to examination by the IRS, and tax year 2002 remains open only for potential adjustments related to certain partnership investments. The Company does not anticipate any material adjustments related to these partnership investments. The Company's various state income tax returns are generally open for tax years 2004 through 2006 based on the individual state statutes of limitation.

The following paragraphs describe an open matter related to the classification of our NOLs.

In July 2006, the Joint Committee of Taxation accepted the audit and the settlement which characterized \$2.1 billion of the tax losses on our Predecessor's investment in Conesco Finance Corp. as life company losses and the remaining amount

as non-life losses prior to the application of the cancellation of indebtedness attribute reductions described below. As a result of the approval of the settlement, we concluded it was appropriate to reduce our valuation allowance by \$260 million in the second quarter of 2006, which was accounted for as an addition to paid-in capital.

The Code provides that any income realized as a result of the cancellation of indebtedness in bankruptcy (cancellation of debt income or "CODI") must reduce NOLs. We realized an estimated \$2.5 billion of CODI when we emerged from bankruptcy. Pursuant to the Company's interpretation of the tax law, the CODI reductions were all used to reduce non-life NOLs. However, if the IRS were to disagree with our interpretation and ultimately prevail, we believe approximately \$631 million of NOLs classified as life company NOLs would be re-characterized as non-life NOLs and subject to the 35% limitation discussed above. Such a re-characterization would also extend the year of expiration as life company NOLs expire after 15 years whereas non-life NOLs expire after 20 years. The Company does not expect the IRS to consider this issue for a number of years.

The Company adopted Statement of Financial Accounting Standards No. 123R "Accounting for Stock-Based Compensation" ("SFAS 123R") in calendar year 2006. Pursuant to this accounting rule, the Company is precluded from recognizing the tax benefits of any tax windfall upon the exercise of a stock option or the vesting of restricted stock unless such deduction resulted in actual cash savings to the Company. Because of the Company's NOLs, no cash savings have occurred. NOL carryforwards of \$1.1 million related to deductions for stock options and restricted stock will be reflected in additional paid-in capital if realized.

Liabilities for Insurance Products

At December 31, 2007, the total balance of our liabilities for insurance products was \$26.7 billion. These liabilities are generally payable over an extended period of time and the profitability of the related products is dependent on the pricing of the products and other factors. Differences between our expectations when we sold these products and our actual experience could result in future losses.

We calculate and maintain reserves for the future payment of claims to our policyholders based on actuarial assumptions. For all our insurance products, we establish an active life reserve, a liability for due and unpaid claims, claims in the course of settlement and incurred but not reported claims. In addition, for our supplemental health insurance business, we establish a reserve for the present value of amounts not yet due on claims. Many factors can affect these reserves and liabilities, such as economic and social conditions, inflation, hospital and pharmaceutical costs, changes in doctrines of legal liability and extra-contractual damage awards. Therefore, our reserves and liabilities are necessarily based on numerous estimates and assumptions as well as historical experience. Establishing reserves is an uncertain process, and it is possible that actual claims will materially exceed our reserves and have a material adverse effect on our results of operations and financial condition. We have incurred significant losses beyond our estimates as a result of actual claim costs and persistency of our long-term care business included in the Other Business in Run-off segment. Our financial results depend significantly upon the extent to which our actual claims experience is consistent with the assumptions we used in determining our reserves and pricing our products. If our assumptions with respect to future claims are incorrect, and our reserves are insufficient to cover our actual losses and expenses, we would be required to increase our liabilities, which would negatively affect our operating results.

Liabilities for insurance products are calculated using management's best judgments, based on our past experience and standard actuarial tables, of mortality, morbidity, lapse rates, investment experience and expense levels.

Accounting for Long-term Care Premium Rate Increases

Many of our long-term care policies were subject to premium rate increases in 2006 and 2007. In some cases, these premium rate increases were reasonably consistent with the assumptions we used to value the particular block of business at the fresh-start date. In other cases, the premium rate increases were materially different from that assumed at the fresh-start date, leading us to change our best estimates of future actuarial assumptions. With respect to the 2006 premium rate increases, some of our policyholders were provided an option to cease paying their premiums and receive a non-forfeiture option in the form of a paid-up policy with limited benefits. In addition, our policyholders could choose to reduce their coverage amounts and premiums in the same proportion, when permitted by our contracts or as required by regulators. The following describes how we account for these premium rate increases and related policyholder options:

o Premium rate increases - In November 2007, we were informed of a request made by the SEC at a meeting on November 2, 2007 between the insurance expert panel of the American Institute of Certified Public Accountants

and the SEC staff. Representatives from Conseco did not attend the meeting and there has been no formal communication from the SEC regarding the matters that were discussed. However, it is our understanding that during the meeting, the SEC staff requested that companies communicate to the SEC their accounting practices if a prospective revision methodology is used when premium rate changes are made to guaranteed renewable health insurance contracts in a period without a premium deficiency. In the critical accounting policies section of our 2006 Form 10-K, we disclosed that we used a prospective revision methodology (also known as "pivoting") to account for premium rate increases on long-term care policies. Under this accounting policy, we prospectively changed reserve assumptions for long-term care policies when premium rate increases differed significantly from our original assumptions. We based the use of this accounting policy on our interpretation of GAAP, including specific reference to the use of a prospective revision methodology when premium rate changes are made to guaranteed renewable health insurance contracts in paragraph 20 of Statement of Position 05-1, "Accounting by Insurance Enterprises for Deferred Acquisition Costs in Connection with Modifications or Exchanges of Insurance Contracts" issued by the Accounting Standards Executive Committee.

In accordance with the request of the SEC staff, we prepared a document which summarized our use of the prospective revision methodology and the authoritative guidance we followed in determining our accounting policy. On February 28, 2008, the SEC staff informed Conseco that the use of this method is not consistent with the guidance of FASB Statement of Financial Accounting Standards No. 60, "Accounting and Reporting by Insurance Enterprises."

As a result, we have restated our results reflecting the elimination of the use of the prospective revision methodology. If premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists.

Our restatement of previously issued financial statements for the year ended December 31, 2006 and quarterly information for 2006 and the first three quarters of 2007, includes adjustments to eliminate the use of the prospective revision methodology. For further information on these and other restatement adjustments, refer to the notes to the consolidated financial statements entitled "Restatement of Previously Issued Financial Statements" and "Restated Quarterly Financial Data (Unaudited)."

o Benefit reductions - If there is a premium rate increase on one of our long-term care policies, a policyholder may choose reduced coverage with a proportionate reduction in premium, when permitted by our contracts. This option does not require additional underwriting. Benefit reductions are treated as a partial lapse of coverage, and the balance of our reserves and deferred insurance acquisition costs is reduced in proportion to the reduced coverage.

o Non-forfeiture benefits offered in conjunction with a rate increase - In some cases, non-forfeiture benefits are offered to policyholders who wish to lapse their policies at the time of a significant rate increase. In these cases, exercise of this option is treated as an extinguishment of the original contract and issuance of a new contract. The balance of our reserves and deferred insurance acquisition costs are released, and a reserve for the new contract is established.

o Florida Order - In 2004, the Florida Office of Insurance Regulation issued an order to our subsidiaries in the Other Business in Run-off segment regarding their long-term care business in Florida. The order required them to offer a choice of three alternatives to holders of home health care policies in Florida subject to premium rate increases as follows:

o retention of their current policy with a rate increase of 50 percent in the first year and actuarially justified increases in subsequent years;

o receipt of a replacement policy with reduced benefits and a rate increase in the first year of 25 percent and no more than 15 percent in subsequent years; or

o receipt of a paid-up policy, allowing the holder to file future claims up to 100 percent of the amount of premiums paid since the inception of the policy.

Reserves for all three groups of policies under the order were prospectively adjusted using the prospective revision methodology described above, as these alternatives were required by the Florida Office of Insurance Regulation. These policies had no insurance acquisition costs established at the Effective Date.

Some of our policyholders may receive a non-forfeiture benefit if they cease paying their premiums pursuant to their original contract (or pursuant to changes made to their original contract as a result of a litigation settlement made prior to the Effective Date or an order issued by the Florida Office of Insurance Regulation). In these cases, exercise of this option is treated as the exercise of a policy benefit, and the reserve for premium paying benefits is reduced, and the reserve for the non-forfeiture benefit is adjusted to reflect the election of this benefit.

Liabilities for Loss Contingencies Related to Lawsuits and Our Guarantees of Bank Loans and Related Interest Loans

We are involved on an ongoing basis in arbitrations and lawsuits, including purported class actions. The ultimate outcome of these legal matters cannot be predicted with certainty. We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. However, it is difficult to measure the actual loss that might be incurred related to litigation. The ultimate outcome of these lawsuits could have a significant impact on our results of operations and financial position.

In conjunction with our bankruptcy reorganization in 2003, \$481.3 million principal amount of bank loans made to certain former directors and employees to enable them to purchase common stock of Old Consecro were transferred to the Company. These loans had been guaranteed by Old Consecro. We received all rights to collect the balances due pursuant to the original terms of these loans. In addition, we hold loans to participants for interest on the loans. The loans and the interest loans are collectively referred to as the "D&O loans." We regularly evaluate the collectibility of these loans in light of the credit worthiness of the participants and the current status of various legal actions we have taken to collect the D&O loans. At December 31, 2007, we have estimated that approximately \$19.2 million of the D&O loan balance (which is included in other assets) is collectible (net of the costs of collection). An allowance has been established to reduce the total D&O loan balance to the amount we estimated was recoverable.

Pursuant to the settlement that was reached with the Official Committee of the Trust Originated Preferred Securities ("TOPrS") Holders and the Official Committee of Unsecured Creditors in connection with our bankruptcy reorganization in 2003, the former holders of TOPrS (issued by Old Consecro's subsidiary trusts and eliminated in our reorganization) who did not opt out of the bankruptcy settlement will be entitled to receive 45 percent of any proceeds from the collection of certain D&O loans in an aggregate amount not to exceed \$30 million. As of December 31, 2007, we had paid \$13.7 million to the former holders of TOPrS and we have established a liability of \$10.2 million (which is included in other liabilities), representing our estimate of the additional amount which will be paid to the former holders of TOPrS pursuant to the settlement.

RESULTS OF OPERATIONS:

We manage our business through the following: three primary operating segments, Bankers Life, Consecos Insurance Group and Colonial Penn which are defined on the basis of product distribution; a fourth segment comprised of other business in run-off; and corporate operations, which consists of holding company activities and certain noninsurance businesses.

Please read this discussion in conjunction with the consolidated financial statements and notes included in this Form 10-K.

The following tables and narratives summarize the operating results of our segments (dollars in millions):

	2007 ----	2006 ---- (Restated)	2005 ---- (Restated)
Income (loss) before net realized investment gains (losses), net of related amortization and income taxes (a non-GAAP measure) (a):			
Bankers Life	\$ 241.8	\$265.3	\$224.9
Consecos Insurance Group.....	(6.0)	32.6	233.4
Colonial Penn.....	18.1	21.6	20.0
Other Business in Run-off.....	(185.9)	(34.5)	90.9
Corporate operations.....	(121.3)	(80.7)	(84.8)
	-----	-----	-----
	(53.3)	204.3	484.4
	-----	-----	-----
Net realized investment gains (losses), net of related amortization:			
Bankers Life	(17.4)	(16.3)	(3.2)
Consecos Insurance Group.....	(98.8)	(12.6)	3.4
Colonial Penn.....	(.2)	.2	.6
Other Business in Run-off.....	2.9	(8.0)	.5
Corporate operations.....	(6.2)	(.4)	(1.4)
	-----	-----	-----
	(119.7)	(37.1)	(.1)
	-----	-----	-----
Income (loss) before income taxes:			
Bankers Life	224.4	249.0	221.7
Consecos Insurance Group.....	(104.8)	20.0	236.8
Colonial Penn.....	17.9	21.8	20.6
Other Business in Run-off.....	(183.0)	(42.5)	91.4
Corporate operations.....	(127.5)	(81.1)	(86.2)
	-----	-----	-----
Income (loss) before income taxes.....	\$(173.0)	\$167.2	\$484.3
	=====	=====	=====

(a) These non-GAAP measures as presented in the above table and in the following segment financial data and discussions of segment results exclude net realized investment gains (losses), net of related amortization and before income taxes. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

These non-GAAP financial measures of "income (loss) before net realized investment gains (losses), net of related amortization, and before income taxes" differ from "income (loss) before income taxes" as presented in our consolidated statement of operations prepared in accordance with GAAP due to the exclusion of before tax realized investment gains (losses), net of related amortization. We measure segment performance for purposes of Financial Accounting Standards No. 131, "Disclosures about Segments of an Enterprise and Related Information" ("SFAS 131"), excluding realized investment gains (losses) because we believe that this performance measure is a better

indicator of the ongoing businesses and trends in our business. Our investment focus is on investment income to support our liabilities for insurance products as opposed to the generation of realized investment gains (losses), and a long-term focus is necessary to maintain profitability over the life of the business. Realized investment gains (losses) depend on market conditions and do not necessarily relate to decisions regarding the underlying business of our segments. However, "income (loss) before net realized investment gains (losses), net of related amortization, and before income taxes" does not replace "income (loss) before income taxes" as a measure of overall profitability. We may experience realized investment gains (losses), which will affect future earnings levels since our underlying business is long-term in nature and we need to earn the assumed interest rates on the investments backing our liabilities for insurance products to maintain the profitability of our business. In addition, management uses this non-GAAP financial measure in its budgeting process, financial analysis of segment performance and in assessing the allocation of resources. We believe these non-GAAP financial measures enhance an investor's understanding of our financial performance and allows them to make more informed judgments about the Company as a whole. These measures also highlight operating trends that might not otherwise be transparent. The table above reconciles the non-GAAP measure to the corresponding GAAP measure.

General: Consecro is the top tier holding company for a group of insurance companies operating throughout the United States that develop, market and administer supplemental health insurance, annuity, individual life insurance and other insurance products. We distribute these products through our Bankers Life segment, which utilizes a career agency force, through our Consecro Insurance Group segment, which utilizes professional independent producers, and through our Colonial Penn segment, which utilizes direct response marketing. Our Other Business in Run-off segment consists of: (i) long-term care products sold in prior years through independent agents; and (ii) a very small amount of major medical insurance. Most of the long-term care business in run-off relates to business written by certain subsidiaries prior to their acquisitions by Old Consecro in 1996 and 1997.

Bankers Life (dollars in millions)

	2007 ----	2006 ---- (Restated)	2005 ---- (Restated)
Premium collections:			
Annuities.....	\$ 885.5	\$ 997.5	\$ 951.1
Supplemental health.....	1,546.1	1,308.3	1,213.7
Life.....	200.0	184.2	152.1
	-----	-----	-----
Total collections.....	\$2,631.6	\$2,490.0	\$2,316.9
	=====	=====	=====
Average liabilities for insurance products:			
Annuities:			
Mortality based.....	\$ 266.0	\$ 271.8	\$ 263.0
Equity-indexed.....	787.4	500.2	324.9
Deposit based.....	4,522.2	4,435.4	4,087.6
Health.....	3,569.7	3,310.2	3,044.7
Life:			
Interest sensitive.....	364.2	341.5	320.3
Non-interest sensitive.....	299.1	246.7	196.5
	-----	-----	-----
Total average liabilities for insurance products, net of reinsurance ceded.....	\$9,808.6	\$9,105.8	\$8,237.0
	=====	=====	=====
Revenues:			
Insurance policy income.....	\$1,780.0	\$1,545.5	\$1,405.7
Net investment income:			
General account invested assets.....	578.7	513.3	450.6
Equity-indexed products based on the change in value of options...	(10.6)	12.3	(2.6)
Other special-purpose portfolios.....	4.2	-	-
Fee revenue and other income.....	12.0	6.0	1.1
	-----	-----	-----
Total revenues.....	2,364.3	2,077.1	1,854.8
	-----	-----	-----
Expenses:			
Insurance policy benefits.....	1,480.6	1,216.2	1,139.7
Amounts added to policyholder account balances:			
Annuity products and interest-sensitive life products other than equity-indexed products.....	180.9	173.6	163.8
Equity-indexed products.....	23.2	20.8	1.7
Amortization related to operations.....	264.0	241.0	184.1
Interest expense on investment borrowings.....	-	.1	1.3
Other operating costs and expenses.....	173.8	160.1	139.3
	-----	-----	-----
Total benefits and expenses.....	2,122.5	1,811.8	1,629.9
	-----	-----	-----
Income before net realized investment losses, net of related amortization and income taxes.....	241.8	265.3	224.9
	-----	-----	-----
Net realized investment losses.....	(19.9)	(19.5)	(4.2)
Amortization related to net realized investment losses.....	2.5	3.2	1.0
	-----	-----	-----
Net realized investment losses, net of related amortization.....	(17.4)	(16.3)	(3.2)
	-----	-----	-----
Income before income taxes.....	\$ 224.4	\$ 249.0	\$ 221.7
	=====	=====	=====

(continued)

(continued from previous page)

	2007 ----	2006 ---- (Restated)	2005 ---- (Restated)
Health benefit ratios:			
All health lines:			
Insurance policy benefits.....	\$1,298.0	\$1,058.8	\$1,006.7
Benefit ratio (a).....	84.4%	79.9%	82.9%
Medicare supplement:			
Insurance policy benefits.....	\$433.3	\$436.6	\$466.5
Benefit ratio (a).....	67.2%	66.6%	71.5%
PDP and PFFS:			
Insurance policy benefits.....	\$231.1	\$59.6	\$ -
Benefit ratio (a).....	85.1%	80.0%	-
Long-term care:			
Insurance policy benefits.....	\$633.6	\$562.6	\$540.2
Benefit ratio (a).....	102.0%	94.5%	96.1%
Interest-adjusted benefit ratio (b).....	70.8%	64.9%	67.6%

(a) We calculate benefit ratios by dividing the related product's insurance policy benefits by insurance policy income.

(b) We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Bankers Life's long-term care products by dividing such product's insurance policy benefits less interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

These non-GAAP financial measures of "interest-adjusted benefit ratios" differ from "benefit ratios" due to the deduction of interest income on the accumulated assets backing the insurance liabilities from the product's insurance policy benefits used to determine the ratio. Interest income is an important factor in measuring the performance of health products that are expected to be in force for a longer duration of time, are not subject to unilateral changes in provisions (such as non-cancelable or guaranteed renewable contracts) and require the performance of various functions and services (including insurance protection) for an extended period of time. The net cash flows from long-term care products generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve increases) that will be paid out as benefits in later policy years (accounted for as reserve decreases). Accordingly, as the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by interest income earned on the accumulated assets. The interest-adjusted benefit ratio reflects the effects of the interest income offset. Since interest income is an important factor in measuring the performance of this product, management believes a benefit ratio that includes the effect of interest income is useful in analyzing product performance. We utilize the interest-adjusted benefit ratio in measuring segment performance for purposes of SFAS 131 because we believe that this performance measure is a better indicator of the ongoing businesses and trends in the business. However, the "interest-adjusted benefit ratio" does not replace the "benefit ratio" as a measure of current period benefits to current period insurance policy income. Accordingly, management reviews both "benefit ratios" and "interest-adjusted benefit ratios" when analyzing the financial results attributable to these products. The investment income earned on the accumulated assets backing Bankers Life's long-term care reserves was \$193.8 million, \$175.9 million and \$160.3 million in 2007, 2006 and 2005, respectively.

Total premium collections were \$2,631.6 million in 2007, up 5.7 percent from 2006, and \$2,490.0 million in 2006, up 7.5 percent from 2005. Premium collections include \$277.8 million and \$76.7 million in 2007 and 2006, respectively, of premiums collected pursuant to the quota-share agreements with Coventry described above under "Accounting for the marketing and reinsurance agreements with Coventry". See "Premium Collections" for further analysis of Bankers Life's premium collections.

Average liabilities for insurance products, net of reinsurance ceded were \$9.8 billion in 2007, up 7.7 percent from 2006, and \$9.1 billion in 2006, up 11 percent from 2005. The increase in such liabilities was primarily due to increases in annuity and health reserves resulting from new sales of these products.

Insurance policy income is comprised of premiums earned on policies which provide mortality or morbidity coverage and fees and other charges assessed on other policies. Insurance policy income includes \$271.4 million and \$74.4 million in 2007 and 2006, respectively, of premium income from the quota-share agreements with Coventry described above under "Accounting for the marketing and reinsurance agreements with Coventry".

Net investment income on general account invested assets (which excludes income on policyholder accounts) increased by 13 percent, to \$578.7 million, in 2007 and by 14 percent, to \$513.3 million, in 2006. The average balance of general account invested assets was \$10.0 billion, \$9.2 billion and \$8.2 billion in 2007, 2006 and 2005, respectively. The yield on these assets was 5.79 percent in 2007, 5.59 percent in 2006 and 5.49 percent in 2005. The increase in general account invested assets is primarily due to sales of our annuity and health products in recent periods. The increase in yield is primarily due to increases in portfolio duration and changes in the investment allocation.

Net investment income related to equity-indexed products based on the change in value of options represents the change in the estimated fair value of options which are purchased in an effort to hedge certain potential benefits accruing to the policyholders of our equity-indexed products. Our equity-indexed products are designed so that the investment income spread earned on the related insurance liabilities is more than adequate to cover the cost of the options and other costs related to these policies. Net investment gains (losses) related to equity-indexed products were \$(11.2) million, \$12.3 million and \$(2.6) million in 2007, 2006 and 2005, respectively. Also, during 2007, we recognized income on trading securities which are held to act as hedges for embedded derivatives related to equity-indexed products. Such trading account income was \$.6 million in 2007. Such amounts are generally offset by the corresponding charge (credit) to amounts added to policyholder account balances for equity-indexed products based on the change in value of the indices. Such income and related charges fluctuate based on the value of options embedded in the segment's equity-indexed annuity policyholder account balances subject to this benefit and to the performance of the index to which the returns on such products are linked.

Net investment income on other special-purpose portfolios includes the income related to Company-owned life insurance ("COLI") which was purchased in the fourth quarter of 2006 as an investment vehicle to fund the agent deferred compensation plan. The COLI assets are not assets of the agent deferred compensation plan, and as a result, are accounted for outside the plan and are recorded in the consolidated balance sheet as other invested assets. Changes in the cash surrender value (which approximates net realizable value) of the COLI assets are recorded as net investment income and totaled \$1.5 million in 2007. We also recognized a death benefit of \$2.7 million under the COLI in 2007.

Fee revenue and other income increased to \$12.0 million in 2007, compared to \$6.0 million in 2006 and \$1.1 million in 2005. We recognized fee income of \$11.0 million and \$5.3 million in 2007 and 2006, respectively, pursuant to the agreements described above under "Accounting for the marketing and reinsurance agreements with Coventry".

Insurance policy benefits fluctuated as a result of the factors summarized below for benefit ratios. Benefit ratios are calculated by dividing the related insurance product's insurance policy benefits by insurance policy income.

The Medicare supplement business consists of both individual and group policies. Government regulations generally require us to attain and maintain a ratio of total benefits incurred to total premiums earned (excluding changes in policy benefit reserves), after three years from the original issuance of the policy and over the lifetime of the policy, of not less than 65 percent on individual products and not less than 75 percent on group products, as determined in accordance with statutory accounting principles. Since the insurance product liabilities we establish for Medicare supplement business are subject to significant estimates, the ultimate claim liability we incur for a particular period is likely to be different than our initial estimate. Our insurance policy benefits reflected the release of reserve redundancies (deficiencies) from prior years of \$3.7 million, \$9.8 million and \$(2.0) million in 2007, 2006 and 2005, respectively. Excluding the effects of prior year claim reserve redundancies (deficiencies), our benefit ratios would have been 67.8 percent, 68.3 percent, and 71.4 percent in 2007,

2006 and 2005, respectively. Such ratios are consistent with our expectations considering premium rate increases implemented in recent periods.

The insurance policy benefits on our PDP and PFFS business result from our quota-share reinsurance agreements with Coventry as described above under "Accounting for marketing and reinsurance agreements with Coventry". We began assuming the PDP business on January 1, 2006 and the PFFS business on January 1, 2007. Effective July 1, 2007, we entered into a new PFFS quota-share reinsurance agreement to assume 50 percent of the business written by Coventry under one large group policy. The benefit ratio related to the PDP and PFFS business increased in 2007 due to the higher loss ratio on the group policy (which was expected).

The net cash flows from our long-term care products generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve increases) which will be paid out as benefits in later policy years (accounted for as reserve decreases). Accordingly, as the policies age, the benefit ratio typically increases, but the increase in reserves is partially offset by investment income earned on the accumulated assets. The benefit ratio on this business has increased over the last year, consistent with the aging of this block. In addition, the older policies have not lapsed at the rate we assumed in our pricing. In the first quarter of 2005, we began introducing several new long-term care products to replace our previous lower-priced products. These new products have been approved by the regulatory authorities in 49 states and the District of Columbia. The benefit ratio on our entire block of long-term care business in the Bankers Life segment was 102.0 percent, 94.5 percent and 96.1 percent in 2007, 2006 and 2005, respectively. The interest-adjusted benefit ratio for long-term care products is calculated by dividing the insurance product's insurance policy benefits less interest income on the accumulated assets backing the insurance liabilities by insurance policy income. The interest-adjusted benefit ratio on this business was 70.8 percent, 64.9 percent and 67.6 percent in 2007, 2006 and 2005, respectively. Since the insurance product liabilities we establish for long-term care business are subject to significant estimates, the ultimate claim liability we incur for a particular period is likely to be different than our initial estimate. Our insurance policy benefits reflected reserve deficiencies from prior years of \$7.4 million, \$5 million and \$4.3 million in 2007, 2006 and 2005, respectively. Excluding the effects of prior year claim reserve deficiencies, our benefit ratios would have been 100.8 percent, 94.4 percent, and 95.3 percent in 2007, 2006 and 2005, respectively. We experienced an increase in the number of incurred claims in 2007.

As a result of higher persistency in our long-term care block in the Bankers Life segment than assumed in the original pricing, our premium rates were too low. Accordingly, we began a program in 2006 to seek approval from regulatory authorities for rate increases on approximately 65 percent of this block. As an alternative to the rate increase, policyholders were offered the option: (i) to reduce their benefits to maintain their previous premium rates; or (ii) to choose a nonforfeiture benefit equal to the sum of accumulated premiums paid less claims received. We have received all expected regulatory approvals and have implemented these rate increases. In addition, another round of increases was filed during the second and third quarters of 2007 on newer long-term care, home health care, and short-term care policies not included in the first round of rate increases. The policies in this round represent approximately 25 percent of the inforce block. As of December 31, 2007, all such filings had been submitted for regulatory approval, and approximately 38 percent of the rate increases had been approved by regulators and implemented. Remaining approvals and implementations are expected to occur over the next nine months.

During the fourth quarter of 2007, we recognized additional insurance policy benefits of \$6.7 million to reflect changes in our estimates of future surrender and premium persistency rates on our universal life insurance block of business.

Amounts added to policyholder account balances for annuity products and interest-sensitive life products were \$180.8 million, \$173.6 million and \$163.8 million in 2007, 2006 and 2005, respectively. The increases were primarily due to increases in annuity reserves (resulting from higher sales of these products). The weighted average crediting rates for these products were 3.7 percent, 3.6 percent and 3.7 percent in 2007, 2006 and 2005, respectively.

Amounts added to equity-indexed products based on change in value of the indices fluctuated with the corresponding related investment income accounts described above.

Amortization related to operations includes amortization of the value of policies inforce at the Effective Date and the cost of policies produced (collectively referred to as "amortization of insurance acquisition costs"). Insurance acquisition costs are generally amortized either: (i) in relation to the estimated gross profits for universal life and investment-type products; or (ii) in relation to actual and expected premium revenue for other products. In addition, for universal life and investment-type products, we are required to adjust the total amortization recorded to date through the statement of operations if actual experience or other evidence suggests that earlier estimates of future gross profits should be revised. Accordingly, amortization for universal life and investment-type products is dependent on the profits realized during the

period and on our expectation of future profits. For other products, we amortize insurance acquisition costs in relation to actual and expected premium revenue, and amortization is only adjusted if expected premium revenue changes or if we determine the balance of these costs is not recoverable from future profits. Bankers Life's amortization expense was \$264.0 million, \$241.0 million and \$184.1 million in 2007, 2006 and 2005, respectively. During the first half of 2007 and 2006, we experienced higher lapses than we anticipated on our Medicare supplement products. These lapses reduced our estimates of future expected premium income and, accordingly, we recognized additional amortization expense of \$25.4 million in the first half of 2007 and \$7.9 million in the first half of 2006. We believe such increases were partially related to competition from Medicare Advantage products.

Other operating costs and expenses in our Bankers Life segment were \$173.8 million in 2007, up 8.6 percent from 2006 and were \$160.1 million in 2006, up 15 percent from 2005. The increase in expenses in 2007 and 2006 reflects the expenses we incurred related to the marketing and quota-share agreements with Coventry. Other operating costs and expenses include the following (dollars in millions):

	2007 ----	2006 ---- (Restated)	2005 ---- (Restated)
Expenses related to the marketing and quota-share agreements with Coventry.....	\$ 24.5	\$ 15.2	\$ -
Commission expense.....	20.8	20.7	18.9
Other operating expenses.....	128.5	124.2	120.4
	-----	-----	-----
Total.....	\$173.8 =====	\$160.1 =====	\$139.3 =====

Net realized investment losses fluctuated each period. During 2007, net realized investment losses in this segment included \$4.6 million of net losses from the sales of investments (primarily fixed maturities), and \$15.3 million of writedowns of investments resulting from declines in fair values that we concluded were other than temporary. During 2006, net realized investment losses in this segment included \$15.1 million of net losses from the sales of investments (primarily fixed maturities), and \$4.4 million of writedowns of investments resulting from declines in fair values that we concluded were other than temporary. During 2005, net realized investment losses in this segment included \$1.5 million of net losses from the sales of investments (primarily fixed maturities), and \$2.7 million of writedowns of investments resulting from declines in fair values that we concluded were other than temporary.

Amortization related to net realized investment losses is the increase or decrease in the amortization of insurance acquisition costs which results from realized investment gains or losses. When we sell securities which back our universal life and investment-type products at a gain (loss) and reinvest the proceeds at a different yield, we increase (reduce) the amortization of insurance acquisition costs in order to reflect the change in estimated gross profits due to the gains (losses) realized and the resulting effect on estimated future yields. Sales of fixed maturity investments resulted in a decrease in the amortization of insurance acquisition costs of \$2.5 million, \$3.2 million and \$1.0 million in 2007, 2006 and 2005, respectively.

Conseco Insurance Group (dollars in millions)

	2007 ----	2006 ---- (Restated)	2005 ---- (Restated)
Premium collections:			
Annuities.....	\$ 368.6	\$ 433.3	\$ 161.7
Supplemental health.....	594.4	611.6	661.5
Life.....	287.3	314.6	335.0
	-----	-----	-----
Total collections.....	\$ 1,250.3 =====	\$ 1,359.5 =====	\$ 1,158.2 =====
Average liabilities for insurance products:			
Annuities:			
Mortality based.....	\$ 230.3	\$ 241.2	\$ 269.8
Equity-indexed.....	1,435.3	1,376.4	1,349.0
Deposit based.....	2,337.7	3,150.8	3,472.4
Separate accounts and investment trust liabilities.....	28.4	29.3	30.6
Health.....	2,457.2	2,424.7	2,407.0
Life:			
Interest sensitive.....	3,044.9	3,061.2	3,124.9
Non-interest sensitive.....	1,380.2	1,416.8	1,431.0
	-----	-----	-----
Total average liabilities for insurance products, net of reinsurance ceded.....	\$10,914.0 =====	\$11,700.4 =====	\$12,084.7 =====
Revenues:			
Insurance policy income.....	\$ 949.4	\$ 994.8	\$ 1,064.0
Net investment income:			
General account invested assets.....	700.5	699.6	718.6
Equity-indexed products based on the change in value of options...	(1.3)	26.0	(16.3)
Trading account income related to policyholder and reinsurer accounts.....	1.4	6.9	(3.3)
Change in value of embedded derivatives related to modified coinsurance agreements.....	1.4	.8	3.0
Other trading accounts.....	(12.8)	-	-
Fee revenue and other income.....	.6	1.0	1.9
	-----	-----	-----
Total revenues.....	1,639.2 -----	1,729.1 -----	1,767.9 -----
Expenses:			
Insurance policy benefits.....	779.8	769.4	831.8
Amounts added to policyholder account balances:			
Annuity products and interest-sensitive life products other than equity-indexed products.....	217.4	251.9	254.5
Equity-indexed products.....	60.7	55.8	12.6
Amortization related to operations.....	177.5	174.5	158.6
Interest expense on investment borrowings.....	17.6	.8	4.9
Costs related to a litigation settlement.....	32.2	165.8	9.2
Loss related to an annuity coinsurance transaction.....	76.5	-	-
Other operating costs and expenses.....	283.5	278.3	262.9
	-----	-----	-----
Total benefits and expenses.....	1,645.2 -----	1,696.5 -----	1,534.5 -----
Income (loss) before net realized investment gains (losses), net of related amortization and income taxes.....	(6.0) -----	32.6 -----	233.4 -----
Net realized investment gains (losses).....	(132.0)	(19.5)	1.6
Amortization related to net realized investment (gains) losses.....	33.2	6.9	1.8
	-----	-----	-----
Net realized investment gains (losses), net of related amortization.....	(98.8) -----	(12.6) -----	3.4 -----
Income (loss) before income taxes.....	\$ (104.8) =====	\$ 20.0 =====	\$ 236.8 =====

(continued)

(continued from previous page)

	2007 ----	2006 ---- (Restated)	2005 ---- (Restated)
Health benefit ratios:			
All health lines:			
Insurance policy benefits.....	\$443.8	\$445.2	\$476.3
Benefit ratio (a).....	74.0%	71.2%	70.8%
Medicare supplement:			
Insurance policy benefits.....	\$156.4	\$158.9	\$178.5
Benefit ratio (a).....	67.6%	61.9%	59.4%
Specified disease:			
Insurance policy benefits.....	\$279.4	\$277.1	\$287.9
Benefit ratio (a).....	77.8%	77.4%	80.2%
Interest-adjusted benefit ratio (b).....	44.7%	45.4%	49.1%
Other:			
Insurance policy benefits.....	\$8.0	\$9.2	\$9.9
Benefit ratio (a).....	84.7%	84.2%	75.9%

-
- (a) We calculate benefit ratios by dividing the related product's insurance policy benefits by insurance policy income.
- (b) We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for Conseco Insurance Group's specified disease products by dividing such product's insurance policy benefits less interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

These non-GAAP financial measures of "interest-adjusted benefit ratios" differ from "benefit ratios" due to the deduction of interest income on the accumulated assets backing the insurance liabilities from the product's insurance policy benefits used to determine the ratio. Interest income is an important factor in measuring the performance of health products that are expected to be in force for a longer duration of time, are not subject to unilateral changes in provisions (such as non-cancelable or guaranteed renewable contracts) and require the performance of various functions and services (including insurance protection) for an extended period of time. In addition, interest income is an important factor in measuring the performance of this product, since approximately three-fourths of these policies have return of premium or cash value riders. The net cash flows from specified disease products generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve increases) that will be paid out as benefits in later policy years (accounted for as reserve decreases). Accordingly, as the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by interest income earned on the accumulated assets. The interest-adjusted benefit ratio reflects the effects of the interest income offset. Since interest income is an important factor in measuring the performance of this product, management believes a benefit ratio that includes the effect of interest income is useful in analyzing product performance. We utilize the interest-adjusted benefit ratio in measuring segment performance for purposes of SFAS 131 because we believe that this performance measure is a better indicator of the ongoing businesses and trends in the business. However, the "interest-adjusted benefit ratio" does not replace the "benefit ratio" as a measure of current period benefits to current period insurance policy income. Accordingly, management reviews both "benefit ratios" and "interest-adjusted benefit ratios" when analyzing the financial results attributable to these products. The investment income earned on the accumulated assets backing the specified disease reserves was \$118.9 million, \$114.7 million and \$111.7 million in 2007, 2006 and 2005, respectively.

Annuity coinsurance agreement. On October 12, 2007, we completed a transaction to coinsure 100 percent of most of the older inforce equity-indexed annuity and fixed annuity business of three of our subsidiaries with REALIC. We recognized a \$76.5 million loss before income taxes on the transaction. Pursuant to the terms of the agreement, the purchase price was based on the January 1, 2007, value of the business ceded. During 2007, we also recognized impairment charges (net of amortization of insurance intangibles) of \$40.6 million as a result of our intent not to hold investments for a period of time sufficient to allow for any anticipated recovery as a result of the assets to be transferred upon the expected completion of

the coinsurance transaction. In addition to the 2007 effect of the coinsurance agreement, our 2008 results will be affected since the revenue and expense in this block will no longer be recorded in our consolidated statement of operations. During the first nine months of 2007, the following revenues and expenses were recognized on this block: net investment income of \$120 million, insurance policy benefits of \$85 million; and amortization expense of \$25 million.

Total premium collections were \$1,250.3 million in 2007, down 8.0 percent from 2006, and \$1,359.5 million in 2006, up 17 percent from 2005. The decrease in 2007 collected premiums was primarily due to lower annuity sales as we changed the pricing of specific products and we no longer emphasized the sale of certain products. Premium collections in 2006 increased primarily due to higher premium collections from our equity-indexed products, partially offset by lower premium collections from Medicare supplement and life insurance products. See "Premium Collections" for further analysis of fluctuations in premiums collected by product.

Average liabilities for insurance products, net of reinsurance ceded were \$10.9 billion in 2007, down 6.7 percent from 2006, and \$11.7 billion in 2006, down 3.2 percent from 2005. The decreases in such liabilities were primarily due to a coinsurance transaction completed in the third quarter of 2007 and policyholder redemptions and lapses exceeding new sales.

Insurance policy income is comprised of premiums earned on traditional insurance policies which provide mortality or morbidity coverage and fees and other charges assessed on other policies. The decrease in insurance policy income is partially due to lower premiums from our life insurance block. The lapses of these policies are exceeding new sales. In addition, we experienced higher lapses than sales from Medicare supplement products in 2007. See "Premium Collections" for further analysis.

Net investment income on general account invested assets (which excludes income on policyholder and reinsurer accounts) increased by .1 percent, to \$700.5 million, in 2007 and decreased by 2.6 percent, to \$699.6 million, in 2006. The average balance of general account invested assets decreased by 3.3 percent in 2007, to \$11.8 billion, and by 3.1 percent in 2006, to \$12.2 billion. The average yield on these assets was 5.92 percent in 2007, 5.74 percent in 2006 and 5.71 percent in 2005. The increase in yield is primarily due to an increase in portfolio duration and changes in investment allocation. The yield was also impacted by income related to prepayments of securities (including prepayment penalties on mortgages, call premiums on fixed maturities and acceleration of discount amortization, net of premium amortization) of \$6.8 million, \$8.2 million and \$22.8 million in 2007, 2006 and 2005, respectively. This additional investment income was partially offset by approximately \$1.1 million, \$4.0 million and \$9.4 million of additional amortization expense in 2007, 2006 and 2005, respectively, to reflect the higher resulting gross profits for universal life and investment-type products.

Net investment income related to equity-indexed products based on the change in value of options represents the change in the estimated fair value of options which are purchased in an effort to hedge certain potential benefits accruing to the policyholders of our equity-indexed products. Our equity-indexed products are designed so that the investment income spread earned on the related insurance liabilities is more than adequate to cover the cost of the options and other costs related to these policies. Net investment gains (losses) related to equity-indexed products were \$2.7 million, \$28.1 million and \$(12.0) million in 2007, 2006 and 2005, respectively. Such amounts also include income on trading securities which are designed to act as hedges for embedded derivatives related to equity-indexed products. Such trading account income (loss) were \$(4.0) million, \$(2.1) million and \$(4.3) million in 2007, 2006 and 2005, respectively. Such amounts were partially offset by the corresponding charge (credit) to amounts added to policyholder account balances for equity-indexed products. Such income and related charges fluctuate based on the value of options embedded in the segment's equity-indexed annuity policyholder account balances subject to this benefit and to the performance of the indices to which the returns on such products are linked.

Trading account income related to policyholder and reinsurer accounts represents the income on trading securities which are held to act as hedges for embedded derivatives related to certain modified coinsurance agreements. In addition, such income includes the income on investments backing the market strategies of certain annuity products which provide for different rates of cash value growth based on the experience of a particular market strategy. The income on our trading account securities is designed to substantially offset: (i) the change in value of embedded derivatives related to modified coinsurance agreements described below; and (ii) certain amounts included in insurance policy benefits related to the aforementioned annuity products.

Change in value of embedded derivatives related to modified coinsurance agreements is described in the note to our consolidated financial statements entitled "Summary of Significant Accounting Policies - Accounting for Derivatives." We have transferred the specific block of investments related to these agreements to our trading securities account, which we carry at estimated fair value with changes in such value recognized as trading account income. The change in the value of the

embedded derivatives has largely been offset by the change in value of the trading securities.

Net investment income on other trading accounts includes: (i) the change in the fair value of a trading securities portfolio; and (ii) the change in fair value of interest rate swaps. The trading securities were carried at estimated fair value with changes in such value recognized as trading income. The change in the value of the interest rate swaps was recognized in trading income. Prior to December 31, 2007, these fixed rate securities were sold and the associated interest rate swaps were terminated.

Insurance policy benefits were affected by a number of items as summarized below.

Insurance margins (insurance policy income less insurance policy benefits) related to life products were \$(.2) million, \$28.9 million and \$37.7 million in 2007, 2006 and 2005, respectively. Such declines were primarily due to increased death claims.

Insurance policy benefits also fluctuated as a result of the factors summarized below for benefit ratios. Benefit ratios are calculated by dividing the related insurance product's insurance policy benefits by insurance policy income.

In 2006 and 2005, the benefit ratios on Conseco Insurance Group's Medicare supplement products were impacted by an increase in policyholder lapses following our premium rate increase actions and competition from companies offering Medicare Advantage products. We establish active life reserves for these policies, which are in addition to amounts required for incurred claims. When policies lapse, active life reserves for such lapsed policies are released, resulting in decreased insurance policy benefits (although such decrease is substantially offset by additional amortization expense). In addition, the insurance product liabilities we establish for our Medicare supplement business are subject to significant estimates and the ultimate claim liability we incur for a particular period is likely to be different than our initial estimate. Our insurance policy benefits reflected claim reserve redundancies from prior years of \$1.0 million, \$5.4 million and \$6.5 million in 2007, 2006 and 2005, respectively. Excluding the effects of prior year claim reserve redundancies, our benefit ratios for the Medicare supplement block would have been 68.0 percent, 64.1 percent and 61.5 percent in 2007, 2006 and 2005, respectively. Governmental regulations generally require us to attain and maintain a ratio of total benefits incurred to total premiums earned (excluding changes in policy benefit reserves), after three years from the original issuance of the policy and over the lifetime of the policy, of not less than 65 percent on these products, as determined in accordance with statutory accounting principles. Insurance margins (insurance policy income less insurance policy benefits) on these products were \$74.9 million, \$97.6 million and \$122.2 million in 2007, 2006 and 2005, respectively. Such decreases are primarily due to a higher benefit ratio and a smaller inforce block of business.

Conseco Insurance Group's specified disease products generally provide fixed or limited benefits. For example, payments under cancer insurance policies are generally made directly to, or at the direction of, the policyholder following diagnosis of, or treatment for, a covered type of cancer. Approximately three-fourths of our specified disease policies inforce (based on policy count) are sold with return of premium or cash value riders. The return of premium rider generally provides that after a policy has been inforce for a specified number of years or upon the policyholder reaching a specified age, we will pay to the policyholder, or a beneficiary under the policy, the aggregate amount of all premiums paid under the policy, without interest, less the aggregate amount of all claims incurred under the policy. The cash value rider is similar to the return of premium rider, but also provides for payment of a graded portion of the return of premium benefit if the policy terminates before the return of premium benefit is earned. Accordingly, the net cash flows from these products generally result in the accumulation of amounts in the early years of a policy (accounted for as reserve increases) which will be paid out as benefits in later policy years (accounted for as reserve decreases). As the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by investment income earned on the accumulated assets.

The benefit ratio will fluctuate depending on the claim experience during the year. Insurance margins (insurance policy income less insurance policy benefits) on these products were \$79.7 million, \$80.8 million and \$71.1 million in 2007, 2006 and 2005, respectively.

The benefit ratios on Conseco Insurance Group's other products are subject to fluctuations due to the smaller size of these blocks of business. We no longer actively market these products.

During the fourth quarter of 2007, we recognized additional insurance policy benefits of \$2.0 million to increase our insurance product liabilities. This increase primarily affects our best estimate of the costs associated with enhancing certain benefits related to a block of excess interest whole life policies in response to various issues in how the policies had been administered. We recognized additional insurance policy benefits of \$8.0 million during the fourth quarter of 2006 based on our

prior estimate of the enhanced benefits associated with these same policies and administrative issues. The policies affected by the adjustments described above were issued through a subsidiary prior to its acquisition by Conseco in 1997.

Amounts added to policyholder account balances for annuity products and interest-sensitive life products were \$217.4 million, \$251.9 million and \$254.5 million in 2007, 2006 and 2005, respectively. The fluctuations are primarily due to a smaller block of annuity business in force due to: (i) lapses exceeding new sales in recent periods; and (ii) the completion of an annuity coinsurance transaction in the third quarter of 2007 as further discussed in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Reinsurance". The weighted average crediting rates for these products were 4.1 percent, 4.1 percent and 4.0 percent in 2007, 2006 and 2005, respectively.

Amounts added to equity-indexed products generally fluctuate with the corresponding related investment income accounts described above. In addition, in 2006, we reduced such amounts by \$8.5 million to reflect a change in the assumptions for the cost of options underlying our equity-indexed products as described below under amortization related to operations. Such decreases were partially offset by a \$4.7 million increase in amortization of insurance acquisition costs related to the assumption changes.

Amortization related to operations includes amortization of insurance acquisition costs. Insurance acquisition costs are generally amortized either:

(i) in relation to the estimated gross profits for universal life and investment-type products; or (ii) in relation to actual and expected premium revenue for other products. In addition, for universal life and investment-type products, we are required to adjust the total amortization recorded to date through the statement of operations if actual experience or other evidence suggests that earlier estimates of future gross profits should be revised. Accordingly, amortization for universal life and investment-type products is dependent on the profits realized during the period and on our expectation of future profits. For other products, we amortize insurance acquisition costs in relation to actual and expected premium revenue, and amortization is only adjusted if expected premium revenue changes or if we determine the balance of these costs is not recoverable from future profits. Lapse rates on our Medicare supplement products have impacted our estimates of future expected premium income and, accordingly, we recognized increased (decreased) amortization expense of \$(3.9) million and \$7.1 million in 2007 and 2006, respectively. The assumptions we use to estimate our future gross profits and premiums involve significant judgment. A revision to our current assumptions could result in increases or decreases to amortization expense in future periods.

During 2007, we were required to accelerate the amortization of insurance acquisition costs related to our universal life products because the prior balance was not recoverable by the value of future estimated gross profits on this block. This additional amortization was necessary so that our insurance acquisition costs would not exceed the value of future estimated gross profits and is expected to continue to be recognized in subsequent periods. Because our insurance acquisition costs are now equal to the value of future estimated gross profits, this block is expected to generate break-even earnings in the future. We continue to hold insurance acquisition costs of approximately \$140 million related to these products, which we determined are recoverable by the value of estimated gross profits. In addition, results for this block are expected to exhibit increased volatility in the future, because the entire difference between our assumptions and actual experience is expected to be reflected in earnings in the period such differences occur.

During the fourth quarter of 2007, we recognized additional amortization expense of \$14.8 million to reflect changes in our estimates of future mortality rates on our universal life business, net of planned increases to associated policyholder charges.

During the fourth quarter of 2006, we recognized additional amortization expense of \$7.8 million to reflect a change in an actuarial assumption related to a block of interest-sensitive life insurance policies based on a change in management's intent on the administration of such policies. The policies affected by the adjustments described above were issued through a subsidiary prior to its acquisition by Conseco in 1996.

During the first quarter of 2006, we made certain adjustments to our assumptions of expected future profits for the annuity and universal life blocks of business in this segment related to investment returns, lapse rates, the cost of options underlying our equity-indexed products and other refinements. We recognized additional amortization expense of \$12.4 million in the first quarter of 2006 due to these changes. This increase to amortization expense was offset by a reduction to insurance policy benefit expense of \$11.5 million, to reflect the effect of the changes in these assumptions on the calculation of certain insurance liabilities, such as the liability to purchase future options underlying our equity-indexed products. Also, during the second quarter of 2006, we changed our estimates of the future gross profits of certain universal life products, which under certain circumstances are eligible for interest bonuses in addition to the declared base rate. These interest bonuses are not required in the current crediting rate environment and our estimates of future gross profits have been changed

to reflect the discontinuance of the bonus. We reduced amortization expense by \$4.0 million during the second quarter of 2006 as a result of this change.

Interest expense on investment borrowings includes \$16.7 million of interest expense on collateralized borrowings in 2007 as further described in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Investment Borrowings and Interest Rate Swaps".

Costs related to a litigation settlement include legal fees and estimated amounts related to a settlement in the class action case referred to as In Re Conesco Life Insurance Company Cost of Insurance Litigation. The costs related to the litigation settlement recognized in 2007 represent changes to our initial estimates based on the ultimate cost of the settlement, including the effect of the sale of shares of our common stock distributed for the benefit of the plaintiffs pursuant to the bankruptcy plan of our Predecessor at lower market prices than previously reflected. For further information related to this case, refer to the caption entitled "Cost of Insurance Litigation" included in the note to our consolidated financial statements entitled "Commitments and Contingencies". A portion of the legal and other costs related to this litigation were incurred by the Corporate Operations segment to defend the non-insurance company allegations made in such lawsuits.

Loss related to an annuity coinsurance transaction resulted from the completion of a transaction to coinsure 100 percent of most of the older inforce equity-indexed annuity and fixed annuity business of three of our insurance subsidiaries with REALIC, a subsidiary of Swiss Re Life & Health America, Inc. Refer to the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Reinsurance" for further information about the transaction.

Other operating costs and expenses were \$283.5 million, \$278.3 million and \$262.9 million in 2007, 2006 and 2005, respectively. Other operating costs and expenses include commissions and other operating expenses. During 2007, the Company recognized expenses of \$7.3 million related to the decision to abandon certain software that will not be used consistent with our current business plan and \$3.7 million of costs related to other operational initiatives and consolidation activities. Other operating costs and expenses include the follow (dollars in millions):

	2007	2006	2005
	----	----	----
Commission expenses.....	\$ 79.3	\$ 87.1	\$ 94.2
Other operating expense.....	204.2	191.2	185.1
Expense recoveries related to bankruptcy.....	-	-	(7.6)
Amounts related to postretirement plan.....	-	-	(8.8)
	-----	-----	-----
	\$283.5	\$278.3	\$262.9
	=====	=====	=====

Net realized investment gains (losses) fluctuate each period. During 2007, net realized investment losses in this segment included: (i) \$44.1 million from the sales of investments (primarily fixed maturities); (ii) \$14.2 million of writedowns of investments resulting from declines in fair values that we concluded were other than temporary; and (iii) \$73.7 million of writedowns of investments (which were subsequently transferred pursuant to a coinsurance agreement as further discussed in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Reinsurance") as a result of our intent not to hold such investments for a period of time sufficient to allow for any anticipated recovery in value. The net investment losses realized on sales of investments in 2007 were primarily recognized on securities collateralized by sub prime residential mortgage loans. We decided to sell these securities given our concerns regarding the effect future adverse developments could have on the future value of these securities. For further information on our sub prime holdings, refer to the caption entitled "Structured Securities Collateralized by Sub Prime Residential Mortgage Loans" in the "Investments" section of Management's Discussion and Analysis of Financial Condition and Results of Operations. During 2006, net realized investment losses included \$10.5 million of net losses from the sales of investments (primarily fixed maturities), and \$9.0 million of writedowns of investments resulting from declines in fair values that we concluded were other than temporary. During 2005, net realized investment gains included \$6.0 million of net gains from the sales of investments (primarily fixed maturities), net of \$4.4 million of writedowns of investments resulting from declines in fair values that we concluded were other than temporary.

Amortization related to net realized investment gains (losses) is the increase or decrease in the amortization of insurance acquisition costs which results from realized investment gains or losses. When we sell securities which back our universal life and investment-type products at a gain (loss) and reinvest the proceeds at a different yield, (or when we no longer have the intent to hold impaired investments for a period of time sufficient to allow for any anticipated recovery), we

increase (reduce) the amortization of insurance acquisition costs in order to reflect the change in estimated gross profits due to the gains (losses) realized and the resulting effect on estimated future yields. Sales of fixed maturity investments resulted in a decrease in the amortization of insurance acquisition costs of \$33.2 million, \$6.9 million and \$1.8 million in 2007, 2006 and 2005, respectively.

Colonial Penn (dollars in millions)

	2007 ----	2006 ----	2005 ----
Premium collections:			
Life.....	\$113.7	\$ 97.2	\$ 85.1
Supplemental health.....	10.4	12.0	13.8
	-----	-----	-----
Total collections.....	\$124.1	\$109.2	\$ 98.9
	=====	=====	=====
Average liabilities for insurance products:			
Annuities:			
Mortality based.....	\$ 85.3	\$ 86.9	\$ 89.5
Deposit based.....	4.2	3.9	4.2
Health.....	22.9	25.6	29.0
Life:			
Interest sensitive.....	25.9	27.6	29.0
Non-interest sensitive.....	558.9	553.6	555.7
	-----	-----	-----
Total average liabilities for insurance products, net of reinsurance ceded.....	\$697.2	\$697.6	\$707.4
	=====	=====	=====
Revenues:			
Insurance policy income.....	\$125.8	\$112.1	\$101.3
Net investment income:			
General account invested assets.....	37.8	38.2	38.2
Trading account income related to reinsurer accounts.....	(.2)	(4.3)	(6.1)
Change in value of embedded derivatives related to modified coinsurance agreements.....	.2	4.3	6.1
Fee revenue and other income.....	.7	.6	.7
	-----	-----	-----
Total revenues.....	164.3	150.9	140.2
	-----	-----	-----
Expenses:			
Insurance policy benefits.....	101.0	95.1	88.1
Amounts added to annuity and interest-sensitive life product account balances.....	1.2	1.3	1.6
Amortization related to operations.....	20.3	17.3	15.1
Interest expense on investment borrowings.....	-	-	.4
Other operating costs and expenses.....	23.7	15.6	15.0
	-----	-----	-----
Total benefits and expenses.....	146.2	129.3	120.2
	-----	-----	-----
Income before net realized investment gains (losses) and income taxes.....	18.1	21.6	20.0
Net realized investment gains (losses).....	(.2)	.2	.6
	-----	-----	-----
Income before income taxes.....	\$ 17.9	\$ 21.8	\$ 20.6
	=====	=====	=====

Reinsurance recapture: In the fourth quarter of 2007, we completed the recapture of a block of traditional life insurance inforce that had been ceded under a coinsurance agreement with REALIC. The recapture of this block resulted in a \$2.8 million gain accounted for as a reduction to insurance policy benefits. During 2008, we expect to recognize net income before tax of approximately \$6.0 million on the business recaptured.

Total premium collections increased by 14 percent, to \$124.1 million, in 2007 and by 10 percent, to \$109.2 million in 2006. See "Premium Collections" for further analysis of Colonial Penn's premium collections.

Average liabilities for insurance products, net of reinsurance ceded, did not fluctuate significantly during the three years ended December 31, 2007.

Insurance policy income is comprised of premiums earned on policies which provide mortality or morbidity coverage and fees and other charges assessed on other policies. See "Premium Collections" for further analysis.

Net investment income on general account invested assets (which excludes income on policyholder and reinsurer accounts) did not fluctuate significantly during the three years ended December 31, 2007. The decrease in average invested assets was offset by higher investment yields. The average balance of general account invested assets was \$660.6 million in 2007, \$688.5 million in 2006 and \$726.9 million in 2005. The average yield on these assets was 5.72 percent in 2007, 5.55 percent in 2006 and 5.26 percent in 2005.

Trading account income related to reinsurer accounts represents the income on trading securities, which are designed to act as hedges for embedded derivatives related to certain modified coinsurance agreements. The income on our trading account securities is designed to be substantially offset by the change in value of embedded derivatives related to modified coinsurance agreements described below.

Change in value of embedded derivatives related to modified coinsurance agreements is described in the note to our consolidated financial statements entitled "Summary of Significant Accounting Policies - Accounting for Derivatives." We have transferred the specific block of investments related to these agreements to our trading account, which we carry at estimated fair value with changes in such value recognized as trading account income. We expect the change in the value of the embedded derivatives to be largely offset by the change in value of the trading securities. As a result of the recapture of the modified coinsurance agreement in the fourth quarter of 2007 (as further discussed below under insurance policy benefits), the embedded derivative related to the agreement was eliminated. The trading account securities designed to act as hedges for the embedded derivative are expected to be sold in 2008.

Insurance policy benefits fluctuated as a result of the growth in this segment in recent periods. In addition, insurance policy benefits have been reduced by \$2.8 million in 2007 as a result of completing the recapture of a block of traditional life insurance in force that had been ceded in 2002 to REALIC. In the transaction, which had an effective date of October 1, 2007, Colonial Penn paid REALIC a recapture fee of \$63 million. Colonial Penn recaptured 100 percent of the liability for the future benefits previously ceded, and will recognize profits from the block as they emerge over time. Colonial Penn already administers the policies that were recaptured.

Amortization related to operations includes amortization of insurance acquisition costs. Insurance acquisition costs in the Colonial Penn segment are amortized in relation to actual and expected premium revenue, and amortization is only adjusted if expected premium revenue changes or if we determine the balance of these costs is not recoverable from future profits. Such amounts were generally consistent with the related premium revenue and gross profits for such periods and the assumptions we made when we established the value of policies in force as of the Effective Date. A revision to our current assumptions could result in increases or decreases to amortization expense in future periods.

Other operating costs and expenses in our Colonial Penn segment increased by 52 percent, to \$23.7 million, in 2007 as compared to 2006 primarily due to the initial marketing costs associated with a pilot program involving the distribution of Coventry's PFFS plan through our direct response distribution channel. Excluding these costs, other operating costs and expenses were comparable in 2007, 2006 and 2005.

Net realized investment gains fluctuated each period. During 2007, net realized investment gains in this segment included \$.4 million of net gains from the sales of investments (primarily fixed maturities), net of \$.6 million of writedowns of investments resulting from declines in fair values that we concluded were other than temporary. During 2006, net realized investment gains in this segment included \$.4 million of net gains from the sales of investments (primarily fixed maturities), net of \$.2 million of writedowns of investments resulting from declines in fair values that we concluded were other than temporary. During 2005, net realized investment gains in this segment included \$.6 million of net gains from the sales of investments (primarily fixed maturities). There were no writedowns in the Colonial Penn segment in 2005.

Other Business in Run-off (dollars in millions)

	2007 ----	2006 ---- (Restated)	2005 ---- (Restated)
Premium collections (all of which are renewal premiums):			
Long-term care.....	\$ 305.8	\$ 323.0	\$ 349.1
Major medical.....	2.3	4.8	2.8
	-----	-----	-----
Total collections.....	\$ 308.1	\$ 327.8	\$ 351.9
	=====	=====	=====
Average liabilities for insurance products:			
Long-term care.....	\$3,350.2	\$3,232.6	\$3,295.3
Major medical.....	24.5	29.2	41.5
	-----	-----	-----
Total average liabilities for insurance products, net of reinsurance ceded.....	\$3,374.7	\$3,261.8	\$3,336.8
	=====	=====	=====
Revenues:			
Insurance policy income.....	\$ 312.1	\$ 336.6	\$ 359.1
Net investment income on general account invested assets.....	193.9	179.5	177.6
Fee revenue and other income.....	.4	.4	.5
	-----	-----	-----
Total revenues.....	506.4	516.5	537.2
	-----	-----	-----
Expenses:			
Insurance policy benefits.....	588.9	448.9	336.2
Amortization related to operations.....	23.2	18.9	24.0
Other operating costs and expenses.....	80.2	83.2	86.1
	-----	-----	-----
Total benefits and expenses.....	692.3	551.0	446.3
	-----	-----	-----
Income (loss) before net realized investment gains (losses) and income taxes.....	(185.9)	(34.5)	90.9
	-----	-----	-----
Net realized investment gains (losses).....	2.9	(8.0)	.5
	-----	-----	-----
Income (loss) before income taxes.....	\$ (183.0)	\$ (42.5)	\$ 91.4
	=====	=====	=====
Health benefit ratios:			
Insurance policy benefits.....	\$588.9	\$448.9	\$336.2
Benefit ratio (a).....	188.7%	133.4%	93.6%
Interest-adjusted benefit ratio (b).....	127.5%	80.7%	45.0%

-
- (a) We calculate benefit ratios by dividing the related product's insurance policy benefits by insurance policy income.
- (b) We calculate the interest-adjusted benefit ratio (a non-GAAP measure) for long-term care products by dividing such product's insurance policy benefits less interest income on the accumulated assets backing the insurance liabilities by policy income. These are considered non-GAAP financial measures. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP.

These non-GAAP financial measures of "interest-adjusted benefit ratios" differ from "benefit ratios" due to the deduction of interest income on the accumulated assets backing the insurance liabilities from the product's insurance policy benefits used to determine the ratio. Interest income is an important factor in measuring the performance of health products that are expected to be in force for a longer duration of time, are not subject to unilateral changes in provisions (such as non-cancelable or guaranteed renewable contracts) and require the performance of various functions and services (including insurance protection) for an extended period of time. The net cash flows from long-term care products generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve

increases) that will be paid out as benefits in later policy years (accounted for as reserve decreases). Accordingly, as the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by interest income earned on the accumulated assets. The interest-adjusted benefit ratio reflects the effects of the interest income offset. Since interest income is an important factor in measuring the performance of this product, management believes a benefit ratio that includes the effect of interest income is useful in analyzing product performance. We utilize the interest-adjusted benefit ratio in measuring segment performance for purposes of SFAS 131 because we believe that this performance measure is a better indicator of the ongoing businesses and trends in the business. However, the "interest-adjusted benefit ratio" does not replace the "benefit ratio" as a measure of current period benefits to current period insurance policy income. Accordingly, management reviews both "benefit ratios" and "interest-adjusted benefit ratios" when analyzing the financial results attributable to these products. The investment income earned on the accumulated assets backing long-term care reserves in our Other Business in Run-off segment was \$190.9 million, \$177.2 million and \$174.5 million in 2007, 2006 and 2005, respectively.

Total premium collections were \$308.1 million in 2007, down 6.0 percent from 2006 and \$327.8 million in 2006, down 6.8 percent from 2005. In 2003, we ceased marketing the long-term care business and major medical business in this segment. Accordingly, collected premiums will decrease over time as policies lapse, partially offset by premium rate increases. See "Premium Collections" for further analysis.

Average liabilities for insurance products, net of reinsurance ceded were approximately \$3.4 billion in 2007 and \$3.3 billion in both 2006 and 2005.

Insurance policy income is comprised of premiums earned on the segment's long-term care and major medical policies. See "Premium Collections" for further analysis.

Net investment income on general account invested assets increased by 8.0 percent, to \$193.9 million, in 2007 and by 1.1 percent, to \$179.5 million, in 2006. The average balance of general account invested assets was \$3.3 billion, \$3.0 billion and \$3.0 billion in 2007, 2006 and 2005, respectively. The average yield on these assets was 5.93 percent, 5.89 percent and 5.95 percent in 2007, 2006 and 2005, respectively. The increase in yield in 2007 was primarily due to the purchase of securities with longer durations. The yield in 2005 included income of \$2.3 million related to prepayments of securities (including prepayment penalties on mortgages, call premiums on fixed maturities, and acceleration of discount amortization, net of premium amortization). There was no significant prepayment income in 2007 or 2006.

Insurance policy benefits fluctuated primarily as a result of the factors summarized below.

Insurance policy benefits were \$588.9 million in 2007, up 31 percent from 2006 and \$448.9 million in 2006, up 34 percent from 2005.

The benefit ratio on our Other Business in Run-off segment (including the long-term care block and the small remaining major medical block) was 188.7 percent, 133.4 percent and 93.6 percent in 2007, 2006 and 2005, respectively. Benefit ratios are calculated by dividing the product's insurance policy benefits by insurance policy income. Since the insurance product liabilities we establish for long-term care business are subject to significant estimates, the ultimate claim liability we incur for a particular period is likely to be different than our initial estimate. Our insurance policy benefits reflected reserve deficiencies from prior years of \$130.1 million, \$61.7 million and \$58.0 million in 2007, 2006 and 2005, respectively. Excluding the effects of prior year claim reserve deficiencies, our benefit ratios would have been 147.0 percent, 115.0 percent and 77.5 percent in 2007, 2006 and 2005, respectively. These ratios reflect the significantly higher level of incurred claims experienced in 2007 and 2006 resulting in increases in reserves for future benefits as discussed below, adverse development on claims incurred in prior periods as discussed below, and decreases in policy income. The prior period deficiencies have resulted from the impact of paid claim experience being different than prior estimates, changes in actuarial assumptions and refinements to claimant data used to determine claim reserves.

The net cash flows from long-term care products generally cause an accumulation of amounts in the early years of a policy (accounted for as reserve increases) which will be paid out as benefits in later policy years (accounted for as reserve decreases). Accordingly, as the policies age, the benefit ratio will typically increase, but the increase in benefits will be partially offset by investment income earned on the assets which have accumulated. The interest-adjusted benefit ratio for long-term care products is calculated by dividing the insurance product's insurance policy benefits less interest income on the accumulated assets backing the insurance liabilities by insurance policy income. The interest-adjusted benefit ratio on this business was 127.5 percent, 80.7 percent and 45.0 percent in 2007, 2006 and 2005, respectively. Excluding the effects of prior year claim reserve deficiencies, our interest-adjusted benefit ratios would have been 85.8 percent, 62.4 percent and 28.9

percent in 2007, 2006 and 2005, respectively.

This segment includes long-term care insurance in force, which was primarily issued through independent agents by certain subsidiaries prior to their acquisitions by Old Consec in 1996 and 1997. The loss experience on these products has been worse than we originally expected. Although we anticipated a higher level of benefits to be paid on these products as the policies aged, the paid claims have exceeded our expectations. In addition, there has been an increase in the incidence and duration of claims in recent periods. This adverse experience is reflected in the higher insurance policy benefits experienced in 2007 and 2006.

In each quarterly period, we calculate our best estimate of claim reserves based on all of the information available to us at that time, which necessarily takes into account new experience emerging during the period. Our actuaries estimate these claim reserves using various generally recognized actuarial methodologies which are based on informed estimates and judgments that are believed to be appropriate. Additionally, an external actuarial firm provides consulting services which involve a review of the Company's judgments and estimates for claim reserves on the long-term care block in the Other Business in Run-off segment on a quarterly basis. As additional experience emerges and other data become available, these estimates and judgments are reviewed and may be revised. Significant assumptions made in estimating claim reserves for long-term care policies include expectations about the: (i) future duration of existing claims; (ii) cost of care and benefit utilization; (iii) interest rate utilized to discount claim reserves; (iv) claims that have been incurred but not yet reported; (v) claim status on the reporting date; (vi) claims that have been closed but are expected to reopen; and (vii) correspondence that has been received that will ultimately become claims that have payments associated with them.

During the second quarter of 2007, we increased claim liabilities for the long-term care insurance block in our Other Business in Run-off segment by \$118 million as a result of changes in our estimates of claim reserves incurred in prior periods. Approximately \$20 million of this increase related to claims with incurrence dates in the first quarter of 2007 and \$98 million related to claims with incurrence dates prior to 2007.

The \$118 million increase in estimates of claims incurred in prior periods included \$110 million of adjustments related to updates to our reserve assumptions and methodologies to reflect emerging trends in our claim experience. The following assumption changes primarily contributed to the \$110 million adjustment:

- o We increased our reserves by \$37 million for changes to our assumptions regarding the future duration of existing claims. We updated these assumptions to reflect our current expectation that policyholders will receive benefits for a longer period based on changing trends in the duration of our claims.

- o We increased our reserves by \$31 million related to a block of long-term care policies originally sold by Transport Life Insurance Company ("Transport") and acquired by Old Consec. We estimate claim reserves for this block of business using an aggregate paid loss development method, which uses historical payment patterns to project ultimate losses for all the claims in a given incurral period. We refined our loss development assumptions by developing separate assumption tables for claimants with and without lifetime benefit periods and for claimants with and without inflationary benefits, since this block's recent loss experience has been extremely sensitive to the mix of its business. This adjustment further improves the estimate that was made during the first quarter of 2007, which is described in further detail below. This adjustment relates to our assumption of future duration of existing claims.

- o We increased our claim reserves by \$23 million to better reflect fluctuations in claim inventories related to certain blocks of business. This increase relates to our estimate of claim status on the reporting date.

- o We increased our claim reserves by \$17 million for our estimate of incurred but not reported claims, reflecting recent experience and the impact of the other adjustments.

During the first quarter of 2007, we recorded a pre-tax adjustment that increased policy benefits for the Transport block by \$22 million. We found that our previous claim estimates on this block were deficient because claims on policies with lifetime benefits and inflation benefits had increased significantly in recent periods. Since the policies with these benefits will have longer average claim payout periods than similar policies without such benefits, a shift in the mix of claimants can have a significant impact on incurred claims that is not immediately reflected using a completion factor methodology. We improved our methodologies to address this and other shortcomings of the aggregate loss development methodology, which resulted in the pre-tax adjustment.

During the fourth quarter of 2006, we increased claim liabilities for the long-term care insurance block in our Other Business in Run-off segment by \$54.1 million as a result of changes in our estimates of claim reserves incurred in prior periods. Approximately \$24.5 million of this increase related to claims with incurrence dates in the first three quarters of 2006 and \$29.6 million related to claims with incurrence dates prior to 2006.

The \$54.1 million adjustment primarily related to two assumption changes reflecting recent trends we noted in our claims experience in the fourth quarter of 2006:

(i) Benefit utilization assumptions: Most of our long-term care policies provide for the payment of covered benefits up to a maximum daily benefit specified in the policy. When we estimate claim reserves for these policies, we make an assumption regarding the percentage of the maximum daily benefit that will be paid (since not all policyholders will incur claims at the maximum daily benefit level). We base our assumptions on studies of actual experience. Such assumptions are periodically adjusted to reflect current trends. In the fourth quarter of 2006, we updated our studies of benefit utilization. Recent experience reflected a trend that we did not observe in previous studies: policyholders are incurring claims closer to the maximum benefit level, and the ratio of incurred claims to maximum benefits is increasing faster as claims age.

Accordingly, we updated our assumptions to reflect these trends, which had the effect of increasing our claim reserves by approximately \$25 million.

(ii) Liabilities for incurred but not reported claims: In determining the estimate of claims incurred in a particular period, we must make an assumption regarding the ultimate liability for claims that have been incurred but not yet reported to us. This assumption is based on historical studies related to claims that are reported to us after the date of our financial statements, but were incurred prior to the date of our financial statements. For the most recent incurral periods, we apply loss ratio adjustments to our estimates of liabilities for incurred but not reported claims in an effort to ensure the ratio of incurred claims to premiums (incurred loss ratio) related to these estimated unreported claims, reflects recent trends in our experience. During 2006, we experienced a significant increase in the incurred loss ratio for 2005 and 2006 incurral periods. We increased the aforementioned loss ratio adjustments in response to this experience, which had the effect of increasing our claim reserves by approximately \$27 million.

In 2006, we experienced increases in our reserves for future benefits due to higher than expected persistency in this block of business. A small variance in persistency can have a significant impact on our earnings as reserves accumulated over the life of a policy are released when coverage terminates. The effect of changes in persistency will vary based on the mix of business that persists. For example, if policies with higher reserves are persisting and policies with lower reserves are lapsing, our earnings could be adversely affected. We estimate that our income before income taxes would be adversely affected by approximately \$10 million in any period that persistency is 40 basis points higher than our original assumptions and such variance is spread evenly over the mix of business in this block. We also estimate that persistency, which is 40 basis points lower than our assumptions, would favorably affect earnings by a similar amount. If actual persistency rates continue to be higher than our assumed rates, this will have an adverse effect on income in this segment.

We have been aggressively seeking actuarially justified rate increases and pursuing other actions on our long-term care policies. During the third quarter of 2006, we began a new program to file requests for rate increases on various long-term care products in the Other Business in Run-off segment as we believe the existing rates were too low to fund expected future benefits. These filings are expected to be the first of three rounds of rate increase filings for many of the same policies, and in some cases we requested three years of successive rate increases. Based on recent experience, certain of the policies in this segment will continue to be unprofitable even if we obtain the three rounds of rate increases, and it is likely that we will request additional rate increases when the current program is complete. We have chosen to request a series of smaller rate increases, rather than a single large increase, to limit the impact on a policyholder's premiums in any single year. The effects of the first round of rate filings have been partially realized in our premium revenue with the remaining impact expected to be realized by the end of 2008. In the second quarter of 2007, we began filing requests for the second round of rate increases on many of the same policies. As of December 31, 2007, almost all of the expected second round filings had been submitted for regulatory approval, and approximately 42 percent of the expected amounts had been approved by regulators. The full effect of all three rounds of rate increases may not be fully realized until 2011. It is possible that it will take more time than we expect to prepare rate increase filings and obtain approval from the state insurance regulators. In addition, it is likely that we will not be able to obtain approval for some of the actuarially justified rate increases currently pending or for the additional rate increases we plan to file especially in light of the magnitude of some past premium rate increases and current consumer and regulator sentiment. Most of our long-term care business is guaranteed renewable, and, if necessary rate increases are not approved, we may be required to write off all or a portion of

the insurance acquisition costs and establish a premium deficiency reserve. If we are unable to raise our premium rates because we fail to obtain approval for actuarially justified rate increases in one or more states, our financial condition and results of operations could be adversely affected.

On April 20, 2004, the Florida Office of Insurance Regulation issued an order to our subsidiary, Conseco Senior, that affected approximately 12,600 home health care policies issued in Florida by Conseco Senior and its predecessor companies. On July 1, 2004, the Florida Office of Insurance Regulation issued a similar order impacting approximately 4,800 home health care policies issued in Florida by our subsidiary, Washington National, and its predecessor companies. Pursuant to the Orders, Conseco Senior and Washington National offered the following three alternatives to holders of these policies subject to rate increases as follows:

o retention of their current policy with a rate increase of 50 percent in the first year and actuarially justified increases in subsequent years (which is also the default election for policyholders who failed to make an election by 30 days prior to the anniversary date of their policies) ("option one");

o receipt of a replacement policy with reduced benefits and a rate increase in the first year of 25 percent and no more than 15 percent in subsequent years ("option two"); or

o receipt of a paid-up policy, allowing the holder to file future claims up to 100 percent of the amount of premiums paid since the inception of the policy ("option three").

Policyholders selecting option one or option two are entitled to receive a contingent non-forfeiture benefit if their policy subsequently lapses. In addition, policyholders could change their initial election any time up to 30 days prior to the anniversary date of their policies. We began to implement premium adjustments with respect to policyholder elections in the fourth quarter of 2005 and the implementation of these premium adjustments was completed in 2007. We did not make any adjustments to the insurance liabilities when these elections were made. Reserves for all three groups of policies under the order were prospectively adjusted using the prospective revision methodology described in the "Critical Accounting Policies - Accounting for Long-term Care Premium Rate Increases" in "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations".

The orders also require Conseco Senior and Washington National to pursue a similar course of action with respect to approximately 24,000 home health care policies in other states, subject to such actions being justified based on the experience of the business and approval by the other state insurance departments. If we are unsuccessful in obtaining rate increases or other forms of relief in those states, or if the policy changes approved by the Florida Office of Insurance Regulation prove inadequate, our future results of operations could be adversely affected.

Amortization related to operations includes amortization of insurance acquisition costs. Fluctuations in amortization of insurance acquisition costs in this segment generally correspond with changes in lapse experience.

Other operating costs and expenses were \$80.2 million in 2007, down 3.6 percent from 2006 and \$83.2 million in 2006, down 3.4 percent from 2005. Other operating costs and expenses, excluding commission expenses, for this segment were \$48.3 million in 2007, \$47.0 million in 2006 and \$46.3 million in 2005.

Net realized investment gains (losses) fluctuated each period. During 2007, net realized investment gains in this segment included \$4.2 million from the sales of investments (primarily fixed maturities), net of \$1.3 million of writedowns of investments resulting from declines in fair values that we concluded were other than temporary. During 2006, net realized investment gains included \$.8 million of net gains from the sales of investments (primarily fixed maturities), net of \$8.8 million of writedowns of investments resulting from declines in fair values that we concluded were other than temporary. During 2005, net realized investment gains included \$6.8 million of net gains from the sales of investments (primarily fixed maturities), net of \$6.3 million of writedowns of investments resulting from declines in fair values that we concluded were other than temporary.

Corporate Operations (dollars in millions)

	2007	2006	2005
	----	----	----
Corporate operations:			
Interest expense on corporate debt.....	\$ (72.3)	\$ (52.9)	\$ (48.1)
Investment income	6.6	4.6	5.4
Fee revenue and other income.....	9.8	10.9	20.2
Net operating results of variable interest entity.....	9.2	4.9	.1
Costs related to a litigation settlement.....	(32.2)	(8.9)	(9.1)
Other operating costs and expenses.....	(42.4)	(38.6)	(49.6)
Loss on extinguishment of debt.....	-	(.7)	(3.7)
	-----	-----	-----
Loss before net realized investment losses and income taxes.....	(121.3)	(80.7)	(84.8)
Net realized investment losses.....	(6.2)	(.4)	(1.4)
	-----	-----	-----
Loss before income taxes.....	\$(127.5)	\$(81.1)	\$(86.2)
	=====	=====	=====

Interest expense on corporate debt has been impacted by: (i) the repayment or amendment of the Company's credit facilities during each of the last three years; and (ii) the issuance in 2005 of \$330 million of 3.5 percent convertible debentures due September 30, 2035. These transactions are further discussed in the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations". Our average corporate debt outstanding was \$1,111.8 million, \$864.3 million and \$773.4 million in 2007, 2006 and 2005, respectively. The average interest rate on our debt was 6.2 percent, 5.7 percent and 5.9 percent in 2007, 2006 and 2005, respectively.

Investment income primarily included income earned on short-term investments held by the Corporate segment and miscellaneous other income and fluctuated along with the change in the amount of invested assets in this segment.

Fee revenue and other income includes: (i) revenues we receive for managing investments for other companies; and (ii) fees received for marketing insurance products of other companies. In 2007, our wholly owned investment management subsidiary recognized performance-based fees of \$2.4 million resulting from the liquidation of two portfolios that were managed by the subsidiary. In 2005, our wholly owned investment management subsidiary recognized a performance-based fee of \$8.1 million earned in conjunction with its management of a \$510 million portfolio of loans for an issuer of structured securities. This portfolio was liquidated and the related securities were redeemed on September 1, 2005, resulting in the receipt of this fee which was largely based on the market value of the managed loan portfolio at the redemption date. Excluding such performance-based fees, fee revenue and other income has decreased primarily as a result of a decrease in the market value of investments managed for others, upon which these fees are based.

Net operating results of variable interest entity represent the operating results of a variable interest entity ("VIE"). The VIE is consolidated in accordance with Financial Accounting Standards Board Interpretation No. 46 "Consolidation of Variable Interest Entities", revised December 2003. Although we do not control this entity, we consolidate it because we are the primary beneficiary. This entity was established to issue securities and use the proceeds to invest in loans and other permitted assets.

Costs related to a litigation settlement include legal and other costs incurred by the Corporate Operations segment to defend the non-insurance company allegations made in the class action case referred to as In Re Conseco Life Insurance Company Cost of Insurance Litigation. Refer to the captions entitled:

(i) "Costs related to the tentative litigation settlement" included in the results of operations section for the Conseco Insurance Group segment; and (ii) "Cost of Insurance Litigation" included in the note to our consolidated financial statements entitled "Commitments and Contingencies" for further information related to this case.

Other operating costs and expenses include general corporate expenses, net of amounts charged to subsidiaries for services provided by the corporate operations. These amounts fluctuate as a result of expenses such as consulting, legal and severance costs which often vary from period to period. In 2006 and 2005, other operating costs and expenses are net of recoveries of \$3.0 million and \$3.2 million, respectively, related to our evaluation of the collectibility of the D&O loans.

In December 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 123 (revised 2004) "Share-Based Payment" ("SFAS 123R"), which revised SFAS 123 and superseded Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" and related interpretations. SFAS 123R provided additional guidance on accounting for share-based payments and required all such awards to be measured at fair value with the related compensation cost recognized in the statement of operations over the related service period. Consecro implemented SFAS 123R using the modified prospective method on January 1, 2006. Under this method, the Company began recognizing compensation cost for all awards granted on or after January 1, 2006. In addition, we are required to recognize compensation cost over the remaining requisite service period for the portion of outstanding awards that were not vested as of January 1, 2006 and were not previously expensed on a pro forma basis pursuant to SFAS 123. In 2007 and 2006, we recognized compensation expense related to stock options totaling \$7.4 million and \$6.5 million, respectively. Refer to the note to our consolidated financial statements entitled "Shareholders' Equity" for further discussion of our share-based payments.

Loss on extinguishment of debt of \$.7 million in 2006 resulted from the write-off of certain issuance costs and other costs incurred related to the Second Amended Credit Facility. The loss of \$3.7 million in 2005 resulted from the write-off of certain debt issuance costs related to the reduction of the principal amount borrowed under the \$447.0 million secured credit agreement (the "Amended Credit Facility").

Net realized investment losses often fluctuate each period. During 2007, net realized investment losses in this segment included \$4.7 million from the sale of investments (primarily fixed maturities) and \$1.5 million of writedowns due to other-than-temporary declines in value on certain securities. During 2006, net realized investment losses in this segment included \$.4 million from the sale of investments. During 2005, net realized investment losses in this segment included \$.1 million of net losses from the sale of investments (primarily fixed maturities), and \$1.3 million of writedowns due to other-than-temporary declines in value on certain securities.

PREMIUM COLLECTIONS

In accordance with GAAP, insurance policy income in our consolidated statement of operations consists of premiums earned for traditional insurance policies that have life contingencies or morbidity features. For annuity and universal life contracts, premiums collected are not reported as revenues, but as deposits to insurance liabilities. We recognize revenues for these products over time in the form of investment income and surrender or other charges.

Our insurance segments sell products through three primary distribution channels -- career agents (our Bankers Life segment), independent producers (our Consecro Insurance Group segment) and direct marketing (our Colonial Penn segment). Our career agency force in the Bankers Life segment sells primarily Medicare supplement and long-term care insurance policies, Medicare Part D contracts, PFFS contracts, life insurance and annuities. These agents visit the customer's home, which permits one-on-one contact with potential policyholders and promotes strong personal relationships with existing policyholders. Our independent producer distribution channel in the Consecro Insurance Group segment consists of a general agency and insurance brokerage distribution system comprised of independent licensed agents doing business in all fifty states, the District of Columbia, and certain protectorates of the United States. Independent producers are a diverse network of independent agents, insurance brokers and marketing organizations. Our independent producer distribution channel sells primarily specified disease and Medicare supplement insurance policies, universal life insurance and annuities. Our direct marketing distribution channel in the Colonial Penn segment is engaged primarily in the sale of "graded benefit life" and simplified issue life insurance policies which are sold directly to the policyholder.

Agents, insurance brokers and marketing companies who market our products and prospective purchasers of our products use the financial strength ratings of our insurance subsidiaries as an important factor in determining whether to market or purchase. Ratings have the most impact on our annuity, interest-sensitive life insurance and long-term care products. The current financial strength ratings of our primary insurance subsidiaries (except Consecro Senior) from A.M. Best, S&P and Moody's are "B+ (Good)", "BB+" and "Baa3", respectively. The current financial strength ratings of Consecro Senior from A.M. Best, S&P and Moody's are "C++ (Marginal)", "CCC-" and "Caa1", respectively. For a description of these ratings and additional information on our ratings, see "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations -- Liquidity for Insurance Operations."

We set premium rates on our health insurance policies based on facts and circumstances known at the time we issue the policies using assumptions about numerous variables, including the actuarial probability of a policyholder incurring a claim, the probable size of the claim, and the interest rate earned on our investment of premiums. We also consider historical claims information, industry statistics, the rates of our competitors and other factors. If our actual claims experience is less

favorable than we anticipated and we are unable to raise our premium rates, our financial results may be adversely affected. We generally cannot raise our health insurance premiums in any state until we obtain the approval of the state insurance regulator. We review the adequacy of our premium rates regularly and file rate increases on our products when we believe such rates are too low. It is likely that we will not be able to obtain approval for all requested premium rate increases. If such requests are denied in one or more states, our net income may decrease. If such requests are approved, increased premium rates may reduce the volume of our new sales and may cause existing policyholders to lapse their policies. If the healthier policyholders allow their policies to lapse, this would reduce our premium income and profitability in the future.

Total premiums collections were as follows:

Bankers Life (dollars in millions)

	2007 ----	2006 ----	2005 ----
Premiums collected by product:			
Annuities:			
Equity-indexed (first-year).....	\$ 437.4 -----	\$ 276.5 -----	\$ 130.3 -----
Other fixed (first-year).....	445.3	718.1	818.0
Other fixed (renewal).....	2.8	2.9	2.8
Subtotal - other fixed annuities.....	448.1 -----	721.0 -----	820.8 -----
Total annuities.....	885.5 -----	997.5 -----	951.1 -----
Supplemental health:			
Medicare supplement (first-year).....	82.5	97.8	74.1
Medicare supplement (renewal).....	553.6	531.3	564.7
Subtotal - Medicare supplement.....	636.1 -----	629.1 -----	638.8 -----
Long-term care (first-year).....	47.0	51.2	65.4
Long-term care (renewal).....	575.4	541.2	498.8
Subtotal - long-term care.....	622.4 -----	592.4 -----	564.2 -----
PDP and PFFS (first year).....	206.4	76.7	-
PDP (renewal).....	71.4	-	-
Subtotal - PDP and PFFS.....	277.8 -----	76.7 -----	- -----
Other health (first-year).....	.9	1.0	1.1
Other health (renewal).....	8.9	9.1	9.6
Subtotal - other health.....	9.8 -----	10.1 -----	10.7 -----
Total supplemental health.....	1,546.1 -----	1,308.3 -----	1,213.7 -----
Life insurance:			
First-year.....	89.2	90.3	74.1
Renewal.....	110.8	93.9	78.0
Total life insurance.....	200.0 -----	184.2 -----	152.1 -----
Collections on insurance products:			
Total first-year premium collections on insurance products.....	1,308.7	1,311.6	1,163.0
Total renewal premium collections on insurance products.....	1,322.9 -----	1,178.4 -----	1,153.9 -----
Total collections on insurance products.....	\$2,631.6 =====	\$2,490.0 =====	\$2,316.9 =====

Annuities in this segment include equity-indexed and other fixed annuities sold to the senior market through our career agents. Annuity collections in this segment decreased by 11 percent, to \$885.5 million, in 2007 and increased by 4.9 percent to \$997.5 million, in 2006. Premium collections from our equity-indexed products were favorably impacted in 2007 by the

general stock market performance which has made these products attractive to certain customers. Premium collections from our equity-indexed products were favorably impacted in 2006 by: (i) the introduction of new equity-indexed products in late 2005; and (ii) the general stock market performance which has made these products attractive to certain customers. The increase in short-term interest rates in recent periods resulted in lower first-year fixed annuity sales as certain other competing products, such as certificates of deposits, have become attractive.

Supplemental health products include Medicare supplement, Medicare Part D contracts, PFFS contracts, long-term care and other insurance products distributed through our career agents. Our profits on supplemental health policies depend on the overall level of sales, the length of time the business remains in force, investment yields, claims experience and expense management.

Collected premiums on Medicare supplement policies in the Bankers Life segment increased by 1.1 percent, to \$636.1 million, in 2007 and decreased by 1.5 percent, to \$629.1 million, in 2006. The increase in premium collections of our Medicare supplement products in 2007 is primarily due to higher persistency, partially offset by lower new sales. During the first half of 2006, we experienced higher lapses than we anticipated. We believe such lapses were partially due to the premium rate increases which had been implemented and competition from companies offering Medicare Advantage products.

Premiums collected on Bankers Life's long-term care policies increased by 5.1 percent, to \$622.4 million, in 2007 and by 5.0 percent, to \$592.4 million, in 2006. The increase in premium collections of our long-term care products in 2007 and 2006 is primarily due to higher premiums associated with the policies that were impacted by the rate increases which became effective in 2007 and 2006.

Premiums collected on PDP and PFFS business relate to various quota-share reinsurance agreements with Coventry. Effective July 1, 2007, we entered into a new PFFS quota-share reinsurance agreement with Coventry pursuant to which we received \$97.3 million of first-year premiums in 2007. These agreements are described in "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations - Critical Accounting Policies".

Other health products relate to collected premiums on other health products which we no longer actively market.

Life products in this segment are sold primarily to the senior market through our career agents. Life premiums collected in this segment increased by 8.6 percent, to \$200.0 million, in 2007 and by 21 percent, to \$184.2 million, in 2006. Collected premiums have been impacted by an increased focus on life products.

Conseco Insurance Group (dollars in millions)

	2007 -----	2006 -----	2005 -----
Premiums collected by product:			
Annuities:			
Equity-indexed (first-year).....	\$ 336.4	\$ 369.4	\$ 94.4
Equity-indexed (renewal).....	8.2	9.1	10.0
	-----	-----	-----
Subtotal - equity-indexed annuities.....	344.6	378.5	104.4
	-----	-----	-----
Other fixed (first-year).....	18.0	46.1	47.5
Other fixed (renewal).....	6.0	8.7	9.8
	-----	-----	-----
Subtotal - other fixed annuities.....	24.0	54.8	57.3
	-----	-----	-----
Total annuities.....	368.6	433.3	161.7
	-----	-----	-----
Supplemental health:			
Medicare supplement (first-year).....	19.4	30.6	15.8
Medicare supplement (renewal).....	206.5	213.6	273.0
	-----	-----	-----
Subtotal - Medicare supplement.....	225.9	244.2	288.8
	-----	-----	-----
Specified disease (first-year).....	31.4	28.1	30.6
Specified disease (renewal).....	327.8	329.6	328.9
	-----	-----	-----
Subtotal - specified disease.....	359.2	357.7	359.5
	-----	-----	-----
Other health (first-year).....	.3	-	-
Other health (renewal).....	9.0	9.7	13.2
	-----	-----	-----
Subtotal - other health.....	9.3	9.7	13.2
	-----	-----	-----
Total supplemental health.....	594.4	611.6	661.5
	-----	-----	-----
Life insurance:			
First-year.....	4.7	6.7	8.2
Renewal.....	282.6	307.9	326.8
	-----	-----	-----
Total life insurance.....	287.3	314.6	335.0
	-----	-----	-----
Collections on insurance products:			
Total first-year premium collections on insurance products.....	410.2	480.9	196.5
Total renewal premium collections on insurance products.....	840.1	878.6	961.7
	-----	-----	-----
Total collections on insurance products.....	\$1,250.3	\$1,359.5	\$1,158.2
	=====	=====	=====

Annuities in this segment include equity-indexed and other fixed annuities sold through professional independent producers. Total annuity collected premiums in this segment decreased by 15 percent, to \$368.6 million, in 2007 and increased by 168 percent, to \$433.3 million, in 2006.

Our equity-indexed annuities have guaranteed minimum cash surrender values, but have potentially higher returns based on a percentage of the change in one of several equity market indices during each year of their term. We purchase options in an effort to hedge increases to policyholder benefits resulting from increases in the indices. Total collected premiums for these products decreased by 9.0 percent, to \$344.6 million, in 2007 and increased by 263 percent, to \$378.5 million, in 2006. During the second half of 2007, we changed the pricing of specific products and we no longer emphasized the sale of certain products resulting in a decrease in collected premiums, partially offset by the sales of several new products distributed through our new national partners. Collected premiums for these products increased in 2006 due to the introduction of several new products. In addition, these products have become relatively attractive due to general stock market conditions in recent periods.

Other fixed rate annuity products include SPDAs, FPDAs and SPIAs, which are credited with a declared rate. SPDA

and FPDA policies typically have an interest rate that is guaranteed for the first policy year, after which we have the discretionary ability to change the crediting rate to any rate not below a guaranteed minimum rate. The interest rate credited on SPIAs is based on market conditions existing when a policy is issued and remains unchanged over the life of the SPIA. Annuity premiums on these products decreased by 56 percent, to \$24.0 million, in 2007 and by 4.4 percent, to \$54.8 million, in 2006. The increase in short-term interest rates in 2007 resulted in lower first-year fixed annuity sales as certain other competing products have become attractive. During the last six months of 2005, collected premiums for these products were impacted by attractive crediting rates on certain products.

Supplemental health products in the Conseco Insurance Group segment include Medicare supplement, specified disease and other insurance products distributed through professional independent producers. Our profits on supplemental health policies depend on the overall level of sales, the length of time the business remains in force, investment yields, claim experience and expense management.

Collected premiums on Medicare supplement policies in the Conseco Insurance Group segment decreased by 7.5 percent, to \$225.9 million, in 2007 and by 15 percent, to \$244.2 million, in 2006. We have experienced lower sales and higher lapses of these products in 2007 and 2006 due to premium rate increases implemented in recent periods and competition from companies offering Medicare Advantage products.

Premiums collected on specified disease products have been comparable from period to period.

First-year premiums collected on other health products are due to the introduction of a new short-term disability product in the fourth quarter of 2007. Renewal premiums collected from other health products decreased by 7.2 percent, to \$9.0 million, in 2007 and by 27 percent, to \$9.7 million, in 2006. Renewal premiums have decreased from period to period as we no longer actively market many of these products.

Life products in the Conseco Insurance Group segment are sold through professional independent producers. Life premiums collected decreased by 8.7 percent, to \$287.3 million, in 2007 and by 6.1 percent, to \$314.6 million, in 2006.

Colonial Penn (dollars in millions)

	2007 ----	2006 ----	2005 ----
Premiums collected by product:			
Life insurance:			
First-year.....	\$ 28.7	\$ 22.9	\$19.4
Renewal.....	85.0	74.3	65.7
	-----	-----	-----
Total life insurance.....	113.7	97.2	85.1
	-----	-----	-----
Supplemental health (all of which are renewal premiums):			
Medicare supplement.....	9.4	10.9	12.4
Other health.....	1.0	1.1	1.4
	-----	-----	-----
Total supplemental health.....	10.4	12.0	13.8
	-----	-----	-----
Collections on insurance products:			
Total first-year premium collections on insurance products.....	28.7	22.9	19.4
Total renewal premium collections on insurance products.....	95.4	86.3	79.5
	-----	-----	-----
Total collections on insurance products.....	\$124.1	\$109.2	\$98.9
	=====	=====	=====

Life products in this segment are sold primarily to the senior market. Life premiums collected in this segment increased by 17 percent, to \$113.7 million, in 2007 and by 14 percent, to \$97.2 million, in 2006. Collected premiums have been affected by increased advertising. Graded benefit life products sold through our direct response marketing channel

accounted for \$108.8 million, \$92.3 million and \$81.2 million of collected premiums in 2007, 2006 and 2005, respectively.

Supplemental health products include Medicare supplement and other insurance products. Our profits on supplemental health policies depend on the overall level of sales, the length of time the business remains in force, investment yields, claims experience and expense management. Premiums collected on these products have decreased as we do not currently market these products through this segment.

Other Business in Run-Off (dollars in millions)

	2007	2006	2005
	----	----	----
Premiums collected by product (all of which are renewal premiums):			
Long-term care.....	\$305.8	\$323.0	\$349.1
Major medical.....	2.3	4.8	2.8
	-----	-----	-----
Total premium collections on insurance products.....	\$308.1	\$327.8	\$351.9
	=====	=====	=====

The Other Business in Run-off segment includes blocks of business that we no longer market or underwrite and are managed separately from our other businesses. This segment consists of: (i) long-term care insurance sold in prior years through independent agents; and (ii) major medical insurance.

Long-term care premiums collected in this segment decreased by 5.3 percent, to \$305.8 million, in 2007 and by 7.5 percent, to \$323.0 million, in 2006. Most of the long-term care premiums in this segment relate to business written by certain subsidiaries prior to their acquisitions by Old Consecro in 1996 and 1997 and was sold through the independent producer distribution channel. The performance of this business did not meet the expectations we had when the blocks were acquired. As a result, we ceased selling new long-term care policies through this distribution channel in 2003. We expect this segment's long-term care premiums to reflect additional policy lapses in the future, partially offset by premium rate increases.

INVESTMENTS

Our investment strategy is to: (i) maintain a predominately investment-grade fixed income portfolio; (ii) provide liquidity to meet our cash obligations to policyholders and others; and (iii) generate stable and predictable investment income through active investment management. Consistent with this strategy, investments in fixed maturity securities, mortgage loans and policy loans made up 96 percent of our \$23.8 billion investment portfolio at December 31, 2007. The remainder of the invested assets were trading securities, equity securities and other invested assets.

The following table summarizes the composition of our investment portfolio as of December 31, 2007 (dollars in millions):

	Carrying value	Percent of total investments
	-----	-----
Actively managed fixed maturities.....	\$20,510.9	86%
Equity securities.....	34.5	-
Mortgage loans.....	2,086.0	9
Policy loans.....	370.4	1
Trading securities.....	665.8	3
Partnership investments.....	28.3	-
Other invested assets.....	106.0	1
	-----	---
Total investments.....	\$23,801.9	100%
	=====	===

Insurance statutes regulate the types of investments that our insurance subsidiaries are permitted to make and limit the amount of funds that may be used for any one type of investment. In light of these statutes and regulations and our business and investment strategy, we generally seek to invest in United States government and government-agency securities and

corporate securities rated investment grade by established nationally recognized rating organizations or in securities of comparable investment quality, if not rated.

The following table summarizes the estimated fair value of our fixed maturity securities by category as of December 31, 2007 (dollars in millions):

	Estimated fair value	Percent of fixed maturities
	-----	-----
Structured securities.....	\$ 4,668.1	22.8%
Manufacturing.....	3,603.4	17.6
Bank and finance.....	2,039.1	9.9
Utilities.....	1,766.2	8.6
Services.....	1,615.2	7.9
Communications.....	1,088.0	5.3
Agriculture, forestry and mining.....	888.6	4.3
Retail and wholesale.....	799.8	3.9
Holding and other investment offices.....	751.4	3.7
Transportation.....	643.9	3.1
U.S. Government.....	634.6	3.1
States and political subdivisions.....	548.4	2.7
Asset-backed securities.....	440.2	2.1
Other.....	1,024.0	5.0
	-----	-----
Total actively managed fixed maturities.....	\$20,510.9	100.0%
	=====	=====

Our fixed maturity securities consist predominantly of publicly traded securities. We classify securities issued in the Rule 144A market as publicly traded. Securities not publicly traded comprise less than 11 percent of our total fixed maturity securities portfolio.

The following table sets forth fixed maturity investments at December 31, 2007, classified by rating categories. The category assigned is the highest rating by a nationally recognized statistical rating organization or, as to \$1,485.3 million fair value of fixed maturities not rated by such firms, the rating assigned by the NAIC. For purposes of the table, NAIC Class 1 is included in the "A" rating; Class 2, "BBB-"; Class 3, "BB-"; and Classes 4-6, "B+ and below" (dollars in millions):

Investment rating	Amortized cost	Estimated fair value	
		Amount	Percent of fixed maturities
-----	-----	-----	-----
AAA.....	\$ 5,717.8	\$ 5,657.6	28%
AA.....	1,577.0	1,528.5	7
A.....	5,767.3	5,607.2	27
BBB+.....	2,099.4	2,068.5	10
BBB.....	2,479.2	2,428.6	12
BBB-.....	1,673.2	1,629.9	8
	-----	-----	---
Investment grade.....	19,313.9	18,920.3	92
	-----	-----	---
BB+	287.2	270.2	1
BB	235.2	218.5	1
BB-	588.2	569.6	3
B+ and below.....	568.2	532.3	3
	-----	-----	---
Below-investment grade (a).....	1,678.8	1,590.6	8
	-----	-----	---
Total fixed maturity securities.....	\$20,992.7	\$20,510.9	100%
	=====	=====	===

(a) Below-investment grade fixed maturity securities with an amortized cost of \$480.3 million and an estimated fair value of \$455.9 million are securities held by a VIE that we are required to consolidate. These fixed maturity securities are legally isolated and are not available to the Company. The liabilities of such VIE will be satisfied from the cash flows generated by these securities and are not obligations of the Company. Refer to the note to the consolidated financial statements entitled "Investment in a Variable Interest Entity" concerning the Company's commitment to provide additional capital of up to \$25 million to the VIE. At December 31, 2007, our total investment in the VIE was \$47.0 million and such investment was rated BBB.

The following table summarizes investment yields earned over the past three years on the general account invested assets of our insurance subsidiaries. General account investments exclude the value of options (dollars in millions).

	2007 ----	2006 ----	2005 ----
Weighted average general account invested assets as defined:			
As reported	\$25,629.5	\$24,738.6	\$25,000.3
Excluding unrealized appreciation (depreciation) (a).....	25,746.5	25,112.2	24,491.6
Net investment income on general account invested assets.....	1,510.9	1,430.6	1,385.0
Yields earned:			
As reported.....	5.90%	5.78%	5.54%
Excluding unrealized appreciation (depreciation) (a).....	5.87%	5.70%	5.66%

(a) Excludes the effect of reporting fixed maturities at fair value as described in the note to our consolidated financial statements entitled "Investments".

Although investment income is a significant component of total revenues, the profitability of certain of our insurance products is determined primarily by the spreads between the interest rates we earn and the rates we credit or accrue to our insurance liabilities. At December 31, 2007 and 2006, the average yield, computed on the cost basis of our actively managed fixed maturity portfolio, was 6.0 percent and 5.7 percent, respectively, and the average interest rate credited or accruing to our total insurance liabilities (excluding interest rate bonuses for the first policy year only and excluding the effect of credited rates attributable to variable or equity-indexed products) was 4.7 percent and 4.6 percent, respectively.

Actively Managed Fixed Maturities

Our actively managed fixed maturity portfolio at December 31, 2007, included primarily debt securities of the United States government, public utilities and other corporations, and structured securities. Structured securities included mortgage-backed securities, CMOs and commercial mortgage-backed securities.

At December 31, 2007, our fixed maturity portfolio had \$149.1 million of unrealized gains and \$630.9 million of unrealized losses, for a net unrealized loss of \$481.8 million. Estimated fair values of fixed maturity investments were determined based on estimates from: (i) nationally recognized pricing services (88 percent of the portfolio); (ii) broker-dealer market makers (6 percent of the portfolio); and (iii) internally developed methods (6 percent of the portfolio).

At December 31, 2007, approximately 6.7 percent of our invested assets (7.8 percent of fixed maturity investments) were fixed maturities rated below-investment grade by nationally recognized statistical rating organizations (or, if not rated by such firms, with ratings below Class 2 assigned by the NAIC). Our level of investments in below-investment-grade fixed maturities could change if market conditions change. Below-investment grade securities have different characteristics than investment grade corporate debt securities. The risk of default by the borrower is significantly greater for below-investment grade securities and in many cases, severity of loss is relatively greater as such securities are generally unsecured and often subordinated to other creditors of the issuer. Also, issuers of below-investment grade securities usually have higher levels of debt and may be more sensitive to adverse economic conditions, such as recession or increasing interest rates, than investment grade issuers. The Company attempts to reduce the overall risk related to its investment in below-investment grade securities, as in all investments, through careful credit analysis, strict investment policy guidelines, and diversification

by issuer and/or guarantor and by industry. At December 31, 2007, our below-investment-grade fixed maturity investments had an amortized cost of \$1,678.8 million and an estimated fair value of \$1,590.6 million.

We continually evaluate the creditworthiness of each issuer whose securities we hold. We pay special attention to large investments and to those securities whose market values have declined materially for reasons other than changes in interest rates or other general market conditions. We evaluate the realizable value of the investment, the specific condition of the issuer and the issuer's ability to comply with the material terms of the security. We review the recent operational results and financial position of the issuer, information about its industry, information about factors affecting the issuer's performance and other information. 40|86 Advisors employs experienced securities analysts in a variety of specialty areas who compile and review such data. If evidence does not exist to support a realizable value equal to or greater than the carrying value of the investment, and such decline in market value is determined to be other than temporary, we reduce the carrying amount to its fair value, which becomes the new cost basis. We report the amount of the reduction as a realized loss. We recognize any recovery of such reductions as investment income over the remaining life of the investment (but only to the extent our current valuations indicate such amounts will ultimately be collected), or upon the repayment of the investment. During 2007, we recorded: (i) \$33.0 million of writedowns of fixed maturity investments and other invested assets; and (ii) \$73.7 million of writedowns of investments (which were subsequently transferred pursuant to a coinsurance agreement as further discussed in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies") as a result of our intent not to hold such investments for a period of time sufficient to allow for any anticipated recovery in value. Our investment portfolio is subject to the risks of further declines in realizable value. However, we attempt to mitigate this risk through the diversification and active management of our portfolio.

Our investment strategy is to maximize, over a sustained period and within acceptable parameters of risk, investment income and total investment return through active investment management. Accordingly, we may sell securities at a gain or a loss to enhance the total return of the portfolio as market opportunities change or to better match certain characteristics of our investment portfolio with the corresponding characteristics of our insurance liabilities. While we have both the ability and intent to hold securities with unrealized losses until they mature or recover in value, we may sell securities at a loss in the future because of actual or expected changes in our view of the particular investment, its industry, its asset class or the general investment environment.

As of December 31, 2007, we had no investments in substantive default (i.e., in default due to nonpayment of interest or principal). 40|86 Advisors employs experienced professionals to manage non-performing and impaired investments. There were no other fixed maturity investments about which we had serious doubts as to the recoverability of the carrying value of the investment.

When a security defaults, our policy is to discontinue the accrual of interest and eliminate all previous interest accruals, if we determine that such amounts will not be ultimately realized in full. Investment income forgone due to defaulted securities was nil, nil and \$.8 million for the years ended December 31, 2007, 2006 and 2005, respectively.

At December 31, 2007, fixed maturity investments included \$4.7 billion of structured securities (or 23 percent of all fixed maturity securities). Structured securities include mortgage-backed securities, CMOs and commercial mortgage-backed securities. The yield characteristics of structured securities differ in some respects from those of traditional fixed-income securities. For example, interest and principal payments on structured securities may occur more frequently, often monthly. In many instances, we are subject to the risk that the timing of principal payments may vary from expectations. For example, prepayments may occur at the option of the issuer and prepayment rates are influenced by a number of factors that cannot be predicted with certainty, including: the relative sensitivity of the underlying assets backing the security to changes in interest rates; a variety of economic, geographic and other factors; and various security-specific structural considerations (for example, the repayment priority of a given security in a securitization structure).

In general, the rate of prepayments on structured securities increases when prevailing interest rates decline significantly in absolute terms and also relative to the interest rates on the underlying assets. The yields recognized on structured securities purchased at a discount to par will increase (relative to the stated rate) when the underlying assets prepay faster than expected. The yield recognized on structured securities purchased at a premium will decrease (relative to the stated rate) when the underlying assets prepay faster than expected. When interest rates decline, the proceeds from prepayments may be reinvested at lower rates than we were earning on the prepaid securities. When interest rates increase, prepayments may decrease. When this occurs, the average maturity and duration of the structured securities increase, which decreases the yield on structured securities purchased at a discount because the discount is realized as income at a slower rate, and it increases the yield on those purchased at a premium because of a decrease in the annual amortization of the premium.

For structured and asset-backed securities included in actively managed fixed maturities that were purchased at a discount or premium, we recognize investment income using an effective yield based on anticipated future prepayments and the estimated final maturity of the securities. Actual prepayment experience is periodically reviewed and effective yields are recalculated when differences arise between the prepayments originally anticipated and the actual prepayments received and currently anticipated. For all other structured and asset-backed securities, the effective yield is recalculated when changes in assumptions are made, and reflected in our income on a retrospective basis. Under this method, the amortized cost basis of the investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the securities. Such adjustments were not significant in 2007.

The following table sets forth the par value, amortized cost and estimated fair value of structured securities, summarized by interest rates on the underlying collateral at December 31, 2007 (dollars in millions):

	Par value	Amortized cost	Estimated fair value
Below 4 percent.....	\$ 128.0	\$ 127.7	\$ 124.8
4 percent - 5 percent.....	557.6	539.8	541.6
5 percent - 6 percent.....	3,315.6	3,261.6	3,189.4
6 percent - 7 percent.....	779.3	749.0	722.2
7 percent - 8 percent.....	66.3	68.0	68.5
8 percent and above.....	23.6	24.0	21.6
	-----	-----	-----
Total structured securities (a).....	\$4,870.4	\$4,770.1	\$4,668.1
	=====	=====	=====

(a) Includes below-investment grade structured securities with an amortized cost and estimated fair value of \$62.6 million and \$55.5 million, respectively.

The amortized cost and estimated fair value of structured securities at December 31, 2007, summarized by type of security, were as follows (dollars in millions):

Type	Amortized Cost	Estimated Fair Value	
		Amount	Percent of fixed maturities
Pass-throughs, sequential and equivalent securities.....	\$2,076.0	\$2,048.0	10%
Planned amortization classes, target amortization class and accretion-directed bonds.....	1,633.1	1,596.1	8
Commercial mortgage-backed securities.....	994.0	965.5	5
Other.....	67.0	58.5	-
	-----	-----	--
Total structured securities (a).....	\$4,770.1	\$4,668.1	23%
	=====	=====	==

(a) Includes below-investment grade structured securities with an amortized cost and estimated fair value of \$62.6 million and \$55.5 million, respectively.

Pass-through securities and sequentials have unique prepayment variability characteristics. Pass-through securities typically return principal to the holders based on cash payments from the underlying mortgage obligations. Sequential classes return principal to tranche holders in a detailed hierarchy. Planned amortization classes, targeted amortization classes and accretion-directed bonds adhere to fixed schedules of principal payments as long as the underlying mortgage loans experience prepayments within certain estimated ranges. Changes in prepayment rates are first absorbed by support or companion classes insulating the timing of receipt of cash flows from the consequences of both faster prepayments (average life shortening) and slower prepayments (average life extension).

Commercial mortgage-backed securities are secured by commercial real estate mortgages, generally income producing properties that are managed for profit. Property types include multi-family dwellings including apartments, retail centers, hotels, restaurants, hospitals, nursing homes, warehouses, and office buildings. Most CMBS have call protection features whereby underlying borrowers may not prepay their mortgages for stated periods of time without incurring prepayment penalties.

During 2007, we sold \$3.3 billion of fixed maturity investments which resulted in gross investment losses (before income taxes) of \$134.0 million. We sell securities at a loss for a number of reasons including but not limited to:

(i) changes in the investment environment; (ii) expectation that the market value could deteriorate further; (iii) desire to reduce our exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected liability cash flows. As discussed in the notes to our consolidated financial statements, the realization of gains and losses affects the timing of the amortization of insurance acquisition costs related to universal life and investment products.

Other Investments

Our investment portfolio includes structured securities collateralized by sub prime residential loans with a market value of \$123.1 million and a book value of \$150.5 million at December 31, 2007. These securities represent .5 percent of our consolidated investment portfolio. Of these securities, \$39.9 million (32 percent) were rated AAA, \$40.8 million (33 percent) were rated AA, \$41.9 million (34 percent) were rated A, and \$.5 million (1 percent) were rated BBB. Sub prime structured securities issued in 2006 and 2007 have experienced higher delinquency and foreclosure rates than originally expected. The Company's investment portfolio includes sub prime structured securities collateralized by residential mortgage loans extended over several years, primarily from 2003 to 2007. At December 31, 2007, we held no sub prime securities collateralized by loans extended in 2006 and we held \$8.7 million extended in 2007.

At December 31, 2007, we held commercial mortgage loan investments with a carrying value of \$2,086.0 million (or 8.8 percent of total invested assets) and a fair value of \$2,137.0 million. The mortgage loan balance was primarily comprised of commercial loans. Noncurrent commercial mortgage loans were insignificant at December 31, 2007. Realized losses on commercial mortgage loans were not significant in any of the past three years. Our allowance for loss on mortgage loans was \$2.4 million at both December 31, 2007 and 2006. Approximately 7 percent, 6 percent, 6 percent, 6 percent and 5 percent of the mortgage loan balance were on properties located in Minnesota, Florida, Arizona, Ohio and Indiana, respectively. No other state comprised greater than 5 percent of the mortgage loan balance.

The following table shows the distribution of our commercial mortgage loan portfolio by property type as of December 31, 2007 (dollars in millions):

	Number of loans -----	Carrying value -----
Retail.....	438	\$1,093.2
Office building.....	196	745.0
Industrial.....	61	164.2
Multi-family.....	37	67.7
Other.....	5	15.9
	---	-----
Total commercial mortgage loans.....	737	\$2,086.0
	===	=====

The following table shows our commercial mortgage loan portfolio by loan size (dollars in millions):

	Number of loans -----	Principal balance -----
Under \$5 million.....	635	\$1,251.7
\$5 million but less than \$10 million.....	84	555.8
\$10 million but less than \$20 million.....	13	171.6
Over \$20 million.....	5	112.3
	---	-----
Total commercial mortgage loans.....	737	\$2,091.4
	===	=====

The following table summarizes the distribution of maturities of our commercial mortgage loans (dollars in millions):

	Number of loans	Principal balance
	-----	-----
2008.....	10	\$ 9.4
2009.....	25	76.5
2010.....	7	2.4
2011.....	25	80.9
2012.....	28	70.7
after 2012.....	642	1,851.5
	---	-----
Total commercial mortgage loans.....	737	\$2,091.4
	===	=====

At December 31, 2007, we held \$665.8 million of trading securities. We carry trading securities at estimated fair value; changes in fair value are reflected in the statement of operations. Our trading securities are held to act as hedges for embedded derivatives related to our equity-indexed annuity products and certain modified coinsurance agreements. See the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Accounting for Derivatives" for further discussion regarding the embedded derivatives and the trading accounts. In addition, the trading account includes investments backing the market strategies of our multibucket annuity products.

Other invested assets also include options backing our equity-indexed products, futures, credit default swaps, forward contracts and certain nontraditional investments, including investments in limited partnerships, promissory notes and real estate investments held for sale.

CONSOLIDATED FINANCIAL CONDITION

Changes in the Consolidated Balance Sheet

Changes in our consolidated balance sheet between December 31, 2007 and December 31, 2006, primarily reflect: (i) our net loss for 2007; (ii) the effect of an annuity coinsurance transaction which was completed in 2007; (iii) the recapture of a block of traditional life insurance business that had previously been ceded; (iv) an increase in amounts outstanding under our Second Amended Credit Facility; (v) common stock repurchases; and (vi) changes in the fair value of actively managed fixed maturity securities.

In accordance with GAAP, we record our actively managed fixed maturity investments, equity securities and certain other invested assets at estimated fair value with any unrealized gain or loss (excluding impairment losses, which are recognized through earnings), net of tax and related adjustments, recorded as a component of shareholders' equity. At December 31, 2007, we decreased the carrying value of such investments by \$481.3 million as a result of this fair value adjustment.

Our capital structure as of December 31, 2007 and 2006, was as follows (dollars in millions):

	2007 ----	2006 ---- (Restated)
Total capital:		
Corporate notes payable	\$1,193.7	\$1,000.8
Shareholders' equity:		
Preferred stock	-	667.8
Common stock.....	1.9	1.5
Additional paid-in capital.....	4,068.6	3,468.0
Accumulated other comprehensive loss.....	(273.3)	(72.6)
Retained earnings.....	438.7	635.4
	-----	-----
Total shareholders' equity.....	4,235.9	4,700.1
	-----	-----
Total capital.....	\$5,429.6	\$5,700.9
	=====	=====

The following table summarizes certain financial ratios as of and for the years ended December 31, 2007 and 2006:

	2007 ----	2006 ---- (Restated)
Book value per common share.....	\$22.94	\$26.50
Book value per common share, excluding accumulated other comprehensive income (loss) (a).....	24.42	26.98
Ratio of earnings to fixed charges.....	(b)	1.33x
Ratio of earnings to fixed charges and preferred dividends.....	(c)	1.19x
Debt to total capital ratios:		
Corporate debt to total capital.....	22%	18%
Corporate debt to total capital, excluding accumulated other comprehensive income (loss) (a).....	21%	17%
Corporate debt and preferred stock to total capital.....	22%	29%
Corporate debt and preferred stock to total capital, excluding accumulated other comprehensive income (loss) (a).....	21%	29%

-
- (a) This non-GAAP measure differs from the corresponding GAAP measure presented immediately above, because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income (loss). Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. However, this measure does not replace the corresponding GAAP measure.
- (b) For such ratio, earnings were \$173.0 million less than fixed charges.
- (c) For such ratio, earnings were \$194.7 million less than fixed charges.

Contractual Obligations

The Company's significant contractual obligations as of December 31, 2007, were as follows (dollars in millions):

	Total	Payment due in			
		2008	2009-2010	2011-2012	Thereafter
Insurance liabilities (a).....	\$57,278.3	\$4,028.5	\$7,564.3	\$6,951.0	\$38,734.5
Notes payable (b).....	1,567.0	80.7	486.3	133.8	866.2
Investment borrowings (c).....	1,334.0	53.9	99.6	202.1	978.4
Postretirement plans (d).....	164.9	3.7	7.6	8.5	145.1
Operating leases and certain other contractual commitments (e).....	220.1	37.5	55.5	40.6	86.5
Total.....	\$60,564.3	\$4,204.3	\$8,213.3	\$7,336.0	\$40,810.7

(a) These cash flows represent our estimates of the payments we expect to make to our policyholders, without consideration of future premiums or reinsurance recoveries. These estimates are based on numerous assumptions (depending on the product type) related to mortality, morbidity, lapses, withdrawals, future premiums, future deposits, interest rates on investments, credited rates, expenses and other factors which affect our future payments. The cash flows presented are undiscounted for interest. As a result, total outflows for all years exceed the corresponding liabilities of \$26.7 billion included in our consolidated balance sheet as of December 31, 2007. As such payments are based on numerous assumptions, the actual payments may vary significantly from the amounts shown.

In estimating the payments we expect to make to our policyholders, we considered the following:

- o For products such as immediate annuities and structured settlement annuities without life contingencies, the payment obligation is fixed and determinable based on the terms of the policy.
 - o For products such as universal life, ordinary life, long-term care, specified disease and fixed rate annuities, the future payments are not due until the occurrence of an insurable event (such as death or disability) or a triggering event (such as a surrender or partial withdrawal). We estimated these payments using actuarial models based on historical experience and our expectation of the future payment patterns.
 - o For short-term insurance products such as Medicare supplement insurance, the future payments relate only to amounts necessary to settle all outstanding claims, including those that have been incurred but not reported as of the balance sheet date. We estimated these payments based on our historical experience and our expectation of future payment patterns.
 - o The average interest rate we assumed would be credited to our total insurance liabilities (excluding interest rate bonuses for the first policy year only and excluding the effect of credited rates attributable to variable or equity-indexed products) over the term of the contracts was 4.7 percent.
- (b) Includes projected interest payments based on market rates, as applicable, as of December 31, 2007. Refer to the notes to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations" for additional information on notes payable.
- (c) These borrowings primarily represent: (i) the securities issued by a VIE and include projected interest payments based on market rates, as applicable, as of December 31, 2007; and (ii) collateralized borrowings from the Federal Home Loan Bank of Indianapolis ("FHLBI").
- (d) Includes benefits expected to be paid pursuant to our deferred compensation plan and postretirement plans based on numerous actuarial assumptions and interest credited at 6.02 percent.
- (e) Refer to the notes to the consolidated financial statements entitled "Commitments and Contingencies" for additional information on operating leases and certain other contractual commitments.

It is possible that the ultimate outcomes of various uncertainties could affect our liquidity in future periods. For example, the following events could have a material adverse effect on our cash flows:

- o An adverse decision in pending or future litigation.
- o An inability to obtain rate increases on certain of our insurance products.
- o Worse than anticipated claims experience.
- o Lower than expected dividends and/or surplus debenture interest payments from our insurance subsidiaries (resulting from inadequate earnings or capital or regulatory requirements).
- o An inability to meet and/or maintain the covenants in our Second Amended Credit Facility.
- o A significant increase in policy surrender levels.
- o A significant increase in investment defaults.
- o An inability of our reinsurers to meet their financial obligations.

While we seek to balance the duration and cash flows of our invested assets with the estimated duration and cash flows of benefit payments arising from contract liabilities, there could be significant variations in the timing of such cash flows. The claim experience on our long-term care business in the Other Business in Run-off segment has been worse than our original pricing expectations. Although we believe our current estimates properly project future claim experience, if these estimates prove to be wrong, and our experience worsens (as it did in some prior periods), our future liquidity could be adversely affected.

Liquidity for Insurance Operations

Our insurance companies (other than Conseco Senior) generally receive adequate cash flows from premium collections and investment income to meet their obligations. Life insurance and annuity liabilities are generally long-term in nature. Policyholders may, however, withdraw funds or surrender their policies, subject to any applicable penalty provisions. We seek to balance the duration of our invested assets with the estimated duration of benefit payments arising from contract liabilities.

In the first quarter of 2007, Conseco Life became a member of the FHLBI. As a member of the FHLBI, Conseco Life has the ability to borrow on a collateralized basis from FHLBI. Conseco Life is required to hold a certain minimum amount of FHLBI common stock as a requirement of membership in the FHLBI, and additional amounts based on the amount of collateralized borrowings. At December 31, 2007, the carrying value of the FHLBI common stock was \$22.5 million. Collateralized borrowings totaled \$450.0 million as of December 31, 2007, and the proceeds were used to purchase fixed maturity securities. The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet. The borrowings are collateralized by investments with an estimated fair value of \$509.0 million at December 31, 2007, which are maintained in a custodial account for the benefit of the FHLBI. The following summarizes the terms of the borrowings (dollars in millions):

Amount borrowed -----	Maturity date ----	Interest rate at December 31, 2007 -----
\$100.0	November 2015	Fixed rate - 4.890%
100.0	December 2015	Fixed rate - 4.710%
54.0	May 2012	Variable rate - 5.015%
146.0	November 2015	Fixed rate - 5.300%
37.0	July 2012	Fixed rate - 5.540%
13.0	July 2012	Variable rate - 5.308%

State laws generally give state insurance regulatory agencies broad authority to protect policyholders in their jurisdictions. Regulators have used this authority in the past to restrict the ability of our insurance subsidiaries to pay any

dividends or other amounts to any non-insurance company parent without prior approval. We cannot be assured that the regulators will not seek to assert greater supervision and control over our insurance subsidiaries' businesses and financial affairs.

In connection with monitoring the financial condition of insurers, certain state insurance departments have requested additional information from two of the Company's insurance subsidiaries, Conseco Senior and Conseco Life, because each such insurance subsidiary has incurred statutory losses in a 12 month period in excess of 50 percent of its capital and surplus. The statutory losses of Conseco Life are primarily attributable to a litigation settlement. For further information related to this case, refer to the caption entitled "Cost of Insurance Litigation" included in the note to our consolidated financial statements entitled "Commitments and Contingencies". The statutory losses of Conseco Senior are primarily attributable to the adverse development of prior period claim reserves, an increase in claims incurred in 2006 and 2007 and strengthening of statutory active life reserves using the prospective unlocking method (as permitted by insurance regulators), all of which related to long-term care policies. Based on our discussions with state regulators, we do not expect the regulators to take any actions against Conseco Senior or Conseco Life that would have a material adverse effect on the financial position or results of operations of these companies.

Conseco Senior has not generated sufficient income to cover its expenses and, in the aggregate, Conseco has made more than \$900 million of capital contributions to Conseco Senior since its acquisition in 1996. During 2007, we elected to make capital contributions to Conseco Senior totaling \$202.0 million, including \$56.0 million which was accrued at December 31, 2007 and paid in February 2008. We were under no obligation to make such capital contributions to Conseco Senior, and we may determine not to make additional contributions in the future. No assurances can be given that we will make future contributions or otherwise make capital available to Conseco Senior. Absent additional capital contributions, Conseco Senior will be reliant on actuarially justified premium rate increases to provide it with sufficient capital.

Conseco Senior has been aggressively seeking actuarially justified rate increases and pursuing other actions on our long-term care policies. During the third quarter of 2006, we began a new program to file requests for rate increases on various long-term care products in the Other Business in Run-off segment as we believe the existing rates were too low to fund expected future benefits. These filings are expected to be the first of three rounds of rate increase filings for many of the same policies, and in some cases we requested three years of successive rate increases. Based on recent experience, certain of the policies in this segment will continue to be unprofitable even if we obtain the three rounds of rate increases, and it is likely that we will request additional rate increases when the current program is complete. We have chosen to request a series of smaller rate increases, rather than a single large increase, to limit the impact on a policyholder's premiums in any single year. The effects of the first round of rate filings have been partially realized in our premium revenue with the remaining impact expected to be realized by the end of 2008. In the second quarter of 2007, we began filing requests for the second round of rate increases on many of the same policies. As of December 31, 2007, almost all of the expected second round filings had been submitted for regulatory approval, and approximately 42 percent of the expected amounts had been approved by regulators. The full effect of all three rounds of rate increases may not be fully realized until 2011. It is possible that it will take more time than we expect to prepare rate increase filings and obtain approval from the state insurance regulators. In addition, it is likely that we will not be able to obtain approval for some of the actuarially justified rate increases currently pending or for the additional rate increases we plan to file especially in light of the magnitude of some past premium rate increases and current consumer and regulator sentiment. Most of our long-term care business is guaranteed renewable, and, if necessary rate increases are not approved, we may be required to write off all or a portion of the insurance acquisition costs and establish a premium deficiency reserve. If we are unable to raise our premium rates because we fail to obtain approval for actuarially justified rate increases in one or more states, our financial condition and results of operations could be adversely affected.

During 2007, the financial statements of three of our subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities reflected the establishment of asset adequacy and premium deficiency reserves primarily related to long-term care and annuity policies. Total asset adequacy and premium deficiency reserves for Washington National, Conseco Insurance Company and Bankers Conseco Life Insurance Company were \$63.8 million, \$35.9 million and \$30.6 million, respectively at December 31, 2007. Due to differences between statutory and GAAP insurance liabilities, we were not required to recognize a similar premium deficiency reserve in our consolidated financial statements prepared in accordance with GAAP.

Financial Strength Ratings of our Insurance Subsidiaries

Financial strength ratings provided by A.M. Best, S&P and Moody's are the rating agency's opinions of the ability of our insurance subsidiaries to repay policyholder claims and obligations when due.

On August 7, 2007, A.M. Best downgraded the financial strength ratings of our primary insurance subsidiaries to "B+ (Good)" from "B++ (Good)", except Consecro Senior, whose "B- (Fair)" rating was downgraded to "C++ (Marginal)".

A.M. Best also revised the outlook for the ratings of our primary insurance subsidiaries, as well as Consecro Senior, to negative from stable. The "B+" rating is assigned to companies that have a good ability, in A.M. Best's opinion, to meet their ongoing obligations to policyholders. The "C++" rating is assigned to companies which have a marginal ability, in A.M. Best's opinion, to meet their ongoing obligations to policyholders, but are financially vulnerable to adverse changes in underwriting and economic conditions. A.M. Best ratings for the industry currently range from "A++ (Superior)" to "F (In Liquidation)" and some companies are not rated. An "A++" rating indicates a superior ability to meet ongoing obligations to policyholders. The "B+" rating and the "C++" rating from A.M. Best are the sixth and ninth highest, respectively, of sixteen possible ratings.

On August 7, 2007, S&P affirmed the financial strength ratings of "BB+" of our primary insurance subsidiaries, except Consecro Senior, whose "CCC" rating was downgraded to "CCC-". S&P also revised the outlook for the ratings of our primary insurance subsidiaries to negative from stable, except for Consecro Senior, whose outlook of negative was affirmed. S&P financial strength ratings range from "AAA" to "R" and some companies are not rated. Rating categories from "BB" to "CCC" are classified as "vulnerable", and pluses and minuses show the relative standing within a category. In S&P's view, an insurer rated "BB" has marginal financial security characteristics and although positive attributes exist, adverse business conditions could lead to an insufficient ability to meet financial commitments. In S&P's view, an insurer rated "CCC" has very weak financial security characteristics and is dependent on favorable business conditions to meet financial commitments. The "BB+" rating and the "CCC-" rating from S&P are the eleventh and nineteenth highest, respectively, of twenty-one possible ratings.

The current financial strength ratings of our primary insurance subsidiaries (except Consecro Senior) from Moody's are "Baa3" and Consecro Senior's rating is "Caal". On September 7, 2007, Moody's affirmed the financial strength ratings of our core insurance subsidiaries and Consecro Senior and revised its outlook on all our insurance subsidiaries to negative from stable. Moody's financial strength ratings range from "Aaa" to "C". Rating categories from "Aaa" to "Baa" are classified as "Secure" by Moody's and rating categories from "Ba" to "C" are considered "vulnerable" and these ratings may be supplemented with numbers "1", "2", or "3" to show relative standing within a category. In Moody's view, an insurer rated "Baa3" offers adequate financial security, however, certain protective elements may be lacking or may be characteristically unreliable over any great length of time. In Moody's view, an insurer rated "Caa" offers very poor financial security and may default on its policyholder obligations or there may be elements of danger with respect to punctual payment of policyholder obligations and claims. The "Baa3" rating and the "Caal" rating from Moody's are the tenth and seventeenth highest, respectively, of twenty-one possible ratings.

Liquidity of the Holding Companies

At December 31, 2007, Consecro Inc. and CDOC held unrestricted cash of \$84.3 million. Consecro Inc. and CDOC are holding companies with no business operations of their own; they depend on their operating subsidiaries for cash to make principal and interest payments on debt, and to pay administrative expenses and income taxes. Consecro and CDOC receive cash from insurance subsidiaries, consisting of dividends and distributions, principal and interest payments on surplus debentures and tax-sharing payments, as well as cash from non-insurance subsidiaries consisting of dividends, distributions, loans and advances. The principal non-insurance subsidiaries that provide cash to Consecro and CDOC are 40|86 Advisors, which receives fees from the insurance subsidiaries for investment services, and Consecro Services, LLC which receives fees from the insurance subsidiaries for providing administrative services. A deterioration in the financial condition, earnings or cash flow of the material subsidiaries of Consecro or CDOC for any reason could hinder such subsidiaries' ability to pay cash dividends or other disbursements to Consecro and/or CDOC, which, in turn, would limit Consecro's and/or CDOC's ability to meet debt service requirements and satisfy other financial obligations. In addition, we may need to contribute additional capital to certain insurance subsidiaries to strengthen their surplus and this could affect the ability of our top tier insurance subsidiary to pay dividends. We made capital contributions totaling \$200.0 million to our top tier insurance subsidiary in 2007.

The ability of our insurance subsidiaries to pay dividends is subject to state insurance department regulations and is based on the financial statements of our insurance subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities, which differ from GAAP. These regulations generally permit dividends to be paid from statutory earned surplus of the insurance company for any 12-month period in amounts equal to the greater of (or in a few states, the lesser of): (i) statutory net gain from operations or net income for the prior year; or (ii) 10 percent of statutory capital and surplus as of the end of the preceding year. Any dividends in excess of these levels require the approval

of the director or commissioner of the applicable state insurance department. During 2007, our top tier insurance subsidiary paid dividends of \$50.0 million to CDOC.

Our cash flow may be affected by a variety of factors, many of which are outside of our control, including insurance and banking regulatory issues, competition, financial markets and other general business conditions. We cannot provide assurance that we will possess sufficient income and liquidity to meet all of our liquidity requirements and other obligations.

If an insurance company subsidiary were to be liquidated, that liquidation would be conducted following the insurance law of its state of domicile with such state's insurance regulator as the receiver for such insurer's property and business. In the event of a default on our debt or our insolvency, liquidation or other reorganization, our creditors and stockholders would have no right to proceed against the assets of our insurance subsidiaries or to cause their liquidation under federal and state bankruptcy laws.

On June 12, 2007, Conseco amended its current credit facility. The amendment of the credit facility provided for, among other things:

- o an increase of \$200.0 million in the principal amount of the facility;
- o an increase in the general basket for restricted payments in an aggregate amount of up to \$300 million over the term of the facility (of which, only \$200 million may be paid in the year commencing June 12, 2007); and
- o the Company to be able to request the addition of up to two new facilities or up to two increases in the credit facility of up to \$330 million (but with the commitment increases made between June 12, 2007 and June 12, 2008 limited to \$130 million), subject to compliance with certain financial covenants and other conditions. Such increases would be effective as of a date that is at least 90 days prior to the scheduled maturity date.

No changes were made to the interest rate or the maturity schedule of the amounts borrowed under the credit facility. We are required to make minimum quarterly principal payments of \$2.2 million through September 30, 2013. The remaining unpaid principal balance is due on October 10, 2013. There were no changes to the various financial ratios and balances that are required to be maintained by the Company. The additional borrowings were used for general corporate purposes, including the repurchase of Conseco common stock and the strengthening of the Company's insurance subsidiaries.

During 2007, we made scheduled principal payments totaling \$7.8 million on our Second Amended Credit Facility. The scheduled repayment of our direct corporate obligations is as follows (dollars in millions):

2008.....	\$	8.7
2009.....		8.7
2010.....		338.8
2011.....		8.7
2012.....		8.8
Thereafter.....		821.8

		\$1,195.5
		=====

The Second Amended Credit Facility includes an \$80.0 million revolving credit facility that can be used for general corporate purposes and that would mature on June 22, 2009. There were no amounts outstanding under the revolving credit facility at December 31, 2007. The Company pays a commitment fee equal to .50 percent of the unused portion of the revolving credit facility on an annualized basis.

Pursuant to the Second Amended Credit Facility, as long as the debt to total capitalization ratio (as defined in the Second Amended Credit Facility) is greater than 20 percent or certain insurance subsidiaries (as defined in the Second Amended Credit Facility) have financial strength ratings of less than A- from A.M. Best, the Company is required to make mandatory prepayments with all or a portion of the proceeds from the following transactions or events including: (i) the issuance of certain indebtedness; (ii) equity issuances; (iii) certain asset sales or casualty events; and (iv) excess cash flows as defined in the Second Amended Credit Facility (the first such payment, if applicable, would not be paid prior to the first quarter of 2009). The Company may make optional prepayments at any time in minimum amounts of \$3.0 million or any multiple of \$1.0 million in excess thereof. As described in the Second Amended Credit Facility, the Company may reinvest any portion of the proceeds from asset sales in assets useful to its business, subject to certain restrictions defined in the

Second Amended Credit Facility. The Company used the majority of the ceding commission received from the annuity coinsurance transaction to fund the recapture of a block of traditional life insurance inforce.

Under the Second Amended Credit Facility, we may pay cash dividends on our common stock or repurchase our common stock in an aggregate amount of up to \$300.0 million over the term of the facility (of which, only \$200.0 million may be paid in the year beginning June 12, 2007). As further discussed in the note to the consolidated financial statements entitled "Shareholders' Equity", we repurchased 5.7 million shares of our common stock for \$87.2 million in 2007 (of which, \$57.6 million was paid in the year beginning June 12, 2007).

Under our Second Amended Credit Facility, we have agreed to a number of covenants and other provisions that restrict our ability to engage in various financing transactions and pursue certain operating activities without the prior consent of the lenders. We have also agreed to meet or maintain various financial ratios. These requirements represent significant restrictions on the manner in which we may operate our business and our ability to meet these financial covenants may be affected by events beyond our control. If we default under any of these requirements (subject to certain remedies), the lenders could declare all outstanding borrowings, accrued interest and fees to be immediately due and payable. If that were to occur, we cannot provide assurance that we would have sufficient liquidity to repay or refinance this indebtedness.

The Second Amended Credit Facility is discussed in further detail in the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations".

MARKET-SENSITIVE INSTRUMENTS AND RISK MANAGEMENT

Our spread-based insurance business is subject to several inherent risks arising from movements in interest rates, especially if we fail to anticipate or respond to such movements. First, interest rate changes can cause compression of our net spread between interest earned on investments and interest credited on customer deposits, thereby adversely affecting our results. Second, if interest rate changes produce an unanticipated increase in surrenders of our spread-based products, we may be forced to sell investment assets at a loss in order to fund such surrenders. Many of our products include surrender charges, market interest rate adjustments or other features to encourage persistency; however at December 31, 2007, approximately 18 percent of our total insurance liabilities, or approximately \$4.8 billion, could be surrendered by the policyholder without penalty. Finally, changes in interest rates can have significant effects on the performance of our structured securities portfolio as a result of changes in the prepayment rate of the loans underlying such securities. We follow asset/liability strategies that are designed to mitigate the effect of interest rate changes on our profitability. However, there can be no assurance that management will be successful in implementing such strategies and achieving adequate investment spreads.

We seek to invest our available funds in a manner that will fund future obligations to policyholders, subject to appropriate risk considerations. We seek to meet this objective through investments that: (i) have similar cash flow characteristics with the liabilities they support; (ii) are diversified among industries, issuers and geographic locations; and (iii) are predominantly investment-grade fixed maturity securities.

Our investment strategy is to maximize, over a sustained period and within acceptable parameters of risk, investment income and total investment return through active investment management. Accordingly, our entire portfolio of fixed maturity securities is available to be sold in response to: (i) changes in market interest rates; (ii) changes in relative values of individual securities and asset sectors; (iii) changes in prepayment risks; (iv) changes in credit quality outlook for certain securities; (v) liquidity needs; and (vi) other factors. From time to time, we invest in securities for trading purposes, although such investments are a relatively small portion of our total portfolio.

The profitability of many of our products depends on the spread between the interest earned on investments and the rates credited on our insurance liabilities. In addition, changes in competition and other factors, including the level of surrenders and withdrawals, may limit our ability to adjust or to maintain crediting rates at levels necessary to avoid narrowing of spreads under certain market conditions. As of December 31, 2007, approximately 38 percent of our insurance liabilities had interest rates that may be reset annually; 47 percent had a fixed explicit interest rate for the duration of the contract; 11 percent had credited rates which approximate the income earned by the Company; and the remainder had no explicit interest rates. At December 31, 2007, the average yield, computed on the cost basis of our actively managed fixed maturity portfolio, was 6.0 percent, and the average interest rate credited or accruing to our total insurance liabilities (excluding interest rate bonuses for the first policy year only and excluding the effect of credited rates attributable to variable or equity-indexed products) was 4.7 percent.

We use computer models to simulate the cash flows expected from our existing insurance business under various interest rate scenarios. These simulations help us to measure the potential gain or loss in fair value of our interest rate-sensitive financial instruments and to manage the relationship between the duration of our assets and the expected duration of our liabilities. When the estimated durations of assets and liabilities are similar, a change in the value of assets should be largely offset by a change in the value of liabilities. At December 31, 2007, the adjusted modified duration of our fixed maturity investments (as modified to reflect payments and potential calls) was approximately 7.6 years and the duration of our insurance liabilities was approximately 7.9 years. We estimate that our fixed maturity securities and short-term investments (net of corresponding changes in insurance acquisition costs) would decline in fair value by approximately \$490 million if interest rates were to increase by 10 percent from their levels at December 31, 2007. This compares to a decline in fair value of \$515 million based on amounts and rates at December 31, 2006. Our computer simulated calculations include numerous assumptions, require significant estimates and assume an immediate change in interest rates without any management of the investment portfolio in reaction to such change. Consequently, potential changes in value of our financial instruments indicated by the simulations will likely be different from the actual changes experienced under given interest rate scenarios, and the differences may be material. Because we actively manage our investments and liabilities, our net exposure to interest rates can vary over time.

We are subject to the risk that our investments will decline in value. This has occurred in the past and may occur again. During 2007, we recognized net realized investment losses of \$155.4 million, which were comprised of: (i) \$48.7 million of net losses from the sales of investments (primarily fixed maturities) with proceeds of \$7.2 billion; (ii) \$33.0 million of writedowns of investments for other than temporary declines in the fair value; and (iii) \$73.7 million of writedowns of investments (which were subsequently transferred pursuant to a coinsurance agreement as further discussed in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies") as a result of our intent not to hold such investments for a period of time sufficient to allow for any anticipated recovery in value. During 2006, we recognized net realized investment losses of \$47.2 million, which were comprised of \$24.8 million of net losses from the sales of investments (primarily fixed maturities) with proceeds of \$6.4 billion, and \$22.4 million of writedowns of investments for other than temporary declines in the fair value. During 2005, we recognized net realized investment losses of \$2.9 million, which were comprised of \$11.8 million of net gains from the sales of investments (primarily fixed maturities) with proceeds of \$11.5 billion, net of \$14.7 million of writedowns of investments for other than temporary declines in the fair value.

The operations of the Company are subject to risk resulting from fluctuations in market prices of our equity securities. In general, these investments have more year-to-year price variability than our fixed maturity investments. However, returns over longer time frames have been consistently higher. We manage this risk by limiting our equity securities to a relatively small portion of our total investments.

Our investment in options backing our equity-linked products is closely matched with our obligation to equity-indexed annuity holders. Market value changes associated with that investment are substantially offset by an increase or decrease in the amounts added to policyholder account balances for equity-indexed products.

Inflation

Inflation rates may impact the financial statements and operating results in several areas. Inflation influences interest rates, which in turn impact the market value of the investment portfolio and yields on new investments. Inflation also impacts a portion of our insurance policy benefits affected by increased medical coverage costs. Operating expenses, including payrolls, are impacted to a certain degree by the inflation rate.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

The information included under the caption "Market-Sensitive Instruments and Risk Management" in Item 7. "Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations" is incorporated herein by reference.

ITEM 8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

Index to Consolidated Financial Statements

	Page
Report of Independent Registered Public Accounting Firm.....	100
Consolidated Balance Sheet at December 31, 2007 and 2006.....	101
Consolidated Statement of Operations for the years ended December 31, 2007, 2006 and 2005.....	103
Consolidated Statement of Shareholders' Equity for the years ended December 31, 2007, 2006 and 2005.....	104
Consolidated Statement of Cash Flows for the years ended December 31, 2007, 2006 and 2005.....	106
Notes to Consolidated Financial Statements.....	107

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors Conseco, Inc.:

In our opinion, the consolidated financial statements listed in the accompanying index present fairly, in all material respects, the financial position of Conseco Inc. and its subsidiaries at December 31, 2007 and 2006, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2007 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company did not maintain, in all material respects, effective internal control over financial reporting as of December 31, 2007, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) because a material weakness in internal control over financial reporting related to the accounting and disclosure of insurance policy benefits, amortization expense, the liabilities for insurance products and the value of policies in force at the Effective Date existed as of that date. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness referred to above is described in Management's Report on Internal Control Over Financial Reporting appearing under Item 9A. We considered this material weakness in determining the nature, timing, and extent of audit tests applied in our audit of the 2007 consolidated financial statements, and our opinion regarding the effectiveness of the Company's internal control over financial reporting does not affect our opinion on those consolidated financial statements. The Company's management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in management's report referred to above. Our responsibility is to express opinions on these financial statements and on the Company's internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

As discussed in Note 2 to the consolidated financial statements, the Company has restated its 2006 and 2005 consolidated financial statements.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ PricewaterhouseCoopers LLP

*Indianapolis, Indiana
March 28, 2008*

CONSECO, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEET

December 31, 2007 and 2006

(Dollars in millions)

ASSETS

	2007	2006
	----	----
		(Restated)
Investments:		
Actively managed fixed maturities at fair value (amortized cost:		
2007 - \$20,992.7; 2006 - \$22,946.9).....	\$20,510.9	\$22,802.9
Equity securities at fair value (cost: 2007 - \$34.0; 2006 - \$23.9).....	34.5	24.8
Mortgage loans.....	2,086.0	1,642.2
Policy loans.....	370.4	412.5
Trading securities.....	665.8	675.2
Other invested assets	134.3	178.8
	-----	-----
Total investments.....	23,801.9	25,736.4
Cash and cash equivalents:		
Unrestricted.....	407.5	385.9
Restricted.....	21.1	24.0
Accrued investment income.....	319.3	344.5
Value of policies inforce at the Effective Date.....	1,722.8	2,136.5
Cost of policies produced.....	1,423.0	1,106.7
Reinsurance receivables.....	3,592.8	850.8
Income tax assets, net.....	1,909.4	1,794.3
Assets held in separate accounts.....	27.4	28.9
Other assets.....	289.6	316.0
	-----	-----
Total assets.....	\$33,514.8	\$32,724.0
	=====	=====

(continued on next page)

The accompanying notes are an integral part of the consolidated financial statements.

CONSECO, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEET (Continued)

December 31, 2007 and 2006

(Dollars in millions)

LIABILITIES AND SHAREHOLDERS' EQUITY

	2007	2006
	----	----
		(Restated)
Liabilities:		
Liabilities for insurance products:		
Interest-sensitive products.....	\$13,169.4	\$13,021.1
Traditional products.....	12,537.4	12,108.0
Claims payable and other policyholder funds.....	928.0	835.0
Liabilities related to separate accounts.....	27.4	28.9
Other liabilities.....	510.0	611.8
Investment borrowings.....	913.0	418.3
Notes payable - direct corporate obligations.....	1,193.7	1,000.8
	-----	-----
Total liabilities.....	29,278.9	28,023.9
	-----	-----
Commitments and Contingencies (Note 9)		
Shareholders' equity:		
Preferred stock.....	-	667.8
Common stock (\$0.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2007 - 184,652,017; 2006 - 152,165,108).....	1.9	1.5
Additional paid-in capital.....	4,068.6	3,468.0
Accumulated other comprehensive loss.....	(273.3)	(72.6)
Retained earnings.....	438.7	635.4
	-----	-----
Total shareholders' equity.....	4,235.9	4,700.1
	-----	-----
Total liabilities and shareholders' equity.....	\$33,514.8	\$32,724.0
	=====	=====

The accompanying notes are an integral part of the consolidated financial statements.

CONSECO, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF OPERATIONS

for the years ended December 31, 2007, 2006 and 2005

(Dollars in millions, except per share data)

	2007 ----	2006 ---- (Restated)	2005 ---- (Restated)
Revenues:			
Insurance policy income.....	\$3,167.3	\$2,989.0	\$2,930.1
Net investment income (loss):			
General account assets.....	1,517.3	1,435.2	1,390.4
Policyholder and reinsurer accounts and other special-purpose portfolios.....	19.3	71.2	(15.8)
Net realized investment losses	(155.4)	(47.2)	(2.9)
Fee revenue and other income.....	23.8	19.2	24.7
	-----	-----	-----
Total revenues.....	4,572.3	4,467.4	4,326.5
	-----	-----	-----
Benefits and expenses:			
Insurance policy benefits.....	3,433.7	3,033.0	2,830.0
Interest expense.....	117.3	73.5	58.3
Amortization.....	449.3	441.6	379.0
Loss on extinguishment of debt.....	-	.7	3.7
Costs related to a litigation settlement.....	64.4	174.7	18.3
Loss related to an annuity coinsurance transaction.....	76.5	-	-
Other operating costs and expenses.....	604.1	576.7	552.9
	-----	-----	-----
Total benefits and expenses.....	4,745.3	4,300.2	3,842.2
	-----	-----	-----
Income (loss) before income taxes.....	(173.0)	167.2	484.3
Income tax expense (benefit):			
Tax expense (benefit) on period income.....	(61.1)	61.2	171.6
Valuation allowance for deferred tax assets.....	68.0	-	-
	-----	-----	-----
Net income (loss).....	(179.9)	106.0	312.7
Preferred stock dividends.....	14.1	38.0	38.0
	-----	-----	-----
Net income (loss) applicable to common stock.....	\$ (194.0)	\$ 68.0	\$ 274.7
	=====	=====	=====
Earnings (loss) per common share:			
Basic:			
Weighted average shares outstanding.....	173,374,000	151,690,000	151,160,000
	=====	=====	=====
Net income (loss).....	\$(1.12)	\$.45	\$1.82
	=====	=====	=====
Diluted:			
Weighted average shares outstanding.....	173,374,000	152,509,000	185,040,000
	=====	=====	=====
Net income (loss).....	\$(1.12)	\$.45	\$1.69
	=====	=====	=====

The accompanying notes are an integral part of the consolidated financial statements.

CONSECO, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY
(Dollars in millions)

	Total	Preferred stock	Common stock and additional paid-in capital	Accumulated other comprehensive income	Retained earnings
	-----	-----	-----	-----	-----
Balance, December 31, 2004 (Restated).....	\$3,891.9	\$667.8	\$2,594.1	\$ 337.3	\$292.7
Comprehensive income, net of tax:					
Net income.....	312.7	-	-	-	312.7
Change in unrealized appreciation of investments (net of applicable income tax benefit of \$148.7).....	(265.6)	-	-	(265.6)	-
Total comprehensive income.....	47.1				
Reduction of deferred income tax valuation allowance.....	585.8	-	585.8	-	-
Stock option and restricted stock plans.....	9.1	-	9.1	-	-
Reduction of tax liabilities related to various contingencies recognized at the fresh-start date.....	1.4	-	1.4	-	-
Dividends on preferred stock.....	(38.0)	-	-	-	(38.0)
Balance, December 31, 2005 (Restated).....	4,497.3	667.8	3,190.4	71.7	567.4
Comprehensive loss, net of tax:					
Net income.....	106.0	-	-	-	106.0
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax benefit of \$77.4).....	(137.9)	-	-	(137.9)	-
Total comprehensive loss.....	(31.9)				
Adjustment to initially apply SFAS No. 158 related to the unrecognized net loss related to deferred compensation plan (net of applicable income tax benefit of \$3.5).....	(6.4)	-	-	(6.4)	-
Reduction of deferred income tax valuation allowance.....	260.0	-	260.0	-	-
Stock option and restricted stock plans.....	12.4	-	12.4	-	-
Reduction of tax liabilities related to various contingencies recognized at the fresh-start date.....	6.7	-	6.7	-	-
Dividends on preferred stock.....	(38.0)	-	-	-	(38.0)
Balance, December 31, 2006 (Restated).....	\$4,700.1	\$667.8	\$3,469.5	\$ (72.6)	\$635.4

(continued on following page)

The accompanying notes are an integral part of the consolidated financial statements.

CONSECO, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (Continued)

(Dollars in millions)

	Total	Preferred stock	Common stock and additional paid-in capital	Accumulated other comprehensive income (loss)	Retained earnings
	-----	-----	-----	-----	-----
Balance, December 31, 2006 (carried forward from prior page) (Restated).....	\$4,700.1	\$ 667.8	\$3,469.5	\$ (72.6)	\$ 635.4
Comprehensive loss, net of tax:					
Net loss.....	(179.9)	-	-	-	(179.9)
Change in unrealized appreciation (depreciation) of investments (net of applicable income tax benefit of \$113.0).....	(202.4)	-	-	(202.4)	-

Total comprehensive loss.....	(382.3)				
Cost of shares acquired.....	(87.2)	-	(87.2)	-	-
Stock option and restricted stock plans.....	14.4	-	14.4	-	-
Change in unrecognized net loss related to deferred compensation plan (net of applicable income tax expense of \$.9 million).....	1.7	-	-	1.7	-
Reduction of tax liabilities related to various contingencies recognized at the fresh-start date in conjunction with adoption of FIN 48.....	6.0	-	6.0	-	-
Cumulative effect of accounting change pursuant to SOP 05-1.....	(2.7)	-	-	-	(2.7)
Conversion of preferred stock into common shares..	-	(667.8)	667.8	-	-
Dividends on preferred stock.....	(14.1)	-	-	-	(14.1)
	-----	-----	-----	-----	-----
Balance, December 31, 2007.....	\$4,235.9	\$ -	\$4,070.5	\$(273.3)	\$ 438.7
	=====	=====	=====	=====	=====

The accompanying notes are an integral part of the consolidated financial statements.

CONSECO, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF CASH FLOWS

for the years ended December 31, 2007, 2006 and 2005

(Dollars in millions)

	2007	2006	2005
	----	----	----
Cash flows from operating activities:			
Insurance policy income.....	\$ 2,818.0	\$ 2,633.4	\$ 2,565.3
Net investment income.....	1,610.0	1,500.5	1,461.0
Fee revenue and other income.....	23.8	19.3	24.7
Net sales (purchases) of trading securities.....	(114.3)	36.0	165.8
Insurance policy benefits.....	(2,339.6)	(2,184.2)	(2,044.8)
Interest expense.....	(114.7)	(66.9)	(40.6)
Policy acquisition costs.....	(545.9)	(484.7)	(400.9)
Other operating costs.....	(631.3)	(523.7)	(596.8)
Taxes.....	(2.7)	1.5	28.4
	-----	-----	-----
Net cash provided by operating activities.....	703.3	931.2	1,162.1
	-----	-----	-----
Cash flows from investing activities:			
Sales of investments.....	7,192.9	6,412.1	11,479.9
Maturities and redemptions of investments.....	948.4	2,038.0	1,455.3
Purchases of investments.....	(9,248.7)	(9,490.8)	(14,438.0)
Change in restricted cash.....	2.9	11.2	(16.3)
Other.....	(24.2)	(21.7)	(31.6)
	-----	-----	-----
Net cash used by investing activities.....	(1,128.7)	(1,051.2)	(1,550.7)
	-----	-----	-----
Cash flows from financing activities:			
Issuance of notes payable, net.....	200.0	196.7	853.7
Issuance of common stock.....	3.4	1.0	.5
Payments to repurchase common stock.....	(87.2)	-	-
Payments on notes payable.....	(7.8)	(48.0)	(770.4)
Amounts received for deposit products.....	1,852.2	2,067.7	1,709.8
Withdrawals from deposit products.....	(1,989.3)	(2,014.5)	(1,787.0)
Investment borrowings.....	494.7	103.2	(118.8)
Dividends paid on preferred stock.....	(19.0)	(38.0)	(38.0)
	-----	-----	-----
Net cash provided (used) by financing activities.....	447.0	268.1	(150.2)
	-----	-----	-----
Net increase (decrease) in cash and cash equivalents.....	21.6	148.1	(538.8)
Cash and cash equivalents, beginning of year.....	385.9	237.8	776.6
	-----	-----	-----
Cash and cash equivalents, end of year.....	\$ 407.5	\$ 385.9	\$ 237.8
	=====	=====	=====

The accompanying notes are an integral part of the consolidated financial statements.

CONSECO, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

1. DESCRIPTION OF BUSINESS

Conseco, Inc., a Delaware corporation ("CNO"), is a holding company for a group of insurance companies operating throughout the United States that develop, market and administer supplemental health insurance, annuity, individual life insurance and other insurance products. CNO became the successor to Conseco, Inc., an Indiana corporation ("Old Conseco" or our "Predecessor"), in connection with our bankruptcy reorganization which became effective on September 10, 2003 (the "Effective Date"). The terms "Conseco", the "Company", "we", "us", and "our" as used in this report refer to CNO and its subsidiaries or, when the context requires otherwise, Old Conseco and its subsidiaries. We focus on serving the senior and middle-income markets, which we believe are attractive, high growth markets. We sell our products through three distribution channels: career agents, professional independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing.

We manage our business through the following: three primary operating segments, Bankers Life, Conseco Insurance Group and Colonial Penn, which are defined on the basis of product distribution; a fourth segment comprised of Other Business in Run-off; and corporate operations. Our segments are described below:

o Bankers Life, which consists of the business of Bankers Life and Casualty Company ("Bankers Life and Casualty"), markets and distributes Medicare supplement insurance, life insurance, long-term care insurance, Medicare Part D prescription drug program, Medicare Advantage products and certain annuity products to the senior market through approximately 5,100 career agents and sales managers. Bankers Life and Casualty markets its products under its own brand name and Medicare Part D and Medicare Advantage products primarily through marketing agreements with Coventry Health Care ("Coventry").

o Conseco Insurance Group, which markets and distributes specified disease insurance, Medicare supplement insurance, and certain life and annuity products to the senior and middle-income markets through approximately 350 independent marketing organizations that represent over 5,200 producing independent agents. This segment markets its products under the "Conseco" and "Washington National" (a wholly-owned insurance subsidiary of Conseco) brand names. Conseco Insurance Group includes primarily the business of Conseco Health Insurance Company ("Conseco Health"), Conseco Life Insurance Company ("Conseco Life") Conseco Insurance Company and Washington National Insurance Company ("Washington National"), other than any run-off long-term care and major medical insurance issued by those companies. Such run-off business is included in the Other Business in Run-off segment.

o Colonial Penn, which consists of the business of Colonial Penn Life Insurance Company ("Colonial Penn"), markets graded benefit and simplified issue life insurance directly to customers through television advertising, direct mail, the internet and telemarketing. Colonial Penn markets its products under its own brand name.

o Other Business in Run-off, which includes blocks of business that we no longer market or underwrite and are managed separately from our other businesses. This segment consists of: (i) long-term care insurance sold in prior years through independent agents; and (ii) major medical insurance. The Other Business in Run-off segment is primarily comprised of long-term care business issued by Conseco Senior Health Insurance Company ("Conseco Senior") and Washington National, subsidiaries that were acquired in 1996 and 1997, respectively. Long-term care collected premiums represented more than 99 percent of this segment's total collected premiums in 2007.

2. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

The Company's management and its audit committee concluded, on February 22, 2008, that we would restate our financial statements for the years ended December 31, 2006 and 2005, along with affected Selected Consolidated Financial Data for 2004 and 2003, and quarterly financial information for 2006 and the first three quarters of 2007. Such conclusion was based on the significance of errors identified in 2007 during the procedures performed in an effort to remediate the material weakness in internal controls disclosed in our 2006 Form 10-K and subsequent quarterly filings with the U.S. Securities and Exchange Commission (the "SEC").

The most significant errors relate to adjustments to insurance policy benefits and the liabilities for insurance products in the specified disease and life blocks in the Conseco Insurance Group segment and in the long-term care block of business in the Other Business in Run-off segment identified in 2007 during the aforementioned remediation procedures.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

We reviewed certain actuarial valuation processes for approximately 2,400 types of policy forms, encompassing insurance products that accounted for more than 80 percent of the total liabilities for the business subject to the remediation procedures.

The errors we discovered through our remediation procedures had the effect of reducing shareholders' equity at December 31, 2006 by \$20.6 million, as summarized below (dollars in millions):

	Understatement (overstatement) of shareholders' equity at December 31, 2006 -----	
Coding errors in actuarial system related to specified disease return of premium features.....	\$ 25.6	(i)
Error related to certain specified disease policies for which return of premium is payable upon first occurrence of claim.....	(15.9)	(ii)
Error in reserve factors for certain specified disease policies.....	(20.4)	(iii)
Error related to certain specified disease policies for which return of premium benefit is not reduced for claims.....	(18.0)	(iv)
Inconsistent performance of procedure to identify terminated long-term care policies.....	10.7	(v)
Coding errors in actuarial system related to universal life policies.....	7.9	(vi)
Error related to certain universal life policies with bonus features.....	(6.5)	(vii)
Errors identified through outlier procedures.....	(14.4)	(viii)
Other errors.....	(1.0)	(ix)

Total errors before income tax effect.....	(32.0)	
Income tax effect.....	11.4	

Total errors after income tax.....	\$(20.6)	
	=====	

-
- (i) The coding in our administrative system related to specified disease policies with a return of premium feature that had been subject to an exchange in the past was inaccurate. This resulted in an overstatement of insurance policy liabilities. This error relates to business in our Consecos Insurance Group segment. The \$25.6 million total for this item includes the \$19.3 million adjustment previously disclosed in Management's Discussion and Analysis of Financial Condition and Results of Operations - Consecos Insurance Group in our Form 10-Q for the quarterly period ended March 31, 2007.
 - (ii) Insurance policy liabilities for certain specified disease policies with a return of premium feature that is payable upon the earlier of the first occurrence of a covered claim or a specified date had not considered the first occurrence provision. This error resulted in an understatement of these reserves. This error relates to business in our Consecos Insurance Group segment.
 - (iii) A key factor used to determine specified disease insurance liabilities for certain policies sold by one of our insurance subsidiaries prior to its acquisition by Consecos was incorrectly set to zero. This resulted in no insurance policy liability being established for these policies. This error relates to business in our Consecos

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Insurance Group segment. The \$20.4 million total for this item includes the \$18.3 million adjustment previously disclosed in Management's Discussion and Analysis of Financial Condition and Results of Operations - Conseco Insurance Group in our Form 10-Q for the quarterly period ended September 30, 2007.

(iv) Insurance policy liabilities for certain specified disease policies with a return of premium provision had been calculated as if the benefit would be reduced by claims paid during the term of the policy, when such offset provision was not applicable to the policies. This error resulted in an understatement of insurance policy liabilities and relates to business in our Conseco Insurance Group segment.

(v) The procedures we had established to identify terminations of long-term care policies due to the death of the insured were not being performed in a consistent manner. This error resulted in an overstatement of insurance policy liabilities and relates to business in our Other Business in Run-off segment.

(vi) Certain coding errors in the actuarial valuation system for universal life policies had resulted in an overstatement of insurance policy liabilities. This error relates to business in our Bankers Life segment.

(vii) Provisions in certain universal life products that provided for future bonus credits were not being reflected in the amortization of the value of policies in force. These errors resulted in an overstatement of the value of policies in force and relates to our Bankers Life segment.

(viii) We perform various procedures in an effort to identify potential errors in our insurance policy liabilities by reviewing amounts that had unusual reserve or benefit balances. These procedures resulted in the identification of certain specified disease, long-term care and life policies with incorrect insurance policy liabilities. The errors include an understatement of reserves of \$9.1 million in our Conseco Insurance Group segment and \$5.3 million in our Other Business in Run-off segment.

(ix) Other miscellaneous errors that resulted in a misstatement of certain insurance policy liabilities and insurance intangible balances. No single error resulted in adjustments exceeding \$5.0 million. The errors relate to our Bankers Life, Conseco Insurance Group and Other Business in Run-off segments.

In addition (as further described in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Accounting for Long-term Care Premium Rate Increases") on February 28, 2008, the SEC's Office of the Chief Accountant (the "SEC staff") informed us that the use of a method which prospectively changes reserve assumptions for long-term care policies when premium rate increases differ significantly from original assumptions is not consistent with the guidance of Statement of Financial Standards No. 60, "Accounting and Reporting by Insurance Enterprises" ("SFAS 60").

As a result, if premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists.

Our restatement of previously issued financial statements for the year ended December 31, 2006 and quarterly information for 2006 and the first three quarters of 2007, includes adjustments to eliminate the use of the prospective revision methodology. After the elimination of the additional reserves we established based on the prospective revision methodology, our liabilities for insurance products for long-term care policies in the two business segments with these blocks (Bankers Life and Other Business in Run-off) were not deficient in the aggregate, but our estimates of future earnings indicated that profits would be recognized in early periods and losses in later periods. In accordance with paragraph 37 of SFAS 60, we are increasing the liabilities for insurance products over the period of profits, by an amount necessary to offset losses that are expected to be recognized in later periods.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

During our process to restate our previously issued financial statements, we also corrected previously identified errors, which had been recognized through cumulative adjustments to previously issued financial statements. We determined that these errors were immaterial, after considering the magnitude of the adjustment in relationship to earnings in the period discovered, offsetting adjustments and other factors. We described these adjustments in the Management's Discussion and Analysis of Consolidated Financial Condition and Results of Operations of our prior filings, including our 2006 Form 10-K. The following is a summary of our prior disclosures:

o During 2006, we determined that we had been carrying insurance liabilities for certain single premium annuities that were no longer in force in the Bankers Life segment. The error resulted in an overstatement of insurance policy liabilities of \$7.4 million.

o During 2005, we determined the method that had been used to calculate insurance policy liabilities for future long-term care benefits on policies with inflation coverage was incorrect. The error resulted in an overstatement of insurance policy liabilities of \$6.4 million in the Bankers Life segment.

o In 2005, we identified errors in the calculation of insurance acquisition costs in the Bankers Life segment. The errors resulted in an overstatement of insurance acquisition costs of \$4.4 million.

o During 2006, we discovered that procedures to appropriately identify deceased policyholders on a timely basis and release the related insurance policy liabilities were not being performed in a consistent manner. The error resulted in an overstatement of insurance policy liabilities of \$4.7 million in the Consecos Insurance Group segment.

o In 2006, we discovered that we had not been establishing insurance policy liabilities for certain specified disease coverages and that factors used to determine these liabilities were incorrect. The errors resulted in an understatement of insurance policy liabilities of \$13.3 million in the Consecos Insurance Group segment. This error was offset by a \$1.6 million understatement of insurance acquisition costs related to the same policies.

o In 2006, we discovered that several errors had been made in estimating claim reserve liabilities for our long-term care business in the Other Business in Run-off segment. In the process of reviewing our claim estimates, we discovered that some claim liabilities related to policies with inflation riders had been estimated excluding inflation benefits. We also discovered that some claim liabilities related to policies providing lifetime benefits had been estimated based on the assumption the benefit period was limited. We also discovered that some claim liabilities for non-forfeiture benefits had been estimated based on the original pool of money benefit, rather than pool amounts reduced by benefits previously paid. These errors resulted in an understatement of claim reserves of \$7.1 million.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

The effects of the restatement adjustments on our consolidated financial statements are as follows:

Consolidated Statement of Operations

Year ended December 31, 2006					
Adjustments					
	As previously reported	Remediation procedures	Accounting for premium rate increases	Previously identified errors	As restated
(Dollars in millions, except per share data)					
Total revenues.....	\$4,467.4	\$ -	\$ -	\$ -	\$4,467.4
Benefits and expenses:					
Insurance policy benefits.....	3,068.4	(5.5)	(30.6)	.7	3,033.0
Interest expense.....	73.5	-	-	-	73.5
Amortization.....	423.4	1.5	16.5	.2	441.6
Loss on extinguishment of debt....	.7	-	-	-	.7
Costs related to tentative litigation settlement.....	174.7	-	-	-	174.7
Other operating costs and expenses.....	574.4	-	-	2.3	576.7
Total benefits and expenses....	4,315.1	(4.0)	(14.1)	3.2	4,300.2
Income before income taxes.....	152.3	4.0	14.1	(3.2)	167.2
Income tax expense.....	55.8	1.5	5.1	(1.2)	61.2
Net income.....	\$ 96.5	\$ 2.5	\$ 9.0	\$ (2.0)	\$ 106.0
Net income per share - basic.....	\$.39				\$.45
Net income per share - diluted.....	\$.38				\$.45

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Year ended December 31, 2005

	Adjustments				As restated
	As previously reported	Remediation procedures	Accounting for premium rate increases	Previously identified errors	
		(Dollars in millions, except per share data)			
Total revenues.....	\$4,326.5	\$ -	\$ -	\$ -	\$4,326.5
Benefits and expenses:					
Insurance policy benefits.....	2,800.6	20.8	-	8.6	2,830.0
Interest expense.....	58.3	-	-	-	58.3
Amortization.....	388.4	1.4	-	(10.8)	379.0
Loss on extinguishment of debt....	3.7	-	-	-	3.7
Costs related to tentative litigation settlement.....	18.3	-	-	-	18.3
Other operating costs and expenses.....	553.8	-	-	(.9)	552.9
Total benefits and expense.....	3,823.1	22.2	-	(3.1)	3,842.2
Income before income taxes.....	503.4	(22.2)	-	3.1	484.3
Income tax expense.....	178.5	(8.0)	-	1.1	171.6
Net income.....	\$ 324.9	\$(14.2)	\$ -	\$ 2.0	\$ 312.7
Net income per share - basic.....	\$1.90				\$1.82
Net income per share - diluted.....	\$1.76				\$1.69

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Selected Consolidated Balance Sheet Accounts

December 31, 2006					
Adjustments					
As previously reported	Remediation procedures	Accounting for premium rate increases	Previously identified errors	As restated	
(Dollars in millions, except per share data)					
Value of policies inforce at the Effective Date.....	\$ 2,137.2	\$ 18.1	\$(16.5)	\$(2.3)	\$ 2,136.5
Income tax assets, net.....	1,786.9	11.6	(5.1)	.9	1,794.3
Total assets.....	32,717.3	29.7	(21.6)	(1.4)	32,724.0
Liabilities for insurance products...	25,973.3	50.3	(30.6)	-	25,993.0
Additional paid-in capital.....	3,473.2	(4.8) (a)	-	(.4)	3,468.0
Retained earnings.....	643.2	(15.8) (a)	9.0	(1.0)	635.4

(a) The total effect of the errors discovered through our remediation procedures was a decrease to shareholders' equity of \$20.6 million. See table above for details.

December 31, 2005					
Adjustments					
As previously reported	Remediation procedures	Accounting for premium rate increases	Previously identified errors	As restated	
(Dollars in millions, except per share data)					
Value of policies inforce at the Effective Date.....	\$ 2,382.0	\$ 19.6	\$ -	\$(2.1)	\$ 2,399.5
Income tax assets, net.....	1,496.6	13.0	-	(.2)	1,509.4
Other assets.....	341.0	-	-	2.3	343.3
Total assets.....	31,525.3	32.6	-	-	31,557.9
Liabilities for insurance products...	25,398.9	55.8	-	(.7)	25,454.0
Additional paid-in capital.....	3,194.1	(4.8)	-	(.4)	3,188.9
Retained earnings.....	584.7	(18.4)	-	1.1	567.4

December 31, 2004					
Adjustments					
As previously reported	Remediation procedures	Accounting for premium rate increases	Previously identified errors	As restated	
(Dollars in millions, except per share data)					
Value of policies inforce at the Effective Date.....	\$ 2,629.6	\$ 21.0	\$ -	\$(15.9)	\$ 2,634.7
Cost of policies produced.....	409.1	-	-	17.6	426.7
Income tax assets, net.....	967.2	5.0	-	.9	973.1
Other assets.....	339.9	-	-	1.4	341.3
Total assets.....	30,764.6	26.0	-	4.0	30,794.6
Liabilities for insurance products...	25,162.2	35.0	-	5.3	25,202.5
Additional paid-in capital.....	2,597.8	(4.8)	-	(.4)	2,592.6
Retained earnings.....	297.8	(4.2)	-	(.9)	292.7

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Selected Consolidated Statement of Cash Flow Amounts

Year ended December 31, 2006					
Adjustments					
As previously reported	Remediation procedures	Accounting for premium rate increases	Previously identified errors	As restated	
(Dollars in millions, except per share data)					
Cash flows from operating activities:					
Net income.....	\$ 96.5	\$ 2.6	\$ 9.0	\$(2.1)	\$106.0
Amortization and depreciation.....	480.7	1.5	16.5	2.5	501.2
Income taxes.....	57.2	1.4	5.1	(1.1)	62.6
Insurance liabilities.....	528.6	(5.5)	(30.6)	.7	493.2
Net cash provided by operating activities.....	931.2	-	-	-	931.2
Year ended December 31, 2005					
Adjustments					
As previously reported	Remediation procedures	Accounting for premium rate increases	Previously identified errors	As restated	
(Dollars in millions, except per share data)					
Cash flows from operating activities:					
Net income.....	\$ 324.9	\$(14.2)	\$ -	\$ 2.0	\$ 312.7
Amortization and depreciation.....	410.8	1.4	-	(11.7)	400.5
Income taxes.....	206.9	(8.0)	-	1.1	200.0
Insurance liabilities.....	391.0	20.8	-	8.6	420.4
Net cash provided by operating activities.....	1,162.1	-	-	-	1,162.1

3. BASIS OF PRESENTATION

We prepare our financial statements in accordance with accounting principles generally accepted in the United States of America ("GAAP"). We follow the accounting standards established by the Financial Accounting Standards Board ("FASB"), the American Institute of Certified Public Accountants and the SEC.

The accompanying financial statements include the accounts of the Company and its subsidiaries. Our consolidated financial statements exclude the results of material transactions between us and our consolidated affiliates, or among our consolidated affiliates.

When we prepare financial statements in conformity with GAAP, we are required to make estimates and assumptions that significantly affect reported amounts of various assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting periods. For example, we use significant estimates and assumptions to calculate values for the cost of policies produced, the value of policies in force at the Effective Date, certain investments (including derivatives), assets and liabilities related to income taxes, liabilities for insurance products, liabilities related to litigation, guaranty fund assessment accruals and amounts recoverable from loans to certain former directors and former employees. If our future experience differs from these estimates and assumptions, our financial statements would be materially affected.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following summary explains the significant accounting policies we use to prepare our financial statements.

Investments

We classify our fixed maturity securities into one of three categories: (i) "actively managed" (which we carry at estimated fair value with any unrealized gain or loss, net of tax and related adjustments, recorded as a component of shareholders' equity); (ii) "trading" (which we carry at estimated fair value with changes in such value recognized as trading income); or (iii) "held to maturity" (which we carry at amortized cost). We had no fixed maturity securities classified as held to maturity during the periods presented in these financial statements.

Equity securities include investments in common stock and non-redeemable preferred stock. We carry these investments at estimated fair value. We record any unrealized gain or loss, net of tax and related adjustments, as a component of shareholders' equity. When declines in value considered to be other than temporary occur, we reduce the amortized cost to estimated fair value and recognize a loss in the statement of operations.

Mortgage loans held in our investment portfolio are carried at amortized unpaid balances, net of provisions for estimated losses. Interest income is accrued on the principal amount of the loan based on the loan's contractual interest rate. Payment terms specified for mortgage loans may include a prepayment penalty for unscheduled payoff of the investment. Prepayment penalties are recognized as investment income when received.

Policy loans are stated at current unpaid principal balances.

Certain of our trading securities are held in an effort to offset the portion of the income statement volatility caused by the effect of interest rate fluctuations on the value of certain embedded derivatives related to our equity-indexed annuity products and certain modified coinsurance agreements. See the sections of this note entitled "Accounting for Derivatives" and "Investment Borrowings and Interest Rate Swaps" for further discussion regarding embedded derivatives and the trading accounts. In addition, the trading account includes investments backing the market strategies of our multibucket annuity products. The change in market value of these securities, which is recognized currently in income from policyholder and reinsurer accounts and other special-purpose portfolios (a component of investment income), is substantially offset by the change in insurance policy benefits for these products. Our trading securities totaled \$665.8 million and \$675.2 million at December 31, 2007 and 2006, respectively.

Other invested assets include: (i) certain call options purchased in an effort to hedge the effects of certain policyholder benefits related to our equity-indexed annuity and life insurance products; and (ii) certain non-traditional investments. We carry the call options at estimated fair value as further described in the section of this note entitled "Accounting for Derivatives". Non-traditional investments include investments in certain limited partnerships, which are accounted for using the equity method, and promissory notes, which are accounted for using the cost method.

We defer any fees received or costs incurred when we originate investments. We amortize fees, costs, discounts and premiums as yield adjustments over the contractual lives of the investments without anticipation of prepayments. We consider anticipated prepayments on mortgage-backed securities in determining estimated future yields on such securities.

When we sell a security (other than trading securities), we report the difference between the sale proceeds and amortized cost (determined based on specific identification) as a realized investment gain or loss.

We regularly evaluate our investments for possible impairment. When we conclude that a decline in a security's net realizable value is other than temporary, the decline is recognized as a realized loss and the cost basis of the security is reduced to its estimated fair value.

Cash and Cash Equivalents

Cash and cash equivalents include commercial paper, invested cash and other investments purchased with original maturities of less than three months. We carry them at amortized cost, which approximates estimated fair value.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Cost of Policies Produced

The costs that vary with, and are primarily related to, producing new insurance business subsequent to September 10, 2003 are referred to as cost of policies produced. For universal life or investment products, we amortize these costs in relation to the estimated gross profits using the interest rate credited to the underlying policies. For other products, we amortize these costs in relation to future anticipated premium revenue using the projected investment earnings rate.

When we realize a gain or loss on investments backing our universal life or investment-type products, we adjust the amortization to reflect the change in estimated gross profits from the products due to the gain or loss realized and the effect on future investment yields. We also adjust the cost of policies produced for the change in amortization that would have been recorded if actively managed fixed maturity securities had been sold at their stated aggregate fair value and the proceeds reinvested at current yields. We include the impact of this adjustment in accumulated other comprehensive income within shareholders' equity.

As of January 1, 2007, we adopted Statement of Position 05-1, "Accounting by Insurance Enterprises for Deferred Acquisition Costs in Connection with Modifications or Exchanges of Insurance Contracts" ("SOP 05-1"). SOP 05-1 provides guidance on accounting by insurance enterprises for the cost of policies produced on internal replacements of insurance and investment contracts other than those specifically described in Statement of Financial Accounting Standards No. 97, "Accounting and Reporting by Insurance Enterprises for Certain Long-Duration Contracts and for Realized Gains and Losses from the Sale of Investments". As a result of the adoption of SOP 05-1 and related guidance, if an internal replacement modification substantially changes a contract, then the cost of policies produced is written off immediately through the consolidated statement of operations and any new definable cost associated with the new replacement are deferred as the cost of policies produced. If a contract modification does not substantially change the contract, the amortization of the cost of policies produced on the original contract will continue and any acquisition costs associated with the related modification are immediately expensed.

We regularly evaluate the recoverability of the unamortized balance of the cost of policies produced. We consider estimated future gross profits or future premiums, expected mortality or morbidity, interest earned and credited rates, persistency and expenses in determining whether the balance is recoverable. If we determine a portion of the unamortized balance is not recoverable, it is charged to amortization expense. In certain cases, the unamortized balance of the cost of policies produced may not be deficient in the aggregate, but our estimates of future earnings indicate that profits would be recognized in early periods and losses in later periods. In this case, we increase the amortization of the cost of policies produced over the period of profits, by an amount necessary to offset losses that are expected to be recognized in the later years.

Value of Policies Inforce at the Effective Date

The value assigned to the right to receive future cash flows from contracts existing at September 10, 2003 is referred to as the value of policies inforce at the Effective Date. We also defer renewal commissions paid in excess of ultimate commission levels related to the existing policies in this account. The balance of this account is amortized, evaluated for recovery, and adjusted for the impact of unrealized gains (losses) in the same manner as described above for the cost of policies produced.

The discount rate we used to determine the value of the value of policies inforce at the Effective Date was 12 percent.

The Company expects to amortize the balance of the value of policies inforce at the Effective Date as of December 31, 2007 as follows: 13 percent in 2008, 12 percent in 2009, 11 percent in 2010, 7 percent in 2011 and 6 percent in 2012.

Assets Held in Separate Accounts

Separate accounts are funds on which investment income and gains or losses accrue directly to certain policyholders. The assets of these accounts are legally segregated. They are not subject to the claims that may arise out of any other business of Consecoco. We report separate account assets at market value; the underlying investment risks are assumed by the contractholders. We record the related liabilities at amounts equal to the separate account assets. We record the fees earned for administrative and contractholder services performed for the separate accounts in insurance policy income.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Recognition of Insurance Policy Income and Related Benefits and Expenses on Insurance Contracts

For universal life and investment contracts that do not involve significant mortality or morbidity risk, the amounts collected from policyholders are considered deposits and are not included in revenue. Revenues for these contracts consist of charges for policy administration, cost of insurance charges and surrender charges assessed against policyholders' account balances. Such revenues are recognized when the service or coverage is provided, or when the policy is surrendered.

We establish liabilities for investment and universal life products equal to the accumulated policy account values, which include an accumulation of deposit payments plus credited interest, less withdrawals and the amounts assessed against the policyholder through the end of the period. Sales inducements provided to the policyholders of these products are recognized as liabilities over the period that the contract must remain in force to qualify for the inducement. The options attributed to the policyholder related to our equity-indexed annuity products are accounted for as embedded derivatives as described in the section of this note entitled "Accounting for Derivatives".

Traditional life and the majority of our accident and health products (including long-term care, Medicare supplement and specified disease products) are long duration insurance contracts. Premiums on these products are recognized as revenues when due from the policyholders.

We also have a small block of short duration accident and health products. Premiums on these products are recognized as revenue over the premium coverage period.

We establish liabilities for traditional life, accident and health insurance, and life contingent payment annuity products using mortality tables in general use in the United States, which are modified to reflect the Company's actual experience when appropriate. We establish liabilities for accident and health insurance products using morbidity tables based on the Company's actual or expected experience. These reserves are computed at amounts that, with additions from estimated future premiums received and with interest on such reserves at estimated future rates, are expected to be sufficient to meet our obligations under the terms of the policy. Liabilities for future policy benefits are computed on a net-level premium method based upon assumptions as to future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses determined when the policies were issued (or with respect to policies in force at August 31, 2003, the Company's best estimate of such assumptions on the Effective Date). We make an additional provision to allow for potential adverse deviation for some of our assumptions. Once established, assumptions on these products are generally not changed unless a premium deficiency exists. In that case, a premium deficiency reserve is recognized and the future pattern of reserve changes are modified to reflect the relationship of premiums to benefits based on the current best estimate of future claim costs, investment yields, mortality, morbidity, withdrawals, policy dividends and maintenance expenses, determined without an additional provision for potential adverse deviation.

We establish claim reserves based on our estimate of the loss to be incurred on reported claims plus estimates of incurred but unreported claims based on our past experience.

Accounting for Long-term Care Premium Rate Increases

Many of our long-term care policies were subject to premium rate increases in 2006 and 2007. In some cases, these premium rate increases were materially consistent with the assumptions we used to value the particular block of business at the fresh-start date. In other cases, the premium rate increases were materially different from that assumed at the fresh-start date, leading us to change our best estimates of future actuarial assumptions. With respect to the 2006 premium rate increases, some of our policyholders were provided an option to cease paying their premiums and receive a non-forfeiture option in the form of a paid-up policy with limited benefits. In addition, our policyholders could choose to reduce their coverage amounts and premiums in the same proportion, when permitted by our contracts or as required by regulators. The following describes how we account for these policyholder options:

o Premium rate increases - If premium rate increases reflect a change in our previous rate increase assumptions, the new assumptions are not reflected prospectively in our reserves. Instead, the additional premium revenue resulting from the rate increase is recognized as earned and original assumptions continue to be used to determine changes to liabilities for insurance products unless a premium deficiency exists.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

o Benefit reductions - A policyholder may choose reduced coverage with a proportionate reduction in premium, when permitted by our contracts. This option does not require additional underwriting. Benefit reductions are treated as a partial lapse of coverage, and the balance of our reserves and deferred insurance acquisition costs is reduced in proportion to the reduced coverage.

o Non-forfeiture benefits offered in conjunction with a rate increase - In some cases, non-forfeiture benefits are offered to policyholders who wish to lapse their policies at the time of a significant rate increase. In these cases, exercise of this option is treated as an extinguishment of the original contract and issuance of a new contract. The balance of our reserves and deferred insurance acquisition costs are released, and a reserve for the new contract is established.

o Florida Order - In 2004, the Florida Office of Insurance Regulation issued an order to our subsidiaries in the Other Business in Run-off segment regarding their long-term care business in Florida. The order required them to offer a choice of three alternatives to holders of home health care policies in Florida subject to premium rate increases as follows:

o retention of their current policy with a rate increase of 50 percent in the first year and actuarially justified increases in subsequent years;

o receipt of a replacement policy with reduced benefits and a rate increase in the first year of 25 percent and no more than 15 percent in subsequent years; or

o receipt of a paid-up policy, allowing the holder to file future claims up to 100 percent of the amount of premiums paid since the inception of the policy.

Reserves for all three groups of policies under the order were prospectively adjusted using a prospective revision methodology, as these alternatives were required by the Florida Office of Insurance Regulation. These policies had no insurance acquisition costs established at the Effective Date.

Some of our policyholders may receive a non-forfeiture benefit if they cease paying their premiums pursuant to their original contract (or pursuant to changes made to their original contract as a result of a litigation settlement made prior to the Effective Date or an order issued by the Florida Office of Insurance Regulation). In these cases, exercise of this option is treated as the exercise of a policy benefit, and the reserve for premium paying benefits is reduced, and the reserve for the non-forfeiture benefit is adjusted to reflect the election of this benefit.

Accounting for marketing and reinsurance agreements with Coventry

Prescription Drug Benefit

The Medicare Prescription Drug, Improvement and Modernization Act of 2003 provided for the introduction of a prescription drug benefit ("PDP"). In order to offer this product to our current and potential future policyholders without investing in management and infrastructure, we entered into a national distribution agreement with Coventry to use our career and independent agents to distribute Coventry's prescription drug plan, Advantra Rx. We receive a fee based on the premiums collected on plans sold through our distribution channels. In addition, Conseco has a quota-share reinsurance agreement with Coventry for Conseco enrollees that provides Conseco with 50 percent of net premiums and related policy benefits subject to a risk corridor. The Part D program was effective January 1, 2006.

The following describes how we account for and report our PDP business:

Our accounting for the national distribution agreement

o We recognize distribution and licensing fee income from Coventry based upon negotiated percentages of collected premiums on the underlying Medicare Part D contracts. This fee income is recognized over the calendar year term as premiums are collected.

o We also pay commissions to our agents who sell the plans on behalf of Coventry. These payments are deferred and amortized over the remaining term of the initial enrollment period (the one-year life of the initial policy).

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Our accounting for the quota-share agreement

- o We recognize premium revenue evenly over the period of the underlying Medicare Part D contracts.
- o We recognize policyholder benefits and ceding commission expense as incurred.
- o We recognize risk-share premium adjustments consistent with Coventry's risk-share agreement with the Centers for Medicare and Medicaid Services.

Private-Fee-For-Service

Conseco expanded its strategic alliance with Coventry by entering into a national distribution agreement under which our career agents began distributing Coventry's Private-Fee-For-Service ("PFFS") plan, beginning January 1, 2007. The Advantra Freedom product is a Medicare Advantage plan designed to provide seniors with more choices and better coverage at lower cost than original Medicare and Medicare Advantage plans offered through HMOs. Under the agreement, we receive a fee based on the number of PFFS plans sold through our distribution channels. In addition, Conseco has a quota-share reinsurance agreement with Coventry for Conseco enrollees that provides Conseco in 2007 with approximately 50 percent of the net premiums and related profits.

We receive distribution fees from Coventry and we pay sales commissions to our agents for these enrollments. In addition, we participate at an approximately 50 percent level in the income (loss) related to this business pursuant to a quota-share agreement with Coventry.

The following summarizes our accounting and reporting practices for the PFFS business.

Our accounting for the distribution agreement

- o We receive distribution income from Coventry and other parties based on a fixed fee per PFFS contract. This income is deferred and recognized over the remaining calendar year term of the initial enrollment period.
- o We also pay commissions to our agents who sell the plans on behalf of Coventry and other parties. These payments are deferred and amortized over the remaining term of the initial enrollment period (the one-year life of the initial policy).

Our accounting for the quota-share agreement

- o We recognize revenue evenly over the period of the underlying PFFS contracts.
- o We recognize policyholder benefits and ceding commission expense as incurred.

Large Group Private-Fee-For-Service Block

Effective July 1, 2007, Conseco entered into a quota-share reinsurance agreement with Coventry related to the PFFS business written by Coventry under one large group policy. Conseco receives 50 percent of the net premiums and related profits associated with this business as long as the ceded revenue margin (as defined in the quota-share reinsurance agreement) is less than or equal to five percent. Conseco receives 25 percent of the net premiums and related profits on the ceded margin in excess of five percent.

Reinsurance

In the normal course of business, we seek to limit our loss exposure on any single insured or to certain groups of policies by ceding reinsurance to other insurance enterprises. We currently retain no more than \$.8 million of mortality risk on any one policy. We diversify the risk of reinsurance loss by using a number of reinsurers that have strong claims-paying ratings. In each case, the ceding Conseco subsidiary is directly liable for claims reinsured even if the assuming company is unable to pay.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

The cost of reinsurance on life and health coverages is recognized over the life of the reinsured policies using assumptions consistent with those used to account for the underlying policy. The cost of reinsurance ceded totaled \$206.5 million, \$213.3 million and \$232.2 million in 2007, 2006 and 2005, respectively. We deduct this cost from insurance policy income. Reinsurance recoveries netted against insurance policy benefits totaled \$353.4 million, \$231.0 million and \$231.6 million in 2007, 2006 and 2005, respectively.

From time-to-time, we assume insurance from other companies. Any costs associated with the assumption of insurance are amortized consistent with the method used to amortize the cost of policies produced described above. Reinsurance premiums assumed totaled \$322.7 million, \$130.3 million and \$60.1 million in 2007, 2006 and 2005, respectively. Reinsurance premiums included amounts assumed pursuant to marketing and quota-share agreements with Coventry of \$271.4 million and \$74.4 million in 2007 and 2006, respectively. The increase in premiums assumed under these agreements in 2007 resulted from two new agreements: (i) we are assuming approximately 50 percent of the PFFS business marketed by our career agents pursuant to a marketing and distribution agreement with Coventry effective January 1, 2007; and (ii) we are assuming 50 percent of the PFFS business written by Coventry under one large group policy effective July 1, 2007.

See the section of this note entitled "Accounting for Derivatives" for a discussion of the derivative embedded in the payable related to certain modified coinsurance agreements.

On October 12, 2007, we completed a transaction to coinsure 100 percent of most of the older inforce equity-indexed annuity and fixed annuity business of three of our insurance subsidiaries with Reassure America Life Insurance Company ("REALIC"), a subsidiary of Swiss Re Life & Health America Inc. The transaction was recorded in our financial statements on September 28, 2007, the date the parties were bound by the coinsurance agreement and all regulatory approvals had been obtained. In the transaction, REALIC: (i) paid a ceding commission of \$76.5 million; and (ii) assumed the investment and persistency risk of these policies. Our insurance subsidiaries ceded approximately \$2.8 billion of policy and other reserves to REALIC, as well as transferred the invested assets backing these policies on October 12, 2007. Our insurance subsidiaries remain primarily liable to the policyholders in the event REALIC does not fulfill its obligations under the agreements. Accordingly, our insurance liabilities continue to include the amounts ceded for these policies, which is offset by a corresponding amount in reinsurance receivables. The increase in reinsurance receivables from December 31, 2006 to December 31, 2007 is largely attributable to this reinsurance agreement. The coinsurance transaction has an effective date of January 1, 2007.

Pursuant to the terms of the annuity coinsurance agreement, the ceding commission was based on the January 1, 2007 value of the assets and liabilities related to the ceded block. The earnings (loss) after income taxes on the business from January 1, 2007 through September 28, 2007, resulted in increases (decreases) to the loss calculated as of January 1, 2007. Such after-tax earnings (loss) include the market value declines on invested assets transferred to the reinsurer occurring during the first three quarters of 2007.

The following summarizes the profits and losses recognized on this business in 2007 (dollars in millions):

	2007
Net earnings on the block before tax.....	\$ 17.0
Realized investment losses, net of amortization of insurance intangibles.....	(40.6)
Loss related to the annuity coinsurance transaction.....	(76.5) (a)
Net loss before income taxes.....	\$ (100.1)
	=====

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

(a) Amount represents the net loss before income taxes recognized on the annuity coinsurance transaction during 2007, including the earnings and losses on the block during that period and the loss recognized upon completion of the transaction. The following summarizes the components of the loss before income taxes (dollars in millions):

Assets received (transferred)	
Investments.....	\$(2,560.8)
Accrued investment income.....	(28.7)
Value of policies inforce at the Effective Date	(198.9)
Cost of policies produced.....	(20.5)
Reinsurance receivables.....	2,764.3
Other.....	(31.9)

Net loss before income taxes.....	\$ (76.5)
	=====

In 2007, we completed the recapture of a block of traditional life insurance in force that had been ceded in 2002 to REALIC. In the transaction, which had an effective date of October 1, 2007, Colonial Penn paid REALIC a recapture fee of \$63 million. The recapture of this block resulted in a \$2.8 million gain accounted for as a reduction to insurance policy benefits. Colonial Penn recaptured 100 percent of the liability for the future benefits previously ceded, and will recognize profits from the block as they emerge over time. Colonial Penn already administers the policies that were recaptured.

As summarized above under "Accounting for marketing and reinsurance agreements with Coventry", we assume reinsurance from Coventry related to a portion of the PDP and PFFS business written through our distribution channels. In addition, we have assumed 50 percent of the PFFS business written by Coventry under one large group policy.

Income Taxes

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities, capital loss carryforwards and net operating loss carryforwards ("NOLs"). We evaluate the realizability of our deferred income tax assets and assess the need for a valuation allowance on an ongoing basis. In evaluating our deferred income tax assets, we consider whether it is more likely than not that the deferred income tax assets will be realized. The ultimate realization of our deferred income tax assets depends upon generating sufficient future taxable income during the periods in which our temporary differences become deductible and before our capital loss carryforwards and NOLs expire. This assessment requires significant judgment. However, recovery is dependent on achieving such projections and failure to do so would result in an increase in the valuation allowance in a future period. Any future increase in the valuation allowance would result in additional income tax expense and reduce shareholders' equity, and such an increase could have a significant impact upon our earnings in the future. In addition, the use of the Company's NOLs is dependent, in part, on whether the Internal Revenue Service (the "IRS") does not take an adverse position in the future regarding the tax position we have taken in our tax returns with respect to the allocation of cancellation of indebtedness income, which is further described in the note entitled "Income Taxes".

Based upon information existing at the time of our emergence from bankruptcy, we established a valuation allowance against our entire balance of net deferred income tax assets as we believed that the realization of such net deferred income tax assets in future periods was uncertain. During 2005 and 2006, we concluded that it was no longer necessary to hold certain portions of the previously established valuation allowance. Accordingly, we reduced our valuation allowance by \$585.8 million and \$260.0 million in 2005 and 2006, respectively. However, we are required to continue to hold a valuation allowance of \$672.9 million at December 31, 2007 because we have determined that it is more likely than not that a portion of our deferred tax assets will not be realized. This determination was made by evaluating each component of the deferred tax asset and assessing the effects of limitations or interpretations on the value of such component to be fully recognized in the future.

Investment Borrowings

In the first quarter of 2007, one of the Company's insurance subsidiaries (Conseco Life) became a member of the Federal Home Loan Bank of Indianapolis ("FHLBI"). As a member of the FHLBI, Conseco Life has the ability to borrow on a collateralized basis from FHLBI. Conseco Life is required to hold a certain minimum amount of FHLBI common stock as

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

a requirement of membership in the FHLBI, and additional amounts based on the amount of the borrowings. At December 31, 2007, the carrying value of the FHLBI common stock was \$22.5 million. Collateralized borrowings from the FHLBI totaled \$450.0 million as of December 31, 2007, and the proceeds were used to purchase fixed maturity securities. The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet. The borrowings are collateralized by investments with an estimated fair value of \$509.0 million at December 31, 2007, which are maintained in a custodial account for the benefit of the FHLBI. Consec Life recognized interest expense of \$16.7 million in 2007 related to the borrowings. The following summarizes the terms of the borrowings (dollars in millions):

Amount borrowed -----	Maturity date ----	Interest rate at December 31, 2007 -----
\$100.0	November 2015	Fixed rate - 4.890%
100.0	December 2015	Fixed rate - 4.710%
54.0	May 2012	Variable rate - 5.015%
146.0	November 2015	Fixed rate - 5.300%
37.0	July 2012	Fixed rate - 5.540%
13.0	July 2012	Variable rate - 5.308%

At December 31, 2007, investment borrowings consisted of: (i) collateralized borrowings from the FHLBI of \$450.0 million; (ii) \$452.3 million of securities issued to other entities by a variable interest entity which is consolidated in our financial statements as further discussed in the note to the consolidated financial statements entitled "Investment in a Variable Interest Entity"; and (iii) other borrowings of \$10.7 million.

At December 31, 2006, investment borrowings consisted of: (i) \$406.8 million of securities issued to other entities by a variable interest entity which is consolidated in our financial statements; and (ii) other borrowings of \$11.5 million.

Accounting for Derivatives

Our equity-indexed annuity products provide a guaranteed base rate of return and a higher potential return that is based on a percentage (the "participation rate") of the amount of increase in the value of a particular index, such as the Standard & Poor's 500 Index, over a specified period. Typically, at the beginning of each policy year, a new index period begins. We are able to change the participation rate at the beginning of each index period, subject to contractual minimums. We typically buy call options on the applicable indices in an effort to hedge potential increases to policyholder benefits resulting from increases in the particular index to which the product's return is linked. Policyholder account balances for these annuities fluctuate in relation to changes in the values of these options. We reflect changes in the estimated market value of these options in net investment income (classified as investment income from policyholder and reinsurer accounts and other special-purpose portfolios). Net investment income (loss) related to equity-indexed products was \$(8.5) million, \$40.4 million and \$(14.6) million during 2007, 2006 and 2005, respectively. These amounts were substantially offset by the corresponding charge to insurance policy benefits. The estimated fair value of these options was \$51.2 million and \$93.7 million at December 31, 2007 and 2006, respectively. We classify these instruments as other invested assets. Pursuant to the annuity coinsurance agreement described above, we continue to hold \$11.9 million of these options for the benefit of the assuming company until such options expire. All future cash flows (including any increases (decreases) in fair value) from these options are transferred to the assuming company. Such options are included in other invested assets, and we have established a liability for the amount due to the assuming company upon their expiration, based on the December 31, 2007 estimated market value of these options.

The Company accounts for the options attributed to the policyholder for the estimated life of the annuity contract as embedded derivatives as defined by Statement of Financial Accounting Standards No. 133, "Accounting for Derivative Instruments and Hedging Activities", as amended by Statement of Financial Accounting Standards No. 137, "Deferral of the Effective Date of FASB Statement No. 133" and Statement of Financial Accounting Standards No. 138, "Accounting for Certain Derivative Instruments and Certain Hedging Activities". We record the changes in the fair values of the embedded derivatives in current earnings as a component of policyholder benefits. The fair value of these derivatives, which are classified as "liabilities for interest-sensitive products", was \$353.2 million (including \$156.9 million which was ceded pursuant to an annuity coinsurance transaction as further described above under the caption "Coinsurance Transaction") and \$275.3 million at December 31, 2007 and 2006, respectively. We maintain a specific block of investments which are equal to the balance of these liabilities in our trading securities account, which we carry at estimated fair value with changes in such value recognized as investment income (classified as investment income from policyholder and reinsurer accounts and other

special-purpose portfolios). The change in value of these trading securities attributable to interest fluctuations will generally offset the change in the value of the embedded derivative provided corporate spreads remain constant.

If the counterparties for the derivatives we hold fail to meet their obligations, we may have to recognize a loss. We limit our exposure to such a loss by diversifying among several counterparties believed to be strong and creditworthy. At December 31, 2007, all of our counterparties were rated "A" or higher by Standard & Poor's Corporation ("S&P").

Certain of our reinsurance payable balances contain embedded derivatives as defined in SFAS No. 133 Implementation Issue No. B36, "Embedded Derivatives:

Modified Coinsurance Arrangements and Debt Instruments that Incorporate Credit Risk Exposures that are Unrelated or Only Partially Related to the Creditworthiness of the Obligor of Those Instruments". Such derivatives had an estimated fair value of \$(1.0) million and \$9.6 million at December 31, 2007 and 2006, respectively. We record the change in the fair value of these derivatives as a component of investment income (classified as investment income from policyholder and reinsurer accounts and other special-purpose portfolios). We maintain a specific block of investments related to these agreements in our trading securities account, which we carry at estimated fair value with changes in such value recognized as investment income (also classified as investment income from policyholder and reinsurer accounts and other special-purpose portfolios). The change in value of these trading securities attributable to interest rate fluctuations will generally offset the change in value of the embedded derivatives provided corporate spreads remain constant.

Multibucket Annuity Product

The Company's multibucket annuity is a fixed annuity product that credits interest based on the experience of a particular market strategy. Policyholders allocate their annuity premium payments to several different market strategies based on different asset classes within the Company's investment portfolio. Interest is credited to this product based on the market return of the given strategy, less management fees, and funds may be moved between different strategies. The Company guarantees a minimum return of premium plus approximately 3 percent per annum over the life of the contract. The investments backing the market strategies of these products are designated by the Company as trading securities. The change in the fair value of these securities is recognized currently in investment income (classified as income from policyholder and reinsurer accounts), which is substantially offset by the change in insurance policy benefits for these products. As of December 31, 2007, we hold insurance liabilities of \$99.0 million related to multibucket annuity products.

Stock Based Compensation

Prior to January 1, 2006, we measured compensation cost for our stock option plans using the intrinsic value method pursuant to Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" and related interpretations ("APB 25"). Under this method, compensation cost was recorded when the quoted market price at the grant date exceeded the amount an employee had to pay to acquire the stock. When the Company issued employee stock options with an exercise price equal to or greater than the market price of our stock on the grant date, no compensation cost was recorded. Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation" ("SFAS 123") and Statement of Financial Accounting Standards No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure" required disclosures of the pro forma effects of using the fair value method of accounting for stock options.

In December 2004, the FASB issued Statement of Financial Accounting Standards No. 123 (revised 2004) "Share-Based Payment" ("SFAS 123R"), which revised SFAS 123 and superseded APB 25. SFAS 123R provided additional guidance on accounting for share-based payments and required all such awards to be measured at fair value with the related compensation cost recognized in the statement of operations over the related service period. Consecro implemented SFAS 123R using the modified prospective method on January 1, 2006. Under this method, the Company began recognizing compensation cost for all awards granted on or after January 1, 2006. In addition, we are required to recognize compensation cost over the remaining requisite service period for the portion of outstanding awards that were not vested as of January 1, 2006 and were not previously expensed on a pro forma basis pursuant to SFAS 123. In accordance with the modified prospective transition method, our consolidated financial statements for prior periods have not been restated to reflect compensation cost determined under the fair value method. SFAS 123R also requires the benefits of tax deductions in excess of recognized compensation cost to be reported as a financing cash flow rather than as an operating cash flow, as previously required. During 2007 and 2006, we did not capitalize any stock-based compensation expense as cost of policies produced or any other asset category.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Fair Values of Financial Instruments

We use the following methods and assumptions to determine the estimated fair values of financial instruments:

Investment securities. For fixed maturity securities (including redeemable preferred stocks) and for equity and trading securities, we use quotes from independent pricing services, where available. For investment securities for which such quotes are not available, we use values obtained from broker-dealer market makers or by discounting expected future cash flows using a current market rate appropriate for the yield, credit quality, and, for fixed maturity securities, the maturity of the investment being priced.

Cash and cash equivalents. The carrying amount for these instruments approximates their estimated fair value.

Mortgage loans and policy loans. We discount future expected cash flows for loans included in our investment portfolio based on interest rates currently being offered for similar loans to borrowers with similar credit ratings. We aggregate loans with similar characteristics in our calculations. The market value of policy loans approximates their carrying value.

Other invested assets. We use quoted market prices, where available. When quotes are not available, we estimate the fair value based on discounted future expected cash flows or independent transactions which establish a value for our investment. When we are unable to estimate a fair value, we assume a market value equal to carrying value.

Insurance liabilities for interest-sensitive products. We discount future expected cash flows based on interest rates currently being offered for similar contracts with similar maturities.

Investment borrowings and notes payable. For publicly traded debt, we use current market values. For other notes, we use discounted cash flow analyses based on our current incremental borrowing rates for similar types of borrowing arrangements.

The estimated fair values of our financial instruments at December 31, 2007 and 2006, were as follows (dollars in millions):

	2007		2006	
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
	-----	-----	-----	-----
			(Restated)	
Financial assets:				
Actively managed fixed maturities.....	\$20,510.9	\$20,510.9	\$22,802.9	\$22,802.9
Equity securities	34.5	34.5	24.8	24.8
Mortgage loans.....	2,086.0	2,137.0	1,642.2	1,684.7
Policy loans.....	370.4	370.4	412.5	412.5
Trading securities.....	665.8	665.8	675.2	675.2
Other invested assets.....	134.3	134.3	178.8	178.8
Cash and cash equivalents.....	428.6	428.6	409.9	409.9
Financial liabilities:				
Insurance liabilities for interest-sensitive products (a).....	\$13,169.4	\$13,169.4	\$13,021.1	\$13,021.1
Investment borrowings.....	913.0	913.0	418.3	418.3
Notes payable - direct corporate obligations.....	1,193.7	1,156.8	1,000.8	999.8

(a) The estimated fair value of insurance liabilities for interest-sensitive products was approximately equal to its carrying value at December 31, 2007 and 2006. This was because interest rates credited on the vast majority of account balances approximate current rates paid on similar products and because these rates are not generally guaranteed beyond one year.

Sales Inducements

Certain of our annuity products offer sales inducements to contract holders in the form of enhanced crediting rates or bonus payments in the initial period of the contract. Certain of our life insurance products offer persistency bonuses credited

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

to the contract holders balance after the policy has been outstanding for a specified period of time. These enhanced rates and persistency bonuses are considered sales inducements under Statement of Position 03-01 "Accounting and Reporting by Insurance Enterprises for Certain Nontraditional Long-Duration Contracts and for Separate Accounts". Such amounts are deferred and amortized in the same manner as the cost of policies produced. Sales inducements deferred totaled \$52.4 million, \$64.0 million and \$49.2 million in 2007, 2006 and 2005, respectively. Amounts amortized totaled \$18.4 million, \$19.1 million and \$17.8 million in 2007, 2006 and 2005, respectively. The unamortized balance of deferred sales inducements was \$149.0 million and \$115.0 million at December 31, 2007 and 2006, respectively. The balance of insurance liabilities for persistency bonus benefits was \$252.8 million and \$296.3 million at December 31, 2007 and 2006, respectively.

Recently Issued Accounting Standards

Pending Accounting Standards

In December 2007, the FASB issued Statement of Financial Accounting Standards No. 160, "Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB No. 51" ("SFAS 160"), which establishes new standards governing the accounting for and reporting of noncontrolling interests (previously referred to as minority interests). SFAS 160 establishes reporting requirements which include, among other things, that noncontrolling interests be reflected as a separate component of equity, not as a liability. It also requires that the interests of the parent and the noncontrolling interest be clearly identifiable. Additionally, increases and decreases in a parent's ownership interest that leave control intact shall be reflected as equity transactions, rather than step acquisitions or dilution gains or losses. SFAS 160 is effective for fiscal years beginning on or after December 15, 2008 and early adoption is prohibited. We do not expect the initial adoption of SFAS 160 to be material to our financial position or results of operations.

In December 2007, the FASB issued Statement of Financial Accounting Standards No. 141 (revised 2007), "Business Combinations" ("SFAS 141R"). SFAS 141R requires the acquiring entity in a business combination to recognize all assets acquired and liabilities assumed in a transaction at the acquisition date fair value, with certain exceptions. Additionally, SFAS 141R requires changes to the accounting treatment of acquisition related items, including, among other items, transaction costs, contingent consideration, restructuring costs, indemnification assets and tax benefits. SFAS 141R also provides for a substantial number of new disclosure requirements. SFAS 141R is effective for business combinations initiated on or after the first annual reporting period beginning after December 15, 2008 and early adoption is prohibited. We expect that SFAS 141R will have an impact on our accounting for future business combinations once the statement is adopted but the effect is dependent upon acquisitions, if any, that are made in the future.

In February 2007, the FASB issued Statement of Financial Accounting Standards No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities - Including an Amendment of FASB Statement No. 115" ("SFAS 159"). SFAS 159 allows entities to choose to measure many financial instruments and certain other items, including insurance contracts, at fair value (on an instrument-by-instrument basis) that are not currently required to be measured at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. SFAS 159 is effective for us on January 1, 2008. We do not expect to elect the fair value option for any of our financial assets or liabilities.

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements" ("SFAS 157"). SFAS 157 defines fair value, establishes a framework for measuring fair value and expands disclosures of fair value measurements. SFAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007. The adoption of SFAS 157 will not have a material effect on our results of operations and financial condition.

Adopted Accounting Standards

In July 2006, the FASB issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109" ("FIN 48"). FIN 48 creates a comprehensive model which addresses how a company should recognize, measure, present and disclose in its financial statements uncertain tax positions that the company has taken or expects to take on a tax return. This guidance is effective for fiscal years beginning after December 15, 2006. The adoption of FIN 48 resulted in a \$6.0 million increase to additional paid-in capital during 2007. The Company classifies interest and, if applicable, penalties as income tax expense in the consolidated statement of operations. No such amounts were recognized in 2007. The liability for accrued interest was not significant at December 31, 2007 or 2006.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

In February 2006, the FASB issued SFAS No. 155, "Accounting for Certain Hybrid Financial Instruments - an amendment of FASB Statements No. 133 and 140" ("SFAS 155"). SFAS 155 amends SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities" ("SFAS 133"), and SFAS 140, "Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities" and resolves issues addressed in SFAS 133 Implementation Issue No. D1, "Application of Statement 133 to Beneficial Interest in Securitized Financial Assets". SFAS 155: (a) permits fair value remeasurement for any hybrid financial instrument that contains an embedded derivative that otherwise would require bifurcation; (b) clarifies which interest-only strips and principal-only strips are not subject to the requirements of SFAS 133; (c) establishes a requirement to evaluate beneficial interests in securitized financial assets to identify interests that are freestanding derivatives or that are hybrid financial instruments that contain an embedded derivative requiring bifurcation; (d) clarifies that concentrations of credit risk in the form of subordination are not embedded derivatives; and, (e) eliminates restrictions on a qualifying special-purpose entity's ability to hold passive derivative financial instruments that pertain to beneficial interests that are or contain a derivative financial instrument. The standard also requires presentation within the financial statements that identifies those hybrid financial instruments for which the fair value election has been applied and information on the income statement impact of the changes in fair value of those instruments. SFAS 155 was effective for all financial instruments acquired or issued in a fiscal year that begins after September 15, 2006. The initial adoption of SFAS 155 did not have a material effect on our financial position or results of operations.

In September 2005, the Accounting Standards Executive Committee issued SOP 05-1. This statement provides guidance on accounting for deferred acquisition costs on an internal replacement which is defined broadly as a modification in product benefits, features, rights, or coverages that occurs by the exchange of an existing contract for a new contract, or by amendment, endorsement, or rider to an existing contract, or by the election of a benefit, feature, right, or coverage within an existing contract. An internal replacement that is determined to result in a replacement contract that is substantially unchanged from the replaced contract should be accounted for as a continuation of the replaced contract. Contract modifications resulting in a replacement contract that is substantially changed from the replaced contract should be accounted for as an extinguishment of the replaced contract and any unamortized deferred acquisition costs, unearned revenue liabilities, and deferred sales inducement assets from the replaced contract should not be deferred in connection with the replacement contract. The provisions of SOP 05-1 are effective for internal replacements beginning January 1, 2007. The initial adoption of SOP 05-1 did not have a material impact on our results of operations or financial position. The adoption of SOP 05-1 resulted in the shortening of the period over which the value of policies inforce at the Effective Date and the cost of policies produced related to a small block of our group health insurance business are amortized. Transition to the shorter amortization period resulted in a January 1, 2007 cumulative effect adjustment to retained earnings of \$2.7 million, net of tax.

In September 2006, the FASB issued SFAS No. 158, "Employers Accounting for Defined Benefit and Other Retirement Plans - an amendment of FASB Statements No. 87, 88, 106 and 132(R)" ("SFAS 158"). SFAS 158 requires employers to recognize the overfunded or underfunded status of defined benefit pension and other postretirement benefit plans as an asset or liability in its statement of financial position, measured as the difference between the fair value of plan assets and the projected benefit obligation as of the end of our fiscal year end. In addition, SFAS 158 requires employers to recognize changes in the funded status of defined benefit pension and other post retirement plans in the year in which the changes occur through other accumulated comprehensive income. SFAS 158 is effective for fiscal years ending after December 15, 2006.

The impact of the adoption of SFAS 158 on our consolidated balance sheet at December 31, 2006, is as follows (dollars in millions):

	Balance before adoption of SFAS 158	Adjustments	Balance after adoption of SFAS 158
	(Restated)		(Restated)
Income tax assets, net.....	\$1,790.8	\$ 3.5	\$1,794.3
Other liabilities.....	601.9	9.9	611.8
Accumulated other comprehensive loss.....	(66.2)	(6.4)	(72.6)

The FASB issued SFAS 123R in December 2004. SFAS 123R revises SFAS 123 and supersedes APB 25. SFAS 123R provides additional guidance on accounting for share-based payments and requires all such awards to be measured at fair value with the related compensation cost recognized in the statement of operations over the related service period. SFAS 123R is effective for all awards granted, modified, repurchased or cancelled and requires the recognition of compensation cost over the

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

remaining requisite service period for the portion of outstanding awards that were not vested as of January 1, 2006 and were not previously expensed on a pro forma basis in the disclosure included under the caption entitled "Accounting for Stock Options". SFAS 123R also requires the benefits of tax deductions in excess of recognized compensation cost to be reported as a financing cash flow rather than as an operating cash flow, as previously required. We previously measured compensation expense for our stock option plans using the intrinsic value method. Effective January 1, 2006, we were required to recognize expense related to our stock option plans consistent with the requirements of SFAS 123R described above. We implemented this requirement using the modified prospective method. In March 2005, the SEC issued Staff Accounting Bulletin No. 107, "Share-Based Payment" ("SAB 107") related to SFAS 123R. We have followed the guidance in SAB 107 in our adoption of SFAS 123R.

5. INVESTMENTS

At December 31, 2007, the amortized cost and estimated fair value of actively managed fixed maturities and equity securities were as follows (dollars in millions):

	Amortized cost ----	Gross unrealized gains -----	Gross unrealized losses -----	Estimated fair value -----
Investment grade:				
Corporate securities.....	\$13,442.7	\$110.2	\$(420.1)	\$13,132.8
United States Treasury securities and obligations of United States government corporations and agencies.....	619.3	16.9	(1.6)	634.6
States and political subdivisions.....	534.8	5.1	(9.4)	530.5
Debt securities issued by foreign governments.....	9.6	.2	-	9.8
Structured securities	4,707.5	13.8	(108.7)	4,612.6
Below-investment grade (primarily corporate securities).....	1,678.8	2.9	(91.1)	1,590.6
	-----	-----	-----	-----
Total actively managed fixed maturities.....	\$20,992.7	\$149.1	\$(630.9)	\$20,510.9
	=====	=====	=====	=====
Equity securities.....	\$34.0	\$.5	\$ -	\$34.5
	=====	====	=====	=====

At December 31, 2006, the amortized cost and estimated fair value of actively managed fixed maturities and equity securities were as follows (dollars in millions):

	Amortized cost ----	Gross unrealized gains -----	Gross unrealized losses -----	Estimated fair value -----
Investment grade:				
Corporate securities.....	\$13,179.2	\$142.0	\$(201.3)	\$13,119.9
United States Treasury securities and obligations of United States government corporations and agencies.....	1,428.6	16.8	(23.3)	1,422.1
States and political subdivisions.....	675.7	5.2	(11.4)	669.5
Debt securities issued by foreign governments.....	117.3	3.6	(.2)	120.7
Structured securities	5,984.7	7.7	(76.6)	5,915.8
Below-investment grade (primarily corporate securities).....	1,561.4	23.0	(29.5)	1,554.9
	-----	-----	-----	-----
Total actively managed fixed maturities.....	\$22,946.9	\$198.3	\$(342.3)	\$22,802.9
	=====	=====	=====	=====
Equity securities.....	\$23.9	\$1.2	\$(.3)	\$24.8
	=====	=====	=====	=====

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Accumulated other comprehensive loss is primarily comprised of the net effect of unrealized appreciation (depreciation) on our investments. These amounts, included in shareholders' equity as of December 31, 2007 and 2006 were as follows (dollars in millions):

	2007	2006
	----	----
Net unrealized depreciation on investments.....	\$(481.3)	\$(136.3)
Adjustment to value of policies inforce at the Effective Date.....	18.3	20.1
Adjustment to cost of policies produced.....	43.7	12.3
Adjustment to initially apply SFAS No. 158 related to the unrecognized net loss related to deferred compensation plan.....	-	(9.9)
Unrecognized net loss related to deferred compensation plan.....	(7.3)	-
Deferred income tax asset.....	153.3	41.2
	-----	-----
Accumulated other comprehensive loss.....	\$(273.3)	\$ (72.6)
	=====	=====

Concentration of Actively Managed Fixed Maturity Securities

The following table summarizes the estimated fair value of our actively managed fixed maturity securities by category as of December 31, 2007 (dollars in millions):

	Estimated fair value	Percent of fixed maturities
	-----	-----
Structured securities.....	\$ 4,668.1	22.8%
Manufacturing.....	3,603.4	17.6
Bank and finance.....	2,039.1	9.9
Utilities.....	1,766.2	8.6
Services.....	1,615.2	7.9
Communications.....	1,088.0	5.3
Agriculture, forestry and mining.....	888.6	4.3
Retail and wholesale.....	799.8	3.9
Holding and other investment offices.....	751.4	3.7
Transportation.....	643.9	3.1
U.S. Government.....	634.6	3.1
States and political subdivisions.....	548.4	2.7
Asset-backed securities.....	440.2	2.1
Other.....	1,024.0	5.0
	-----	-----
Total actively managed fixed maturities.....	\$20,510.9	100.0%
	=====	=====

Below-Investment Grade Securities

At December 31, 2007, the amortized cost of the Company's below-investment grade fixed maturity securities was \$1,678.8 million, or 8.0 percent of the Company's fixed maturity portfolio. The estimated fair value of the below-investment grade portfolio was \$1,590.6 million, or 95 percent of the amortized cost.

Below-investment grade fixed maturity securities with an amortized cost of \$480.3 million and an estimated fair value of \$455.9 million are securities held by a variable interest entity that we are required to consolidate. These fixed maturity securities are legally isolated and are not available to the Company. The liabilities of such variable interest entity will be satisfied from the cash flows generated by these securities and are not obligations of the Company. Refer to the note to the consolidated financial statements entitled "Investment in a Variable Interest Entity" concerning the Company's commitment to provide additional capital of up to \$25 million to the variable interest entity. At December 31, 2007, our total investment in the variable interest entity was \$47.0 million and such investment was rated BBB.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Below-investment grade securities have different characteristics than investment grade corporate debt securities. Based on historical performance, risk of default by the borrower is significantly greater for below-investment grade securities and in many cases, severity of loss is relatively greater as such securities are generally unsecured and often subordinated to other indebtedness of the issuer. Also, issuers of below-investment grade securities usually have higher levels of debt and may be more financially leveraged, hence, all other things being equal, more sensitive to adverse economic conditions, such as recession or increasing interest rates. The Company attempts to reduce the overall risk related to its investment in below-investment grade securities, as in all investments, through careful credit analysis, strict investment policy guidelines, and diversification by issuer and/or guarantor and by industry.

Contractual Maturity

The following table sets forth the amortized cost and estimated fair value of actively managed fixed maturities at December 31, 2007, by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties. Most of the structured securities shown below provide for periodic payments throughout their lives (dollars in millions):

	Amortized cost ----	Estimated fair value ----
Due in one year or less.....	\$ 99.2	\$ 99.2
Due after one year through five years.....	1,613.9	1,610.7
Due after five years through ten years.....	5,882.2	5,772.0
Due after ten years.....	8,627.3	8,360.9
	-----	-----
Subtotal.....	16,222.6	15,842.8
Structured securities (a).....	4,770.1	4,668.1
	-----	-----
Total actively managed fixed maturities	\$20,992.7	\$20,510.9
	=====	=====

(a) Includes below-investment grade structured securities with an amortized cost and estimated fair value of \$62.6 million and \$55.5 million, respectively.

Net Investment Income

Net investment income consisted of the following (dollars in millions):

	2007 ----	2006 ----	2005 ----
Fixed maturities.....	\$1,346.4	\$1,293.6	\$1,266.1
Trading income related to policyholder and reinsurer accounts and other special-purpose portfolios.....	31.2	32.9	3.1
Equity securities.....	1.6	1.8	.5
Mortgage loans.....	123.3	101.9	92.4
Policy loans.....	26.5	25.0	26.3
Change in value of options related to equity-indexed products.....	(11.9)	38.3	(18.9)
Other invested assets.....	11.2	13.8	9.6
Cash and cash equivalents.....	27.0	19.1	18.2
	-----	-----	-----
Gross investment income.....	1,555.3	1,526.4	1,397.3
Less investment expenses.....	18.7	20.0	22.7
	-----	-----	-----
Net investment income.....	\$1,536.6	\$1,506.4	\$1,374.6
	=====	=====	=====

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

At both December 31, 2007 and 2006, we had no fixed maturity investments or mortgage loans that were not accruing investment income.

Net Realized Investment Gains (Losses)

Net realized investment gains (losses) were included in revenue as follows (dollars in millions):

	2007	2006	2005
	----	----	----
Fixed maturities:			
Gross gains.....	\$ 94.9	\$ 70.1	\$ 86.5
Gross losses.....	(134.0)	(98.5)	(82.3)
Other-than-temporary declines in fair value.....	(99.5)	(12.0)	(4.5)
	-----	-----	-----
Net realized investment gains (losses) from fixed maturities.....	(138.6)	(40.4)	(.3)
Equity securities.....	(5.0)	.2	1.6
Mortgages.....	(.1)	-	3.2
Other-than-temporary declines in fair value of equity securities and other invested assets.....	(7.2)	(10.4)	(10.2)
Other	(4.5)	3.4	2.8
	-----	-----	-----
Net realized investment losses.....	\$(155.4)	\$(47.2)	\$ (2.9)
	=====	=====	=====

During 2007, net realized investment losses included: (i) \$48.7 million of net losses from the sales of investments (primarily fixed maturities) with proceeds of \$7.2 billion; (ii) \$33.0 million of writedowns of investments for other than temporary declines in fair value (no single investment accounted for more than \$5.0 million of such writedowns); and (iii) \$73.7 million of writedowns of investments (which were subsequently transferred pursuant to a coinsurance agreement as further discussed in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Reinsurance") as a result of our intent not to hold such investments for a period of time sufficient to allow for any anticipated recovery in value. During 2006, we recognized net realized investment losses of \$47.2 million, which were comprised of \$24.8 million of net losses from the sales of investments (primarily fixed maturities) with proceeds of \$6.4 billion, and \$22.4 million of writedowns of investments for other than temporary declines in fair value. During 2005, we recognized net realized investment losses of \$2.9 million, which were comprised of \$11.8 million of net gains from the sales of investments (primarily fixed maturities) with proceeds of \$11.5 billion, net of \$14.7 million of writedowns of investments for other than temporary declines in fair value. At December 31, 2007, there were no investments in default as to the payment of principal or interest.

During 2007, we sold \$3.3 billion of fixed maturity investments which resulted in gross investment losses (before income taxes) of \$134.0 million. We sell securities at a loss for a number of reasons including, but not limited to; (i) changes in the investment environment; (ii) expectation that the market value could deteriorate further; (iii) desire to reduce our exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected liability cash flows. During 2007, we sold 10 investments at a loss which had been continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis. Such investments were continuously in an unrealized loss position for less than six months prior to sale and had an amortized cost and estimated fair value of \$52.3 million and \$19.5 million, respectively.

We regularly evaluate our investments for possible impairment. When we conclude that a decline in a security's net realizable value is other than temporary, the decline is recognized as a realized loss and the cost basis of the security is reduced to its estimated fair value.

Our assessment of whether unrealized losses are "other than temporary" requires significant judgment. Factors considered include: (i) the extent to which market value is less than the cost basis; (ii) the length of time that the market value has been less than cost; (iii) whether the unrealized loss is event driven, credit-driven or a result of changes in market interest rates or risk premium; (iv) the near-term prospects for improvement of the issuer and/or its industry; (v) the investment's rating and whether the investment is investment-grade and/or has been downgraded since its purchase; (vi)

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

whether the issuer is current on all payments in accordance with the contractual terms of the investment and is expected to meet all of its obligations under the terms of the investment; (vii) our ability and intent to hold the investment for a period of time sufficient to allow for any anticipated recovery; (viii) the underlying current and prospective asset and enterprise values of the issuer and the extent to which the recoverability of the carrying value of our investment may be affected by changes in such values; (ix) unfavorable changes in cash flows on mortgage-backed and asset-backed securities; and (x) other subjective factors, including information from regulators and credit agencies.

Future events may occur, or additional information may become available, which may necessitate future realized losses of securities in our portfolio. Significant losses in the carrying values of our investments could have a material adverse effect on our earnings in future periods.

Investments with Unrealized Losses

The following table sets forth the amortized cost and estimated fair value of those actively managed fixed maturities with unrealized losses at December 31, 2007, by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties. Most of the structured securities shown below provide for periodic payments throughout their lives (dollars in millions):

	Amortized cost	Estimated fair value
	-----	-----
Due in one year or less.....	\$ 29.6	\$ 29.3
Due after one year through five years.....	614.3	591.1
Due after five years through ten years.....	3,687.3	3,529.1
Due after ten years.....	5,958.7	5,625.4
	-----	-----
Subtotal.....	10,289.9	9,774.9
Structured securities.....	3,214.4	3,098.5
	-----	-----
Total.....	\$13,504.3	\$12,873.4
	=====	=====

The following summarizes the investments in our portfolio rated below-investment grade which have been continuously in an unrealized loss position exceeding 20 percent of the cost basis for the period indicated as of December 31, 2007 (dollars in millions):

Period	Number of issuers	Cost basis	Unrealized loss	Estimated fair value
-----	-----	-----	-----	-----
Less than 6 months.....	16	\$51.5	\$(13.5)	\$38.0
Greater than or equal to 6 months and less than 12 months.....	1	10.7	(3.6)	7.1

Our investment strategy is to maximize, over a sustained period and within acceptable parameters of risk, investment income and total investment return through active investment management. Accordingly, we may sell securities at a gain or a loss to enhance the total return of the portfolio as market opportunities change or to better match certain characteristics of our investment portfolio with the corresponding characteristics of our insurance liabilities. While we have both the ability and intent to hold securities with unrealized losses until they mature or recover in value, we may sell securities at a loss in the future because of actual or expected changes in our view of the particular investment, its industry, its type or the general investment environment.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2007 (dollars in millions):

Description of securities	Less than 12 months		12 months or greater		Total	
	Fair value	Unrealized losses	Fair value	Unrealized losses	Fair value	Unrealized losses
United States Treasury securities and obligations of United States government corporations and agencies.....	\$ 23.1	\$ (.1)	\$ 52.3	\$ (1.5)	\$ 75.4	\$ (1.6)
States and political subdivisions..	151.1	(6.2)	140.9	(5.6)	292.0	(11.8)
Debt securities issued by foreign governments.....	4.0	(.2)	-	-	4.0	(.2)
Corporate securities.....	6,627.0	(284.0)	2,776.5	(217.4)	9,403.5	(501.4)
Structured securities.....	1,801.4	(76.1)	1,297.1	(39.8)	3,098.5	(115.9)
Total actively managed fixed maturities.....	\$8,606.6	\$(366.6)	\$4,266.8	\$(264.3)	\$12,873.4	\$(630.9)

The following table summarizes the gross unrealized losses and fair values of our investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that such securities have been in a continuous unrealized loss position, at December 31, 2006 (dollars in millions):

Description of securities	Less than 12 months		12 months or greater		Total	
	Fair value	Unrealized losses	Fair value	Unrealized losses	Fair value	Unrealized losses
United States Treasury securities and obligations of United States government corporations and agencies.....	\$ 86.8	\$ (1.2)	\$1,252.7	\$ (22.1)	\$ 1,339.5	\$ (23.3)
States and political subdivisions...	218.6	(3.1)	185.2	(8.3)	403.8	(11.4)
Debt securities issued by foreign governments.....	23.1	(.2)	6.9	(.1)	30.0	(.3)
Corporate securities.....	4,711.6	(75.2)	4,413.8	(155.5)	9,125.4	(230.7)
Structured securities.....	1,724.5	(13.2)	2,904.8	(63.4)	4,629.3	(76.6)
Total actively managed fixed maturities.....	\$6,764.6	\$(92.9)	\$8,763.4	\$(249.4)	\$15,528.0	\$(342.3)
Equity securities.....	\$1.6	\$(.2)	\$3.0	\$(.1)	\$4.6	\$(.3)

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Based on management's current assessment of investments with unrealized losses at December 31, 2007, the Company believes the issuers of the securities will continue to meet their obligations (or with respect to equity-type securities, the investment value will recover to its cost basis). We generally intend to hold securities in unrealized loss positions until they recover. However, from time to time, our intent on an individual security may change, based upon market or other unforeseen developments. In such instances, we sell securities in the ordinary course of managing our portfolio to meet diversification, credit quality, yield, duration and liquidity requirements. If a loss is recognized from a sale subsequent to a balance sheet date due to these unexpected developments, the loss is recognized in the period in which the intent to hold the securities to recovery no longer exists.

Structured Securities

At December 31, 2007, fixed maturity investments included \$4.7 billion of structured securities (or 23 percent of all fixed maturity securities). Structured securities include mortgage-backed securities, collateralized mortgage obligations and commercial mortgage-backed securities. The yield characteristics of structured securities differ in some respects from those of traditional fixed-income securities. For example, interest and principal payments on structured securities may occur more frequently, often monthly. In many instances, we are subject to the risk that the timing of principal payments may vary from expectations. For example, prepayments may occur at the option of the issuer and prepayment rates are influenced by a number of factors that cannot be predicted with certainty, including: the relative sensitivity of the underlying assets backing the security to changes in interest rates; a variety of economic, geographic and other factors; and various security-specific structural considerations (for example, the repayment priority of a given security in a securitization structure).

In general, the rate of prepayments on structured securities increases when prevailing interest rates decline significantly in absolute terms and also relative to the interest rates on the underlying assets. The yields recognized on structured securities purchased at a discount to par will increase (relative to the stated rate) when the underlying assets prepay faster than expected. The yields recognized on structured securities purchased at a premium will decrease (relative to the stated rate) when the underlying assets prepay faster than expected. When interest rates decline, the proceeds from prepayments may be reinvested at lower rates than we were earning on the prepaid securities. When interest rates increase, prepayments may decrease. When this occurs, the average maturity and duration of the structured securities increase, which decreases the yield on structured securities purchased at a discount because the discount is realized as income at a slower rate, and it increases the yield on those purchased at a premium because of a decrease in the annual amortization of the premium.

For structured and asset-backed securities included in actively managed fixed maturities that were purchased at a discount or premium, we recognize investment income using an effective yield based on anticipated future prepayments and the estimated final maturity of the securities. Actual prepayment experience is periodically reviewed and effective yields are recalculated when differences arise between the prepayments originally anticipated and the actual prepayments received and currently anticipated. For credit sensitive mortgage-backed and asset-backed securities, and for securities that can be prepaid or settled in a way that we would not recover substantially all of our investment, the effective yield is recalculated on a prospective basis. Under this method, the amortized cost basis in the security is not immediately adjusted and a new yield is applied prospectively. For all other structured and asset-backed securities, the effective yield is recalculated when changes in assumptions are made, and reflected in our income on a retrospective basis. Under this method, the amortized cost basis of the investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the acquisition of the securities. Such adjustments were not significant in 2007.

The following table sets forth the par value, amortized cost and estimated fair value of structured securities, summarized by interest rates on the underlying collateral, at December 31, 2007 (dollars in millions):

	Par value -----	Amortized cost ----	Estimated fair value -----
Below 4 percent.....	\$ 128.0	\$ 127.7	\$ 124.8
4 percent - 5 percent.....	557.6	539.8	541.6
5 percent - 6 percent.....	3,315.6	3,261.6	3,189.4
6 percent - 7 percent.....	779.3	749.0	722.2
7 percent - 8 percent.....	66.3	68.0	68.5
8 percent and above.....	23.6	24.0	21.6
	-----	-----	-----
Total structured securities (a).....	\$4,870.4	\$4,770.1	\$4,668.1
	=====	=====	=====

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

(a) Includes below-investment grade structured securities with an amortized cost and estimated fair value of \$62.6 million and \$55.5 million, respectively.

The amortized cost and estimated fair value of structured securities at December 31, 2007, summarized by type of security, were as follows (dollars in millions):

Type	Amortized cost	Estimated fair value Amount	Percent of fixed maturities
Pass-throughs, sequential and equivalent securities.....	\$2,076.0	\$2,048.0	10%
Planned amortization classes, target amortization class and accretion-directed bonds.....	1,633.1	1,596.1	8
Commercial mortgage-backed securities.....	994.0	965.5	5
Other.....	67.0	58.5	-
Total structured securities (a).....	\$4,770.1	\$4,668.1	23%

(a) Includes below-investment grade structured securities with an amortized cost and estimated fair value of \$62.6 million and \$55.5 million, respectively.

Pass-through securities and sequentials have unique prepayment variability characteristics. Pass-through securities typically return principal to the holders based on cash payments from the underlying mortgage obligations. Sequential classes return principal to tranche holders in a detailed hierarchy. Planned amortization classes, targeted amortization class and accretion-directed bonds adhere to fixed schedules of principal payments as long as the underlying mortgage loans experience prepayments within certain estimated ranges. Changes in prepayment rates are first absorbed by support or companion classes insulating the timing of receipt of cash flows from the consequences of both faster prepayments (average life shortening) and slower prepayments (average life extension).

Commercial mortgage-backed securities ("CMBS") are secured by commercial real estate mortgages, generally income producing properties that are managed for profit. Property types include multi-family dwellings including apartments, retail centers, hotels, restaurants, hospitals, nursing homes, warehouses, and office buildings. Most CMBS have call protection features whereby underlying borrowers may not prepay their mortgages for stated periods of time without incurring prepayment penalties.

Structured Securities Collateralized by Sub Prime Residential Loans

Our investment portfolio includes structured securities collateralized by sub prime residential loans with a market value of \$123.1 million and a book value of \$150.5 million at December 31, 2007. These securities represent .5 percent of our consolidated investment portfolio. Of these securities, \$39.9 million (32 percent) were rated AAA, \$40.8 million (33 percent) were rated AA, \$41.9 million (34 percent) were rated A, and \$.5 million (1 percent) were rated BBB. Sub prime structured securities issued in 2006 and 2007 have experienced higher delinquency and foreclosure rates than originally expected. The Company's investment portfolio includes sub prime structured securities collateralized by residential loans extended over several years, primarily from 2003 to 2007. At December 31, 2007, we held no sub prime securities collateralized by residential loans extended in 2006 and we held \$8.7 million extended in 2007.

Commercial Mortgage Loans

At December 31, 2007, the mortgage loan balance was primarily comprised of commercial loans. Approximately 7 percent, 6 percent, 6 percent, 6 percent and 5 percent of the mortgage loan balance were on properties located in Minnesota, Florida, Arizona, Ohio and Indiana, respectively. No other state comprised greater than 5 percent of the mortgage loan balance. Substantially less than one percent of the commercial mortgage loan balance was noncurrent at December 31, 2007. Our allowance for losses on mortgage loans was \$2.4 million at both December 31, 2007 and 2006.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Other Investment Disclosures

Life insurance companies are required to maintain certain investments on deposit with state regulatory authorities. Such assets had aggregate carrying values of \$104.8 million and \$99.9 million at December 31, 2007 and 2006, respectively.

Conseco had two fixed maturity investments in excess of 10 percent of shareholders' equity at both December 31, 2007 and 2006 (other than investments issued or guaranteed by the United States government or a United States government agency), which are summarized below (dollars in millions):

Issuer	2007		2006	
	Amortized cost	Estimated fair value	Amortized cost	Estimated fair value
Federal Home Loan Mortgage Corporation.....	\$1,400.1	\$1,392.0	\$2,426.4	\$2,387.2
Federal National Mortgage Association.....	752.3	750.3	1,414.3	1,396.7

6. LIABILITIES FOR INSURANCE PRODUCTS

These liabilities consisted of the following (dollars in millions):

	Withdrawal assumption	Mortality assumption	Interest rate assumption	2007	2006
	-----	-----	-----	----	----
Future policy benefits:					(Restated)
Interest-sensitive products:					
Investment contracts.....	N/A	N/A	(c)	\$ 9,389.7	\$ 9,326.0
Universal life contracts.....	N/A	N/A	N/A	3,779.7	3,695.1
Total interest-sensitive products.....				13,169.4	13,021.1
Traditional products:					
Traditional life insurance contracts....	Company experience	(a)	5%	2,289.0	2,264.2
Limited-payment annuities.....	Company experience, if applicable	(b)	5%	944.3	970.7
Individual and group accident and health	Company experience	Company experience	6%	9,304.1	8,873.1
Total traditional products.....				12,537.4	12,108.0
Claims payable and other policyholder funds	N/A	N/A	N/A	928.0	835.0
Liabilities related to separate accounts....	N/A	N/A	N/A	27.4	28.9
Total.....				\$26,662.2	\$25,993.0

-
- (a) Principally, modifications of the 1965 - 70 and 1975 - 80 Basic, Select and Ultimate Tables.
 - (b) Principally, the 1984 United States Population Table and the NAIC 1983 Individual Annuitant Mortality Table.
 - (c) In 2007 and 2006, all of this liability represented account balances where future benefits are not guaranteed.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

The Company establishes reserves for insurance policy benefits based on assumptions as to investment yields, mortality, morbidity, withdrawals, lapses and maintenance expenses. These reserves include amounts for estimated future payment of claims based on actuarial assumptions. The balance is based on the Company's best estimate of the future policyholder benefits to be incurred on this business, given recent and expected future changes in experience.

Changes in the unpaid claims reserve (included in claims payable) and disabled life reserves related to accident and health insurance (included in individual and group accident and health liabilities) were as follows (dollars in millions):

	2007	2006	2005
	----	----	-----
Balance, beginning of the year.....	\$1,772.3	\$1,636.0	\$1,576.9
Incurred claims (net of reinsurance) related to:			
Current year.....	1,921.7	1,667.2	1,554.7
Prior years (a).....	105.5	43.0	60.3
	-----	-----	-----
Total incurred.....	2,027.2	1,710.2	1,615.0
	-----	-----	-----
Interest on claim reserves.....	95.5	88.2	80.3
	-----	-----	-----
Paid claims (net of reinsurance) related to:			
Current year.....	982.0	844.9	811.3
Prior years.....	848.3	807.7	814.8
	-----	-----	-----
Total paid.....	1,830.3	1,652.6	1,626.1
	-----	-----	-----
Net change in balance for reinsurance assumed and ceded.....	(45.3)	(9.5)	(10.1)
	-----	-----	-----
Balance, end of the year.....	\$2,019.4	\$1,772.3	\$1,636.0
	=====	=====	=====

(a) The reserves and liabilities we establish are necessarily based on estimates, assumptions and prior years' statistics. It is possible that actual claims will exceed our reserves and have a material adverse effect on our results of operations and financial condition. We have incurred significant losses beyond our estimates as a result of actual claim costs exceeding our initial estimates in the Other Business in Run-off segment. For example, our insurance policy benefits in that segment reflected reserve deficiencies from prior years of \$130.1 million, \$61.7 million and \$58.0 million in 2007, 2006 and 2005, respectively.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

7. INCOME TAXES

The components of income tax expense (benefit) were as follows (dollars in millions):

	2007	2006	2005
	----	----	----
Current tax expense.....	\$ 2.7	(Restated) \$ 1.4	(Restated) \$ -
Deferred tax provision (benefit).....	(63.8)	59.8	171.6
	-----	-----	-----
Income tax expense (benefit) on period income.....	(61.1)	61.2	171.6
Valuation allowance.....	68.0	-	-
	-----	-----	-----
Total income tax expense.....	\$ 6.9	\$61.2	\$171.6
	=====	=====	=====

A reconciliation of the U.S. statutory corporate tax rate to the effective rate reflected in the consolidated statement of operations is as follows:

	2007	2006	2005
	----	----	----
U.S. statutory corporate rate.....	(35.0)%	(Restated) 35.0%	(Restated) 35.0%
Valuation allowance.....	39.3	-	-
Other nondeductible expenses (benefit).....	.2	1.4	.4
State taxes.....	(1.1)	.3	.7
Provision for tax issues, tax credits and other.....	.6	(.1)	(.7)
	-----	-----	-----
Effective tax rate.....	4.0%	36.6%	35.4%
	=====	=====	=====

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

The components of the Company's income tax assets and liabilities were as follows (dollars in millions):

	2007 ----	2006 ---- (Restated)
Deferred tax assets:		
Net federal operating loss carryforwards attributable to:		
Life insurance subsidiaries.....	\$ 892.1	\$ 800.4
Non-life companies.....	843.8	780.0
Net state operating loss carryforwards.....	32.1	29.7
Tax credits.....	13.7	14.2
Capital loss carryforwards.....	259.7	391.6
Deductible temporary differences:		
Insurance liabilities.....	1,074.6	1,327.1
Unrealized depreciation of investments.....	153.3	41.2
Reserve for loss on loan guarantees.....	71.9	145.8
Other.....	4.4	-
	-----	-----
Gross deferred tax assets.....	3,345.6	3,530.0
	-----	-----
Deferred tax liabilities:		
Actively managed fixed maturities.....	(32.8)	(42.2)
Value of policies inforce at the Effective Date and cost of policies produced.....	(732.9)	(764.5)
Other.....	-	(147.3)
	-----	-----
Gross deferred tax liabilities.....	(765.7)	(954.0)
	-----	-----
Net deferred tax assets before valuation allowance.....	2,579.9	2,576.0
Valuation allowance.....	(672.9)	(777.8)
	-----	-----
Net deferred tax assets.....	1,907.0	1,798.2
Current income taxes prepaid (accrued).....	2.4	(3.9)
	-----	-----
Income tax assets, net.....	\$1,909.4	\$1,794.3
	=====	=====

Our income tax expense includes deferred income taxes arising from temporary differences between the financial reporting and tax bases of assets and liabilities, capital loss carryforwards and NOLs. We evaluate the realizability of our deferred income tax assets and assess the need for a valuation allowance on an ongoing basis. In evaluating our deferred income tax assets, we consider whether it is more likely than not that the deferred income tax assets will be realized. The ultimate realization of our deferred income tax assets depends upon generating sufficient future taxable income during the periods in which our temporary differences become deductible and before our capital loss carryforwards and NOLs expire. This assessment requires significant judgment. However, recovery is dependent on achieving such projections and failure to do so would result in an increase in the valuation allowance in a future period. Any future increase in the valuation allowance would result in additional income tax expense and reduce shareholders' equity, and such an increase could have a significant impact upon our earnings in the future. In addition, the use of the Company's NOLs is dependent, in part, on whether the IRS does not take an adverse position in the future regarding the tax position we have taken in our tax returns with respect to the allocation of cancellation of indebtedness income.

The Internal Revenue Code (the "Code") limits the extent to which losses realized by a non-life entity (or entities) may offset income from a life insurance company (or companies) to the lesser of: (i) 35 percent of the income of the life insurance company; or (ii) 35 percent of the total loss of the non-life entities (including NOLs of the non-life entities). There is no limitation on the extent to which losses realized by a life insurance entity (or entities) may offset income from a non-life entity (or entities).

In addition, the timing and manner in which the Company will be able to utilize some of its NOLs is limited by Section 382 of the Code. Section 382 imposes limitations on a corporation's ability to use its NOLs when the company undergoes an ownership change. Because the Company underwent an ownership change pursuant to its reorganization, this

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

limitation applies to the Company. Any losses that are subject to the Section 382 limitation will only be utilized by the Company up to approximately \$142 million per year with any unused amounts carried forward to the following year. Our Section 382 limitation for 2008 will be approximately \$587 million (including \$445 million of unused amounts carried forward from prior years).

Based upon information existing at the time of our emergence from bankruptcy, we established a valuation allowance against our entire balance of net deferred income tax assets as we believed that the realization of such net deferred income tax assets in future periods was uncertain. During 2005 and 2006, we concluded that it was no longer necessary to hold certain portions of the previously established valuation allowance. Accordingly, we reduced our valuation allowance by \$585.8 million in 2005 and \$260.0 million in 2006. However, we were required to continue to record a valuation allowance of \$672.9 million at December 31, 2007 because we have determined that it is more likely than not that a portion of our deferred tax assets will not be realized. This determination was made by evaluating each component of the deferred tax asset and assessing the effects of limitations or interpretations on the value of such component to be fully recognized in the future.

Changes in our valuation allowance are summarized as follows (dollars in millions):

Balance at December 31, 2004.....	\$1,629.6
Release of valuation allowance (a).....	(585.8)

Balance at December 31, 2005.....	1,043.8
Expiration of NOL and capital loss carryforwards.....	(6.0)
Release of valuation allowance (a).....	(260.0)

Balance at December 31, 2006.....	777.8
Increase in 2007.....	68.0
Expiration of capital loss carryforwards.....	(157.6)
Write off of certain state NOLs (recovery is remote).....	(15.3)

Balance at December 31, 2007.....	\$ 672.9
	=====

(a) There is a corresponding increase to additional paid-in capital.

We have also evaluated the likelihood that we will have sufficient taxable income to offset the available deferred tax assets. This assessment required significant judgment. Based upon our current projections of future income that we completed at December 31, 2007, we believe that we will more likely than not recover \$1.9 billion of our deferred tax assets through reductions of our tax liabilities in future periods. However, recovery is dependent on achieving such projections and failure to do so would result in an increase in the valuation allowance in a future period. Any future increase in the valuation allowance would result in additional income tax expense and reduce shareholders' equity, and such an increase could have a significant impact upon our earnings in the future.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

As of December 31, 2007, we had \$5.0 billion of federal NOLs and \$.7 billion of capital loss carryforwards, which expire as follows (dollars in millions):

Year of expiration	Net operating loss carryforwards(a)		Capital loss carryforwards	Total loss carryforwards	Total loss carryforwards	
	Life	Non-life			Subject to ss.382	Not subject to ss.382
2008	\$ -	\$ -	\$583.7	\$ 583.7	\$583.7	\$ -
2009.....	-	.9	86.2	87.1	.9	86.2
2010.....	-	1.0	-	1.0	1.0	-
2011.....	-	.1	-	.1	.1	-
2012.....	-	10.6	72.2	82.8	10.6	72.2
2016.....	16.9	-	-	16.9	16.9	-
2017.....	33.2	-	-	33.2	33.2	-
2018.....	2,170.6 (a)	20.3	-	2,190.9	64.4	2,126.5
2020.....	-	2.5	-	2.5	2.5	-
2021.....	61.8	-	-	61.8	-	61.8
2022.....	266.2	.6	-	266.8	-	266.8
2023.....	-	2,092.9 (a)	-	2,092.9	71.7	2,021.2
2024.....	-	3.2	-	3.2	-	3.2
2025.....	-	118.8	-	118.8	-	118.8
2026.....	-	1.6	-	1.6	-	1.6
2027.....	-	158.3	-	158.3	-	158.3
Total.....	\$2,548.7	\$2,410.8	\$742.1	\$5,701.6	\$785.0	\$4,916.6

(a) The allocation of the NOLs summarized above assumes the IRS does not take an adverse position in the future regarding the tax position we plan to take in our tax returns with respect to the allocation of cancellation of indebtedness income. If the IRS disagrees with the tax position we plan to take with respect to the allocation of cancellation of indebtedness income, and their position prevails, approximately \$631 million of the NOLs expiring in 2018 would be characterized as non-life NOLs.

As of December 31, 2007, we had deferred tax assets related to NOLs for state income taxes of \$32.1 million. The related state NOLs are available to offset future state taxable income in certain states through 2015.

The Company adopted FIN 48 on January 1, 2007, which resulted in a \$6 million increase to additional paid-in capital. As of January 1, 2007 and December 31, 2007, the amount of unrecognized tax benefits was not significant. While it is expected that the amount of unrecognized tax benefits will change in the next twelve months, the Company does not expect the change to have a significant impact on its results of operations.

As more fully discussed below, the Company's interpretation of the tax law, as it relates to the application of the cancellation of indebtedness income to its NOLs, is an uncertain tax position. Since all other life NOLs must be utilized prior to this portion of the NOL, it has not yet been utilized nor is it expected to be utilized within the next twelve months. As a result, an uncertain tax position has not yet been taken on the Company's tax return.

Although FIN 48 allowed a change in accounting, the Company has chosen to continue its past accounting policy of classifying interest and penalties as income tax expense in the consolidated statement of operations. No such amounts were recognized in 2007. The liability for accrued interest and penalties was not significant at December 31, 2007 or December 31, 2006.

Tax years 2004 through 2006 are open to examination by the IRS, and tax year 2002 remains open only for potential adjustments related to certain partnership investments. The Company does not anticipate any material adjustments related to these partnership investments. The Company's various state income tax returns are generally open for tax years 2004 through 2006 based on the individual state statutes of limitation.

The following paragraphs describe an open matter related to the classification of our NOLs.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

In July 2006, the Joint Committee of Taxation accepted the audit and the settlement which characterized \$2.1 billion of the tax losses on our Predecessor's investment in Conseco Finance Corp. as life company losses and the remaining amount as non-life losses prior to the application of the cancellation of indebtedness attribute reductions described below. As a result of the approval of the settlement, we concluded it was appropriate to reduce our valuation allowance by \$260 million in the second quarter of 2006, which was accounted for as an addition to paid-in capital.

The Code provides that any income realized as a result of the cancellation of indebtedness in bankruptcy (cancellation of debt income or "CODI") must reduce NOLs. We realized an estimated \$2.5 billion of CODI when we emerged from bankruptcy. Pursuant to the Company's interpretation of the tax law, the CODI reductions were all used to reduce non-life NOLs. However, if the IRS were to disagree with our interpretation and ultimately prevail, we believe \$631 million of NOLs classified as life company NOLs would be re-characterized as non-life NOLs and subject to the 35% limitation discussed above. Such a re-characterization would also extend the year of expiration as life company NOLs expire after 15 years whereas non-life NOLs expire after 20 years. The Company does not expect the IRS to consider this issue for a number of years.

The Company adopted SFAS 123R in calendar year 2006. Pursuant to this accounting rule, the Company is precluded from recognizing the tax benefits of any tax windfall upon the exercise of a stock option or the vesting of restricted stock unless such deduction resulted in actual cash savings to the Company. Because of the Company's NOLs, no cash savings have occurred. NOL carryforwards of \$1.1 million related to deductions for stock options and restricted stock will be reflected in additional paid-in capital if realized.

Prior to January 1, 1984, life insurance subsidiaries of the Company were entitled to exclude certain amounts from taxable income and accumulate such amounts in a "Policyholders Surplus Account". The aggregate balance in this account at December 31, 2005 was \$150.7 million, which could have resulted in federal income taxes payable of \$52.7 million if such amounts had been distributed or deemed distributed from the Policyholders Surplus Account. No provision for taxes had ever been made for this item since the affected subsidiaries had no intention of distributing such amounts. Pursuant to provisions of the American Jobs Creation Act of 2004, our subsidiaries distributed amounts from the Policyholders Surplus Account in 2006 without incurring any tax liability, thereby permanently eliminating this potential tax liability.

8. NOTES PAYABLE - DIRECT CORPORATE OBLIGATIONS

The following notes payable were direct corporate obligations of the Company as of December 31, 2007 and 2006 (dollars in millions):

	2007	2006
	-----	-----
3.50% convertible debentures.....	\$ 330.0	\$ 330.0
Secured credit agreement.....	865.5	673.3
Unamortized discount on convertible debentures.....	(1.8)	(2.5)
	-----	-----
Direct corporate obligations.....	\$1,193.7	\$1,000.8
	=====	=====

In August 2005, we completed the private offering of \$330 million of 3.50% Convertible Debentures due September 30, 2035 (the "Debentures"). The net proceeds from the offering of approximately \$320 million were used to repay term loans outstanding under the Company's \$800.0 million secured credit facility (the "Credit Facility"). The terms of the Debentures are governed by an indenture dated as of August 15, 2005 between the Company and The Bank of New York Trust Company, N.A., as trustee (the "Indenture"). At December 31, 2007 and 2006, unamortized issuance costs (classified as other assets) related to the Debentures were \$4.4 million and \$5.9 million, respectively, and are amortized as an increase to interest expense through September 30, 2010, which is the earliest date the Debenture holders may require the Company to repurchase them.

The Debentures are senior, unsecured obligations and bear interest at a rate of 3.50 percent per year, payable semi-annually, beginning on March 31, 2006 and ending on September 30, 2010. Thereafter, the principal balance of the Debentures will accrete at a rate that provides holders with an aggregate yield to maturity of 3.50 percent, computed on a semi-annual, bond-equivalent basis. Beginning with the six-month interest period commencing September 30, 2010, the Company will pay contingent interest on the Debentures if the average trading price per Debenture for the five trading day period immediately preceding the six-month interest period equals or exceeds a certain level, as described in the Indenture.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Upon the occurrence of certain specified events, the Debentures will be convertible, at the option of the holders, into cash or, under certain circumstances, cash and shares of the Company's common stock at an initial conversion price of approximately \$26.66 per share. The number of shares to be received by a converting holder is subject to adjustment for certain dilutive events. The amount of cash to be received upon conversion is equal to the lesser of: (i) the accreted principal amount of the converting Debenture; or (ii) the conversion value of such Debentures (as calculated in accordance with the Indenture).

On or after October 5, 2010, the Company may redeem for cash all or a portion of the Debentures at any time at a redemption price equal to 100 percent of the accreted principal amount of the Debentures plus accrued and unpaid interest, including additional interest and contingent interest, if any, to the redemption date. Holders may require the Company to repurchase in cash all or any portion of the Debentures on September 30, 2010, 2015, 2020, 2025 and 2030 at a repurchase price equal to 100 percent of the accreted principal amount of the Debentures to be repurchased, plus accrued and unpaid interest, including additional interest and contingent interest, if any, to the applicable repurchase date.

If an event of default occurs and is continuing with respect to the Debentures, either the trustee or the holders of at least 25 percent of the aggregate accreted principal amount of the Debentures then outstanding may declare the accreted principal amount, plus accrued and unpaid interest, including additional interest and contingent interest, if any, on the Debentures to be due and payable immediately. If an event of default relating to certain events of bankruptcy, insolvency or reorganization occurs, the accreted principal amount plus accrued and unpaid interest, including additional interest and contingent interest, if any, on the Debentures will become immediately due and payable. The following are events of default with respect to the Debentures:

- o default for 30 days in payment of any interest, contingent interest or additional interest due and payable on the Debentures;
- o default in payment of accreted principal of the Debentures at maturity, upon redemption, upon repurchase or following a fundamental change, when the same becomes due and payable;
- o default by the Company or any of its subsidiaries in the payment of principal, interest or premium when due under any other instruments of indebtedness having an aggregate outstanding principal amount of \$50.0 million (or its equivalent in any other currency or currencies) or more following a specified period for cure;
- o default in the Company's conversion obligations upon exercise of a holder's conversion right, following a specified period for cure;
- o default in the Company's obligations to give notice of the occurrence of a fundamental change within the time required to give such notice;
- o acceleration of any of the Company's indebtedness or the indebtedness of any of its subsidiaries under any instrument or instruments evidencing indebtedness (other than the Debentures) having an aggregate outstanding principal amount of \$50.0 million (or its equivalent in any other currency or currencies) or more, subject to certain exceptions; and
- o certain events of bankruptcy, insolvency and reorganization of the Company or any of its subsidiaries.

The Company's credit facilities have been repaid or amended during each of the last three years as further described below.

In August 2005, we entered into a \$447.0 million secured credit agreement (the "Amended Credit Facility"). The proceeds of the Amended Credit Facility were used to repay the remaining principal amount of the Credit Facility. The Company recognized a \$3.7 million loss on the extinguishment of debt during 2005 for the write off of certain debt issuance

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

costs related to the reduction of the principal amount borrowed under the Amended Credit Facility. The Amended Credit Facility provided for a one-time increase in the facility or the addition of a new facility of up to \$325.0 million. In December 2005, we borrowed an additional \$80.0 million pursuant to this provision. The proceeds from the additional borrowing were used to increase the capital and surplus of our insurance subsidiaries. During 2005, we made principal payments totaling \$2.4 million on our Amended Credit Facility as well as a mandatory prepayment of \$.9 million on the Credit Facility (after consideration of a \$28.0 million prepayment made in December 2004) based on the Company's excess cash flows at December 31, 2004, as defined in the Credit Facility. During 2006, we made scheduled principal payments totaling \$1.3 million on our Amended Credit Facility as well as a mandatory prepayment of \$45.0 million based on the Company's excess cash flows at December 31, 2005, as defined in the Amended Credit Facility.

On October 10, 2006, we entered into a \$675.0 million secured credit agreement (the "Second Amended Credit Facility"). As a result of the refinancing, the principal amount outstanding under the credit facility was increased from \$478.3 million to \$675.0 million. Approximately \$195 million of the proceeds were used to strengthen the capital of our insurance subsidiaries. The Company recognized a \$.7 million loss on the extinguishment of debt during the fourth quarter of 2006 for the write off of certain debt issuance costs and other costs incurred related to the transaction. The Second Amended Credit Facility extends the maturity date from June 22, 2010 to October 10, 2013. On June 12, 2007, Consecoco amended its current credit facility. The amendment of the credit facility provided for, among other things:

- o an increase of \$200.0 million in the principal amount of the facility;

- o an increase in the general basket for restricted payments in an aggregate amount of up to \$300 million over the term of the facility (of which only \$200 million may be paid in the year commencing June 12, 2007); and

- o the Company to be able to request the addition of up to two new facilities or up to two increases in the credit facility of up to \$330 million (but with the commitment increases made between June 12, 2007 and June 12, 2008 limited to \$130 million), subject to compliance with certain financial covenants and other conditions. Such increases would be effective as of a date that is at least 90 days prior to the scheduled maturity date.

No changes were made to the interest rate or the maturity schedule of the amounts borrowed under the credit facility. We are required to make minimum quarterly principal payments of \$2.2 million through September 30, 2013. The remaining unpaid principal balance is due on October 10, 2013. There were no changes to the various financial ratios and balances that are required to be maintained by the Company. The additional borrowings were used for general corporate purposes, including the repurchase of Consecoco common stock and the strengthening of the Company's insurance subsidiaries.

During 2007, we made scheduled principal payments totaling \$7.8 million on our Second Amended Credit Facility. There were \$6.8 million and \$6.2 million of unamortized issuance costs (classified as other assets) related to our Second Amended Credit Facility at December 31, 2007 and 2006, respectively.

The amounts outstanding under the Second Amended Credit Facility bear interest, payable at least quarterly, based on either a Eurodollar rate or a base rate. The Eurodollar rate is equal to LIBOR plus 2 percent. The base rate is equal to 1 percent plus the greater of: (i) the Federal funds rate plus .50 percent; or (ii) Bank of America's prime rate. Under the terms of the Second Amended Credit Facility, if the Company's senior secured long-term debt is rated at least "Ba2" by Moody's Investors Service, Inc. and "BB" by S&P, in each case with a stable outlook, the margins on the Eurodollar rate or the base rate would each be reduced by .25 percent. At December 31, 2007, the interest rate on our Second Amended Credit Facility was 6.8 percent.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

The scheduled repayment of our direct corporate obligations is as follows (dollars in millions):

2008.....	\$ 8.7
2009.....	8.7
2010.....	338.8
2011.....	8.7
2012.....	8.8
Thereafter.....	821.8

	\$1,195.5
	=====

Pursuant to the Second Amended Credit Facility, as long as the debt to total capitalization ratio (as defined in the Second Amended Credit Facility) is greater than 20 percent or certain insurance subsidiaries (as defined in the Second Amended Credit Facility) have financial strength ratings of less than A- from A.M. Best Company, the Company is required to make mandatory prepayments with all or a portion of the proceeds from the following transactions or events including: (i) the issuance of certain indebtedness; (ii) equity issuances; (iii) certain asset sales or casualty events; and (iv) excess cash flows as defined in the Second Amended Credit Facility (the first such payment, if applicable, would not be paid prior to the first quarter of 2009). The Company may make optional prepayments at any time in minimum amounts of \$3.0 million or any multiple of \$1.0 million in excess thereof. As described in the Second Amended Credit Facility, the Company may reinvest any portion of the proceeds from asset sales in assets useful to its business, subject to certain restrictions defined in the Second Amended Credit Facility. The Company used the majority of the ceding commission received from REALIC in a coinsurance transaction to fund the recapture of a block of traditional life insurance inforce. Such reinsurance transactions are further described in the note to the consolidated financial statements entitled "Summary of Significant Accounting Policies - Reinsurance".

The Second Amended Credit Facility requires the Company to maintain various financial ratios and balances, as defined in the agreement, including: (i) a debt to total capitalization ratio of not more than 30 percent at all times (such ratio was 21 percent at December 31, 2007); (ii) an interest coverage ratio greater than or equal to 2.0 to 1 for each rolling four quarters (such ratio exceeded the minimum requirement for the four quarters ending December 31, 2007); (iii) an aggregate risk-based capital ratio, as defined in the Second Amended Credit Facility, greater than or equal to 250 percent for each quarter (such ratio exceeded the minimum risk-based capital requirements at December 31, 2007); and (iv) a combined statutory capital and surplus level of greater than \$1,270.0 million (combined statutory capital and surplus at December 31, 2007 exceeded such requirement).

The Second Amended Credit Facility includes an \$80.0 million revolving credit facility that can be used for general corporate purposes and that would mature on June 22, 2009. There were no amounts outstanding under the revolving credit facility at December 31, 2007 or 2006. The Company pays a commitment fee equal to .50 percent of the unused portion of the revolving credit facility on an annualized basis. The revolving credit facility bears interest based on either a Eurodollar rate or a base rate in the same manner as described above for the Second Amended Credit Facility.

The Second Amended Credit Facility prohibits or restricts, among other things: (i) the payment of cash dividends on our common stock; (ii) the repurchase of our common stock; (iii) the issuance of additional debt or capital stock; (iv) liens; (v) certain asset dispositions; (vi) affiliate transactions; (vii) certain investment activities; (viii) change in business; and (ix) prepayment of indebtedness (other than the Second Amended Credit Facility). The obligations under our Second Amended Credit Facility are guaranteed by Consecos current and future domestic subsidiaries, other than: (i) its insurance companies; (ii) subsidiaries of the insurance companies; or (iii) certain immaterial subsidiaries as defined in the Second Amended Credit Facility. This guarantee was secured by granting liens on substantially all the assets of the guarantors, including the capital stock of our top tier insurance company, Consecos Life Insurance Company of Texas. Under the Second Amended Credit Facility, we may pay cash dividends on our common stock or repurchase our common stock in an aggregate amount of up to \$300.0 million over the term of the facility (of which, only \$200.0 million may be paid in the year beginning June 12, 2007). As further discussed in the note to the consolidated financial statements entitled "Shareholders' Equity", we repurchased 5.7 million shares of our common stock for \$87.2 million in 2007 (of which, \$57.6 million was paid in the year beginning June 12, 2007).

9. COMMITMENTS AND CONTINGENCIES

Litigation

Legal Proceedings

The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred. Although there can be no assurances, at the present time the Company does not anticipate that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the financial condition, operating results or cash flows of the Company. The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict. In the event of an adverse outcome in one or more of these matters, the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies, which could adversely affect the future profitability of the related insurance policies.

In the cases described below, we have disclosed any specific dollar amounts sought in the complaints. In our experience, monetary demands in complaints bear little relation to the ultimate loss, if any, to the Company. However, for the reasons stated above, it is not possible to make meaningful estimates of the amount or range of loss that could result from some of these matters at this time. The Company reviews these matters on an ongoing basis and follows the provisions of Statement of Financial Accounting Standards No. 5, "Accounting for Contingencies", when making accrual and disclosure decisions. When assessing reasonably possible and probable outcomes, the Company bases its decisions on its assessment of the ultimate outcome following all appeals.

Securities Litigation

After our Predecessor announced its intention to restructure on August 9, 2002, eight purported securities fraud class action lawsuits were filed in the United States District Court for the Southern District of Indiana. The complaints named us as a defendant, along with certain of our former officers. These lawsuits were filed on behalf of persons or entities who purchased our Predecessor's common stock on various dates between October 24, 2001 and August 9, 2002. The plaintiffs allege claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and allege material omissions and dissemination of materially misleading statements regarding, among other things, the liquidity of Old Conesco and alleged problems in Conesco Finance Corp.'s manufactured housing division, allegedly resulting in the artificial inflation of our Predecessor's stock price. These cases were consolidated into one case in the United States District Court for the Southern District of Indiana, captioned Franz Schleicher, et al. v. Conesco, Inc., Gary Wendt, William Shea, Charles Chokel and James Adams, et al., Case No. 02-CV-1332 DFH-TAB. The complaint seeks an unspecified amount of damages. The plaintiffs filed an amended consolidated class action complaint with respect to the individual defendants on December 8, 2003. Our liability with respect to this lawsuit was discharged in our Predecessor's plan of reorganization and our obligation to indemnify individual defendants who were not serving as an officer or director on the Effective Date is limited to \$3 million in the aggregate under such plan. Our liability to indemnify individual defendants who were serving as an officer or director on the Effective Date, of which there is one such defendant, is not limited by such plan. A motion to dismiss was filed on behalf of defendants Shea, Wendt and Chokel and on July 14, 2005, this matter was dismissed. Plaintiffs filed a second amended complaint on August 24, 2005. We filed a motion to dismiss the second amended complaint on November 7, 2005. This motion was denied on September 12, 2007. James S. Adams filed for bankruptcy on July 29, 2005, Case No. 1:02-cv-1332-DFH-TAB (Southern District, Indiana). Plaintiffs are to file their motion for class certification by April 18, 2008. The matter is scheduled for a jury trial on May 10, 2010. We believe this lawsuit is without merit and intend to defend it vigorously; however, the ultimate outcome cannot be predicted with certainty. Our current estimate of the maximum loss that we could reasonably incur on this case is approximately \$2.0 million. We do not believe that the potential loss related to the individual defendant who served as an officer on the Effective Date is material.

Cost of Insurance Litigation

The Company and certain subsidiaries, including principally Conesco Life, have been named in numerous purported

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

class action and individual lawsuits alleging, among other things, breach of contract, fraud and misrepresentation with regard to a change made in 2003 and 2004 in the way cost of insurance charges are calculated for life insurance policies sold primarily under the names "Lifestyle" and "Lifetime". Approximately 86,500 of these policies were subject to the change, which resulted in increased monthly charges to the policyholders' accounts. Many of the purported class action lawsuits were filed in Federal courts across the United States. In June 2004, the Judicial Panel on Multidistrict Litigation consolidated these lawsuits into the action now referred to as In Re Conseco Life Insurance Co. Cost of Insurance Litigation, Cause No. MDL 1610 (Central District, California). In September 2004, plaintiffs in the multi-district action filed an amended consolidated complaint and, at that time, added Conseco, Inc. as a defendant. The amended complaint alleged, among other things, that the change enabled Conseco, Inc. to add \$360 million to its balance sheet. The amended complaint sought unspecified compensatory, punitive and exemplary damages as well as an injunction that would require the Company to reinstate the prior method of calculating cost of insurance charges and refund any increased charges that resulted from the change. On April 26, 2005, the Judge in the multi-district action certified a nationwide class on the claims for breach of contract and injunctive relief. On April 27, 2005, the Judge issued an order certifying a statewide California class for injunctive and restitutionary relief pursuant to California Business and Professions Code Section 17200 and breach of the duty of good faith and fair dealing, but denied certification on the claims for fraud and intentional misrepresentation and fraudulent concealment. The Company announced on August 1, 2006, that it had reached a proposed settlement of this case. Under the proposed settlement, inforce policyholders were given an option to choose a form of policy benefit enhancement and certain former policyholders will share in a settlement fund by either receiving cash or electing to reinstate their policies with enhanced benefits. The settlement was subject to court review and approval, a fairness hearing, notice to all class members, election of options by the class members, implementation of the settlement and other conditions. At the May 21, 2007 fairness hearing, the court granted final approval of the settlement and issued an order doing so on June 8, 2007. The Court entered final judgment in the case on July 5, 2007. We began implementing the settlement with the inforce and certain former policyholders in the last half of 2007.

We incurred total costs related to this litigation settlement of \$64.4 million, \$174.7 million and \$18.3 million in 2007, 2006 and 2005, respectively. The costs recognized in 2007 represent adjustments to our initial estimates based on the ultimate cost of the settlement.

The implementation of the settlement includes enhanced benefits to the inforce insurance policies, which eliminates the future estimated profits from these policies in periods subsequent to the settlement date, if the experience of the policies is consistent with our expectations. We recognized income before income taxes on these policies of approximately \$6.0 million in the six months ended June 30, 2006.

Other cases that remain pending with respect to life insurance policies sold primarily under the names "Lifestyle" and "Lifetime" include purported nationwide class actions in Indiana and California state courts. Those cases filed in Indiana state courts have been consolidated into the case now referred to as Arlene P. Mangelson, et al. v. Conseco Life Insurance Company, Cause No. 29D01-0403-PL-211 (Superior Court, Hamilton County, Indiana). This case was settled in connection with the In Re Conseco Life Insurance Co. Cost of Insurance Litigation, Cause No. MDL 1610 (Central District, California), as further described above. Four putative nationwide and/or statewide class-action lawsuits filed in California state courts have been consolidated and are being coordinated in the Superior Court of San Francisco County under the new caption Cost of Insurance Cases, Judicial Council Coordination Proceeding No. 4384 (Judicial Council of California). In November 2007, this matter was settled, with the exception of the claims of one plaintiff (who will be the sole remaining plaintiff in this lawsuit). The amount recognized as expense in 2007 related to the settlement of this case was not significant to our business, financial condition, results of operations or cash flows. On January 25, 2005 an Amended Complaint making similar allegations was filed in the case captioned William Schwartz v. Jeffrey Landerman, Diann P. Urbanek, Metro Insurance, Inc., Samuels Jacky Insurance Agency, Conseco Life Insurance Company, Successor to Philadelphia Life Insurance Company, Case No. GD 00-011432 (Court of Common Pleas, Allegheny County, Pennsylvania). Additionally, on February 11, 2005 Mr. Schwartz filed a purported nationwide class action captioned William Schwartz and Rebeca R. Frankel, Trustee of the Robert M. Frankel Irrevocable Insurance Trust v. Conseco Life Ins. Co. et al., Case No. GD 05-3742 (Court of Common Pleas, Allegheny County, Pennsylvania). On May 12, 2006 these two Schwartz cases were consolidated under both original case numbers. The Schwartz matters were settled in January 2008. The amount recognized as expense in 2007 related to the settlement of these cases was not significant to our business, financial condition, results of operations or cash flows. On May 24, 2005 a purported class action lawsuit was filed in Illinois on behalf of a putative statewide class captioned William J. Harte, individually and on behalf of all others similarly situated v. Conseco Life Insurance Company, Case No. 05CH08925 (Circuit Court of Cook County, Illinois, Chancery Division), which has been removed to the United States District Court for the Northern District of Illinois, transferred to California and consolidated and coordinated with MDL 1610.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Other non-class action cases regarding these policies include a lawsuit filed on September 14, 2005 in Hawaii captioned AE Ventures for Archie Murakami, et al. v. Consecos, Inc., Consecos Life Insurance Company; And Doe Defendants 1-100, Case No. CV05-00594 (United States District Court, District of Hawaii). This suit involves approximately 800 plaintiffs all of whom purport to have opted out of the In Re Consecos Life Insurance Co. Cost of Insurance Litigation multi-district action. The complaint alleges nondisclosure, breach of fiduciary duty, violations of HRS 480 (unfair and/or deceptive business practices), declaratory and injunctive relief, insurance bad faith, punitive damages, and seeks to impose alter ego liability.

The ultimate outcome of the cost of insurance lawsuits that have not been settled cannot be predicted with certainty and an adverse outcome could exceed the amount we have accrued and could have a material impact on the Company's consolidated financial condition, cash flows or results of operations.

Agent Litigation

On September 18, 2006, a purported class action was filed in the Superior Court of the State of California for the County of Los Angeles, Holly Walker, individually, and on behalf of all others similarly situated, and on behalf of the general public v. Bankers Life & Casualty Company, an insurance company domiciled in the State of Illinois, and Does 1 to 100, Case No. BC358690. In her complaint, plaintiff alleged Bankers Life and Casualty Company intentionally misclassified its California insurance agents as independent contractors when they should have been classified as employees. Plaintiff sought relief on behalf of the class alleging claims for preliminary and permanent injunction, misclassification, indemnification, conversion and unfair business practices. Bankers Life and Casualty Company caused the case to be removed to the U.S. District Court, Central District of California on October 18, 2006. An order was entered on November 20, 2006 transferring the case to the U.S. District Court, Northern District of Illinois, Case No. 06C6906. The Court has dismissed with prejudice plaintiff's allegations of preliminary and permanent injunction and misclassification. A first amended complaint was filed on June 12, 2007 adding Carole Paradise as the new class representative and naming Holly Walker as an individual plaintiff. This complaint alleges claims of indemnification, conversion and unfair business practices. On October 1, 2007, the court granted the plaintiff's motion for class certification. Bankers Life and Casualty Company subsequently appealed to the 7th Circuit Court of Appeals, which denied the appeal. This matter is set for trial on July 21, 2008. We believe the action is without merit and we intend to defend the case vigorously. The ultimate outcome of the action cannot be predicted with certainty.

Other Litigation

On November 17, 2005, a complaint was filed in the United States District Court for the Northern District of California, Robert H. Hansen, an individual, and on behalf of all others similarly situated v. Consecos Insurance Company, an Illinois corporation f/k/a Consecos Annuity Assurance Company, Cause No. C0504726. Plaintiff in this putative class action purchased an annuity in 2000 and is claiming relief on behalf of the proposed national class for alleged violations of the Racketeer Influenced and Corrupt Organizations Act; elder abuse; unlawful, deceptive and unfair business practices; unlawful, deceptive and misleading advertising; breach of fiduciary duty; aiding and abetting of breach of fiduciary duty; and unjust enrichment and imposition of constructive trust. On January 27, 2006, a similar complaint was filed in the same court entitled Friou P. Jones, on Behalf of Himself and All Others Similarly Situated v. Consecos Insurance Company, an Illinois company f/k/a Consecos Annuity Assurance Company, Cause No. C06-00537. Mr. Jones had purchased an annuity in 2003. Each case alleged that the annuity sold was inappropriate and that the annuity products in question are inherently unsuitable for seniors age 65 and older. On March 3, 2006 a first amended complaint was filed in the Hansen case adding causes of action for fraudulent concealment and breach of the duty of good faith and fair dealing. In an order dated April 14, 2006, the court consolidated the two cases under the original Hansen cause number and retitled the consolidated action: In re Consecos Insurance Co. Annuity Marketing & Sales Practices Litig. A motion to dismiss the amended complaint was granted in part and denied in part, and the plaintiffs filed a second amended complaint on April 27, 2007. The second amended complaint includes the same causes of action as the prior complaint, but added as defendants Consecos, Inc., Consecos Services, LLC, Consecos Marketing, LLC and 40|86 Advisors, Inc. while deleting Friou Jones as a named plaintiff. We filed a motion to dismiss the second amended complaint and it was granted in part and denied in part. A motion to dismiss Consecos, Inc., Consecos Services, LLC, Consecos Marketing, LLC and 40|86 Advisors, Inc. was filed on September 14, 2007, and we await a ruling on the motion. The court has not yet made a determination whether the case should go forward as a class action, and we intend to oppose any form of class action treatment of these claims. We believe the action is without merit, and intend to defend it vigorously. The ultimate outcome of the action cannot be predicted with certainty.

On September 24, 2004, a purported statewide class action was filed in the 18th Judicial District Court, Parish of

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Iberville, Louisiana, Diana Doiron, Individually And On Behalf of All Others Similarly Situated v. Conseco Health Insurance Company, Case No. 61,534. In her complaint, plaintiff claims that she was damaged due to Conseco Health Insurance Company's failure to pay claims made under her cancer policy, and seeks compensatory and statutory damages in an unspecified amount along with declaratory and injunctive relief. Conseco caused the case to be removed to the United States District Court for the Middle District of Louisiana on November 3, 2004, and it was assigned Case No. 04-784-D-M2. An order was issued on February 15, 2007 granting plaintiff's motion for class certification. The order specifically certifies two sub-classes identifying them as the radiation treatment sub-class and the chemotherapy treatment sub-class. We have appealed the certification order to the 5th Circuit Court of Appeals, and an oral argument was heard by that court on March 3, 2008. We believe the action is without merit, and we intend to defend the case vigorously. The ultimate outcome of the action cannot be predicted with certainty.

Beneficial Standard Life Insurance Company, a predecessor company to Conseco Insurance Company, filed suit for declaratory judgment against J.C. Penney Life Insurance Company a/k/a Stonebridge Life Insurance Company ("Stonebridge") in a case captioned, Beneficial Standard Life Insurance Company v. J.C. Penney Life Insurance Company and J.C. Penney Company, Inc., United States District Court for the Central District of California, Case No. CV-98-02792-SVW. This litigation arises from the 1967 sale of Beneficial Fire & Casualty ("BF&C") by Beneficial Standard Life Insurance Company to J.C. Penney Company, Inc. The subject of the case is whether Conseco Insurance Company must indemnify Stonebridge for losses and expenses incurred as a result of claims arising under presale BF&C insurance policies. Conseco Insurance Company filed suit in April 1998 seeking a judicial declaration that: (1) it is not generally obligated to indemnify Stonebridge under the terms of the agreement governing the 1967 sale; and (2) that it is not obligated to indemnify Stonebridge for losses or expenses incurred in connection with specific known claims. Penney counterclaimed for breach of contract and declaratory relief. On July 25, 2006, a second action was filed in the Circuit Court of Hamilton County, Indiana, captioned Conseco Insurance Company v. Stonebridge Life Insurance Company and J.C. Penney Life Insurance Company. Penney removed the case to federal court on August 16, 2006, Case No. 1:06-CV-1229 SEB-VSS (Southern District, Indiana) and filed a motion to dismiss. On September 27, 2007, the court transferred this case to the State of California for consolidation with the pending matter there. The subject of this second action is whether Conseco Insurance Company's indemnification obligation with respect to specific known claims is excused by Stonebridge's failure to pursue available reinsurance. The parties have reached a settlement and the cases are to be dismissed with prejudice. The amount recognized as expense in 2007 related to the settlement of this case was not significant to our business, financial condition, results of operations or cash flows.

On November 3, 2006, an action was filed in the U.S. District Court for the Central District of California Ruth Ross v. Pioneer National Life Insurance Company and Washington National Insurance Company, Case No. CV 06 7081. In that case, the plaintiff alleges breach of contract, bad faith and violation of California consumer protection laws in the handling of her claim for benefits under a Washington National Insurance Company policy of long-term care insurance. The Company paid out in excess of the \$150,000 per occurrence maximum benefit and declined to pay additional claims, but the plaintiff contends she should receive the balance of a \$250,000 lifetime maximum benefit. The parties disagree as to whether the plaintiff's continuing confinement is caused by one or more than one occurrence as defined under the policy. In her complaint, the plaintiff claims loss of benefits of \$.1 million, and compensatory damages for mental anguish of \$.9 million, together with punitive damages of \$5 million plus attorney fees, interest and costs of litigation. The parties were unable to conclude the matter at a mediation which occurred June 22, 2007. The matter is scheduled for jury trial May 27, 2008. The Company believes the claim is without merit and intends to defend it vigorously. The ultimate outcome of the action cannot be predicted with certainty.

On August 7, 2006, an action was filed in the United States District Court for the Southern District of New York, Sheldon H. Solow v. Conseco, Inc. and Carmel Fifth, LLC, Case No. 06-CV-5988 (BSJ). The plaintiff alleges breach of duty to hold a fair auction, fraud, promissory estoppel, unjust enrichment and a declaratory judgment with respect to the sale by defendants of the GM Building in New York City in 2003. Plaintiff was a losing bidder on the building. In the complaint, plaintiff seeks damages of \$35 million on the unjust enrichment count and damages in an amount to be determined at trial on the remaining counts. Defendants filed a motion to dismiss the complaint on September 18, 2006. On January 11, 2008, the court ruled on the motion to dismiss, granting the motion with respect to the unjust enrichment and declaratory judgment counts, and denying the motion with respect to the remaining three counts. Discovery will now be proceeding in the matter. The Company believes the action is without merit and intends to defend it vigorously. The ultimate outcome of the action cannot be predicted with certainty.

In addition, the Company and its subsidiaries are involved on an ongoing basis in other arbitrations and lawsuits, including purported class actions, related to their operations. The ultimate outcome of all of these other legal matters pending

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

against the Company or its subsidiaries cannot be predicted, and, although such lawsuits are not expected individually to have a material adverse effect on the Company, such lawsuits could have, in the aggregate, a material adverse effect on the Company's consolidated financial condition, cash flows or results of operations.

Director and Officer Loan Program Litigation

Collection efforts by the Company and Consecos Services related to the 1996-1999 director and officer loan programs are ongoing against two past board members with outstanding loan balances, James D. Massey and Dennis E. Murray, Sr. In addition, these directors have sued the companies for declaratory relief concerning their liability for the loans. The specific lawsuits now pending include: Murray and Massey v. Consecos, Case No. 1:03-CV-1701-LJM-VSS (Southern District, Indiana); Consecos Services v. Murray, Case No. 29D02-0404-CC-381 (Superior Court, Hamilton County, Indiana); Consecos Services v. Massey, Case No. 29D01-0406-CC-477 (Superior Court, Hamilton County, Indiana); Consecos, Inc. v. Massey, Case No. 2005-L-011316 (Circuit Court, Cook County, Illinois) and Consecos and Consecos Services v. J. David Massey et al., Case No. 29D02-0611-PL-1169 (Superior Court, Hamilton County, Indiana). On June 21, 2006, in the Hamilton County case, the Company obtained a partial summary judgment against Mr. Massey in the sum of \$4.4 million plus interest at 11.5 percent from June 30, 2002. The trial court stayed execution of the judgment pending appeal. The trial which was set for October 22, 2007, has been continued without date. On January 22, 2008, the Indiana Court of Appeals, in Massey v. Consecos Services, LLC Case No. 29A05-0610-CV-565, affirmed the judgment entered in the Hamilton County case in favor of the Company and the dismissal of Massey's counterclaims. Mr. Massey has filed a petition for rehearing with the Court of Appeals. The Murray U.S. District Court case is currently set for trial on February 2, 2009.

The Company and Consecos Services believe that all amounts due under the director and officer loan programs, including all applicable interest, are valid obligations owed to the companies. As part of our Predecessor's plan of reorganization, we have agreed to pay 45 percent of any net proceeds recovered in connection with these lawsuits, in an aggregate amount not to exceed \$30 million, to former holders of our Predecessor's trust preferred securities that did not opt out of a settlement reached with the committee representing holders of these securities. As of December 31, 2007, we have paid \$13.7 million to the former holders of trust preferred securities under this arrangement. We intend to prosecute these claims to obtain the maximum recovery possible. Further, with regard to the various claims brought against the Company and Consecos Services by certain former directors and officers, we believe that these claims are without merit and intend to defend them vigorously. The ultimate outcome of the lawsuits cannot be predicted with certainty. At December 31, 2007, we estimated that approximately \$19.2 million, net of collection costs, of the remaining amounts due under the loan program will be collected (including amounts that remain to be collected from borrowers with whom we have settled) and of that amount \$10.2 million will be paid to the former holders of our Predecessor's trust preferred securities.

Regulatory Examinations and Fines

Insurance companies face significant risks related to regulatory investigations and actions. Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, changing the way cost of insurance charges are calculated for certain life insurance products or recommending unsuitable products to customers. We are, in the ordinary course of our business, subject to various examinations, inquiries and information requests from state, federal and other authorities. The ultimate outcome of these regulatory actions cannot be predicted with certainty. In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and we could suffer significant reputational harm as a result of these matters, which could also have a material adverse effect on our business, financial condition, results of operations or cash flows.

Consecos received a letter from the Congressional Committee on Energy and Commerce (the "Committee") dated May 23, 2007 indicating the Committee is conducting an investigation of companies that underwrite, market, and sell long-term nursing home and home health care insurance policies. In that letter, the Committee requested various documents from Consecos with regard to long-term care insurance. Representatives from Consecos subsequently met with the Committee staffers and reached an agreement on the scope of the documents requested. Consecos responded to all agreed upon document requests by June 27, 2007. Consecos intends to continue to fully cooperate with regard to this investigation.

Consecos received a letter from Senator Grassley of the United States Senate Finance Committee dated September 27, 2007 indicating his interest in learning how long-term care insurance providers manage their policies, serve their beneficiaries, and decide which claims to approve and which to deny. Senator Grassley requested answers to questions

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

regarding Consecos policies and practices and requested various documents. Representatives from Consecos subsequently met with two of the Senator's staffers and reached an agreement on the scope of the information requested. Consecos is in the process of providing the information requested and intends to continue to fully cooperate with regard to this inquiry.

The states of Pennsylvania, Illinois, Texas, Florida and Indiana are leading a multistate examination of the long-term care claims administration and complaint handling practices of Consecos Senior and Bankers Life and Casualty Company, as well as the sales and marketing practices of Bankers Life and Casualty Company. This examination commenced in July 2007. More than 35 other states have joined or expressed an interest in joining the multistate examination. This examination will cover the years 2005, 2006 and 2007.

Certain state insurance regulators have previously requested information with respect to actions of the Company related to the cost of insurance charges for life insurance policies sold primarily under the names "Lifestyle" and "Lifetime". Such policies are subject to the litigation settlement described in the section of this note entitled "Cost of Insurance Litigation".

Guaranty Fund Assessments

The balance sheet at December 31, 2007, included: (i) accruals of \$7.0 million, representing our estimate of all known assessments that will be levied against the Company's insurance subsidiaries by various state guaranty associations based on premiums written through December 31, 2007; and (ii) receivables of \$3.4 million that we estimate will be recovered through a reduction in future premium taxes as a result of such assessments. At December 31, 2006, such guaranty fund assessment accruals were \$7.2 million and such receivables were \$3.4 million. These estimates are subject to change when the associations determine more precisely the losses that have occurred and how such losses will be allocated among the insurance companies. We recognized expense for such assessments of \$1.3 million, \$2.5 million and \$4.0 million in 2007, 2006 and 2005, respectively.

Guarantees

We hold bank loans made to certain former directors and employees to enable them to purchase common stock of Old Consecos. These loans, with a principal amount of \$481.3 million, had been guaranteed by our Predecessor. We received all rights to collect the balances due pursuant to the original terms of these loans. In addition, we hold loans to participants for interest on the loans. The loans and the interest loans are collectively referred to as the "D&O loans." We regularly evaluate the collectibility of these loans in light of the credit worthiness of the participants and the current status of various legal actions we have taken to collect the D&O loans. At December 31, 2007, we have estimated that approximately \$19.2 million of the D&O loan balance (which is included in other assets) is collectible (net of the costs of collection). An allowance has been established to reduce the total D&O loan balance to the amount we estimated was recoverable. In 2006 and 2005, other operating costs and expenses are net of recoveries of \$3.0 million and \$3.2 million, respectively, related to our evaluation of the collectibility of the D&O loans.

Pursuant to the settlement that was reached with the Official Committee of the Trust Originated Preferred Securities ("TOPrS") Holders and the Official Committee of Unsecured Creditors in the Plan, the former holders of TOPrS (issued by Old Consecos's subsidiary trusts and eliminated in our reorganization) who did not opt out of the bankruptcy settlement, will be entitled to receive 45 percent of any net proceeds from the collection of certain D&O loans in an aggregate amount not to exceed \$30 million. As of December 31, 2007, we had paid \$13.7 million to the former holders of TOPrS and we have established a liability of \$10.2 million (which is included in other liabilities), representing our estimate of the amount which will be paid to the former holders of TOPrS pursuant to the settlement.

In accordance with the terms of the employment agreements of two of the Company's former chief executive officers, certain wholly-owned subsidiaries of the Company are the guarantors of the former executives' nonqualified supplemental retirement benefits. The liability for such benefits was \$22.5 million at both December 31, 2007 and 2006, and is included in the caption "Other liabilities" in the consolidated balance sheet.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Leases and Certain Other Long-Term Commitments

The Company rents office space, equipment and computer software under noncancellable operating lease agreements. In addition, the Company has entered into certain sponsorship agreements which require future payments. Total expense pursuant to these lease and sponsorship agreements was \$44.8 million, \$43.3 million and \$41.3 million in 2007, 2006 and 2005, respectively. Future required minimum payments as of December 31, 2007, were as follows (dollars in millions):

2008	\$ 37.5
2009	30.8
2010	24.7
2011	21.4
2012	19.2
Thereafter	86.5

Total	\$220.1
		=====

10. OTHER DISCLOSURES

Agent Deferred Compensation Plan and Postretirement Plans

For our agent deferred compensation plan and postretirement plans, it is our policy to immediately recognize changes in the actuarial benefit obligation resulting from either actual experience being different than expected or from changes in actuarial assumptions.

One of our insurance subsidiaries has a noncontributory, unfunded deferred compensation plan for qualifying members of its career agency force. Benefits are based on years of service and career earnings. The actuarial measurement date of this deferred compensation plan is December 31. The liability recognized in the consolidated balance sheet for the agents' deferred compensation plan was \$94.5 million and \$94.6 million at December 31, 2007 and 2006, respectively. Costs incurred on this plan were \$5.8 million, \$8.9 million and \$11.3 million during 2007, 2006 and 2005, respectively (including the recognition of gains (losses) of \$3.3 million, \$(.1) million and \$(4.0) million in 2007, 2006 and 2005, respectively, resulting from actual experience being different than expected or from changes in actuarial assumptions). The estimated net loss for the agent deferred compensation plan that will be amortized from accumulated other comprehensive income into the net periodic benefit cost during 2008 is \$.2 million. In 2006, we purchased Company-owned life insurance ("COLI") as an investment vehicle to fund the agent deferred compensation plan. The COLI assets are not assets of the agent deferred compensation plan, and as a result, are accounted for outside the plan and are recorded in the consolidated balance sheet as other invested assets. The carrying value of the COLI assets was \$40.9 million and \$19.7 million at December 31, 2007 and 2006, respectively. Changes in the cash surrender value (which approximates net realizable value) of the COLI assets are recorded as net investment income.

Effective December 31, 2005, the Company terminated certain postretirement benefit plans. Prior to the termination of such plans, we provided certain health care and life insurance benefits for certain eligible retired employees under partially funded and unfunded plans in existence at the date on which certain subsidiaries were acquired. Certain postretirement benefit plans were contributory, with participants' contributions adjusted annually. Actuarial measurement dates of September 30 and December 31 were used for those postretirement benefit plans. In 2005, we recognized gains of \$13.2 million on the termination of these plans. The remaining liability at December 31, 2006, related to benefits paid in 2007. Amounts related to the postretirement benefit plans were as follows (dollars in millions):

	2007	2006
Benefit obligation, beginning of year.....	\$.3	\$.5
Benefits paid.....	(.3)	(.2)
	-----	-----
Benefit obligation, end of year.....	\$ -	\$.3
	=====	=====
Funded status - accrued benefit cost.....	\$ -	\$.3
	=====	=====

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

We used the following assumptions for the deferred compensation plan to calculate:

	2007	2006
	----	----
Benefit obligations:		
Discount rate.....	6.02%	5.75%
Net periodic cost:		
Discount rate.....	5.75%	5.50%

The discount rate is based on the yield of a hypothetical portfolio of high quality debt instruments which could effectively settle plan benefits on a present value basis as of the measurement date. At both December 31, 2007 and 2006, for our deferred compensation plan for qualifying members of our career agency force, we assumed a 5 percent annual increase in compensation until the participant's normal retirement date (age 65 and completion of five years of service).

There was no expense recognized in 2006 or 2007 related to the postretirement benefit plans which were terminated in 2005. Components of the cost (benefit) we recognized related to such postretirement plans in 2005 were as follows (dollars in millions):

	2005

Cost of postretirement benefits:	
Interest cost.....	\$.6
Curtailment gains.....	(13.2)
Recognized net actuarial gain.....	-

Net periodic cost (benefit).....	\$(12.6)
	=====

The benefits expected to be paid pursuant to our agent deferred compensation plan and postretirement benefit plans as of December 31, 2007 were as follows (dollars in millions):

2008.....	\$ 3.7
2009.....	3.8
2010.....	3.8
2011.....	4.2
2012.....	4.3
2013 - 2017.....	30.3

The Company has qualified defined contribution plans for which substantially all employees are eligible. Company contributions, which match certain voluntary employee contributions to the plan, totaled \$4.2 million, \$4.1 million and \$4.0 million in 2007, 2006 and 2005, respectively. Employer matching contributions are discretionary.

Reclassification Adjustments Included in Comprehensive Income (Loss)

The changes in unrealized appreciation (depreciation) included in comprehensive income (loss) are net of reclassification adjustments for after-tax net gains (losses) from the sale of investments included in net income (loss) of approximately \$(4) million, \$70 million and \$165 million for the years ended December 31, 2007, 2006 and 2005, respectively.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

11. SHAREHOLDERS' EQUITY

In the second quarter of 2004, we completed the public offerings, including underwriter over-allotments, of 50.6 million shares of our common stock at an offering price of \$18.25 per share and 27.6 million shares of our 5.5 percent Class B mandatorily convertible preferred stock (the "Preferred Stock") at an offering price of \$25 per share. Proceeds from the offerings, net of issuance costs of \$63.4 million, totaled \$1,550.1 million. Such proceeds were used as follows:

- o \$928.9 million to redeem all outstanding shares of our class A preferred stock.
- o \$620.7 million to repay indebtedness under our Previous Credit Facility, including accrued interest of \$.7 million.
- o \$.5 million for general corporate purposes.

In May 2007, all of our Preferred Stock was converted into shares of Consecos common stock in accordance with the terms of issuance. Under those terms, each of the 27.6 million shares of Preferred Stock outstanding was converted into 1.3699 shares of common stock. As a result of the conversion, our common shares outstanding increased by 37.8 million.

Pursuant to the Plan, we issued warrants to purchase 6.0 million shares of our common stock (the "Series A Warrants") entitling the holders to purchase shares of CNO common stock at a price of \$27.60 per share. The Series A Warrants expire on September 10, 2008. The exercise price and number of common shares issuable are subject to adjustment based on the occurrence of certain events, including: (i) stock dividends; (ii) stock splits; and (iii) the issuance of instruments or securities which are exercisable for or convertible into shares of common stock entitling the holders to purchase shares of common stock at a price per share that is less than the market price on the date of issuance.

In December 2006, the Company's board of directors authorized a common share repurchase program of up to \$150 million. In May 2007, the Company's board of directors increased the authorized common share repurchase program to a maximum of \$350 million. As further discussed in the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations," we currently may pay cash dividends on our common stock or repurchase our common stock in an aggregate amount of up to \$300 million over the term of our credit facility (of which, only \$200 million may be paid in the year beginning June 12, 2007). Our share repurchase program may be implemented through purchases made from time to time in either the open market or through private transactions. With respect to \$25 million of the program, the Company entered into an accelerated share buy back agreement ("ASB") to repurchase 1.2 million shares. The initial price paid per share as part of the ASB transaction was \$20.12. The repurchased shares were subject to a settlement price adjustment based upon the difference between: (i) the volume weighted average price of Consecos common stock (as defined in the ASB); and (ii) \$20.12. The settlement price adjustment was calculated to be \$.3 million and was paid to the Company. The Company recognized a reduction in common stock and additional paid-in capital of \$24.7 million in the first quarter of 2007 related to the ASB transaction.

During 2007, the Company repurchased an additional 4.5 million shares of its common stock for \$62.5 million.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Changes in the number of shares of common stock outstanding were as follows (shares in thousands):

	2007	2006	2005
	----	----	----
Balance, beginning of year.....	152,165	151,513	151,058
Treasury stock purchased and retired.....	(5,699)	-	-
Conversion of preferred stock into common shares.....	37,809	-	-
Stock options exercised.....	207	48	23
Shares issued under employee benefit compensation plans.....	177 (a)	645 (a)	443 (a)
Other.....	(7)	(41)	(11)
	-----	-----	-----
Balance, end of year.....	184,652	152,165	151,513
	=====	=====	=====

(a) In 2007, 2006 and 2005, such amounts were reduced by 24 thousand shares, 220 thousand shares and 148 thousand shares, respectively, which were tendered for the payment of federal and state taxes owned on the issuance of restricted stock.

The Company has a long-term incentive plan which permits the grant of CNO incentive or non-qualified stock options, restricted stock awards, stock appreciation rights, performance shares or units and certain other equity-based awards to certain directors, officers and employees of the Company and certain other individuals who perform services for the Company. A maximum of 10 million shares may be issued under the plan. Our stock option awards are generally granted with an exercise price equal to the market price of the Company's stock on the date of grant. For options granted in 2006 and prior years, our stock option awards generally vest on a graded basis over a four year service term and expire ten years from the date of grant. Our stock option awards granted in 2007 generally vest on a graded basis over a three year service term and expire five years from the date of grant. The vesting periods for our restricted stock awards range from immediate vesting to a period of four years.

A summary of the Company's stock option activity and related information for 2007 is presented below (shares in thousands):

	Shares	Weighted average exercise price	Weighted average remaining life	Aggregate intrinsic value
	-----	-----	----	-----
Outstanding at the beginning of the year.....	4,217	\$20.76		
Options granted.....	1,671	17.37		
Exercised.....	(207)	16.31		\$1.3
Forfeited or terminated.....	(853)	20.54		

Outstanding at the end of the year.....	4,828	19.82	5.9 years	\$28.1
	=====		===	
Options exercisable at the end of the year.....	2,462		6.0 years	\$16.6
	=====		===	
Available for future grant.....	2,794			
	=====			

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

A summary of the Company's stock option activity and related information for 2006 is presented below (shares in thousands):

	Shares -----	Weighted average exercise price -----	Weighted average remaining life ----	Aggregate intrinsic value -----
Outstanding at the beginning of the year.....	3,536	\$19.89		
Options granted.....	1,295	22.57		
Exercised.....	(48)	20.80		\$.3
Forfeited or terminated.....	(566) -----	19.47		
Outstanding at the end of the year.....	4,217 =====	20.76	7.6 years ===	\$27.4
Options exercisable at the end of the year.....	2,257 =====		6.4 years ===	\$14.9
Available for future grant.....	4,020 =====			

A summary of the Company's stock option activity and related information for 2005 is presented below (shares in thousands):

	2005 -----	
	Shares -----	Weighted average exercise price -----
Outstanding at the beginning of the year.....	3,448	\$19.82
Options granted.....	560	21.22
Exercised.....	(23)	20.83
Forfeited or terminated.....	(449) -----	20.92
Outstanding at the end of the year.....	3,536 =====	19.89
Options exercisable at the end of the year.....	1,406 =====	
Available for future grant.....	4,247 =====	

We recognized compensation expense related to stock options totaling \$7.4 million (\$4.8 million after income taxes) in 2007 and \$6.5 million (\$4.2 million after income taxes) in 2006. Compensation expense related to stock options reduced both basic and diluted earnings (loss) per share by 3 cents in 2007 and 2006. At December 31, 2007, the unrecognized compensation expense for non-vested stock options totaled \$12.4 million which is expected to be recognized over a weighted average period of 2.3 years. Cash received from the exercise of stock options was \$3.4 million, \$1.0 million and \$.5 million during 2007, 2006 and 2005, respectively.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

If compensation cost had been determined based on the fair value at the grant dates for all awards issued after January 1, 1995, the Company's pro forma net income and pro forma earnings per share would have been as follows (dollars in millions, except per share amounts):

	2005

Net income, as reported	(Restated) \$312.7
Less stock-based employee compensation ..expense determined under the fair value method for all awards, net of income taxes.....	3.5 -----
Pro forma net income.....	\$309.2 =====
Earnings per share:	
Basic, as reported.....	\$1.82 =====
Basic, pro forma.....	\$1.79 =====
Diluted, as reported.....	\$1.69 =====
Diluted, pro forma.....	\$1.67 =====

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option valuation model with the following weighted average assumptions:

	2007 Grants	2006 Grants	2005 Grants
	-----	-----	-----
Weighted average risk-free interest rates.....	4.4%	5.0%	4.0%
Weighted average dividend yields.....	0.0%	0.0%	0.0%
Volatility factors.....	22%	22%	25%
Weighted average expected life.....	3.7 years	6.2 years	6.1 years
Weighted average fair value per share.....	\$4.22	\$7.90	\$7.06

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield is based on the Company's history and expectation of dividend payouts. Volatility factors are based on the weekly historical volatility of the Company's common stock since our emergence from bankruptcy in September 2003. The expected life is based on the average of the graded vesting period and the contractual terms of the option.

The exercise price was equal to the market price of our stock for all options granted in 2007, 2006 and 2005.

The following table summarizes information about stock options outstanding at December 31, 2007 (shares in thousands):

	Options outstanding			Options exercisable	
	Number outstanding	Remaining life (in years)	Average exercise price	Number exercisable	Average exercise price
\$12.96 - \$18.97.....	1,806	4.8	\$17.46	345	\$18.06
\$19.61 - \$25.45.....	3,022	6.6	21.23	2,117	20.86
	4,828			2,462	
	=====			=====	

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

During 2007, 2006 and 2005, the Company granted .1 million, .1 million and .2 million restricted shares, respectively, of CNO common stock to certain directors, officers and employees of the Company at a weighted average fair value of \$18.39 per share, \$22.68 per share and \$21.41 per share, respectively. The fair value of such grants totaled \$1.7 million, \$1.3 million and \$4.7 million in 2007, 2006 and 2005, respectively. Such amounts are recognized as compensation expense over the vesting period of the restricted stock. A summary of the Company's non-vested restricted stock activity for 2007 is presented below (shares in thousands):

	Shares	Weighted average grant date fair value
	-----	-----
Non-vested shares, beginning of year.....	245	\$20.06
Granted.....	91	18.39
Vested.....	(201)	19.58
Forfeited.....	(23)	20.90

Non-vested shares, end of year.....	112	19.38
	====	

At December 31, 2007, the unrecognized compensation expense for non-vested restricted stock totaled \$1.3 million which is expected to be recognized over a weighted average period of 1.7 years. At December 31, 2006, the unrecognized compensation expense for non-vested restricted stock totaled \$3.3 million. We recognized compensation expense related to restricted stock awards totaling \$3.2 million, \$10.2 million and \$11.4 million in 2007, 2006 and 2005, respectively. The fair value of restricted stock that vested during 2007, 2006 and 2005 was \$3.9 million, \$16.1 million and \$11.5 million, respectively.

SFAS 123R also requires us to estimate the amount of unvested stock-based awards that will be forfeited in future periods and reduce the amount of compensation expense recognized over the applicable service period to reflect this estimate. In accordance with SFAS 123R, we periodically evaluate our forfeiture assumptions to more accurately reflect our actual forfeiture experience.

The Company does not currently recognize tax benefits resulting from tax deductions in excess of the compensation expense recognized because of NOLs which are available to offset future taxable income.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

A reconciliation of net income (loss) and shares used to calculate basic and diluted earnings (loss) per share is as follows (dollars in millions and shares in thousands):

	2007 ----	2006 ---- (Restated)	2005 ---- (Restated)
Net income (loss).....	\$(179.9)	\$106.0	\$312.7
Preferred stock dividends.....	(14.1)	(38.0)	(38.0)
	-----	-----	-----
Net income (loss) applicable to common stock for basic earnings per share.....	(194.0)	68.0	274.7
Effect of dilutive securities:			
Preferred stock dividends.....	-	-	38.0
	-----	-----	-----
Net income (loss) applicable to common stock and assumed conversions for diluted earnings per share.....	\$(194.0)	\$ 68.0	\$312.7
	=====	=====	=====
Shares:			
Weighted average shares outstanding for basic earnings per share.....	173,374	151,690	151,160
	-----	-----	-----
Effect of dilutive securities on weighted average shares:			
Class B Mandatorily convertible preferred stock.....	-	-	33,027
Stock option and restricted stock plans.....	-	819	853
	-----	-----	-----
Dilutive potential common shares.....	-	819	33,880
	-----	-----	-----
Weighted average shares outstanding for diluted earnings per share.....	173,374	152,509	185,040
	=====	=====	=====

There were no dilutive common stock equivalents during 2007 because of the net loss recognized by the Company during such period. Therefore, all potentially dilutive shares are excluded in the weighted average shares outstanding for diluted earnings per share, and the preferred stock dividends on the Class B mandatorily convertible preferred stock (related to the period prior to their conversion) are not added back to net income (loss) applicable to common stock. The potentially dilutive shares related to the Class B mandatorily convertible preferred stock were not dilutive during 2006, but the common stock equivalents related to stock option and restricted stock plans were dilutive.

The following summarizes the equivalent common shares for securities that were not included in the computation of diluted earnings per share, because doing so would have been antidilutive in such periods (shares in thousands).

	2007 ----	2006 ----	2005 ----
Equivalent common shares that were antidilutive during the year:			
Class B mandatorily convertible preferred stock.....	14,334	32,178	-
Stock option and restricted stock plans.....	144	-	-
	-----	-----	-----
Antidilutive equivalent common shares.....	14,478	32,178	-
	=====	=====	=====

In 2007, the Company granted 420,900 performance shares pursuant to its long-term incentive plan to certain officers of the Company. The criteria for payment related to 252,540 of such awards (which had a grant date fair value of \$1.7 million) is based upon the cumulative return on the Company's stock with dividends reinvested ("total shareholder return")

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

compared to the total shareholder return of a group of Consecos peers (represented by the companies comprising the Standard & Poor's Life and Health Index and the Russell 3000 Health and Life Index) over a three year performance measurement period ending December 31, 2009. If the Company's results are below the 50th percentile of the comparison group, no portion of the award is earned. If the Company's results are equal to or greater than the 75th percentile, then the maximum award is earned. The criteria for payment of the remaining 168,360 performance shares (which had a grant date fair value of \$3.0 million) is based upon the Company's operating return on equity, as defined in the award agreement, for the year ended December 31, 2009. If the Company's operating return on equity is less than 10.0 percent, no portion of the award is earned. If the Company's operating return on equity is equal to or greater than 12.0 percent, then the maximum award is earned. Unless antidilutive, the diluted weighted average shares outstanding would reflect the number of performance shares expected to be issued, using the treasury stock method.

In August 2005, we completed the private offering of the Debentures. In future periods, our diluted shares outstanding may include incremental shares issuable upon conversion of all or part of such Debentures. Since the \$330.0 million principal amount can only be redeemed for cash, it has no impact on the diluted earnings per share calculation. In accordance with the conversion feature of these Debentures, we may be required to pay a stock premium along with redeeming the accreted principal amount for cash, if our common stock reaches a certain market price. In accordance with the consensus from EITF No. 04-8, "The Effect of Contingently Convertible Instruments on Diluted Earnings per Share", we will include the dilutive effect of our Debentures in the calculation of diluted earnings per share when the impact is dilutive. During 2007, 2006 and 2005, the conversion feature of these Debentures did not have a dilutive effect because the weighted average market price of our common stock did not exceed the initial conversion price of \$26.66. Therefore, the Debentures had no effect on our diluted shares outstanding or our diluted earnings per share in 2007, 2006 or 2005.

Basic earnings (loss) per common share is computed by dividing net income (loss) applicable to common stock by the weighted average number of common shares outstanding for the period. Restricted shares (including our performance shares) are not included in basic earnings (loss) per share until vested. Diluted earnings (loss) per share reflect the potential dilution that could occur if outstanding stock options were exercised and restricted stock was vested. The dilution from options and restricted shares is calculated using the treasury stock method. Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock) will be used to purchase shares of our common stock at the average market price during the period, reducing the dilutive effect of the exercise of the options (or the vesting of the restricted stock).

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

12. OTHER OPERATING STATEMENT DATA

Insurance policy income consisted of the following (dollars in millions):

	2007 ----	2006 ----	2005 ----
Traditional products:			
Direct premiums collected.....	\$ 4,549.6	\$ 4,749.8	\$ 4,434.4
Reinsurance assumed.....	329.0	124.0	60.1
Reinsurance ceded.....	(203.9)	(215.2)	(232.2)
	-----	-----	-----
Premiums collected, net of reinsurance.....	4,674.7	4,658.6	4,262.3
Change in unearned premiums.....	.4	48.5	18.3
Less premiums on universal life and products without mortality and morbidity risk which are recorded as additions to insurance liabilities	(1,852.2)	(2,067.7)	(1,709.8)
	-----	-----	-----
Premiums on traditional products with mortality or morbidity risk.....	2,822.9	2,639.4	2,570.8
Fees and surrender charges on interest-sensitive products.....	344.4	349.6	359.3
	-----	-----	-----
Insurance policy income.....	\$ 3,167.3	\$ 2,989.0	\$ 2,930.1
	=====	=====	=====

The four states with the largest shares of 2007 collected premiums were Florida (8.5 percent), California (7.3 percent), Texas (6.6 percent) and Pennsylvania (6.1 percent). No other state accounted for more than five percent of total collected premiums.

Other operating costs and expenses were as follows (dollars in millions):

	2007 ----	2006 ----	2005 ----
Commission expense.....	\$147.3	(Restated) \$151.4	(Restated) \$154.0
Salaries and wages.....	184.9	184.0	186.0
Other.....	271.9	241.3	212.9
	-----	-----	-----
Total other operating costs and expenses.....	\$604.1	\$576.7	\$552.9
	=====	=====	=====

Changes in the value of policies inforce at the Effective Date were as follows (dollars in millions):

	2007 ----	2006 ----	2005 ----
Balance, beginning of year.....	\$2,136.5	(Restated) \$2,399.5	(Restated) \$2,602.7
Additional acquisition expense.....	1.9	2.1	2.6
Amortization.....	(268.7)	(294.4)	(282.3)
Cumulative effect of accounting change related to the adoption of SOP 05-1.....	(2.6)	-	-
Effect of annuity coinsurance transaction.....	(191.2)	-	-
Effect of reinsurance recapture.....	56.3	-	-
Amounts related to fair value adjustment of actively managed fixed maturities.....	(9.4)	29.3	76.5
	-----	-----	-----
Balance, end of year.....	\$1,722.8	\$2,136.5	\$2,399.5
	=====	=====	=====

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Based on current conditions and assumptions as to future events on all policies inforce, the Company expects to amortize approximately 13 percent of the December 31, 2007 balance of the value of policies inforce at the Effective Date in 2008, 12 percent in 2009, 11 percent in 2010, 7 percent in 2011 and 6 percent in 2012. The discount rate used to determine the amortization of the value of policies inforce at the Effective Date averaged approximately 5 percent in the years ended December 31, 2007, 2006 and 2005.

In accordance with SFAS 97, we are required to amortize the value of policies inforce in relation to estimated gross profits for universal life products and investment-type products. SFAS 97 also requires that estimates of expected gross profits used as a basis for amortization be evaluated regularly, and that the total amortization recorded to date be adjusted by a charge or credit to the statement of operations, if actual experience or other evidence suggests that earlier estimates should be revised.

Changes in the cost of policies produced were as follows (dollars in millions):

	2007 ----	2006 ----	2005 ----
Balance, beginning of year.....	\$1,106.7	\$ 758.8	(Restated) \$ 426.7
Additions.....	487.6	482.5	424.9
Amortization.....	(180.6)	(147.2)	(102.7)
Cumulative effect of accounting change related to the adoption of SOP 05-1.....	(1.6)	-	-
Effect of annuity coinsurance transaction.....	(19.3)	-	-
Amounts related to fair value adjustment of actively managed fixed maturities.....	30.2	12.6	9.9
	-----	-----	-----
Balance, end of year.....	\$1,423.0 =====	\$1,106.7 =====	\$ 758.8 =====

13. CONSOLIDATED STATEMENT OF CASH FLOWS

The following disclosures supplement our consolidated statement of cash flows (dollars in millions):

	2007 ----	2006 ----	2005 ----
Non-cash items not reflected in the investing and financing activities sections of the consolidated statement of cash flows:			
Stock option and restricted stock plans.....	\$ 11.0	\$11.4	\$8.6
Conversion of preferred stock into common shares.....	667.8	-	-
Reduction of tax liabilities related to various contingencies recognized at the fresh-start date.....	6.0	6.7	1.4

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

The following reconciles net income to net cash provided by operating activities (dollars in millions):

	2007 ----	2006 ---- (Restated)	2005 ---- (Restated)
Cash flows from operating activities:			
Net income (loss).....	\$(179.9)	\$ 106.0	\$ 312.7
Adjustments to reconcile net income to net cash provided by operating activities:			
Amortization and depreciation.....	483.2	501.2	400.5
Income taxes.....	4.2	62.6	200.0
Insurance liabilities.....	744.8	493.2	420.4
Accrual and amortization of investment income.....	73.4	(5.8)	86.4
Deferral of policy acquisition costs.....	(545.9)	(484.6)	(400.9)
Net realized investment losses.....	155.4	47.2	2.9
Loss on extinguishment of debt.....	-	.3	3.4
Net sales (purchases) of trading securities.....	(114.3)	36.0	165.8
Loss related to an annuity coinsurance transaction.....	76.5	-	-
Other.....	5.9	175.1	(29.1)
	-----	-----	-----
Net cash provided by operating activities.....	\$ 703.3 =====	\$ 931.2 =====	\$1,162.1 =====

At December 31, 2007 and 2006, restricted cash and cash equivalents consisted of: (i) \$16.1 million and \$15.7 million, respectively, held by a variable interest entity; (ii) \$1.9 million and \$.1 million, respectively, of segregated cash held for the benefit of the former holders of TOPrS; and (iii) \$3.1 million and \$8.2 million, respectively, held in an escrow account pursuant to a litigation settlement.

14. STATUTORY INFORMATION (BASED ON NON-GAAP MEASURES)

Statutory accounting practices prescribed or permitted by regulatory authorities for the Company's insurance subsidiaries differ from GAAP. The Company's insurance subsidiaries reported the following amounts to regulatory agencies, after appropriate elimination of intercompany accounts among such subsidiaries (dollars in millions):

	2007 ----	2006 ----
Statutory capital and surplus.....	\$1,336.2	\$1,554.5
Asset valuation reserve.....	161.3	179.1
Interest maintenance reserve.....	196.7	249.7
	-----	-----
Total.....	\$1,694.2 =====	\$1,983.3 =====

Statutory capital and surplus included investments in upstream affiliates of \$52.4 million at both December 31, 2007 and 2006, respectively, which were eliminated in the consolidated financial statements prepared in accordance with GAAP.

Statutory earnings build the capital required by ratings agencies and regulators. Statutory earnings, fees and interest paid by the insurance companies to the parent company create the "cash flow capacity" the parent company needs to meet its obligations, including debt service. The consolidated statutory net income (loss) (a non-GAAP measure) of our insurance subsidiaries was \$(321.3) million, \$(232.4) million and \$97.3 million in 2007, 2006 and 2005, respectively. Included in such net income (loss) were net realized capital gains (losses), net of income taxes, of \$(38.5) million, \$(1.8) million and \$7.8 million in 2007, 2006 and 2005, respectively. In addition, such net income (loss) included pre-tax amounts for fees and interest to Consecor or its non-life subsidiaries totaling \$162.8 million, \$157.6 million and \$145.6 million in 2007, 2006 and 2005, respectively.

The statutory data discussed above reflects our current financial statement filings with various regulatory authorities. It is our intention to evaluate each of the items that have been restated in our consolidated financial statements prepared in accordance with GAAP to determine whether restatement to our previously filed statutory financial statements is needed. We cannot reasonably estimate the effects of any such restatements should they occur.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Insurance regulators may prohibit the payment of dividends or other payments by our insurance subsidiaries to parent companies if they determine that such payment could be adverse to our policyholders or contract holders. Otherwise, the ability of our insurance subsidiaries to pay dividends is subject to state insurance department regulations. Insurance regulations generally permit dividends to be paid from statutory earned surplus of the insurance company without regulatory approval for any 12-month period in amounts equal to the greater of (or in a few states, the lesser of): (i) statutory net gain from operations or statutory net income for the prior year; or (ii) 10 percent of statutory capital and surplus as of the end of the preceding year. Any dividends in excess of these levels require the approval of the director or commissioner of the applicable state insurance department. All of the dividends we plan to have our insurance subsidiaries pay in 2008 will require regulatory approval. During 2007, our top tier insurance subsidiary paid dividends of \$50.0 million to CDOC, Inc. ("CDOC"). Also, during 2007, CDOC made capital contributions totaling \$200.0 million to our top tier insurance subsidiary including \$50.0 million of capital contributions which were accrued at December 31, 2006, and paid in February 2007.

In connection with monitoring the financial condition of insurers, certain state insurance departments have requested additional information from two of the Company's insurance subsidiaries, Consecos Senior and Consecos Life, because each such insurance subsidiary has incurred statutory losses in a 12 month period in excess of 50 percent of its capital and surplus. The statutory losses of Consecos Life are primarily attributable to a litigation settlement. For further information related to this case, refer to the caption entitled "Cost of Insurance Litigation" included in the note to our consolidated financial statements entitled "Commitments and Contingencies". The statutory losses of Consecos Senior are primarily attributable to the adverse development of prior period claim reserves, an increase in claims incurred during 2006 and 2007 and strengthening of statutory active life reserves using the prospective unlocking method (as permitted by insurance regulators), all of which related to long-term care policies. Based on our discussions with state insurance departments, we do not expect the regulators to take any actions against Consecos Senior or Consecos Life.

Consecos Senior has been aggressively seeking actuarially justified rate increases and pursuing other actions on our long-term care policies. During the third quarter of 2006, we began a new program to file requests for rate increases on various long-term care products in the Other Business in Run-off segment as we believe the existing rates are too low to fund expected future benefits. These filings are expected to be the first of three rounds of rate increase filings for many of the same policies, and in some cases we requested three years of successive rate increases. The effects of the first round of rate filings have been partially realized in our premium revenue. Most of our long-term care business is guaranteed renewable, and, if necessary rate increases are not approved, we may be required to write off all or a portion of the insurance acquisition costs and establish a premium deficiency reserve.

In accordance with orders from the Florida Office of Insurance Regulation, Consecos Senior may not distribute funds to any affiliate or shareholder unless such distributions have been approved by the Florida Office of Insurance Regulation and Washington National Insurance Company may not make similar distributions without prior notice to the Florida Office of Insurance Regulation. In addition, the risk-based capital and other capital requirements described below can also limit, in certain circumstances, the ability of our insurance subsidiaries to pay dividends.

Risk-Based Capital ("RBC") requirements provide a tool for insurance regulators to determine the levels of statutory capital and surplus an insurer must maintain in relation to its insurance and investment risks and the need for possible regulatory attention. The RBC requirements provide four levels of regulatory attention, varying with the ratio of the insurance company's total adjusted capital (defined as the total of its statutory capital and surplus, AVR and certain other adjustments) to its RBC (as measured on December 31 of each year) as follows: (i) if a company's total adjusted capital is less than 100 percent but greater than or equal to 75 percent of its RBC, the company must submit a comprehensive plan to the regulatory authority proposing corrective actions aimed at improving its capital position (the "Company Action Level"); (ii) if a company's total adjusted capital is less than 75 percent but greater than or equal to 50 percent of its RBC, the regulatory authority will perform a special examination of the company and issue an order specifying the corrective actions that must be taken; (iii) if a company's total adjusted capital is less than 50 percent but greater than or equal to 35 percent of its RBC, the regulatory authority may take any action it deems necessary, including placing the company under regulatory control; and (iv) if a company's total adjusted capital is less than 35 percent of its RBC, the regulatory authority must place the company under its control. In addition, the RBC requirements provide for a trend test if a company's total adjusted capital is between 100 percent and 125 percent of its RBC at the end of the year. The trend test calculates the greater of the decrease in the margin of total adjusted capital over RBC: (i) between the current year and the prior year; and (ii) for the average of the last 3 years. It assumes that such decrease could occur again in the coming year. Any company whose trended total adjusted capital is less than 95 percent of its RBC would trigger a requirement to submit a comprehensive plan as described above for the Company Action Level.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

During 2007 and 2006, we made capital contributions to Conseco Senior to maintain total adjusted capital in excess of the levels subjecting it to any regulatory action. As a result of losses on the long-term care business, we made capital contributions to Conseco Senior of \$202.0 million (including \$56.0 million which was accrued at December 31, 2007, and paid in February 2008) in 2007 and \$110.0 million (including \$80 million which was accrued at December 31, 2006 and paid in February 2007) in 2006.

In addition to the RBC requirements, certain states have established minimum capital requirements for insurance companies licensed to do business in their state. These additional requirements generally have not had a significant impact on the Company's insurance subsidiaries, but the capital requirements in Florida have caused Conseco Health to maintain a higher level of capital and surplus than it would otherwise maintain and have thus limited its ability to pay dividends.

In addition, although we are under no obligation to do so, we may elect to contribute additional capital to strengthen the surplus of certain insurance subsidiaries. Any election regarding the contribution of additional capital to our insurance subsidiaries could affect the ability of our insurance subsidiaries to pay dividends to the holding company. The ability of our insurance subsidiaries to pay dividends is also impacted by various criteria established by rating agencies to maintain or receive higher ratings and by the capital levels that we target for our insurance subsidiaries. During 2007, we made capital contributions of \$48.0 million (including \$25.0 million which was accrued at December 31, 2007, and paid in February 2008) to Conseco Life.

During 2007, the financial statements of three of our subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities reflected the establishment of asset adequacy and premium deficiency reserves primarily related to long-term care and annuity policies. Total asset adequacy and premium deficiency reserves for Washington National, Conseco Insurance Company and Bankers Conseco Life Insurance Company were \$63.8 million, \$35.9 million and \$30.6 million, respectively at December 31, 2007.

At December 31, 2007, the consolidated RBC ratio of our insurance subsidiaries exceeded the minimum risk-based capital requirement included in our Second Amended Credit Facility. See the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations" for further discussion of various financial ratios and balances we are required to maintain. We calculate the consolidated RBC ratio by assuming all of the assets, liabilities, capital and surplus and other aspects of the business of our insurance subsidiaries are combined together in one insurance subsidiary, with appropriate intercompany eliminations.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

15. BUSINESS SEGMENTS

We manage our business through the following: three primary operating segments, Bankers Life, Consec Insurance Group and Colonial Penn, which are defined on the basis of product distribution; a fourth segment comprised of other business in run-off; and corporate operations, which consists of holding company activities and certain noninsurance businesses.

We measure segment performance for purposes of Financial Accounting Standards No. 131, "Disclosures about Segments of an Enterprise and Related Information", excluding realized investment gains (losses) because we believe that this performance measure is a better indicator of the ongoing business and trends in our business. Our investment focus is on investment income to support our liabilities for insurance products as opposed to the generation of realized investment gains (losses), and a long-term focus is necessary to maintain profitability over the life of the business. Realized investment gains (losses) depend on market conditions and do not necessarily relate to decisions regarding the underlying business of our segments. We may experience realized investment gains (losses), which will affect future earnings levels since our underlying business is long-term in nature and we need to earn the assumed interest rates on the investments backing our liabilities for insurance products to maintain the profitability of our business.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Operating information by segment was as follows (dollars in millions):

	2007	2006		2005	
	-----	-----	-----	-----	-----
		(Restated)	As reported	(Restated)	As reported
Revenues:					
Bankers Life:					
Insurance policy income:					
Annuities.....	\$ 67.6	\$ 64.7	\$ 64.7	\$ 58.6	\$ 58.6
Supplemental health.....	1,456.4	1,240.7	1,240.7	1,203.7	1,203.7
Life.....	175.4	155.5	155.5	132.7	132.7
Other.....	80.6	84.6	84.6	10.7	10.7
Net investment income (a).....	572.3	525.6	525.6	448.0	448.0
Fee revenue and other income (a).....	12.0	6.0	6.0	1.1	1.1
	-----	-----	-----	-----	-----
Total Bankers Life revenues.....	2,364.3	2,077.1	2,077.1	1,854.8	1,854.8
	-----	-----	-----	-----	-----
Conseco Insurance Group:					
Insurance policy income:					
Annuities.....	14.3	16.0	16.0	18.6	18.6
Supplemental health.....	590.4	614.4	614.4	659.6	659.6
Life.....	335.3	353.4	353.4	372.7	372.7
Other.....	9.4	11.0	11.0	13.1	13.1
Net investment income (a).....	689.2	733.3	733.3	702.0	702.0
Fee revenue and other income (a).....	.6	1.0	1.0	1.9	1.9
	-----	-----	-----	-----	-----
Total Conseco Insurance Group revenues.....	1,639.2	1,729.1	1,729.1	1,767.9	1,767.9
	-----	-----	-----	-----	-----
Colonial Penn:					
Insurance policy income:					
Supplemental health.....	9.7	11.1	11.1	13.0	13.0
Life.....	115.0	99.7	99.7	86.8	86.8
Other.....	1.1	1.3	1.3	1.5	1.5
Net investment income (a).....	37.8	38.2	38.2	38.2	38.2
Fee revenue and other income (a).....	.7	.6	.6	.7	.7
	-----	-----	-----	-----	-----
Total Colonial Penn revenues.....	164.3	150.9	150.9	140.2	140.2
	-----	-----	-----	-----	-----
Other Business in Run-off:					
Insurance policy income - supplemental health...	312.1	336.6	336.6	359.1	359.1
Net investment income (a).....	193.9	179.5	179.5	177.6	177.6
Fee revenue and other income (a).....	.4	.4	.4	.5	.5
	-----	-----	-----	-----	-----
Total Other Business in Run-off revenues.....	506.4	516.5	516.5	537.2	537.2
	-----	-----	-----	-----	-----
Corporate operations:					
Net investment income (a).....	43.4	29.8	29.8	8.8	8.8
Fee and other income.....	10.1	11.2	11.2	20.5	20.5
	-----	-----	-----	-----	-----
Total corporate revenues.....	53.5	41.0	41.0	29.3	29.3
	-----	-----	-----	-----	-----
Total segment revenues.....	4,727.7	4,514.6	4,514.6	4,329.4	4,329.4
	-----	-----	-----	-----	-----

(continued on next page)

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

(continued from previous page)

	2007	2006		2005	
	-----	-----	-----	-----	-----
		(Restated)	As reported	(Restated)	As reported
Expenses:					
Bankers Life:					
Insurance policy benefits.....	1,684.7	1,410.6	1,437.0	1,305.2	1,294.2
Amortization.....	264.0	241.0	223.8	184.1	184.7
Interest expense on investment borrowings.....	-	.1	.1	1.3	1.3
Other operating costs and expenses.....	173.8	160.1	157.8	139.3	140.2
	-----	-----	-----	-----	-----
Total Bankers Life expenses.....	2,122.5	1,811.8	1,818.7	1,629.9	1,620.4
	-----	-----	-----	-----	-----
Conseco Insurance Group:					
Insurance policy benefits.....	1,057.9	1,077.1	1,077.7	1,098.9	1,065.6
Amortization.....	177.5	174.5	174.5	158.6	168.6
Interest expense on investment borrowings.....	17.6	.8	.8	4.9	4.9
Costs related to a litigation settlement.....	32.2	165.8	165.8	9.2	9.2
Loss related to an annuity coinsurance transaction.....	76.5	-	-	-	-
Other operating costs and expenses.....	283.5	278.3	278.3	262.9	262.9
	-----	-----	-----	-----	-----
Total Conseco Insurance Group expenses.....	1,645.2	1,696.5	1,697.1	1,534.5	1,511.2
	-----	-----	-----	-----	-----
Colonial Penn:					
Insurance policy benefits.....	102.2	96.4	96.4	89.7	89.7
Amortization.....	20.3	17.3	17.3	15.1	15.1
Interest expense on investment borrowings.....	-	-	-	.4	.4
Other operating costs and expenses.....	23.7	15.6	15.6	15.0	15.0
	-----	-----	-----	-----	-----
Total Colonial Penn expenses.....	146.2	129.3	129.3	120.2	120.2
	-----	-----	-----	-----	-----
Other Business in Run-off:					
Insurance policy benefits.....	588.9	448.9	457.3	336.2	351.1
Amortization.....	23.2	18.9	17.9	24.0	22.8
Other operating costs and expenses.....	80.2	83.2	83.2	86.1	86.1
	-----	-----	-----	-----	-----
Total Other Business in Run-off expenses.....	692.3	551.0	558.4	446.3	460.0
	-----	-----	-----	-----	-----
Corporate operations:					
Interest expense on corporate debt.....	72.3	52.9	52.9	48.1	48.1
Interest expense on variable interest entity.....	27.4	19.7	19.7	3.6	3.6
Costs related to a litigation settlement.....	32.2	8.9	8.9	9.1	9.1
Other operating costs and expenses.....	42.9	39.5	39.5	49.6	49.6
Loss on extinguishment of debt.....	-	.7	.7	3.7	3.7
	-----	-----	-----	-----	-----
Total corporate expenses.....	174.8	121.7	121.7	114.1	114.1
	-----	-----	-----	-----	-----
Total segment expenses.....	4,781.0	4,310.3	4,325.2	3,845.0	3,825.9
	-----	-----	-----	-----	-----
Income (loss) before net realized investment gains (losses), net of related amortization, and income taxes:					
Bankers Life.....	241.8	265.3	258.4	224.9	234.4
Conseco Insurance Group.....	(6.0)	32.6	32.0	233.4	256.7
Colonial Penn.....	18.1	21.6	21.6	20.0	20.0
Other Business in Run-off.....	(185.9)	(34.5)	(41.9)	90.9	77.2
Corporate operations.....	(121.3)	(80.7)	(80.7)	(84.8)	(84.8)
	-----	-----	-----	-----	-----
Segment income (loss) before net realized investment gains (losses), net of related amortization, and income taxes.....	\$ (53.3)	\$ 204.3	\$ 189.4	\$ 484.4	\$ 503.5
	=====	=====	=====	=====	=====

(a) It is not practicable to provide additional components of revenue by product or services.

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

A reconciliation of segment revenues and expenses to consolidated revenues and expenses is as follows (dollars in millions):

	2007	2006		2005	
	-----	(Restated)	As reported	(Restated)	As reported
Total segment revenues.....	\$4,727.7	\$4,514.6	\$4,514.6	\$4,329.4	\$4,329.4
Net realized investment gains (losses).....	(155.4)	(47.2)	(47.2)	(2.9)	(2.9)
	-----	-----	-----	-----	-----
Consolidated revenues.....	\$4,572.3	\$4,467.4	\$4,467.4	\$4,326.5	\$4,326.5
	=====	=====	=====	=====	=====
Total segment expenses.....	\$4,781.0	\$4,310.3	\$4,325.2	\$3,845.0	\$3,825.9
Amortization related to net realized investment gains (losses).....	(35.7)	(10.1)	(10.1)	(2.8)	(2.8)
	-----	-----	-----	-----	-----
Consolidated expenses.....	\$4,745.3	\$4,300.2	\$4,315.1	\$3,842.2	\$3,823.1
	=====	=====	=====	=====	=====

Segment balance sheet information was as follows (dollars in millions):

	2007	2006	
	-----	(Restated)	As reported
Assets:			
Bankers Life.....	\$12,705.7	\$11,867.4	\$11,880.1
Conseco Insurance Group.....	15,662.8	15,669.5	15,652.7
Colonial Penn.....	936.7	866.4	866.4
Other Business in Run-off.....	3,945.7	3,680.6	3,678.0
Corporate operations.....	263.9	640.1	640.1
	-----	-----	-----
Total assets.....	\$33,514.8	\$32,724.0	\$32,717.3
	=====	=====	=====
Liabilities:			
Bankers Life.....	\$11,079.3	\$10,204.6	\$10,222.6
Conseco Insurance Group.....	12,483.7	12,323.0	12,276.3
Colonial Penn.....	794.6	729.4	729.4
Other Business in Run-off.....	3,732.3	3,289.2	3,298.2
Corporate operations.....	1,189.0	1,477.7	1,477.7
	-----	-----	-----
Total liabilities.....	\$29,278.9	\$28,023.9	\$28,004.2
	=====	=====	=====

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

The following table presents selected financial information of our segments (dollars in millions):

Segment	Value of policies inforce at the		Insurance liabilities	Value of policies inforce at the		Insurance liabilities
	Effective Date	Cost of policies produced		Effective Date	Cost of policies produced	
2007						
Bankers Life.....	\$ 781.6	\$ 941.6	\$10,610.9			
Conseco Insurance Group.....	663.6	351.0	11,820.7			
Colonial Penn.....	119.4	130.4	709.7			
Other Business in Run-off.....	158.2	-	3,520.9			
	-----	-----	-----			
Total.....	\$1,722.8	\$1,423.0	\$26,662.2			
	=====	=====	=====			
		Restated			As reported	
		-----			-----	
2006						
Bankers Life.....	\$ 904.9	\$ 740.5	\$ 9,945.3	\$ 914.7	\$ 740.5	\$ 9,963.3
Conseco Insurance Group.....	979.9	277.3	11,944.1	979.9	277.3	11,897.4
Colonial Penn.....	71.7	88.9	714.1	71.7	88.9	714.1
Other Business in Run-off.....	180.0	-	3,389.5	170.9	-	3,398.5
	-----	-----	-----	-----	-----	-----
Total.....	\$2,136.5	\$1,106.7	\$25,993.0	\$2,137.2	\$1,106.7	\$25,973.3
	=====	=====	=====	=====	=====	=====

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

(b) The effects of the restatement adjustments on our results of operations for the first three quarters of 2007 are as follows:

Quarter ended March 31, 2007

	Adjustments				As restated
	As previously reported	Remediation procedures	Accounting for premium rate increases	Previously identified errors	
	(Dollars in millions, except per share data)				
Total revenues.....	\$1,114.5	\$ -	\$ -	\$ -	\$1,114.5
Benefits and expenses:					
Insurance policy benefits.....	801.3	19.6	(3.5)	-	817.4
Interest expense.....	23.6	-	-	-	23.6
Amortization.....	116.2	.6	.5	(.2)	117.1
Costs related to tentative litigation settlement.....	13.0	-	-	-	13.0
Other operating costs and expenses.....	144.2	-	-	-	144.2
Total benefits and expenses....	1,098.3	20.2	(3.0)	(.2)	1,115.3
Income (loss) before income taxes.....	16.2	(20.2)	3.0	.2	(.8)
Income tax expense (benefit).....	5.8	(7.3)	1.1	.1	(.3)
Net income (loss).....	\$ 10.4	\$(12.9)	\$ 1.9	\$.1	\$ (.5)
Net income (loss) per share - basic..	\$.01				\$(.07)
Net income (loss) per share - diluted	\$.01				\$(.07)

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Quarter ended June 30, 2007

	Adjustments			
As previously reported	Remediation procedures	Accounting for premium rate increases	As restated	
(Dollars in millions, except per share data)				
Total revenues.....	\$1,169.2	\$ -	\$ -	\$1,169.2
<hr style="border-top: 1px dashed black;"/>				
Benefits and expenses:				
Insurance policy benefits.....	930.9	(2.3)	(3.3)	925.3
Interest expense.....	27.9	-	-	27.9
Amortization.....	116.3	.6	(2.4)	114.5
Costs related to tentative litigation settlement.....	35.0	-	-	35.0
Other operating costs and expenses.....	151.8	-	-	151.8
<hr style="border-top: 1px dashed black;"/>				
Total benefits and expenses....	1,261.9	(1.7)	(5.7)	1,254.5
<hr style="border-top: 1px dashed black;"/>				
Income (loss) before income taxes.....	(92.7)	1.7	5.7	(85.3)
Income tax expense (benefit).....	(32.8)	.6	2.1	(30.1)
<hr style="border-top: 1px dashed black;"/>				
Net income (loss).....	\$ (59.9)	\$ 1.1	\$ 3.6	\$ (55.2)
<hr style="border-top: 1px dashed black;"/>				
Net loss per share - basic.....	\$ (.38)			\$ (.35)
<hr style="border-top: 1px dashed black;"/>				
Net loss per share - diluted.....	\$ (.38)			\$ (.35)
<hr style="border-top: 1px dashed black;"/>				

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Quarter ended September 30, 2007

	Adjustments				As restated
	As previously reported	Remediation procedures	Accounting for premium rate increases	Previously identified errors	
	(Dollars in millions, except per share data)				
Total revenues.....	\$1,175.2	\$ -	\$ -	\$(4.5)	\$1,170.7
Benefits and expenses:					
Insurance policy benefits.....	888.8	(1.5)	(1.5)	-	885.8
Interest expense.....	33.3	-	-	-	33.3
Amortization.....	93.3	.5	(1.7)	-	92.1
Costs related to tentative litigation settlement.....	16.4	-	-	-	16.4
Loss related to an annuity coinsurance transaction.....	76.5	-	-	-	76.5
Other operating costs and expenses.....	153.7	-	-	(1.8)	151.9
Total benefits and expenses....	1,262.0	(1.0)	(3.2)	(1.8)	1,256.0
Income (loss) before income taxes.....	(86.8)	1.0	3.2	(2.7)	(85.3)
Income tax expense (benefit).....	(33.1)	.4	1.2	(1.1)	(32.6)
Net income (loss).....	\$ (53.7)	\$.6	\$ 2.0	\$(1.6)	\$ (52.7)
Net loss per share - basic.....	\$ (.29)				\$ (.28)
Net loss per share - diluted.....	\$ (.29)				\$ (.28)

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

(b) The effects of the restatement adjustments on our 2006 quarterly results of operations are as follows:

Quarter ended March 31, 2006				

Adjustments				

	As previously reported	Remediation procedures	Previously identified errors	As restated

(Dollars in millions, except per share data)				
Total revenues.....	\$1,121.7	\$ -	\$ -	\$1,121.7

Benefits and expenses:				
Insurance policy benefits.....	726.8	3.3	3.7	733.8
Interest expense.....	16.4	-	-	16.4
Amortization.....	118.6	.4	.1	119.1
Costs related to tentative litigation settlement.....	17.7	-	-	17.7
Other operating costs and expenses.....	141.1	-	-	141.1

Total benefits and expense.....	1,020.6	3.7	3.8	1,028.1

Income (loss) before income taxes.....	101.1	(3.7)	(3.8)	93.6
Income tax expense (benefit).....	36.5	(1.3)	(1.4)	33.8

Net income (loss).....	\$ 64.6	\$(2.4)	\$ (2.4)	\$ 59.8
=====				
Net income per share - basic.....	\$.36			\$.33
=====				
Net income per share - dilute.....	\$.35			\$.33
=====				

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Quarter ended June 30, 2006

	Adjustments			
As previously reported	Remediation procedures	Previously identified errors	As restated	
(Dollars in millions, except per share data)				
Total revenues.....	\$1,084.1	\$ -	\$ -	\$1,084.1
Benefits and expenses:				
Insurance policy benefits.....	705.2	.5	(5.6)	700.1
Interest expense.....	17.1	-	-	17.1
Amortization.....	97.6	.4	(.1)	97.9
Costs related to tentative litigation settlement.....	157.0	-	-	157.0
Other operating costs and expenses.....	142.1	-	2.3	144.4
Total benefits and expense.....	1,119.0	.9	(3.4)	1,116.5
Income (loss) before income taxes.....	(34.9)	(.9)	3.4	(32.4)
Income tax expense (benefit).....	(12.6)	(.3)	1.2	(11.7)
Net income (loss).....	\$ (22.3)	\$ (.6)	\$ 2.2	\$ (20.7)
Net loss per share - basic.....	\$ (.21)			\$ (.20)
Net loss per share - diluted.....	\$ (.21)			\$ (.20)

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Quarter ended September 30, 2006

	Adjustments				As restated
	As previously reported	Remediation procedures	Accounting for premium rate increases	Previously identified errors	
		(Dollars in millions, except per share data)			
Total revenues.....	\$1,118.3	\$ -	\$ -	\$ -	\$1,118.3
Benefits and expenses:					
Insurance policy benefits.....	772.6	.3	(22.7)	2.3	752.5
Interest expense.....	17.8	-	-	-	17.8
Amortization.....	104.2	.3	14.4	.1	119.0
Other operating costs and expenses.....	147.0	-	-	-	147.0
Total benefits and expenses....	1,041.6	.6	(8.3)	2.4	1,036.3
Income (loss) before income taxes.....	76.7	(.6)	8.3	(2.4)	82.0
Income tax expense (benefit).....	28.3	(.2)	3.0	(.8)	30.3
Net income (loss).....	\$ 48.4 =====	\$ (.4) =====	\$ 5.3 =====	\$ (1.6) =====	\$ 51.7 =====
Net income per share - basic.....	\$.26 =====				\$.28 =====
Net income per share - diluted.....	\$.26 =====				\$.28 =====

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

Quarter ended December 31, 2006

	Adjustments				As restated
	As previously reported	Remediation procedures	Accounting for premium rate increases	Previously identified errors	
	(Dollars in millions, except per share data)				
Total revenues.....	\$1,143.3	\$ -	\$ -	\$ -	\$1,143.3
Benefits and expenses:					
Insurance policy benefits.....	863.8	(9.6)	(7.9)	.3	846.6
Interest expense.....	22.2	-	-	-	22.2
Amortization.....	103.0	.4	2.1	.1	105.6
Loss on extinguishment of debt....	.7	-	-	-	.7
Other operating costs and expenses.....	144.2	-	-	-	144.2
Total benefits and expenses....	1,133.9	(9.2)	(5.8)	.4	1,119.3
Income (loss) before income taxes.....	9.4	9.2	5.8	(.4)	24.0
Income tax expense (benefit).....	3.6	3.3	2.1	(.2)	8.8
Net income (loss).....	\$ 5.8	\$ 5.9	\$ 3.7	\$ (.2)	\$ 15.2
Net income (loss) per share - basic..	\$ (.02)				\$.04
Net income (loss) per share - diluted	\$ (.02)				\$.04

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

17. INVESTMENT IN A VARIABLE INTEREST ENTITY

The Company has an investment in a special purpose entity, that is a variable interest entity under Financial Accounting Standards Board Interpretation No. 46 "Consolidation of Variable Interest Entities, revised December 2003" ("FIN 46R"). The following is description of our significant investment in a variable interest entity:

Fall Creek CLO Ltd.

Fall Creek CLO Ltd. ("Fall Creek") is a collateralized loan trust that was established to issue securities and use the proceeds to invest in loans and other permitted investments. The assets held by the trust are legally isolated and are not available to the Company. The liabilities of Fall Creek will be satisfied from the cash flows generated by the underlying loans, not from the assets of the Company. Repayment of the principal balance of the investment borrowings of Fall Creek begin in 2012 based on available cash flows from the assets and such borrowings mature in 2017. The carrying value of our investment in Fall Creek was \$47.0 million and \$48.8 million at December 31, 2007 and 2006, respectively. The following tables provide supplemental information about the assets, liabilities, revenues and expenses of Fall Creek which have been consolidated in accordance with FIN 46R, after giving effect to the elimination of our investment in Fall Creek and investment management fees earned by a subsidiary of the Company (dollars in millions):

	December 31,	
	2007	2006
	-----	-----
Assets:		
Actively managed fixed maturities.....	\$465.9	\$454.5
Cash and cash equivalents - restricted.....	16.1	15.7
Accrued investment income.....	5.1	3.9
Other assets.....	6.9	7.5
	-----	-----
Total assets.....	\$494.0	\$481.6
	=====	=====
Liabilities:		
Other liabilities.....	\$ 12.2	\$ 26.8
Investment borrowings due to others.....	447.2	401.7
Investment borrowings due to the Company.....	47.0	47.0
	-----	-----
Total liabilities.....	506.4	475.5
	-----	-----
Equity (deficit):		
Capital provided by the Company.....	1.6	1.8
Capital provided by others.....	4.1	4.7
Accumulated other comprehensive loss.....	(25.0)	(2.1)
Retained earnings.....	6.9	1.7
	-----	-----
Total equity (deficit).....	(12.4)	6.1
	-----	-----
Total liabilities and equity (deficit).....	\$494.0	\$481.6
	=====	=====

CONSECO, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements

	Years ended December 31,		
	2007	2006	2005
Revenues:			
Net investment income.....	\$36.8	\$25.2	\$3.4
Fee revenue and other income.....	.3	.3	.5
	-----	-----	-----
Total revenues.....	37.1	25.5	3.9
	-----	-----	-----
Expenses:			
Interest expense.....	27.4	19.7	3.5
Other operating expenses.....	.5	.9	.3
	-----	-----	-----
Total expenses.....	27.9	20.6	3.8
	-----	-----	-----
Income before net realized investment losses and income taxes.....	9.2	4.9	.1
Net realized investment losses.....	(.4)	(.3)	(.1)
	-----	-----	-----
Income before income taxes.....	\$ 8.8	\$ 4.6	\$ -
	=====	=====	=====

The investment borrowings of Fall Creek would become due and payable if certain threshold ratios (based on the entity's leverage and the market value of its assets) are not met for a specified period of time. During the first quarter of 2008, such threshold ratio would not have been met and was amended, following the sale of assets of \$90 million (which resulted in net realized investment losses of approximately \$10 million), the pay down of investment borrowings of \$83.5 million and our commitment to provide additional capital to Fall Creek for up to \$25 million (under defined circumstances), \$5 million of which was contributed through March 27, 2008.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures. Consecos management, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of Consecos disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures.

During the evaluation of disclosure controls and procedures as of December 31, 2006 conducted during the preparation of Consecos financial statements to be included in the Annual Report on Form 10-K for the year ended December 31, 2006, a material weakness in internal control was identified relating to the actuarial reporting process and the design of controls to ensure the completeness and accuracy of certain inforce policies. As a result, Consecos Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2006, Consecos disclosure controls and procedures were not effective.

Under the direction of its Chief Financial Officer, Consecos implemented plans in an effort to remediate the material control weakness during 2007. The status of the remediation efforts has been regularly reviewed with management and the Company's Audit and Enterprise Risk Committee of the Board of Directors. This committee was advised of issues encountered and key decisions reached by management relating to the remediation efforts.

On February 25, 2008, Consecos announced that it had identified certain errors in its previously filed financial statements, the majority of which were identified during procedures performed in an effort to remediate the material weakness in internal control over financial reporting described above. Due to the significance of these errors, Consecos has restated its financial statements for the years ended December 31, 2006 and 2005, along with affected Selected Consolidated Financial Data for 2004 and 2003, and quarterly financial information for 2006 and the first three quarters of 2007.

As of December 31, 2007, the material weakness relating to the actuarial reporting process continued to exist. As a result, the Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2007, Consecos disclosure controls and procedures were not effective.

Management's Report on Internal Control over Financial Reporting. Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Consecos management assessed the effectiveness of the Company's internal control over financial reporting as of December 31, 2007. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework. Based on this assessment, management concluded that the Company's internal control over financial reporting was not effective at December 31, 2007.

A material weakness is a deficiency, or a combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements would not be prevented or detected on a timely basis. Consecos management has concluded that, as of December 31, 2007, the following material weakness relating to the controls over the actuarial reporting process existed:

Consecos did not maintain effective controls over the accounting and disclosure of insurance policy benefits, amortization expense, the liabilities for insurance products and the value of policies inforce at the Effective Date. Specifically, controls over the actuarial reporting process related to the design of controls to ensure the completeness and

accuracy of certain inforce policies in our Bankers Life segment, Conseco Insurance Group segment and Other Business in Run-off segment were not effective. These control deficiencies resulted in the misstatement of our insurance policy benefits, amortization expense, the liabilities for insurance products and the value of policies inforce at the Effective Date and related disclosures in the consolidated financial statements, and in the restatement of our consolidated financial statements for 2006 and 2005, each of the quarters of 2006 and the first three quarters of 2007. Additionally, these control deficiencies could result in the misstatement of the aforementioned accounts and disclosures that would result in a material misstatement in our annual or interim consolidated financial statements that would not be prevented or detected. Accordingly, our management has determined that these control deficiencies constitute a material weakness.

The effectiveness of our internal control over financial reporting as of December 31, 2007, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included herein.

Remediation Efforts. Conseco has devoted significant efforts and resources towards remediation of the material weakness relating to the actuarial reporting process. Nonetheless, the material weakness continued to exist as of December 31, 2007. Conseco's management continues to assign the highest priority to Conseco's remediation efforts, with the goal of remediating the material weakness by the end of 2008. However, due to the nature of the remediation process and the need to allow adequate time after implementation to evaluate and test the effectiveness of the revised controls, no assurance can be given as to the timing of achievement of remediation. Conseco recognizes that further improvement in its internal control over the actuarial reporting process is essential. Over time, Conseco intends to reduce its reliance on manual controls and procedures. As part of its remediation efforts, Conseco intends to develop improved systems and processes which will allow it to rely on front-end preventative controls which will be more sustainable over the long term. Conseco recognizes that further investment is needed to improve the actuarial reporting systems and processes and is committed to making the investments for these improvements.

Changes to Internal Control Over Financial Reporting. There were the following changes in the Company's internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) during the quarter ended December 31, 2007, that have materially affected, or are reasonably likely to materially affect, Conseco's internal control over financial reporting. We have implemented several initiatives to streamline our administrative procedures and improve our actuarial valuation systems at our insurance subsidiaries. Our efforts included improvements to our policy administrative procedures.

ITEM 9B. OTHER INFORMATION.

None.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

We will provide information that is responsive to this Item 10 in our definitive proxy statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated by reference into this Item 10. Additional information called for by this item is contained in Part I of this Annual Report under the caption "Executive Officers of the Registrant."

ITEM 11. EXECUTIVE COMPENSATION.

We will provide information that is responsive to this Item 11 in our definitive proxy statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated by reference into this Item 11.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

We will provide information that is responsive to this Item 12 in our definitive proxy statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated by reference into this item 12.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

We will provide information that is responsive to this Item 13 in our definitive proxy statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated by reference into this Item 13.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

We will provide information that is responsive to this Item 14 in our definitive proxy statement or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report. That information is incorporated by reference into this Item 14.

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

(a) 1. Financial Statements. See Index to Consolidated Financial Statements on page 99 for a list of financial statements included in this Report.

2. Financial Statement Schedules. The following financial statement schedules are included as part of this Report immediately following the signature page:

Schedule II -- Condensed Financial Information of Registrant (Parent Company)

Schedule IV -- Reinsurance

All other schedules are omitted, either because they are not applicable, not required, or because the information they contain is included elsewhere in the consolidated financial statements or notes.

3. Exhibits. See Exhibit Index immediately preceding the Exhibits filed with this report.

SIGNATURES

Pursuant to the requirements of Section 13 of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, this 28th day of March, 2008.

CONSECO, INC.

By: /s/ C. James Prieur

C. James Prieur
Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

Signature -----	Title (Capacity) -----	Date -----
/s / C. JAMES PRIEUR ----- C. James Prieur	Director and Chief Executive Officer (Principal Executive Officer)	March 28, 2008
/s / EDWARD J. BONACH ----- Edward J. Bonach	Executive Vice President and Chief Financial Officer (Principal Financial Officer)	March 28, 2008
/s / JOHN R. KLINE ----- John R. Kline	Senior Vice President and Chief Accounting Officer (Principal Accounting Officer)	March 28, 2008
/s / R. GLENN HILLIARD ----- R. Glenn Hilliard	Director	March 28, 2008
/s / NEAL SCHNEIDER ----- Neal Schneider	Director	March 28, 2008
/s / PHILIP R. ROBERTS ----- Philip R. Roberts	Director	March 28, 2008
/s / JOHN G. TURNER ----- John G. Turner	Director	March 28, 2008
/s / MICHAEL T. TOKARZ ----- Michael T. Tokarz	Director	March 28, 2008
/s / MICHAEL S. SHANNON ----- Michael S. Shannon	Director	March 28, 2008
/s / DEBRA J. PERRY ----- Debra J. Perry	Director	March 28, 2008
/s / DONNA A. JAMES ----- Donna A. James	Director	March 28, 2008
/s / DOREEN A. WRIGHT ----- Doreen A. Wright	Director	March 28, 2008

Report of Independent Registered Public Accounting Firm
on Financial Statement Schedules

To the Shareholders and Board of Directors Conseco, Inc.:

Our audits of the consolidated financial statements, of management's assessment of the effectiveness of internal control over financial reporting and of the effectiveness of internal control over financial reporting of Conseco, Inc. and subsidiaries referred to in our report dated March 28, 2008 appearing under Item 8 of this Form 10-K also included an audit of the financial statement schedules at December 31, 2007 and 2006 and for the years ended December 31, 2007, 2006 and 2005 listed in Item 15(a)(2) of this Form 10-K. In our opinion, these financial statement schedules present fairly, in all material respects, the information set forth therein when read in conjunction with the related consolidated financial statements.

As discussed in Note 2 to the consolidated financial statements, the Company has restated its 2006 and 2005 consolidated financial schedules.

/s/ PricewaterhouseCoopers LLP

Indianapolis, Indiana
March 28, 2008

CONSECO, INC. AND SUBSIDIARIES

SCHEDULE II

Condensed Financial Information of Registrant (Parent Company) Balance Sheet as of December 31, 2007 and 2006

(Dollars in millions)

ASSETS

	2007	2006
	----	----
		(Restated)
Cash and cash equivalents:		
Unrestricted.....	\$ 84.3	\$ 95.8
Restricted.....	1.9	.1
Other invested assets.....	.2	.2
Investment in wholly-owned subsidiaries (eliminated in consolidation).....	5,596.9	5,798.6
Receivable from subsidiaries (eliminated in consolidation).....	6.6	68.9
Income tax assets, net.....	2.2	59.1
Other assets.....	36.4	45.0
	-----	-----
Total assets.....	\$5,728.5	\$6,067.7
	=====	=====

LIABILITIES AND SHAREHOLDERS' EQUITY

Liabilities:		
Notes payable.....	\$1,193.7	\$1,000.8
Payable to subsidiaries (eliminated in consolidation).....	241.5	295.4
Other liabilities.....	57.4	71.4
	-----	-----
Total liabilities.....	1,492.6	1,367.6
	-----	-----
Commitments and Contingencies		
Shareholders' equity:		
Preferred stock.....	-	667.8
Common stock and additional paid-in capital (\$.01 par value, 8,000,000,000 shares authorized, shares issued and outstanding: 2007 - 184,652,017; 2006 - 152,165,108)	4,070.5	3,469.5
Accumulated other comprehensive loss.....	(273.3)	(72.6)
Retained earnings.....	438.7	635.4
	-----	-----
Total shareholders' equity.....	4,235.9	4,700.1
	-----	-----
Total liabilities and shareholders' equity.....	\$5,728.5	\$6,067.7
	=====	=====

The accompanying notes are an integral part of the condensed financial information.

CONSECO, INC. AND SUBSIDIARIES
SCHEDULE II

Condensed Financial Information of Registrant (Parent Company) Statement of Operations for the years ended December 31, 2007, 2006 and 2005

(Dollars in millions)

	2007 ----	2006 ---- (Restated)	2005 ---- (Restated)
Revenues:			
Net investment income.....	\$ 3.6	\$ 1.9	\$ 3.7
Fee and interest income from subsidiaries (eliminated in consolidation).....	3.1	.7	-
	-----	-----	-----
Total revenues.....	6.7	2.6	3.7
	-----	-----	-----
Expenses:			
Interest expense on notes payable.....	72.3	52.9	48.1
Intercompany expenses (eliminated in consolidation).....	15.8	15.2	8.7
Costs related to a litigation settlement.....	32.2	8.9	9.1
Operating costs and expenses.....	41.2	35.6	39.8
Loss on extinguishment of debt.....	-	.7	3.7
	-----	-----	-----
Total expenses.....	161.5	113.3	109.4
	-----	-----	-----
Loss before income taxes and equity in undistributed earnings of subsidiaries.....	(154.8)	(110.7)	(105.7)
Income tax benefit on period income.....	(62.1)	(41.7)	(40.1)
	-----	-----	-----
Loss before equity in undistributed earnings of subsidiaries.....	(92.7)	(69.0)	(65.6)
Equity in undistributed earnings of subsidiaries (eliminated in consolidation).....	(87.2)	175.0	378.3
	-----	-----	-----
Net income (loss).....	(179.9)	106.0	312.7
Preferred stock dividends.....	14.1	38.0	38.0
	-----	-----	-----
Income (loss) applicable to common stock.....	\$(194.0)	\$ 68.0	\$ 274.7
	=====	=====	=====

The accompanying notes are an integral part of the condensed financial information.

CONSECO, INC. AND SUBSIDIARIES
SCHEDULE II

Condensed Financial Information of Registrant (Parent Company)

Statement of Cash Flows

for the years ended December 31, 2007, 2006 and 2005

(Dollars in millions)

	2007	2006	2005
	----	----	----
Cash flows used by operating activities.....	\$(126.6)	\$ (39.4)	\$ (92.8)
	-----	-----	-----
Cash flows from investing activities:			
Investments and advances to consolidated subsidiaries*.....	(86.0)	.4	(80.1)
Change in restricted cash.....	(1.8)	1.9	1.9
	-----	-----	-----
Net cash used by investing activities.....	(87.8)	2.3	(78.2)
	-----	-----	-----
Cash flows from financing activities:			
Issuance of notes payable, net.....	200.0	196.7	853.7
Issuance of common stock.....	3.4	1.0	.5
Payments to repurchase common stock.....	(87.2)	-	-
Payments on notes payable.....	(7.8)	(48.0)	(770.4)
Issuance of notes payable to affiliates*.....	223.8	324.9	250.3
Payments on notes payable to affiliates*.....	(110.3)	(393.1)	(63.5)
Dividends paid on preferred stock.....	(19.0)	(38.0)	(38.0)
	-----	-----	-----
Net cash provided by financing activities.....	202.9	43.5	232.6
	-----	-----	-----
Net increase (decrease) in cash and cash equivalents.....	(11.5)	6.4	61.6
Cash and cash equivalents, beginning of the year.....	95.8	89.4	27.8
	-----	-----	-----
Cash and cash equivalents, end of the year.....	\$ 84.3	\$ 95.8	\$ 89.4
	=====	=====	=====

* Eliminated in consolidation

The accompanying notes are an integral part of the condensed financial information.

**CONSECO, INC. AND SUBSIDIARIES
SCHEDULE II**

Notes to Condensed Financial Information

1. Basis of Presentation

The condensed financial information should be read in conjunction with the consolidated financial statements of Conseco, Inc. The condensed financial information includes the accounts and activity of the parent company. Refer to the note to the consolidated financial statements entitled "Restatement of Previously Issued Financial Statements" for further information related to the restatement.

CONSECO, INC. AND SUBSIDIARIES

SCHEDULE IV

Reinsurance

for the years ended December 31, 2007, 2006 and 2005

(Dollars in millions)

	2007 ----	2006 ----	2005 ----
Life insurance inforce:			
Direct.....	\$ 67,831.1	\$ 69,674.2	\$ 71,682.6
Assumed.....	873.5	860.5	839.4
Ceded.....	(14,717.2)	(16,583.4)	(17,989.3)
	-----	-----	-----
Net insurance inforce.....	\$ 53,987.4	\$ 53,951.3	\$ 54,532.7
	=====	=====	=====
Percentage of assumed to net	1.6%	1.6%	1.5%
	===	===	===
	2007 ----	2006 ----	2005 ----
Insurance policy income:			
Direct.....	\$2,706.7	\$2,722.4	\$2,742.9
Assumed.....	322.7	130.3	60.1
Ceded.....	(206.5)	(213.3)	(232.2)
	-----	-----	-----
Net premiums.....	\$2,822.9	\$2,639.4	\$2,570.8
	=====	=====	=====
Percentage of assumed to net.....	11.4%	4.9%	2.3%
	====	===	===

EXHIBIT INDEX

Exhibit No. ---	Description -----
2.1	Sixth Amended Joint Plan of Reorganization of Conseco, Inc. and affiliated Debtors, incorporated by reference to Exhibit 2.2 of our Current Report on Form 8-K filed September 15, 2003.
2.2	Order Confirming Reorganizing Debtors' Sixth Amended Joint Plan of Reorganization, incorporated by reference to Exhibit 2.3 of our Current Report on Form 8-K filed September 15, 2003.
3.1	Amended and Restated Certificate of Incorporation of Conseco, Inc., incorporated by reference to Exhibit 3.1 of our Current Report on Form 8-K filed September 15, 2003.
3.2	Amended and Restated Bylaws of Conseco, Inc. dated as of April 23, 2007, incorporated by reference to Exhibit 3.2 of our Current Report on Form 8-K filed April 27, 2007.
4.2	Series A Warrant Agreement between Conseco, Inc. and Wachovia Bank, N.A., as Warrant Agent, incorporated by reference to Exhibit 4.2 of our Current Report on Form 8-K filed September 15, 2003.
4.4	Indenture dated as of August 15, 2005 for 3.50% Convertible Debentures due September 30, 2035 between Conseco, Inc. and The Bank of New York Trust Company, N.A., as Trustee, incorporated by reference to Exhibit 4.4 of our Current Report on Form 8-K filed August 16, 2005.
4.5	Registration Rights Agreement dated as of August 15, 2005 among Conseco, Inc. and Goldman, Sachs & Co., Morgan Stanley & Co. Incorporated and J.P. Morgan Securities, Inc., as representatives of the several purchasers of the 3.50% Convertible Debentures due September 30, 2035, incorporated by reference to Exhibit 4.5 of our Current Report on Form 8-K filed August 16, 2005.
10.1	Second Amended and Restated Credit Agreement dated as of October 10, 2006 among Conseco, Inc., Bank of America, N.A., as Agent, J.P. Morgan Chase Bank, N.A., as Syndication Agent, and other parties, incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed October 11, 2006 and Amendment No. 1 thereto dated as of June 12, 2007, incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed June 15, 2007.
10.4	Guarantee and Security Agreement dated as of June 22, 2004 among Conseco, Inc., the Subsidiary Guarantors Party Thereto and Bank of America, N.A., as Agent, incorporated by reference to Exhibit 10.4 of our Current Report on Form 8-K filed June 23, 2004.
10.10	Employment Agreement dated as of September 10, 2003 between Conseco, Inc. and Eugene M. Bullis, incorporated by reference to Exhibit 10.9 of our Registration Statement on Form S-1 filed January 29, 2004 (No. 333-112312), as amended by Amendment to Employment Agreement dated June 13, 2006 between Conseco, Inc. and Eugene M. Bullis, incorporated by reference to Exhibit 10.10.1 of our Current Report on Form 8-K filed June 19, 2006.
10.11	Letter of agreement dated as of August 3, 2007 between Conseco Services, LLC and John R. Kline, incorporated by reference to Exhibit 10.11 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007.
10.12	Amended and Restated Employment Agreement dated as of October 6, 2006 between 40 86 Advisors, Inc. and Eric R. Johnson, incorporated by reference to Exhibit 10.12 of our Current Report on Form 8-K filed October 12, 2006, as amended by Amendment dated as of September 25, 2007, incorporated by reference to Exhibit 10.12 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007.

- 10.13 Conseco, Inc. 2003 Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit A of our Proxy Statement filed on July 26, 2005.
- 10.14 Form of executive stock option agreement under Conseco, Inc. 2003 Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.14 of our Annual Report on Form 10-K for the year ended December 31, 2005.
- 10.15 Form of executive restricted stock agreement under Conseco, Inc. 2003 Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.15 of our Annual Report on Form 10-K for the year ended December 31, 2004.
- 10.16 Form of Indemnification Agreement among Conseco, Inc., CDOC, Inc., Conseco Services, LLC and each director of Conseco, Inc., incorporated by reference to Exhibit 10.14 of Amendment No. 3 to our Registration Statement on Form S-1 (No. 333-112312).
- 10.18 Closing Agreement on Final Determination Covering Specific Matters, incorporated by reference to Exhibit 10.14 of our Current Report on Form 8-K filed September 14, 2004.
- 10.20 Conseco, Inc. Pay for Performance Incentive Plan, incorporated by reference to Exhibit 10.20 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2005.
- 10.21 Closing Agreement on Final Determination Covering Specific Matters, incorporated by reference to Exhibit 10.21 of our Current Report on Form 8-K filed August 1, 2006.
- 10.22 Form of performance unit award agreement under the Conseco, Inc. 2003 Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.22 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2006.
- 10.23 Employment Agreement dated as of August 9, 2006 between Conseco, Inc. and C. James Prieur, incorporated by reference to Exhibit 10.23 of our Current Report on Form 8-K filed August 9, 2006.
- 10.24 Conseco Inc. Deferred Compensation Plan effective January 1, 2007, incorporated by reference to Exhibit 10.24 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2006, as amended by First Amendment of the Conseco Deferred Compensation Plan, effective January 1, 2007.
- 10.25 Amended and Restated Employment Agreement dated as of August 17, 2007 between Conseco Services, LLC and Susan L. Menzel, incorporated by reference to Exhibit 10.25 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007.
- 10.26 Amended and Restated Employment Agreement dated as of February 27, 2008 between Conseco Services, LLC and Russell M. Bostick.
- 10.27 Employment Agreement dated as of September 8, 2005 between Conseco Services, LLC and Christopher J. Nickele, incorporated by reference to Exhibit 10.27 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2006.
- 10.28 Employment Agreement dated as of October 1, 2004 between Conseco Services, LLC and Scott R. Perry, incorporated by reference to Exhibit 10.28 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2006.
- 10.30 Employment Agreement dated as of November 6, 2006 between Conseco Services, LLC and Michael J. Dubes, incorporated by reference to Exhibit 10.30 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2006.

- 10.31 Stipulation of Settlement - In Re Conseco Life Insurance Co. Cost of Insurance Litigation, Cause No. MDL 1610 (Central District, California), incorporated by reference to Exhibit 10.31 of our Annual Report on Form 10-K for the year ended December 31, 2006.
- 10.32 Employment Agreement dated as of April 23, 2007 between Conseco, Inc. and Edward J. Bonach, incorporated by reference to Exhibit 10.32 of our Current Report on Form 8-K filed April 27, 2007.
- 10.33 Employment Agreement dated as of May 8, 2007 between Conseco Services, LLC and Mark E. Alberts incorporated by reference to Exhibit 10.33 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007.
- 10.34 Coinsurance and Administration Agreement between Conseco Insurance Company and Reassure American Life Insurance Company, incorporated by reference to Exhibit 10.34 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007.
- 10.35 Employment Agreement effective as of December 10, 2007 between Conseco Services, LLC and Dan R. Bardin.
- 10.36 Employment Agreement dated as of July 13, 2005 between Conseco Services, LLC and Steven M. Stecher.
- 12.1 Computation of Ratio of Earnings to Fixed Charges and Preferred Dividends.
- 21 Subsidiaries of the Registrant.
- 23.1 Consent of PricewaterhouseCoopers LLP.
- 31.1 Certification Pursuant to the Securities Exchange Act Rule 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification Pursuant to the Securities Exchange Act Rule 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

COMPENSATION PLANS AND ARRANGEMENTS

- 10.10 Employment Agreement dated as of September 10, 2003 between Conseco, Inc. and Eugene M. Bullis, incorporated by reference to Exhibit 10.9 of our Registration Statement on Form S-1 filed January 29, 2004 (No. 333-112312), as amended by Amendment to Employment Agreement dated June 13, 2006 between Conseco, Inc. and Eugene M. Bullis incorporated by reference to Exhibit 10.10.1 of our Current Report on Form 8-K filed June 19, 2006.
- 10.11 Letter of agreement dated as of August 3, 2007 between Conseco Services, LLC and John R. Kline, incorporated by reference to Exhibit 10.11 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007.
- 10.12 Amended and Restated Employment Agreement dated as of October 6, 2006 between 40|86 Advisors, Inc. and Eric R. Johnson, incorporated by reference to Exhibit 10.12 of our Current Report on Form 8-K filed October 12, 2006, as amended by Amendment dated as of September 25, 2007, incorporated by reference to Exhibit 10.12 of our quarterly Report on Form 10-Q for the quarter ended September 30, 2007.

- 10.13 Conseco, Inc. 2003 Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit A of our Proxy Statement filed on July 26, 2005.
- 10.14 Form of executive stock option agreement under Conseco, Inc. 2003 Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.14 of our Annual Report on Form 10-K for the year ended December 31, 2005.
- 10.15 Form of executive restricted stock agreement under Conseco, Inc. 2003 Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.15 of our Annual Report on Form 10-K for the year ended December 31, 2004.
- 10.20 Conseco, Inc. Pay for Performance Incentive Plan, incorporated by reference to Exhibit 10.20 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2005.
- 10.22 Form of performance unit award agreement under the Conseco, Inc. 2003 Amended and Restated Long-Term Incentive Plan, incorporated by reference to Exhibit 10.22 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2006.
- 10.23 Employment Agreement dated as of August 9, 2006 between Conseco, Inc. and C. James Prieur, incorporated by reference to Exhibit 10.23 of our Current Report on Form 8-K filed August 9, 2006.
- 10.24 Conseco Inc. Deferred Compensation Plan effective January 1, 2007, incorporated by reference to Exhibit 10.24 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2006, as amended by First Amendment of the Conseco Deferred Compensation Plan, effective January 1, 2007.
- 10.25 Amended and Restated Employment Agreement dated as of August 17, 2007 between Conseco Services, LLC and Susan L. Menzel, incorporated by reference to Exhibit 10.25 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007.
- 10.26 Amended and Restated Employment Agreement dated as of February 27, 2008 between Conseco Services, LLC and Russell M. Bostick.
- 10.27 Employment Agreement dated as of September 8, 2005 between Conseco Services, LLC and Christopher J. Nickele, incorporated by reference to Exhibit 10.27 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2006.
- 10.28 Employment Agreement dated as of October 1, 2004 between Conseco Services, LLC and Scott R. Perry, incorporated by reference to Exhibit 10.28 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2006.
- 10.30 Employment Agreement dated as of November 6, 2006 between Conseco Services, LLC and Michael J. Dubes, incorporated by reference to Exhibit 10.30 of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2006.
- 10.32 Employment Agreement dated as of April 23, 2007 between Conseco, Inc. and Edward J. Bonach, incorporated by reference to Exhibit 10.32 of our Current Report on Form 8-K filed April 27, 2007.
- 10.33 Employment Agreement dated as of May 8, 2007 between Conseco Services, LLC and Mark E. Alberts, incorporated by reference to Exhibit 10.33 of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007.

- 10.35 Employment Agreement effective December 10, 2007 between Conseco Services, LLC and Dan R. Bardin.
- 10.36 Employment Agreement dated as of July 13, 2005 between Conseco Services, LLC and Steven M. Stecher.

**FIRST AMENDMENT
OF THE
CONSECO DEFERRED COMPENATION PLAN**
(Effective as of January 1, 2007)

WHEREAS, Conseco Services, LLC (the "Company") maintains the Conseco Deferred Compensation Plan (Effective as of January 1, 2007) (the "Plan"); and

WHEREAS, the Company desires to amend to the Plan to permit designated Plan participants to schedule distribution dates for Company contributions made to the Plan on their behalf;

NOW, THEREFORE, pursuant to the power reserved to the Company under Section 12.2 of the Plan and delegated to the undersigned officer of the Company, the Plan is hereby amended, effective as of January 1, 2007, in the following particulars:

1. By deleting the period at the end of subsection 1.8(e) and inserting the following:

"; or"

2. By adding a new subsection 1.8(f) to read as follows:

"(f) A Scheduled Distribution."

3. By replacing Section 4.1 in its entirety with the following:

"4.1 Scheduled Distribution. In connection with each election to defer an Annual Deferral Amount, a Participant may irrevocably elect to receive a Scheduled Distribution, in the form of a lump sum payment, from the Plan with respect to all or a portion of the Annual Deferral Amount. In addition, a Participant may elect a Scheduled Distribution for a Company Contribution Amount or a Supplemental Contribution Amount or both (as permitted by the Committee in its sole discretion), provided that the election is delivered to the Committee either (i) within thirty (30) days of the Participant's commencement date and accepted by the Committee, or (ii) by the December 31st preceding the Plan Year in which the Company Contribution Amount or Supplemental Contribution Amount or both are deposited in the Participant's Annual Account, or before such other deadline established by the Committee in accordance with the requirements of Code Section 409A and related Treasury guidance or Regulations.

The Scheduled Distribution shall be a lump sum payment in an amount that is equal to the portion of the Annual Deferral Amount and/or Company Contribution Amount or Supplemental Contribution Amount the Participant elected to have distributed as a Scheduled Distribution, plus amounts credited or debited in the manner provided in Section 3.9

above

on that amount, calculated as of the close of business on or as soon as reasonably practicable following the date on which the Scheduled Distribution becomes payable. Subject to the other terms and conditions of this Plan, each Scheduled Distribution elected shall be paid out during a sixty (60) day period commencing immediately after the first day of the Plan Year designated by the Participant (the "Scheduled Distribution Date"). The Plan Year designated by the Participant must be at least three (3) Plan Years after the end of the Plan Year to which the Participant's deferral election described in Section 3.3 relates, unless otherwise provided on an Election Form approved by the Committee in its sole discretion. By way of example, if a Scheduled Distribution is elected for Annual Deferral Amounts, Company Contribution Amounts and/or Supplemental Contribution Amounts that are earned in the Plan Year commencing January 1, 2007, the earliest Scheduled Distribution Date that may be designated by a Participant would be January 1, 2011, and the Scheduled Distribution would become payable during the sixty (60) day period commencing immediately after such Scheduled Distribution Date."

4. By adding the words ", Company Contribution Amount or Supplemental Contribution Amount or both" after the words "Annual Deferral Amount" in the first sentence of Section 4.3.

IN WITNESS WHEREOF, the Company has caused this amendment to be executed on its behalf by the undersigned officer this 4th day of March, 2008, but effective as of January 1, 2007.

CONSECO SERVICES, LLC

/s/ Edward J. Bonach

Edward J. Bonach, President

ATTEST:

/s/ Karl W. Kindig

Karl W. Kindig

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

This AMENDED AND RESTATED EMPLOYMENT AGREEMENT, dated as of the 27th day of February, 2008, is between Conseco Services, LLC, an Indiana limited liability company ("Company"), and Russell M. Bostick ("Executive").

WHEREAS, the Company and Executive entered into an Employment Agreement dated March 7, 2005 and they now desire to amend and restate such agreement.

WHEREAS, the continued services of Executive and his managerial and professional experience are of value to the Company.

WHEREAS, the Company desires to have the benefit and advantage of the services of Executive to assist the Company and Conseco, Inc. ("Conseco") upon the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. **Employment.** The Company hereby employs Executive and Executive hereby accepts employment upon the terms and conditions hereinafter set forth.
2. **Term.** The effective date of this agreement (the "Agreement") shall be the date set forth above (the "Effective Date"). Subject to the provisions for termination as provided in Section 10 hereof, the term of Executive's employment under this Agreement shall be the period beginning on the Effective Date and ending on March 7, 2009 (the "Term"). The Term shall not be automatically renewed and shall end upon any earlier termination of Executive's employment with the Company.
3. **Duties.** During the Term, Executive shall be engaged by the Company in the capacity of Executive Vice President, Chief Information Officer, with responsibility for Information Technology on an enterprise-wide basis, or in such other senior executive capacity as the Chief Executive Officer of Conseco shall specify. Executive shall report to the Chief Executive Officer of Conseco or such other executive of the Company or Conseco as the Chief Executive Officer of Conseco may specify regarding the performance of his duties.
4. **Extent of Services.** During the Term, subject to the direction and control of the Chief Executive Officer of Conseco, Executive shall have the power and authority commensurate with his executive status and necessary to perform his duties hereunder. Executive shall devote his entire employable time, attention and best efforts to the business of the Company and, during the Term, shall not, without the consent of the Company, be actively engaged in any other business activity, whether or not such business activity is pursued for gain, profit or other pecuniary advantage; provided, however, that, subject to Section 9 hereof, this shall not be construed as preventing Executive from serving on boards of professional,

community, civic, education, charitable and corporate organizations on which he presently serves or may choose to serve or investing his assets in such form or manner as will not require any services on the part of Executive in the operation of the affairs of the companies in which such investments are made (to the extent not in violation of the non-solicitation provisions of Section 9 hereof); provided, however, that corporate organizations shall be limited to those mutually agreed upon by Executive and the Company.

5. Compensation. During the Term:

(a) As compensation for services hereunder rendered during the Term hereof, Executive shall receive a base salary ("Base Salary") of Three Hundred Twenty-One Thousand Three Hundred Sixty Dollars (\$321,360) per year payable in equal installments in accordance with the Company's payroll procedure for its salaried executives. Salary payments and other payments under this Agreement shall be subject to withholding of taxes and other appropriate and customary amounts. Executive may receive increases in his Base Salary from time to time, based upon his performance, subject to approval of the Company.

(b) In addition to Base Salary, Executive will have an opportunity to earn a bonus each year, as determined by the Company, with a target annual bonus equal to 50% of Executive's Base Salary (the "Target Bonus") and a maximum annual bonus of 100% of Executive's Base Salary with respect to any calendar year, with such bonus payable at such time that other similar payments are made to other Company executives but in no event later than March 15 of the year following the year with respect to which such bonus was payable, unless the bonus amounts to be paid cannot be confirmed and paid on or before March 15, in which event the bonuses will be paid within 15 days after the bonus amounts have been confirmed by the Company. For purposes of clarification, annual executive bonuses are generally paid on or before March 15 of the year following the year with respect to which such bonuses are payable, if Executive remains employed with the Company through such date or as otherwise payable under Section 11 of this Agreement. Notwithstanding the above, the 2008 bonus will be paid at the same time that similar payments are made to other Company executives if Executive remains employed through the end of the Term. The performance requirements for Target Bonuses will be based on financial and other objective targets that the Conesco Board of Directors (the "Board") or the Human Resources and Compensation Committee of the Board (the "Compensation Committee") believes are reasonably attainable at the time that they are set.

(c) Executive shall be eligible to participate in and receive future grants under any Conesco stock or equity-based program offered to senior executives, subject to the discretion of the Board or the Compensation Committee.

6. Fringe Benefits. During the Term:

(a) Executive shall be entitled to participate in such existing executive benefit plans and insurance programs offered by the Company, or which it may adopt from time to time, for its executive management or supervisory personnel generally, in accordance with the eligibility requirements for participation therein. Nothing herein shall be construed so as to prevent the Company from modifying or terminating any executive benefit plans or programs, or executive fringe benefits, that it may adopt from time to time.

(b) Executive shall be entitled to four weeks of vacation with pay each year.

(c) Executive may incur reasonable expenses for promoting the Company's business, including expenses for entertainment, travel, and similar items. The Company shall reimburse Executive for all such reasonable expenses upon Executive's periodic presentation of an itemized account of such expenditures in accordance with the Company's policies and procedures; provided, however, that any such reimbursement will be made no later than March 31 of the year following the year in which the expense was incurred. The Company agrees to pay Executive an additional amount to cover the incremental additional income taxes incurred by Executive, if any, with respect to payment or reimbursement of any reasonable business expenses pursuant to this subsection (c); provided, however, that any such payment will be made no later than March 31 of the year following the year in which the income tax was incurred.

(d) Executive shall be permitted to make elective contributions to any Company-sponsored, non-qualified deferred compensation plan in accordance with the terms of such plan.

7. Disability.

(a) If Executive shall become physically or mentally disabled during the Term to the extent that his ability to perform his duties and services hereunder is materially and adversely impaired, his Base Salary, bonus and other compensation provided herein shall continue while he remains employed by the Company; provided, that if such disability (as determined in the Company's reasonable judgment, exercised in good faith) continues for at least three (3) consecutive months, the Company may terminate Executive's employment hereunder, in which case the Company within 10 business days shall pay Executive a cash payment equal to (i) his annual Base Salary as provided in Section 5(a) hereof to the extent earned but unpaid as of the date of termination ("Unpaid Salary"), (ii) the bonus payable pursuant to Section 5(b) for the fiscal year of the Company ending prior to the date of termination (to the extent earned based on performance under the goals and objectives of the applicable plan but not previously paid) ("Unpaid Bonus"), (iii) Executive's then accrued but unused vacation ("Unpaid Vacation") (the Unpaid Salary, Unpaid Bonus and Unpaid Vacation referred to sometimes together as the "Accrued Amounts") and (iv) a pro-rata portion of the Target Bonus for the year in which the termination for disability occurs. All options, restricted stock and/or other awards held by Executive on the date of termination for disability shall vest only through the date

of termination according to the normal vesting schedule applicable to such options or restricted stock and Executive shall be treated in accordance with the applicable award agreements.

(b) No payments or vesting under this Section 7 will be made if such disability arose primarily from (a) chronic use of intoxicants, drugs or narcotics (other than drugs prescribed to Executive by a physician and used by Executive for their intended purpose for which they had been prescribed) or (b) intentionally self-inflicted injury or intentionally self-induced illness.

8. Disclosure of Information. Executive acknowledges that, in and as a result of his employment with the Company, he will be making use of, acquiring and/or adding to confidential information of the Company and its affiliates of a special and unique nature and value. As a material inducement to the Company to enter into this Agreement and to pay to Executive the compensation stated in Section 5, as well as any additional benefits stated herein, Executive covenants and agrees that he shall not, at any time while he is employed by the Company or at any time thereafter, directly or indirectly, divulge or disclose for any purpose whatsoever, any confidential information (whether or not specifically labeled or identified as "confidential information"), in any form or medium, that has been obtained by or disclosed to him as a result of his employment with the Company and which the Company or any of its affiliates has taken appropriate steps to safeguard, except to the extent that such confidential information (a) becomes a matter of public record or is published in a newspaper, magazine or other periodical available to the general public, other than as a result of any act or omission of Executive, (b) is required to be disclosed by any law, regulation or order of any court or regulatory commission, department or agency, in which event Executive shall give prompt notice of such requirement to the Company to enable the Company to seek an appropriate protective order or confidential treatment, (c) must be disclosed to enable Executive properly to perform his duties under this Agreement or (d) was developed by Executive prior to his employment by the Company. Upon the termination of Executive's employment, Executive shall return such information (in whatever form) obtained from or belonging to the Company or any of its affiliates which he may have in his possession or control.

9. Covenants Against Solicitation. Executive acknowledges that the services he is to render to the Company and its affiliates are of a special and unusual character, with a unique value to the Company and its affiliates, the loss of which cannot adequately be compensated by damages or an action at law. In view of the unique value to the Company and its affiliates of the services of Executive for which the Company has contracted hereunder, because of the confidential information to be obtained by, or disclosed to, Executive as set forth in Section 8 above, and as a material inducement to the Company to enter into this Agreement and to pay to Executive the compensation stated in Section 5 hereof, as well as any additional benefits stated herein, and other good and valuable consideration, Executive covenants and agrees that throughout the period Executive remains employed or compensated hereunder and for one year thereafter, Executive shall not, directly or indirectly, anywhere in the United States of America (i) solicit or attempt to convert to other insurance carriers or other corporations, persons or other entities providing these same or similar products or services provided by the Company and its affiliates, any customers or policyholders of the Company or any of its affiliates or (ii) solicit for

employment or employ any employee of the Company or any of its affiliates. Should any particular covenant or provision of this Section 9 be held unreasonable or contrary to public policy for any reason, including, without limitation, the time period, geographical area, or scope of activity covered by any restrictive covenant or provision, the Company and Executive acknowledge and agree that such covenant or provision shall automatically be deemed modified such that the contested covenant or provision shall have the closest effect permitted by applicable law to the original form and shall be given effect and enforced as so modified to whatever extent would be reasonable and enforceable under applicable law.

10. Termination. During the Term:

(a) Either the Company or Executive may terminate his employment at any time for any reason upon written notice to the other. The Company may terminate Executive's employment for Just Cause pursuant to Section 10(b) below or in a Control Termination pursuant to Section 10(c) below. Executive's employment shall also terminate (i) upon the death of Executive or, (ii) after disability of Executive pursuant to Section 7 hereof.

(b) The Company may terminate Executive's employment at any time for Just Cause. For purposes of this Agreement, "Just Cause" shall mean:

(i) (A) material breach by Executive of this Agreement not cured within 15 days after written notice to Executive by the Company, (B) a material breach of Executive's duty of loyalty to the Company or its affiliates not cured within 15 days after written notice to Executive by the Company, or (C) willful malfeasance or fraud or dishonesty of a substantial nature in performing Executive's services on behalf of the Company or its affiliates, which in each case is willful and deliberate on Executive's part and committed in bad faith or without reasonable belief that such breach or action is in the best interests of the Company or its affiliates;

(ii) Executive's use of alcohol or drugs (other than drugs prescribed to Executive by a physician and used by Executive for their intended purposes for which they had been prescribed) or other repeated conduct which materially and repeatedly interferes with the performance of his duties hereunder, which materially compromises the integrity or the reputation of the Company or its affiliates, or which results in other substantial economic harm to the Company or its affiliates;

(iii) Executive's conviction by a court of law, admission that he is guilty, or entry of a plea of nolo contendere with regard to a felony or other crime involving moral turpitude;

(iv) Executive's unscheduled absence from his employment duties other than as a result of illness or disability, for whatever cause, for a period of more

than three (3) consecutive days, without consent from the Company prior to the expiration of the three (3) day period;

- (v) Executive's failure to take action or to abstain from taking action, as directed in writing by a member of the Board or a higher ranking executive of the Company or Conseco, where such failure continues after Executive has been given written notice of such failure and at least five (5) business days thereafter to cure such failure; or
- (vi) Any intentional wrongful act or omission by Executive that results in the restatement of Conseco's financial statements due to a violation of the Sarbanes-Oxley Act of 2002.

No termination shall be deemed to be a termination by the Company for Just Cause if the termination is as a result of Executive refusing to act in a manner that would be a violation of applicable law or where Executive acts (or refrains from taking action) in good faith in accordance with directions of a member of the Board or higher ranking executive but was unable to attain the desired results because such results were inherently unreasonable or unattainable.

(c) The Company may terminate Executive's employment in a Control Termination. A "Control Termination" shall mean any termination by the Company (or its successor) of Executive's employment for any reason within six months in anticipation of or within two years following a Change in Control.

The term "Change in Control" shall mean the occurrence of any of the following:

- (i) the acquisition (other than an acquisition in connection with a "Non-Control Transaction") by any "person" (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the "1934 Act")) of "beneficial ownership" (as such term is defined in Rule 13d-3 promulgated under the 1934 Act), directly or indirectly, of securities of Conseco or its Ultimate Parent representing 51% or more of the combined voting power of the then outstanding securities of Conseco or its Ultimate Parent entitled to vote generally with respect to the election of the Board or the board of directors of Conseco's Ultimate Parent; or
- (ii) as a result of or in connection with a tender or exchange offer or contest for election of directors, individual board members of Conseco (identified as of the date of commencement of such tender or exchange offer, or the commencement of such election contest, as the case may be) cease to constitute at least a majority of the Board; or
- (iii) the consummation of a merger, consolidation or reorganization with or into Conseco unless (x) the stockholders of Conseco immediately before such transaction beneficially own, directly or indirectly, immediately following such transaction securities representing 51% or more of the combined voting power of

the then outstanding securities entitled to vote generally with respect to the election of the board of directors of Conseco (or its successor) or, if applicable, the Ultimate Parent and (y) individual board members of Conseco (identified as of the date that a binding agreement providing for such transaction is signed) constitute at least a majority of the board of directors of Conseco (or its successor) or, if applicable, the Ultimate Parent (a transaction to which clauses (x) and (y) apply, a "Non-Control Transaction").

For purposes of this Agreement, "Ultimate Parent" shall mean the parent corporation (or if there is more than one parent corporation, the ultimate parent corporation) that, following a transaction, directly or indirectly beneficially owns a majority of the voting power of the outstanding securities entitled to vote with respect to the election of the board of directors of Conseco (or its successor).

(d) At Executive's option, he may terminate employment with the Company "With Reason" provided one or more of the following conditions are met: (i) any reduction in Executive's Base Salary or Target Bonus without his consent, or (ii) there is a "Change in Control" as defined in Section 10(c) and, following Executive's written request made prior to the Change in Control, the ultimate parent entity or entities directly or indirectly gaining control of a majority of the Board or outstanding securities entitled to vote with respect to the Board fails to affirm and guarantee the Company's current and future obligations under this Agreement.

(e) Upon termination of Executive's employment with the Company for any reason (whether voluntary or involuntary), Executive shall be deemed to have voluntarily resigned from all positions that Executive may then hold with the Company and any of its affiliates; provided that such deemed resignation shall not adversely affect Executive's rights to compensation or benefits under this Agreement and shall not affect the determination of whether Executive's termination was for Just Cause or With Reason.

11. Payments Following Termination.

(a) In the event that Executive's employment is terminated by the Company for Just Cause or if Executive voluntarily resigns, then the Company within 10 business days shall pay Executive a cash payment of his Base Salary as provided in Section 5(a) hereof that was earned but unpaid as of the date of termination. No bonus for the year of termination will be earned or paid to Executive. All stock options, restricted stock and/or other awards held by Executive on the date of termination shall be treated in accordance with the applicable award agreements.

(b) In the event Executive's employment is terminated by the death of Executive, then the Company shall pay Executive's estate within 30 days (i) the Accrued Amounts and (ii) a pro-rata portion of the Target Bonus for the year in which his death occurs. All stock options, restricted stock and/or other awards held by Executive on the date of termination shall be treated in accordance with the applicable award agreements.

(c) In the event that Executive is terminated by the Company without Just Cause (and other than a termination due to expiration of the Term, death, disability or a Control Termination) or by Executive With Reason, then the Company shall pay Executive within 30 days (i) the Accrued Amounts, (ii) a pro-rata portion of the Target Bonus for the year in which his termination occurs and (iii) a cash lump sum equal to his Base Salary and Target Bonus. All stock options, restricted stock and/or other awards held by Executive on the date of termination shall be treated in accordance with the applicable award agreements.

(d) In the event that Executive is terminated by the Company (or its successor) in a Control Termination as so defined, then the Company shall pay Executive within 30 days (i) the Accrued Amounts, (ii) a cash lump sum equal to his Target Bonus and one and one-half times his Base Salary and

(iii) a cash lump sum equal to a pro-rata portion of the Target Bonus for the year in which the date of termination occurs. All stock options, restricted stock and/or other awards held by Executive upon the occurrence of the Change in Control shall be treated in accordance with the applicable award agreements.

(e) Notwithstanding anything to the contrary, payment of any severance under this Agreement is conditioned upon the execution by Executive of a separation and release agreement in a form acceptable to the Company and the observation of such waiting or revocation periods, if any, before and after execution of the agreement by Executive as are required by law, such as, for example, the waiting or revocation periods required for a waiver and release to be effective with respect to claims under the Age Discrimination in Employment Act, provided that the Company delivers to Executive such agreement within seven days of the date of his termination.

12. Character of Termination Payments. The amounts payable to Executive upon any termination of his employment shall be considered severance pay in consideration of past services rendered on behalf of the Company and his continued service from the date hereof to the date he becomes entitled to such payments and shall be the sole amount of severance pay to which Executive is entitled from the Company and its affiliates upon termination of his employment during the Term. Executive shall have no duty to mitigate his damages by seeking other employment and, should Executive actually receive compensation from any such other employment, the payments required hereunder shall not be reduced or offset by any such other compensation.

13. Representations of the Parties.

(a) The Company represents and warrants to Executive that (i) this Agreement has been duly authorized, executed and delivered by the Company and constitutes valid and binding obligations of the Company; and (ii) the employment of Executive on the terms and conditions contained in this Agreement will not conflict with, result in a breach or violation of, constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to: (A) the certificate of formation, (B) the terms of any indenture, contract, lease, mortgage,

deed of trust, note, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company is a party or bound or to which its property is subject, or (C) any statute, law, rule, regulation, judgment, order or decree applicable to the Company, or any regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company.

(b) Executive represents and warrants to the Company that: (i) this Agreement has been duly executed and delivered by Executive and constitutes a valid and binding obligation of Executive; and (ii) neither the execution of this Agreement by Executive nor his employment by the Company on the terms and conditions contained herein will conflict with, result in a breach or violation of, or constitute a default under any agreement, obligation, condition, covenant or instrument to which Executive is a party or bound or to which his property is subject, or any statute, law, rule, regulation, judgment, order or decree applicable to Executive of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over Executive or any of his property.

14. Arbitration of Disputes; Injunctive Relief.

(a) Arbitration. Except as provided in subsection (b) below, any controversy or claim arising out of or relating to this Agreement or the breach thereof shall be settled by binding arbitration in the City of Indianapolis, Indiana, in accordance with the laws of the State of Indiana by three arbitrators, one of whom shall be appointed by the Company, one by Executive, and the third of whom shall be appointed by the first two arbitrators. If the first two arbitrators cannot agree on the appointment of a third arbitrator, then the third arbitrator shall be appointed by the Chief Judge of the United States District Court for the Southern District of Indiana. The arbitration shall be conducted in accordance with the rules of the American Arbitration Association, except with respect to the selection of arbitrators, which shall be as provided in this Section. Judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. All reasonable costs and expenses (including fees and disbursements of counsel) incurred by Executive pursuant to this Section 14 shall be paid on behalf of or reimbursed to Executive promptly by the Company; provided, however, that in the event the Company prevails in such proceedings, Executive shall immediately repay all such amounts to the Company.

(b) Executive acknowledges that a breach or threatened breach by Executive of Sections 8 or 9 of this Agreement will give rise to irreparable injury to the Company and that money damages will not be adequate relief for such injury. Notwithstanding paragraph (a) above, the Company and Executive agree that the Company may seek and obtain injunctive relief, including, without limitation, temporary restraining orders, preliminary injunctions and/or permanent injunctions, in a court of proper jurisdiction to restrain or prohibit a breach or threatened breach of Section 8 or 9 of this Agreement. Nothing herein shall be construed as prohibiting the Company from pursuing any other remedies available to the Company for such breach or threatened breach, including the recovery of damages from Executive.

15. Notices. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered mail to his residence, in the case of Executive, or to the business office of its General Counsel, in the case of the Company.

16. Waiver of Breach and Severability. The waiver by either party of a breach of any provision of this Agreement by the other party shall not operate or be construed as a waiver of any subsequent breach by either party. In the event any provision of this Agreement is found to be invalid or unenforceable, it may be severed from the Agreement, and the remaining provisions of the Agreement shall continue to be binding and effective.

17. Entire Agreement. Other than any equity award agreements entered into pursuant to the Conseco, Inc. 2003 Amended and Restated Long-Term Incentive Plan or any subsequent incentive plan, this instrument contains the entire agreement of the parties and, as of the Effective Date, supersedes all other obligations of the Company and its affiliates under other agreements or otherwise. The compensation and benefits to be paid under the terms of this Agreement are in lieu of all other compensation or benefits to which Executive is entitled from Conseco, the Company, and its affiliates, and upon termination of Executive's employment with the Company Executive will not be entitled to receive any severance or other payments beyond those specified in this Agreement. This Agreement may not be changed orally, but only by an instrument in writing signed by the party against whom enforcement of any waiver, change, modification, extension or discharge is sought.

18. Binding Agreement and Governing Law; Assignment Limited. This Agreement shall be binding upon and shall inure to the benefit of the parties and their lawful successors in interest (including, without limitation, Executive's estate, heirs and personal representatives) and, except for issues or matters as to which federal law is applicable, shall be construed in accordance with and governed by the laws of the State of Indiana. This Agreement is personal to each of the parties hereto, and neither party may assign or delegate any of its rights or obligations hereunder without the prior written consent of the other.

19. Indemnification. If Executive was or is made a party or is threatened to be made a party to or is otherwise involved (including involvement as a witness) in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a "Proceeding"), by reason of the fact that he or she is or was an officer or employee of the Company or any of its affiliates, Executive shall be indemnified and held harmless by the Company to the fullest extent authorized by the Delaware General Corporation Law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Company to provide broader indemnification rights than permitted prior thereto), against all expense, liability and loss (including attorneys' fees, judgments, fines, excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by Executive in connection therewith and such indemnification shall continue as to Executive if he ceases to be an officer or employee and shall inure to the benefit of Executive's heirs, executors and administrators; provided, however, that the Company shall indemnify Executive in connection with a proceeding (or part thereof) initiated by Executive only if such Proceeding (or part thereof) was authorized by the managing member of the Company. The right to indemnification conferred in this paragraph shall include the obligation of the Company to pay the expenses incurred in defending any such proceeding in advance of its final disposition (an "Advance of Expenses"); provided, however, that, if and to the extent that the Delaware General Corporation

Law requires, an Advance of Expenses incurred by Executive in his capacity as an officer or employee shall be made only upon delivery to the Company of an undertaking, by or on behalf of Executive, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that Executive is not entitled to be indemnified for such expenses under this paragraph or otherwise.

20. No Third Party Beneficiaries. The terms and provisions of this Agreement are intended solely for the benefit of each party hereto and their respective successors or permitted assigns, and it is not intended to confer third-party beneficiary rights upon any other person.

21. Counterparts: This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written, effective as of the Effective Date.

**COMPANY:
CONSECO SERVICES, LLC**

/s/ Edward J. Bonach

*Edward J. Bonach
President*

EXECUTIVE:

/s/ Russell M. Bostick

Russell M. Bostick

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT, dated as of the ____ day of October, 2007, is between Conseco Services, LLC, an Indiana limited liability company ("Company"), and Dan R. Bardin ("Executive").

WHEREAS, the services of Executive and his managerial and professional experience are of value to the Company.

WHEREAS, the Company desires to have the benefit and advantage of the services of Executive to assist the Company and Conseco, Inc. ("Conseco") upon the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. **Employment.** The Company hereby employs Executive and Executive hereby accepts employment upon the terms and conditions hereinafter set forth.
2. **Term.** The effective date of this agreement (the "Agreement") shall be the date set forth above (the "Effective Date"). Subject to the provisions for termination as provided in Section 10 hereof, the term of Executive's employment under this Agreement shall be the period beginning on December 10, 2007 and ending on December 31, 2010 (the "Term"). The Term shall not be automatically renewed and shall end upon any earlier termination of Executive's employment with the Company.
3. **Duties.** During the Term, Executive shall be engaged by the Company in the capacity of President of Conseco Insurance Group, or in such other capacity as the Chief Executive Officer of Conseco shall specify. Executive shall report to the Chief Executive Officer of Conseco or such other executive of the Company or Conseco as the Chief Executive Officer of Conseco may specify regarding the performance of his duties. Executive's primary office shall be at the Company's offices in Carmel, Indiana.
4. **Extent of Services.** During the Term, subject to the direction and control of the Chief Executive Officer of Conseco, Executive shall have the power and authority commensurate with his executive status and necessary to perform his duties hereunder. Executive shall devote his entire employable time, attention and best efforts to the business of the Company and, during the Term, shall not, without the consent of the Company, be actively engaged in any other business activity, whether or not such business activity is pursued for gain, profit or other pecuniary advantage; provided, however, that, subject to Section 9 hereof, this shall not be construed as preventing Executive from serving on boards of professional, community, civic, education, charitable and corporate organizations on which he presently serves or may choose to serve or investing his assets in such form or manner as will not require any services on the part of Executive in the operation of the affairs of the companies in which such

investments are made (to the extent not in violation of the noncompete and non-solicitation provisions of Section 9 hereof); provided, however, that corporate organizations shall be limited to those mutually agreed upon by Executive and the Company.

5. Compensation. During the Term:

(a) As compensation for services hereunder rendered during the Term hereof, Executive shall receive a base salary ("Base Salary") of Five Hundred Thousand Dollars (\$500,000) per year payable in equal installments in accordance with the Company's payroll procedure for its salaried executives. Salary payments and other payments under this Agreement shall be subject to withholding of taxes and other appropriate and customary amounts. Executive may receive increases in his Base Salary from time to time, based upon his performance, subject to approval of the Company.

(b) In addition to Base Salary, Executive will have an opportunity to earn a bonus each year, beginning in 2008, as determined by the Company, with a target annual bonus equal to 100% of Executive's Base Salary (the "Target Bonus") and a maximum annual bonus of 200% of Executive's Base Salary with respect to any calendar year, with such bonus payable at such time that other similar payments are made to other Company executives but in no event later than March 15 of the year following the year with respect to which such bonus was payable. For purposes of clarification, annual executive bonuses are generally paid on or before March 15 of the year following the year with respect to which such bonuses are payable, if Executive remains employed with the Company through such date or as otherwise payable under Section 11 of this Agreement. Notwithstanding the above, the 2010 bonus will be paid at the same time that similar payments are made to other Company executives but in no event later than March 15, 2011 if Executive remains employed through the end of the Term. The performance requirements for Target Bonuses will be based on financial and other objective targets that the Conesco Board of Directors (the "Board") or the Human Resources and Compensation Committee of the Board (the "Compensation Committee") believes are reasonably attainable at the time that they are set.

(c) Subject to the approval of the Compensation Committee, Executive shall be entitled to receive a non-qualified option to purchase 90,000 shares of Conesco common stock (which shall vest in two equal annual installments on the second and third anniversaries of the date of grant and shall have a five-year term). The Company will also recommend to the Compensation Committee that Executive be granted 35,000 performance shares for the 2008 - 2010 performance period. Executive shall not be entitled to receive any other stock options or performance shares in 2008 but he shall be eligible to participate in and receive grants in subsequent years under any Conesco stock or equity-based program, subject to the discretion of the Board or the Compensation Committee.

(d) Executive shall receive a signing bonus of \$75,000, payable within 30 days after the Commencement Date. If Executive resigns (other than With Reason) or the Company terminates Executive with Just Cause, in each case prior to January 1, 2009, Executive will repay such bonus to the Company within five business days after such resignation or termination.

6. Fringe Benefits. During the Term:

- (a) Executive shall be entitled to participate in such existing executive benefit plans and insurance programs offered by the Company, or which it may adopt from time to time, for its executive management or supervisory personnel generally, in accordance with the eligibility requirements for participation therein. Nothing herein shall be construed so as to prevent the Company from modifying or terminating any executive benefit plans or programs, or executive fringe benefits, that it may adopt from time to time.
- (b) Executive shall be entitled to four weeks of vacation with pay each year and will not be eligible for any other paid time-off program (other than paid holidays).
- (c) Executive may incur reasonable expenses for promoting the Company's business, including expenses for entertainment, travel, and similar items. The Company shall reimburse Executive for all such reasonable expenses upon Executive's periodic presentation of an itemized account of such expenditures. The Company agrees to pay Executive an additional amount to cover the incremental additional income taxes incurred by Executive, if any, with respect to payment or reimbursement of any reasonable business expenses pursuant to this subsection (c).
- (d) Executive shall be entitled to reimbursement of reasonable relocation expenses for moving his family to the Carmel, Indiana area in accordance with the Company's current executive relocation policy, provided that these expenses shall be capped at \$50,000. All expenses must be appropriately documented by Executive to the Company. In the event that Executive's employment is terminated for Just Cause or if he terminates his employment other than With Reason prior to the first anniversary of the Commencement Date, Executive agrees to repay such expenses to the Company.
- (e) The Company shall reimburse Executive for, or provide at its expense, up to three months of temporary housing in the Carmel, Indiana area in an amount not to exceed \$5,000 per month.
- (f) Executive shall be permitted to make elective contributions to any Company-sponsored, non-qualified deferred compensation plan in accordance with the terms of such plan.

7. Disability.

- (a) If Executive shall become physically or mentally disabled during the Term to the extent that his ability to perform his duties and services hereunder is materially and adversely impaired, his Base Salary, bonus and other compensation provided herein shall continue while he remains employed by the Company; provided, that if such disability (as determined in the Company's reasonable judgment, exercised in good faith) continues for at least three (3) consecutive months, the Company may terminate Executive's employment hereunder, in which case the Company within 10 business days shall pay Executive a cash payment equal to (i) his annual Base Salary as provided in Section 5(a)

hereof to the extent earned but unpaid as of the date of termination ("Unpaid Salary"), (ii) the bonus payable pursuant to Section 5(b) for the fiscal year of the Company ending prior to the date of termination (to the extent earned based on performance under the goals and objectives of the applicable plan but not previously paid) ("Unpaid Bonus"), (iii) Executive's then accrued but unused vacation ("Unpaid Vacation") (the Unpaid Salary, Unpaid Bonus and Unpaid Vacation referred to sometimes together as the "Accrued Amounts"), (iv) a pro-rata portion of the Target Bonus for the year in which the termination for disability occurs and (v) one times his Base Salary. All options, restricted stock and/or other awards held by Executive on the date of termination for disability shall vest only through the date of termination according to the normal vesting schedule applicable to such options or restricted stock and Executive shall be treated in accordance with the applicable award agreements.

(b) No payments or vesting under this Section 7 will be made if such disability arose primarily from (a) chronic use of intoxicants, drugs or narcotics (other than drugs prescribed to Executive by a physician and used by Executive for their intended purpose for which they had been prescribed) or (b) intentionally self-inflicted injury or intentionally self-induced illness.

8. Disclosure of Information. Executive acknowledges that, in and as a result of his employment with the Company, he will be making use of, acquiring and/or adding to confidential information of the Company and its affiliates of a special and unique nature and value. As a material inducement to the Company to enter into this Agreement and to pay to Executive the compensation stated in Section 5, as well as any additional benefits stated herein, Executive covenants and agrees that he shall not, at any time while he is employed by the Company or at any time thereafter, directly or indirectly, divulge or disclose for any purpose whatsoever, any confidential information (whether or not specifically labeled or identified as "confidential information"), in any form or medium, that has been obtained by or disclosed to him as a result of his employment with the Company and which the Company or any of its affiliates has taken appropriate steps to safeguard, except to the extent that such confidential information (a) becomes a matter of public record or is published in a newspaper, magazine or other periodical available to the general public, other than as a result of any act or omission of Executive, (b) is required to be disclosed by any law, regulation or order of any court or regulatory commission, department or agency, in which event Executive shall give prompt notice of such requirement to the Company to enable the Company to seek an appropriate protective order or confidential treatment, (c) must be disclosed to enable Executive properly to perform his duties under this Agreement or (d) was developed by Executive prior to his employment by the Company. Upon the termination of Executive's employment, Executive shall return such information (in whatever form) obtained from or belonging to the Company or any of its affiliates which he may have in his possession or control.

9. Covenants Against Competition and Solicitation. Executive acknowledges that the services he is to render to the Company and its affiliates are of a special and unusual character, with a unique value to the Company and its affiliates, the loss of which cannot adequately be compensated by damages or an action at law. In view of the unique value to the Company and its affiliates of the services of Executive for which the Company has contracted

hereunder, because of the confidential information to be obtained by, or disclosed to, Executive as set forth in Section 8 above, and as a material inducement to the Company to enter into this Agreement and to pay to Executive the compensation stated in Section 5 hereof, as well as any additional benefits stated herein, and other good and valuable consideration, Executive covenants and agrees that throughout the period Executive remains employed or compensated hereunder and for one year thereafter, Executive shall not, directly or indirectly, anywhere in the United States of America (i) render any services, as an agent, independent contractor, consultant or otherwise, or become employed or compensated by any other corporation, person or entity that derives a non-incidental portion of its revenue from the business of selling or providing annuity, life, accident or health insurance products or services; (ii) in any manner compete with the Company or any of its affiliates with respect to lines of business that the Company and its affiliates derive more than a non-incidental portion of their revenue from or with respect to which the Company and its affiliates have made a significant investment in; (iii) solicit or attempt to convert to other insurance carriers or other corporations, persons or other entities providing these same or similar products or services provided by the Company and its affiliates, any customers or policyholders of the Company or any of its affiliates or (iv) solicit for employment or employ any employee of the Company or any of its affiliates. Should any particular covenant or provision of this Section 9 be held unreasonable or contrary to public policy for any reason, including, without limitation, the time period, geographical area, or scope of activity covered by any restrictive covenant or provision, the Company and Executive acknowledge and agree that such covenant or provision shall automatically be deemed modified such that the contested covenant or provision shall have the closest effect permitted by applicable law to the original form and shall be given effect and enforced as so modified to whatever extent would be reasonable and enforceable under applicable law.

10. Termination. During the Term:

(a) Either the Company or Executive may terminate his employment at any time for any reason upon written notice to the other. The Company may terminate Executive's employment for Just Cause pursuant to Section 10(b) below or in a Control Termination pursuant to Section 10(c) below. Executive's employment shall also terminate (i) upon the death of Executive or, (ii) after disability of Executive pursuant to Section 7 hereof.

(b) The Company may terminate Executive's employment at any time for Just Cause. For purposes of this Agreement, "Just Cause" shall mean:

(i) (A) material breach by Executive of this Agreement not cured within 15 days after written notice to Executive by the Company, (B) a material breach of Executive's duty of loyalty to the Company or its affiliates not cured within 15 days after written notice to Executive by the Company, or (C) willful malfeasance or fraud or dishonesty of a substantial nature in performing Executive's services on behalf of the Company or its affiliates, which in each case is willful and deliberate on Executive's part and committed in bad faith or without reasonable belief that such breach or action is in the best interests of the Company or its affiliates;

- (ii) Executive's use of alcohol or drugs (other than drugs prescribed to Executive by a physician and used by Executive for their intended purposes for which they had been prescribed) or other repeated conduct which materially and repeatedly interferes with the performance of his duties hereunder, which materially compromises the integrity or the reputation of the Company or its affiliates, or which results in other substantial economic harm to the Company or its affiliates;
- (iii) Executive's conviction by a court of law, admission that he is guilty, or entry of a plea of nolo contendere with regard to a felony or other crime involving moral turpitude;
- (iv) Executive's unscheduled absence from his employment duties other than as a result of illness or disability, for whatever cause, for a period of more than three (3) consecutive days, without consent from the Company prior to the expiration of the three (3) day period;
- (v) Executive's failure to take action or to abstain from taking action, as directed in writing by a member of the Board or a higher ranking executive of the Company or Conesco, where such failure continues after Executive has been given written notice of such failure and at least five (5) business days thereafter to cure such failure; or
- (vi) Any intentional wrongful act or omission by Executive that results in the restatement of Conesco's financial statements due to a violation of the Sarbanes-Oxley Act of 2002.

No termination shall be deemed to be a termination by the Company for Just Cause if the termination is as a result of Executive refusing to act in a manner that would be a violation of applicable law or where Executive acts (or refrains from taking action) in good faith in accordance with directions of a member of the Board or higher ranking executive but was unable to attain the desired results because such results were inherently unreasonable or unattainable.

(c) The Company may terminate Executive's employment in a Control Termination. A "Control Termination" shall mean any termination by the Company (or its successor) of Executive's employment for any reason within six months in anticipation of or within two years following a Change in Control.

The term "Change in Control" shall mean the occurrence of any of the following:

(i) the acquisition (other than an acquisition in connection with a "Non-Control Transaction") by any "person" (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the "1934 Act")) of "beneficial ownership" (as such term is defined in Rule 13d-3 promulgated under

the 1934 Act), directly or indirectly, of securities of Conseco or its Ultimate Parent representing 51% or more of the combined voting power of the then outstanding securities of Conseco or its Ultimate Parent entitled to vote generally with respect to the election of the Board or the board of directors of Conseco's Ultimate Parent; or

(ii) as a result of or in connection with a tender or exchange offer or contest for election of directors, individual board members of Conseco (identified as of the date of commencement of such tender or exchange offer, or the commencement of such election contest, as the case may be) cease to constitute at least a majority of the Board; or

(iii) the consummation of a merger, consolidation or reorganization with or into Conseco unless (x) the stockholders of Conseco immediately before such transaction beneficially own, directly or indirectly, immediately following such transaction securities representing 51% or more of the combined voting power of the then outstanding securities entitled to vote generally with respect to the election of the board of directors of Conseco (or its successor) or, if applicable, the Ultimate Parent and (y) individual board members of Conseco (identified as of the date that a binding agreement providing for such transaction is signed) constitute at least a majority of the board of directors of Conseco (or its successor) or, if applicable, the Ultimate Parent (a transaction to which clauses (x) and (y) apply, a "Non-Control Transaction").

For purposes of this Agreement, "Ultimate Parent" shall mean the parent corporation (or if there is more than one parent corporation, the ultimate parent corporation) that, following a transaction, directly or indirectly beneficially owns a majority of the voting power of the outstanding securities entitled to vote with respect to the election of the board of directors of Conseco (or its successor).

(d) At Executive's option, he may terminate employment with the Company "With Reason" provided one or more of the following conditions are met: (i) any reduction in Executive's Base Salary or Target Bonus without his consent, or (ii) there is a "Change in Control" as defined in Section 10(c) and, following Executive's written request made prior to the Change in Control, the ultimate parent entity or entities directly or indirectly gaining control of a majority of the Board or outstanding securities entitled to vote with respect to the Board fails to affirm and guarantee the Company's current and future obligations under this Agreement.

(e) Upon termination of Executive's employment with the Company for any reason (whether voluntary or involuntary), Executive shall be deemed to have voluntarily resigned from all positions that Executive may then hold with the Company and any of its affiliates; provided that such deemed resignation shall not adversely affect Executive's rights to compensation or benefits under this Agreement and shall not affect the determination of whether Executive's termination was for Just Cause or With Reason.

11. Payments Following Termination.

(a) In the event that Executive's employment is terminated by the Company for Just Cause or if Executive voluntarily resigns, then the Company within 10 business days shall pay Executive a cash payment of his Base Salary as provided in Section 5(a) hereof that was earned but unpaid as of the date of termination. No bonus for the year of termination will be earned or paid to Executive. All stock options, restricted stock and/or other awards held by Executive on the date of termination shall be treated in accordance with the applicable award agreements.

(b) In the event Executive's employment is terminated by the death of Executive, then the Company shall pay Executive's estate within 30 days (i) the Accrued Amounts and (ii) a pro-rata portion of the Target Bonus for the year in which his death occurs. All stock options, restricted stock and/or other awards held by Executive on the date of termination shall be treated in accordance with the applicable award agreements.

(c) In the event that Executive is terminated by the Company without Just Cause (and other than a termination due to expiration of the Term, death, disability or a Control Termination) or by Executive With Reason, then the Company shall pay Executive within 30 days (i) the Accrued Amounts, (ii) a pro-rata portion of the Target Bonus for the year in which his termination occurs and (iii) a cash lump sum equal to his Base Salary and Target Bonus. All stock options, restricted stock and/or other awards held by Executive on the date of termination shall be treated in accordance with the applicable award agreements.

(d) In the event that Executive is terminated by the Company (or its successor) in a Control Termination as so defined, then the Company shall pay Executive within 30 days (i) the Accrued Amounts, (ii) a cash lump sum equal to his Target Bonus and one and one-half times his Base Salary and (iii) a cash lump sum equal to a pro-rata portion of the Target Bonus for the year in which the date of termination occurs. All stock options, restricted stock and/or other awards held by Executive upon the occurrence of the Change in Control shall be treated in accordance with the applicable award agreements.

(e) Notwithstanding anything to the contrary, payment of any severance under this Agreement is conditioned upon the execution by Executive of a separation and release agreement in a form acceptable to the Company and the observation of such waiting or revocation periods, if any, before and after execution of the agreement by Executive as are required by law, such as, for example, the waiting or revocation periods required for a waiver and release to be effective with respect to claims under the Age Discrimination in Employment Act, provided that the Company delivers to Executive such agreement within seven days of the date of his termination.

12. Character of Termination Payments. The amounts payable to Executive upon any termination of his employment shall be considered severance pay in consideration of past services rendered on behalf of the Company and his continued service from the date hereof to the date he becomes entitled to such payments and shall be the sole amount of severance pay to

which Executive is entitled from the Company and its affiliates upon termination of his employment during the Term. Executive shall have no duty to mitigate his damages by seeking other employment and, should Executive actually receive compensation from any such other employment, the payments required hereunder shall not be reduced or offset by any such other compensation.

13. Representations of the Parties.

(a) The Company represents and warrants to Executive that (i) this Agreement has been duly authorized, executed and delivered by the Company and constitutes valid and binding obligations of the Company; and (ii) the employment of Executive on the terms and conditions contained in this Agreement will not conflict with, result in a breach or violation of, constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to: (A) the certificate of formation, (B) the terms of any indenture, contract, lease, mortgage, deed of trust, note, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company is a party or bound or to which its property is subject, or (C) any statute, law, rule, regulation, judgment, order or decree applicable to the Company, or any regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company.

(b) Executive represents and warrants to the Company that: (i) this Agreement has been duly executed and delivered by Executive and constitutes a valid and binding obligation of Executive; and (ii) neither the execution of this Agreement by Executive nor his employment by the Company on the terms and conditions contained herein will conflict with, result in a breach or violation of, or constitute a default under any agreement, obligation, condition, covenant or instrument to which Executive is a party or bound or to which his property is subject, or any statute, law, rule, regulation, judgment, order or decree applicable to Executive of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over Executive or any of his property.

14. Arbitration of Disputes; Injunctive Relief.

(a) Arbitration. Except as provided in subsection (b) below, any controversy or claim arising out of or relating to this Agreement or the breach thereof shall be settled by binding arbitration in the City of Indianapolis, Indiana, in accordance with the laws of the State of Indiana by three arbitrators, one of whom shall be appointed by the Company, one by Executive, and the third of whom shall be appointed by the first two arbitrators. If the first two arbitrators cannot agree on the appointment of a third arbitrator, then the third arbitrator shall be appointed by the Chief Judge of the United States District Court for the Southern District of Indiana. The arbitration shall be conducted in accordance with the rules of the American Arbitration Association, except with respect to the selection of arbitrators, which shall be as provided in this Section. Judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. All reasonable costs and expenses (including fees and disbursements of counsel) incurred by Executive pursuant to this Section 14 shall be paid on behalf of or

reimbursed to Executive promptly by the Company; provided, however, that in the event the Company prevails in such proceedings, Executive shall immediately repay all such amounts to the Company.

(b) Executive acknowledges that a breach or threatened breach by Executive of Sections 8 or 9 of this Agreement will give rise to irreparable injury to the Company and that money damages will not be adequate relief for such injury. Notwithstanding paragraph (a) above, the Company and Executive agree that the Company may seek and obtain injunctive relief, including, without limitation, temporary restraining orders, preliminary injunctions and/or permanent injunctions, in a court of proper jurisdiction to restrain or prohibit a breach or threatened breach of Section 8 or 9 of this Agreement. Nothing herein shall be construed as prohibiting the Company from pursuing any other remedies available to the Company for such breach or threatened breach, including the recovery of damages from Executive.

15. Notices. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered mail to his residence, in the case of Executive, or to the business office of its General Counsel, in the case of the Company.

16. Waiver of Breach and Severability. The waiver by either party of a breach of any provision of this Agreement by the other party shall not operate or be construed as a waiver of any subsequent breach by either party. In the event any provision of this Agreement is found to be invalid or unenforceable, it may be severed from the Agreement, and the remaining provisions of the Agreement shall continue to be binding and effective.

17. Entire Agreement. Other than any equity award agreements entered into pursuant to the Conseco, Inc. 2003 Amended and Restated Long-Term Incentive Plan or any subsequent incentive plan, this instrument contains the entire agreement of the parties and, as of the Effective Date, supersedes all other obligations of the Company and its affiliates under other agreements or otherwise. The compensation and benefits to be paid under the terms of this Agreement are in lieu of all other compensation or benefits to which Executive is entitled from Conseco, the Company, and its affiliates, and upon termination of Executive's employment with the Company Executive will not be entitled to receive any severance or other payments beyond those specified in this Agreement. This Agreement may not be changed orally, but only by an instrument in writing signed by the party against whom enforcement of any waiver, change, modification, extension or discharge is sought.

18. Binding Agreement and Governing Law; Assignment Limited. This Agreement shall be binding upon and shall inure to the benefit of the parties and their lawful successors in interest (including, without limitation, Executive's estate, heirs and personal representatives) and, except for issues or matters as to which federal law is applicable, shall be construed in accordance with and governed by the laws of the State of Indiana. This Agreement is personal to each of the parties hereto, and neither party may assign or delegate any of its rights or obligations hereunder without the prior written consent of the other.

19. Indemnification. If Executive was or is made a party or is threatened to be made a party to or is otherwise involved (including involvement as a witness) in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a "Proceeding"), by reason

of the fact that he or she is or was an officer or employee of the Company or any of its affiliates, Executive shall be indemnified and held harmless by the Company to the fullest extent authorized by the Delaware General Corporation Law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Company to provide broader indemnification rights than permitted prior thereto), against all expense, liability and loss (including attorneys' fees, judgments, fines, excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by Executive in connection therewith and such indemnification shall continue as to Executive if he ceases to be an officer or employee and shall inure to the benefit of Executive's heirs, executors and administrators; provided, however, that the Company shall indemnify Executive in connection with a proceeding (or part thereof) initiated by Executive only if such Proceeding (or part thereof) was authorized by the Board of Directors of the Company. The right to indemnification conferred in this paragraph shall include the obligation of the Company to pay the expenses incurred in defending any such proceeding in advance of its final disposition (an "Advance of Expenses"); provided, however, that, if and to the extent that the Delaware General Corporation Law requires, an Advance of Expenses incurred by Executive in his capacity as an officer or employee shall be made only upon delivery to the Company of an undertaking, by or on behalf of Executive, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that Executive is not entitled to be indemnified for such expenses under this paragraph or otherwise.

20. No Third Party Beneficiaries. The terms and provisions of this Agreement are intended solely for the benefit of each party hereto and their respective successors or permitted assigns, and it is not intended to confer third-party beneficiary rights upon any other person.

21. Counterparts: This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written, effective as of the Effective Date.

**COMPANY:
CONSECO SERVICES, LLC**

/s/ Edward J. Bonach

Edward J. Bonach
President

EXECUTIVE:

/s/ Dan R. Bardin

Dan R. Bardin

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT, dated as of the 13th day of July, 2005 is between Conseco Services, LLC, an Indiana limited liability company ("Company"), and Steven M. Stecher ("Executive").

WHEREAS, the services of Executive and his managerial and professional experience are of value to the Company.

WHEREAS, the Company desires to continue to have the benefit and advantage of the services of Executive for an extended period to assist the Company and Conseco, Inc. ("Conseco") upon the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. **Employment.** The Company hereby employs Executive and Executive hereby accepts employment upon the terms and conditions hereinafter set forth.
2. **Term.** The effective date of this agreement (the "Agreement") shall be the date set forth above (the "Effective Date"). Subject to the provisions for termination as provided in Section 10 hereof, the term of Executive's employment under this Agreement shall be the period beginning on the Effective Date and ending on the third anniversary of the Effective Date. The term of Executive's employment shall be automatically renewed for successive one-year terms on July 13, 2008 and each succeeding July 13 unless either party elects not to renew this Agreement by serving written notice of such election not to renew on the other party at least 90 days prior to such July 13. As used in this Agreement, the "Term" is the period ending on July 13, 2008 or, if this Agreement has been renewed, the one-year period relating to the last renewal. The Term shall end upon the termination of Executive's employment with the Company.
3. **Duties.** During the Term, Executive shall be engaged by the Company in the capacity of Executive Vice President, Chief Operations Officer of Conseco Insurance Group, and shall have responsibility for management of the day-to-day operations of Conseco Insurance Group. Executive shall report to the President of Conseco Insurance Group regarding the performance of his duties.
4. **Extent of Services.** During the Term, subject to the direction and control of the President of Conseco Insurance Group and the President of Conseco, Executive shall have the power and authority commensurate with his executive status and necessary to perform his duties hereunder. Executive shall devote his entire employable time, attention and best efforts to the business of the Company and, during the Term, shall not, without the consent of the Company, be actively engaged in any other business activity, whether or not such business activity is pursued for gain, profit or other pecuniary advantage; provided, however, that, subject to Section 9 hereof, this shall not be construed as preventing Executive from serving on boards of professional, community, civic, education, charitable and corporate organizations on which he

presently serves or may choose to serve or investing his assets in such form or manner as will not require any services on the part of Executive in the operation of the affairs of the companies in which such investments are made (to the extent not in violation of the noncompete and nonsolicitation provisions of

Section 9 hereof); provided, however, that corporate organizations shall be limited to those which Executive presently serves, if any, as listed on Exhibit A and such others as mutually agreed upon by Executive and the Company.

5. Compensation. During the Term:

(a) As compensation for services hereunder rendered during the Term hereof, Executive shall receive a base salary ("Base Salary") of Three Hundred Twenty-Five Thousand Dollars (\$325,000) per year payable in equal installments in accordance with the Company's payroll procedure for its salaried executives, provided, however, that Executive's Base Salary shall increase to Four Hundred Thousand Dollars (\$400,000) per year after Executive acquires residential housing in the Indianapolis/Carmel area which he utilizes as his primary residence (the "Relocation Effective Date"). Salary payments and other payments under this Agreement shall be subject to withholding of taxes and other appropriate and customary amounts. Executive may receive increases in his Base Salary from time to time, based upon his performance, subject to approval of the Company.

(b) In addition to Base Salary, Executive will have an opportunity to earn a bonus each year as determined by the Company, with a target annual bonus equal to 50% of Executive's Base Salary (the "Target Bonus") and a maximum annual bonus of 100% of Executive's Base Salary with respect to any calendar year, with such bonus payable at such time that other similar payments are made to other Company executives, provided, however, that Executive's Target Bonus shall increase to 100% of Executive's Base Salary with a maximum annual bonus of 200% of Executive's Base Salary after the Relocation Effective Date. For purposes of clarification, annual executive bonuses are generally paid in March of the year following the year with respect to which such bonuses are payable, if Executive remains employed with the Company through such date or as otherwise payable under Section 11 of this Agreement. Notwithstanding the above, (i) Executive's 2005 bonus (payable in 2006) will be calculated on a pro rata basis based on the number of days in 2005 prior to the Relocation Effective Date and the number of days from and after the Relocation Effective Date (taking into account his Target Bonus percentage for each respective period in 2005) and (ii) a pro-rata portion of the 2008 bonus (or a pro-rata portion of the applicable bonus in any year this Agreement is not renewed) will be paid at the same time that similar payments are made to other Company executives if Executive remains employed through the end of the Term. The Target Bonuses will be based on financial and other objective targets that the Company believes are reasonably attainable at the time that they are set.

(c) As soon as reasonably practicable after the Relocation Effective Date, Executive will receive an award of options to purchase 30,000 shares of common stock with an exercise price equal to the fair market value on the date of the grant and an award of 10,000 shares of restricted stock. One hundred percent (100%) of the options will vest over a 4-year period beginning on the date of the grant of the equity awards (the "Grant Date"), with one-fourth vesting on each anniversary of the Grant Date. Fifty percent (50%) of the restricted stock will vest on the second anniversary of the Grant Date, with

the other fifty percent (50%) vesting on the third anniversary of the Grant Date. Executive shall also be eligible to participate in and receive future grants under any stock option or equity-based program offered by Consecro to executives of similar title and responsibility, if any, subject to the discretion of the Board of Directors of Consecro (the "Board").

(d) Executive agrees to secure residential housing in the Indianapolis/Carmel area, as soon as reasonably practicable after the Effective Date, which he shall utilize as his primary residence. The Company shall reimburse Executive for relocation expenses, with reimbursement of (i) the first \$60,000 to be paid in cash as soon as reasonably practical after the Relocation Effective Date, (ii) up to \$35,000 based on a 7% commission on the sale of his current primary residence to be paid in cash after Executive notifies the Company of such sale and provides applicable documentation and (iii) up to \$15,000 for packing and transporting household possessions by a national van line to be paid in cash after Executive provides applicable documentation of such cost; provided, however, if Executive voluntarily resigns from employment with the Company (other than With Reason) prior to the second anniversary of the Relocation Effective Date, Executive shall repay the Company all such relocation expenses reimbursed or otherwise paid by the Company. Executive shall not be entitled to reimbursement of any amount set forth above unless the Relocation Effective Date is on or before September 15, 2005.

6. Fringe Benefits. During the Term:

(a) Executive shall be entitled to participate in such existing executive benefit plans and insurance programs offered by the Company (including, without limitation, any group life, medical, dental, accident or disability insurance programs and any pension, profit sharing, retirement, deferred compensation or savings program), or which it may adopt from time to time, for its executive management or supervisory personnel generally, in accordance with the eligibility requirements for participation therein. Nothing herein shall be construed so as to prevent the Company from modifying or terminating any executive benefit plans or programs, or executive fringe benefits, that it may adopt from time to time.

(b) Executive shall be entitled to four weeks of vacation with pay each year.

(c) Executive may incur reasonable expenses for promoting the Company's business, including expenses for entertainment, travel, and similar items. The Company shall reimburse Executive for all such reasonable expenses upon Executive's periodic presentation of an itemized account of such expenditures. The Company agrees to pay Executive an additional amount to cover the incremental additional income taxes incurred by Executive, if any, with respect to payment or reimbursement of any reasonable business expenses pursuant to this subsection (c).

7. Disability. If Executive shall become physically or mentally disabled during the Term to the extent that his ability to perform his duties and services hereunder is materially and adversely impaired, his Base Salary, bonus and other compensation provided herein shall continue while he remains employed by the Company; provided, that if such disability (as confirmed by competent medical evidence) continues for at least six (6) consecutive months, the

Company may terminate Executive's employment hereunder, in which case the Company immediately shall pay Executive a cash payment equal to (i) his annual Base Salary as provided in Section 5(a) hereof to the extent earned but unpaid as of the date of termination, (ii) a pro-rata portion of the Target Bonus for the year in which his disability occurs plus the Target Bonus for the preceding year if his disability occurs after year-end but before such bonuses are paid and (iii) the amounts payable pursuant to Section 5(d) hereof (to the extent not already paid). However, any options or restricted stock held by Executive on the date of termination shall vest only through the date of termination according to the normal vesting schedule applicable to such options or restricted stock and Executive shall not receive any accelerated or additional vesting of such stock or options due to termination under this Section 7 on or after such date. No payments or vesting under this paragraph will be made if such disability arose primarily from (a) chronic use of intoxicants, drugs or narcotics (other than drugs prescribed to Executive by a physician and used by Executive for their intended purpose for which they had been prescribed) or (b) intentionally self-inflicted injury or intentionally self-induced illness.

8. Disclosure of Information. Executive acknowledges that, in and as a result of his employment with the Company, he has been and will be making use of, acquiring and/or adding to confidential information of the Company and its affiliates of a special and unique nature and value. As a material inducement to the Company to enter into this Agreement and to pay to Executive the compensation stated in Section 5, as well as any additional benefits stated herein, Executive covenants and agrees that he shall not, at any time while he is employed by the Company or at any time thereafter, directly or indirectly, divulge or disclose for any purpose whatsoever, any confidential information (whether or not specifically labeled or identified as "confidential information"), in any form or medium, that has been obtained by or disclosed to him as a result of his employment with the Company and which the Company or any of its affiliates has taken appropriate steps to safeguard, except to the extent that such confidential information (a) becomes a matter of public record or is published in a newspaper, magazine or other periodical available to the general public, other than as a result of any act or omission of Executive, (b) is required to be disclosed by any law, regulation or order of any court or regulatory commission, department or agency, in which event Executive shall give prompt notice of such requirement to the Company to enable the Company to seek an appropriate protective order or confidential treatment, or (c) must be disclosed to enable Executive properly to perform his duties under this Agreement. Upon the termination of Executive's employment, Executive shall return such information (in whatever form) obtained from or belonging to the Company or any of its affiliates which he may have in his possession or control.

9. Covenants Against Competition and Solicitation. Executive acknowledges that the services he is to render to the Company and its affiliates are of a special and unusual character, with a unique value to the Company and its affiliates, the loss of which cannot adequately be compensated by damages or an action at law. In view of the unique value to the Company and its affiliates of the services of Executive for which the Company has contracted hereunder, because of the confidential information to be obtained by, or disclosed to, Executive as set forth in Section 8 above, and as a material inducement to the Company to enter into this Agreement and to pay to Executive the compensation stated in Section 5 hereof, as well as any additional benefits stated herein, and other good and valuable consideration, Executive covenants and agrees that throughout the period Executive remains employed or compensated hereunder

and for one year thereafter, Executive shall not, directly or indirectly, anywhere in the United States of America (i) render any services, as an agent, independent contractor, consultant or otherwise, or become employed or compensated by any other corporation, person or entity that derives a non-incidental portion of its revenue from the business of selling or providing annuity, life, accident or health insurance products or services; (ii) in any manner compete with the Company or any of its affiliates with respect to lines of business that the Company and its affiliates derive more than a non-incidental portion of their revenue from or with respect to which the Company and its affiliates have made a significant investment in; (iii) solicit or attempt to convert to other insurance carriers or other corporations, persons or other entities providing these same or similar products or services provided by the Company and its affiliates, any customers or policyholders of the Company or any of its affiliates or (iv) solicit for employment or employ any individual who was employed by the Company or any of its affiliates during the term of this Agreement. Notwithstanding the preceding sentence, if the Company terminates Executive for Just Cause (as defined in Section 10(b) of this Agreement), the provisions of clauses (i) and (ii) of the preceding sentence will not apply. Should any particular covenant or provision of this Section 9 be held unreasonable or contrary to public policy for any reason, including, without limitation, the time period, geographical area, or scope of activity covered by any restrictive covenant or provision, the Company and Executive acknowledge and agree that such covenant or provision shall automatically be deemed modified such that the contested covenant or provision shall have the closest effect permitted by applicable law to the original form and shall be given effect and enforced as so modified to whatever extent would be reasonable and enforceable under applicable law.

10. Termination.

(a) Either the Company or Executive may terminate his employment at any time for any reason upon written notice to the other. The Company may terminate Executive's employment for Just Cause pursuant to Section 10(b) below or in a Control Termination pursuant to Section 10(c) below. Executive's employment shall also terminate (i) upon non renewal of the Agreement, (ii) upon the death of Executive, (iii) after disability of Executive pursuant to Section 7 hereof or (iv) by Executive's termination of employment With Reason.

(b) The Company may terminate Executive's employment at any time for Just Cause. For purposes of this Agreement, "Just Cause" shall mean: (i) (A) a material breach by Executive of this Agreement, (B) a material breach of Executive's duty of loyalty to the Company or its affiliates, or (C) willful malfeasance or fraud or dishonesty of a substantial nature in performing Executive's services on behalf of the Company or its affiliates, which in each case is willful and deliberate on Executive's part and committed in bad faith or without reasonable belief that such breach or action is in the best interests of the Company or its affiliates; (ii) Executive's use of alcohol or drugs (other than drugs prescribed to Executive by a physician and used by Executive for their intended purposes for which they had been prescribed) or other repeated conduct which materially and repeatedly interferes with the performance of his duties hereunder, which materially compromises the integrity or the reputation of the Company or its affiliates, or which results in other substantial economic harm to the Company or its affiliates;

(iii) Executive's conviction by a court of law, admission that he is guilty, or entry of a plea of nolo contendere with regard to a felony or other crime involving moral turpitude; (iv) Executive's unscheduled absence from his employment duties other than as a result of illness or disability, for whatever cause, for a period of more than ten (10) consecutive days, without consent from the Company prior to the expiration of the ten (10) day period; or (v) Executive's failure to take action or to abstain from taking action, as directed in writing by a member of the board or a higher ranking executive of the Company or Conseco, where such failure continues after Executive has been given written notice of such failure and at least five (5) business days thereafter to cure such failure.

No termination shall be deemed to be a termination by the Company for Just Cause if the termination is as a result of Executive refusing to act in a manner that would be a violation of applicable law or where Executive acts (or refrains from taking action) in good faith in accordance with directions of a member of the board or higher ranking executive but was unable to attain the desired results because such results were inherently unreasonable or unattainable.

(c) The Company may terminate Executive's employment in a Control Termination. A "Control Termination" shall mean any termination by the Company (or its successor) of Executive's employment for any reason within six months in anticipation of or within two years following a Change in Control of the Company.

The term "Change in Control" shall mean the occurrence of any of the following:

(i) the acquisition (other than an acquisition in connection with a "Non-Control Transaction") by any "person" (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the "1934 Act")) of "beneficial ownership" (as such term is defined in Rule 13d-3 promulgated under the 1934 Act), directly or indirectly, of securities of the Company or its Ultimate Parent representing 51% or more of the combined voting power of the then outstanding securities of Conseco or its Ultimate Parent entitled to vote generally with respect to the election of the board of directors of the Company or its Ultimate Parent; or

(ii) as a result of or in connection with a tender or exchange offer or contest for election of directors, individual board members of Conseco (identified as of the date of commencement of such tender or exchange offer, or the commencement of such election contest, as the case may be) cease to constitute at least a majority of the board of directors of Conseco; or

(iii) the consummation of a merger, consolidation or reorganization with or into Conseco unless (x) the stockholders of Conseco immediately before such transaction beneficially own, directly or indirectly, immediately following such transaction securities representing 51% or more of the combined voting power of the then outstanding securities entitled to vote generally with respect to the election of the board of directors of Conseco (or its successor) or, if applicable,

the Ultimate Parent and (y) individual board members of Conseco (identified as of the date that a binding agreement providing for such transaction is signed) constitute at least a majority of the board of directors of Conseco (or its successor) or, if applicable, the Ultimate Parent (a transaction to which clauses (x) and (y) apply, a "Non-Control Transaction").

For purposes of this Agreement, "Ultimate Parent" shall mean the parent corporation (or if there is more than one parent corporation, the ultimate parent corporation) that, following a transaction, directly or indirectly beneficially owns a majority of the voting power of the outstanding securities entitled to vote with respect to the election of the board of directors of Conseco (or its successor).

(d) At Executive's option, he may terminate employment with the Company "With Reason" provided one or more of the following conditions are met: (i) his role or duties have been materially diminished by changes in responsibilities or authority; (ii) Executive is required to report to anyone other than the President of Conseco (or such other senior officer of Conseco or Conseco Insurance Group designated by the President of Conseco);

(iii) Executive is required to relocate his primary office more than 25 miles from Carmel, Indiana, without Executive's consent, (iv) any reduction in Executive's Base Salary or Target Bonus, or (v) there is a "Change in Control" as defined in Section 10(c) and, following Executive's written request made prior to the Change in Control, the ultimate parent entity or entities directly or indirectly gaining control of a majority of Conseco's Board or outstanding securities entitled to vote with respect to Conseco's Board fails to affirm and guarantee the Company's current and future obligations under this Agreement.

(e) Upon termination of Executive's employment with the Company for any reason (whether voluntary or involuntary), Executive shall be deemed to have voluntarily resigned from all positions that Executive may then hold with the Company and any of its affiliates; provided that such deemed resignation shall not adversely affect Executive's rights to compensation or benefits under Section 11 of this Agreement and shall not affect the determination of whether Executive's termination was for Just Cause.

11. Payments Following Termination.

(a) In the event that Executive's employment is terminated by the Company for Just Cause (as defined herein), upon non-renewal by the Company or Executive, or Executive voluntarily resigns (other than With Reason), then the Company immediately shall pay Executive a cash payment of his Base Salary as provided in Section 5(a) hereof that was earned but unpaid as of the date of termination. If Executive's employment ends upon non-renewal by the Company or Executive, then Executive shall also be entitled to receive the applicable bonus under Section 5(b) hereof at the same time that similar payments are made to other Company executives if Executive remains employed through the end of the Term. Any options or restricted stock held by Executive on the date of termination for the reasons set forth in this Section 11(a) shall vest only through the date of termination according to the normal vesting schedule applicable to such options or

restricted stock, and Executive shall not receive any accelerated or additional vesting of such stock or options on or after such date.

(b) In the event Executive's employment is terminated by the death of Executive, then the Company shall pay Executive's estate a cash lump sum of the sum of (i) the remaining payments of Base Salary described in Section 5(a) that would have been payable to Executive through the date of death,

(ii) a pro-rata portion of the Target Bonus for the year in which his death occurs plus the Target Bonus for the preceding year if his death occurs after year-end but before such bonuses are paid and (iii) the amounts payable pursuant to Section 5(d) hereof (to the extent not already paid). Any options or restricted stock held by Executive on the date of termination for the reasons set forth in this Section 11(b) shall vest only through the date of termination according to the normal vesting schedule applicable to such options or restricted stock, and Executive shall not receive any accelerated or additional vesting of such stock or options on or after such date.

(c) In the event that Executive is terminated by the Company without Just Cause (and other than non-renewal, death, disability or a Control Termination) or by Executive With Reason, then the Company shall pay Executive (i) on a basis consistent with the timing of the Company's normal payroll processing, the remaining payments of Base Salary described in Section 5(a) that would have been payable to Executive through the date of his termination of employment, (ii) his Base Salary (in the form of salary continuation on a pro-rata basis with or without medical and dental benefits, at the Executive's election and cost) for the 12-month period following his termination of employment, (iii) a cash lump sum equal to a pro-rata portion of the Target Bonus for the year in which the date of termination occurs plus the Target Bonus for the preceding year if termination occurs after year-end but before such bonuses are paid and (iv) the amounts payable pursuant to Section 5(d) hereof (to the extent not already paid). Any options or restricted stock held by Executive on the date of termination for the reasons set forth in this Section 11(c) shall vest only through the date of termination according to the normal vesting schedule applicable to such options or restricted stock, and Executive shall not receive any accelerated or additional vesting of such stock or options on or after such date.

(d) In the event that Executive is terminated by the Company (or its successor) in a Control Termination as so defined, then the Company shall pay Executive (i) on a basis consistent with the timing of the Company's normal payroll processing, the remaining payments of Base Salary described in Section 5(a) that would have been payable to Executive through the date of his termination of employment, (ii) his Base Salary and Target Bonus (in the form of salary continuation on a pro-rata basis with or without medical and dental benefits at the cost charged to active employees) for the 12-month period following his termination of employment, (iii) a cash lump sum equal to a pro-rata portion of the Target Bonus for the year in which the date of termination occurs plus the Target Bonus for the preceding year if termination occurs after year-end but before such bonuses are paid and (iv) the amounts payable pursuant to Section 5(d) hereof (to the extent not already paid). To the extent that Executive is terminated in a

Control Termination that occurs in anticipation of a Change in Control, any options or restricted stock held by Executive shall fully vest, retroactive to the date of termination, upon the occurrence of the Change in Control.

(e) Notwithstanding anything to the contrary, in the event that Executive's employment terminates, the Company shall pay to Executive, in accordance with its standard payroll practice, Executive's accrued vacation.

(f) Notwithstanding anything to the contrary, payment of severance under this Agreement is conditioned upon the execution by Executive of a separation and release agreement in a form acceptable to the Company and the observation of such waiting or revocation periods, if any, before and after execution of the agreement by Executive as are required by law, such as, for example, the waiting or revocation periods required for a waiver and release to be effective with respect to claims under the Age Discrimination in Employment Act, provided that the Company delivers to Executive such agreement within seven days of the date of his termination.

12. Change in Control. In the event of a Change in Control, Executive will be entitled to the full vesting of any options and restricted stock held by Executive on the date of such Change in Control.

13. Character of Termination Payments. The amounts payable to Executive upon any termination of his employment shall be considered severance pay in consideration of past services rendered on behalf of the Company and his continued service from the date hereof to the date he becomes entitled to such payments and shall be the sole amount of severance pay to which Executive is entitled from the Company and its affiliates upon termination of his employment during the Term. Executive shall have no duty to mitigate his damages by seeking other employment.

14. Representations of the Parties.

(a) The Company represents and warrants to Executive that (i) this Agreement has been duly authorized, executed and delivered by the Company and constitutes valid and binding obligations of the Company; and (ii) the employment of Executive on the terms and conditions contained in this Agreement will not conflict with, result in a breach or violation of, constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to: (A) the certificate of formation, (B) the terms of any indenture, contract, lease, mortgage, deed of trust, note, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company is a party or bound or to which its property is subject, or (C) any statute, law, rule, regulation, judgment, order or decree applicable to the Company, or any regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company.

(b) Executive represents and warrants to the Company that: (i) this Agreement has been duly executed and delivered by Executive and constitutes a valid and binding

obligation of Executive; and (ii) neither the execution of this Agreement by Executive nor his employment by the Company on the terms and conditions contained herein will conflict with, result in a breach or violation of, or constitute a default under any agreement, obligation, condition, covenant or instrument to which Executive is a party or bound or to which his property is subject, or any statute, law, rule, regulation, judgment, order or decree applicable to Executive of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over Executive or any of his property.

15. Arbitration of Disputes; Injunctive Relief.

(a) Except as provided in subsection (b) below, any controversy or claim arising out of or relating to this Agreement or the breach thereof shall be settled by binding arbitration in the City of Indianapolis, Indiana, in accordance with the laws of the State of Indiana by three arbitrators, one of whom shall be appointed by the Company, one by Executive, and the third of whom shall be appointed by the first two arbitrators. If the first two arbitrators cannot agree on the appointment of a third arbitrator, then the third arbitrator shall be appointed by the Chief Judge of the United States District Court for the Southern District of Indiana. The arbitration shall be conducted in accordance with the rules of the American Arbitration Association, except with respect to the selection of arbitrators, which shall be as provided in this Section. Judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. Each party shall pay its own costs and expenses incurred in connection with the enforcement of this Agreement, regardless of the final outcome.

(b) Executive acknowledges that a breach or threatened breach by Executive of Sections 8 or 9 of this Agreement will give rise to irreparable injury to the Company and that money damages will not be adequate relief for such injury. Notwithstanding paragraph (a) above, the Company and Executive agree that the Company may seek and obtain injunctive relief, including, without limitation, temporary restraining orders, preliminary injunctions and/or permanent injunctions, in a court of proper jurisdiction to restrain or prohibit a breach or threatened breach of Section 8 or 9 of this Agreement. Nothing herein shall be construed as prohibiting the Company from pursuing any other remedies available to the Company for such breach or threatened breach, including the recovery of damages from Executive.

16. Notices. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered mail to his residence, in the case of Executive, or to the business office of its General Counsel, in the case of the Company.

17. Waiver of Breach and Severability. The waiver by either party of a breach of any provision of this Agreement by the other party shall not operate or be construed as a waiver of any subsequent breach by either party. In the event any provision of this Agreement is found to be invalid or unenforceable, it may be severed from the Agreement, and the remaining provisions of the Agreement shall continue to be binding and effective.

18. Entire Agreement. Other than any equity award agreements entered into pursuant to an applicable long-term incentive plan, this instrument contains the entire agreement of the

parties and, as of the Effective Date, supersedes all other obligations of the Company and its affiliates under other agreements or otherwise. The compensation and benefits to be paid under the terms of this Agreement are in lieu of all other compensation or benefits to which Executive is entitled from Conesco, the Company, and its affiliates. This Agreement may not be changed orally, but only by an instrument in writing signed by the party against whom enforcement of any waiver, change, modification, extension or discharge is sought.

19. Binding Agreement and Governing Law; Assignment Limited. This Agreement shall be binding upon and shall inure to the benefit of the parties and their lawful successors in interest (including, without limitation, Executive's estate, heirs and personal representatives) and, except for issues or matters as to which federal law is applicable, shall be construed in accordance with and governed by the laws of the State of Indiana. This Agreement is personal to each of the parties hereto, and neither party may assign or delegate any of its rights or obligations hereunder without the prior written consent of the other.

20. Indemnification. If Executive was or is made a party or is threatened to be made a party to or is otherwise involved (including involvement as a witness) in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a "Proceeding"), by reason of the fact that he or she is or was an officer or employee of the Company or any of its affiliates, Executive shall be indemnified and held harmless by the Company to the fullest extent authorized by the Delaware General Corporation Law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Company to provide broader indemnification rights than permitted prior thereto), against all expense, liability and loss (including attorneys' fees, judgments, fines, excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by Executive in connection therewith and such indemnification shall continue as to Executive if he ceases to be an officer or employee and shall inure to the benefit of Executive's heirs, executors and administrators; provided, however, that the Company shall indemnify Executive in connection with a proceeding (or part thereof) initiated by Executive only if such Proceeding (or part thereof) was authorized by the Board of Directors of the Company. The right to indemnification conferred in this paragraph shall include the obligation of the Company to pay the expenses incurred in defending any such proceeding in advance of its final disposition (an "Advance of Expenses"); provided, however, that, if and to the extent that the Delaware General Corporation Law requires, an Advance of Expenses incurred by Executive in his capacity as an officer or employee shall be made only upon delivery to the Company of an undertaking, by or on behalf of Executive, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that Executive is not entitled to be indemnified for such expenses under this paragraph or otherwise.

21. No Third Party Beneficiaries. The terms and provisions of this Agreement are intended solely for the benefit of each party hereto and their respective successors or permitted assigns, and it is not intended to confer third-party beneficiary rights upon any other person.

22. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written, effective as of the Effective Date.

**COMPANY:
CONSECO SERVICES, LLC**

/s/ Daniel J. Murphy

Daniel J. Murphy
President

EXECUTIVE:

/s/ Steven M. Stecher

Steven M. Stecher

Exhibit 12.1
 Computation of Ratio of Earnings to
 Fixed Charges and Preferred Dividends
 (Dollars in millions)

	Successor					Predecessor
	2007	2006	2005	2004	Four months ended December 31, 2003	Eight months ended August 31, 2003(b)
	-----	-----	-----	-----	-----	-----
		(Restated)	(Restated)	(Restated)	(Restated)	
Pretax income (loss) from operations:						
Net income (loss).....	\$(179.9)	\$106.0	\$312.7	\$289.7	\$ 96.3	\$2,201.7
Add income tax expense (benefit).....	6.9	61.2	171.6	156.4	53.2	(13.5)
Add discontinued operations.....	-	-	-	-	-	(16.0)
	-----	-----	-----	-----	-----	-----
Pretax income (loss) from operations.....	(173.0)	167.2	484.3	446.1	149.5	2,172.2
	-----	-----	-----	-----	-----	-----
Add fixed charges:						
Interest expense on corporate debt.....	72.3	52.9	48.1	71.5	34.4	223.2
Interest expense on investment borrowings.....	45.0	20.6	10.2	8.0	2.4	8.3
Interest added to policyholder account balances.....	399.5	426.8	419.9	410.4	145.5	307.9
Portion of rental (a).....	13.7	13.2	12.6	13.5	6.4	8.9
	-----	-----	-----	-----	-----	-----
Fixed charges.....	530.5	513.5	490.8	503.4	188.7	548.3
	-----	-----	-----	-----	-----	-----
Adjusted earnings (loss).....	\$ 357.5	\$680.7	\$975.1	\$949.5	\$338.2	\$2,720.5
	=====	=====	=====	=====	=====	=====
Ratio of earnings to fixed charges...	(c)	1.33X	1.99X	1.89X	1.79X	4.96X
	=	=====	=====	=====	=====	=====
Fixed charges.....	\$ 530.5	\$513.5	\$490.8	\$503.4	\$188.7	\$ 548.3
Add dividends on preferred stock, including dividends on preferred stock of subsidiaries (divided by the ratio of income to pretax income).....	21.7	59.9	58.9	100.9	43.2	-
	-----	-----	-----	-----	-----	-----
Fixed charges plus preferred dividends.....	\$ 552.2	\$573.4	\$549.7	\$604.3	\$231.9	\$ 548.3
	=====	=====	=====	=====	=====	=====
Adjusted earnings (loss).....	\$ 357.5	\$680.7	\$975.1	\$949.5	\$338.2	\$2,720.5
	=====	=====	=====	=====	=====	=====
Ratio of earnings to fixed charges and preferred dividends.....	(d)	1.19X	1.77X	1.57X	1.46X	4.96X
	=	=====	=====	=====	=====	=====

(a) Interest portion of rental is estimated to be 33 percent.

(b) Earnings for the eight months ended August 31, 2003 included reorganization items totaling \$2,130.5 million. The reorganization items included: (i) \$3,151.4 million related to the gain on the discharge of prepetition liabilities; (ii) \$(950.0) million related to fresh start adjustments; and (iii) \$(70.9) million related to professional fees. The ratios for the eight months ended August 31, 2003, excluding such reorganization items would be as follows: (i) ratio of earnings to fixed charges - 1.08X; and (ii) ratio of earnings to fixed charges excluding interest added to policyholder account balances - 1.17X. There were no preferred stock dividends or distributions on Company-obligated mandatorily redeemable preferred securities of subsidiary trusts during the eight months ended August 31, 2003.

(c) For such ratio, earnings were \$173.0 million less than fixed charges.

(d) For such ratio, earnings were \$194.7 million less than fixed charges.

Subsidiaries of Conseco, Inc.

Name	State or Other Jurisdiction
----	-----
40 86 Advisors, Inc.	Delaware
Conseco Equity Sales, Inc.	Texas
Design Benefit Plans, Inc.	Illinois
NAL Financial Group, Inc.	Delaware
CDOC, Inc.	Delaware
Conseco Securities, Inc.	Delaware
K. F. Insurance Agency of Massachusetts, Inc.	Massachusetts
K. F. Agency, Inc.	Illinois
Administrators Service Corporation	Illinois
Hawthorne Advertising Agency, Incorporated	Pennsylvania
Geneva International Insurance Company, Inc.	Turks and Caicos
General Acceptance Corporation Reinsurance Limited	Turks and Caicos
American Life and Casualty Marketing Division Co.	Iowa
40 86 Mortgage Capital, Inc.	Delaware
Conseco Management Services Company	Texas
Conseco Services, LLC	Indiana
Conseco Marketing, L.L.C.	Indiana
Conseco Data Services (India) Private Limited	India
Codelinks, LLC	Indiana
Conseco Health Services, Inc.	Pennsylvania
Performance Matters Associates, Inc.	Delaware
Performance Matters Associates of Texas, Inc.	Texas
Erie International Insurance Company, Inc.	Turks and Caicos
Association Management Corporation	Illinois
Conseco Life Insurance Company of Texas	Texas
Colonial Penn Life Insurance Company	Pennsylvania
C.P. Real Estate Services Corp.	New Jersey
Conseco Health Insurance Company	Arizona
Conseco Senior Health Insurance Company	Pennsylvania
Bankers Conseco Life Insurance Company	New York
Washington National Insurance Company	Illinois
Conseco Life Insurance Company	Indiana
Conseco Insurance Company	Illinois
Bankers Life and Casualty Company	Illinois
BLC Financial Services, Inc.	Illinois
Carmel Fifth, LLC	Delaware
ResortPort Holding of Delaware, Inc.	Delaware
3037953 Nova Scotia Company	Nova Scotia

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-108835) of Consecro, Inc. of our report dated March 28, 2008 relating to the consolidated financial statements and the effectiveness of internal control over financial reporting, which is included in this Annual Report on Form 10-K for the year ended December 31, 2007. We also consent to the incorporation by reference of our report dated March 28, 2008 relating to the financial statement schedules, which appear in this Form 10-K.

/s/ PricewaterhouseCoopers LLP

*Indianapolis, Indiana
March 28, 2008*

CONSECO, INC. AND SUBSIDIARIES

CERTIFICATION

I, C. James Prieur, certify that:

1. I have reviewed this annual report on Form 10-K of Conseco, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the year covered by this annual report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the years presented in this annual report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the year in which this annual report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the year covered by this annual report; and
 - (d) Disclosed in this annual report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 28, 2008

/s/ C. James Prieur

C. James Prieur,

Chief Executive Officer

CONSECO, INC. AND SUBSIDIARIES

CERTIFICATION

I, Edward J. Bonach, certify that:

1. I have reviewed this annual report on Form 10-K of Conseco, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the year covered by this annual report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the years presented in this annual report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the year in which this annual report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the year covered by this annual report; and
 - (d) Disclosed in this annual report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 28, 2008

/s/ Edward J. Bonach

*-----
Edward J. Bonach, Executive Vice President
and Chief Financial Officer*

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO**

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Consecro, Inc. (the "Company") on Form 10-K for the year ending December 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, C. James Prieur, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my actual knowledge:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ C. James Prieur

C. James Prieur
Chief Executive Officer
March 28, 2008

A signed original of this written statement required by Section 906 has been provided to Consecro, Inc. and will be retained by Consecro, Inc. and furnished to the Securities and Exchange Commission upon request.

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO**

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Consecro, Inc. (the "Company") on Form 10-K for the year ending December 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Edward J. Bonach, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my actual knowledge:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Edward J. Bonach

Edward J. Bonach

Executive Vice President and Chief Financial Officer

March 28, 2008

A signed original of this written statement required by Section 906 has been provided to Consecro, Inc. and will be retained by Consecro, Inc. and furnished to the Securities and Exchange Commission upon request.